CA2613365A1 - Phenoxy acetic acids as ppar delta activators - Google Patents

Phenoxy acetic acids as ppar delta activators Download PDF

Info

Publication number
CA2613365A1
CA2613365A1 CA002613365A CA2613365A CA2613365A1 CA 2613365 A1 CA2613365 A1 CA 2613365A1 CA 002613365 A CA002613365 A CA 002613365A CA 2613365 A CA2613365 A CA 2613365A CA 2613365 A1 CA2613365 A1 CA 2613365A1
Authority
CA
Canada
Prior art keywords
substituted
occurrence
phenoxy
acetic acid
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002613365A
Other languages
French (fr)
Other versions
CA2613365C (en
Inventor
Soren Ebdrup
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
vTv Therapeutics LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2613365A1 publication Critical patent/CA2613365A1/en
Application granted granted Critical
Publication of CA2613365C publication Critical patent/CA2613365C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/10—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C323/18—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C07C323/20—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton with singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/10—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C323/11—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/16—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/64—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton
    • C07C323/65—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton containing sulfur atoms of sulfone or sulfoxide groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C07D213/643—2-Phenoxypyridines; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Abstract

The present invention describes phenoxy-acetic acids and pharmaceutical compositions containing the same and methods of using the same. The phenoxy- acetic acids are activators of PPAR-.delta. and should be useful for treatin g conditions mediated by the same.

Description

PHENOXY ACETIC ACIDS AS PPAR DELTA ACTIVATORS

FIELD OF THE INVENTION
[0001] The present invention relates to novel phenoxy-acetic acids, pharmaceuticals com-prising the same, and methods of using the same. The phenoxy-acetic acids are activators of peroxisome proliferator-activated receptors (PPAR)-8.

BACKGROUND OF THE INVENTION
[0002] Coronary artery disease (CAD) is the major cause of death in Type 2 diabetic and metabolic syndrome patients (i.e., patients that fall within the 'deadly quartet' category of im-paired glucose tolerance, insulin resistance, hypertriglyceridaemia and/or obesity).
[0003] The hypolipidaemic fibrates and antidiabetic thiazolidinediones separately display moderately effective triglyceride-lowering activities, although they are neither potent nor effi-cacious enough to be a single therapy of choice for the dyslipidaemia often observed in Type 2 diabetic or metabolic syndrome patients. The thiazolidinediones also potently lower circu-lating glucose levels of Type 2 diabetic animal models and humans. However, the fibrate class of compounds are without beneficial effects on glycaemia. Studies on the molecular ac-tions of these compounds indicate that thiazolidinediones and fibrates exert their action by activating distinct transcription factors of the peroxisome proliferator activated receptor (PPAR) family, resulting in increased and decreased expression of specific enzymes and apol-ipoproteins respectively, both key-players in regulation of plasma triglyceride content.
[0004] PPAR-8 activation was initially reported not to be involved in modulation of glucose or triglyceride levels. (Berger et al., J. Biol. Chem. 1999, 274, 6718-6725).
Later it was shown that PPAR-8 activation leads to increased levels of HDL cholesterol in db/db mice (Leibowitz et al., FEBS letters 2000, 473, 333-336). Further, a PPAR-8 agonist when dosed to insulin-resistant middle-aged obese rhesus monkeys caused a dramitic dose-dependent rise in serum HDL cholesterol while lowering the levels of small dense LDL, fasting triglycerides and fasting insulin (Oliver et al., PNAS 2001, 98, 5306-5311). The same paper also showed that PPAR-8 activation increased the reverse cholesterol transporter ATP-binding cassette Al and induced apolipoprotein Al-specific cholesterol efflux. The involvement of PPAR-8 in fatty acid oxidation in muscles was further substantiated in PPAR-oc knock-out mice. Muoio et al. (J. Biol. CheYrz. 2002, 277, 26089-26097) showed that the high levels of PPAR-8 in skeletal muscle can compensate for deficiency in PPAR-oc. In addition to the effects on cholesterol homeostasis, PPAR8 treatment was observed to lower plasma glucose and insulin and improve insulin sensitivity in diabetic ob/ob and db/db mice and high fat diet induced insulin resistant mice (PNAS 2003, 100, 15924-15929; PNAS 2006, 103, 3444-3449).Taken together these observations suggest that PPAR-8 activation is useful in the treatment and prevention of Type 2 diabetes, cardiovascular diseases and conditions including athero-sclerosis, hypertriglyceridemia, and mixed dyslipidaemia (WO 01/00603).
A number of PPAR-8 compounds have been reported to be useful in the treatment of hyperglycemia, hyperlipidemia and hypercholesterolemia (WO 02/59098, WO
01/603, WO
01/25181, WO 02/14291, WO 01/79197, WO 99/4815, WO 97/28149, WO 98/27974, WO
97/28115, WO 97/27857, WO 97/28137, and WO 97/27847). WO 2004093879, WO
2004092117, WO 2004080947, WO 2004080943, WO 2004073606,WO 2004063166, WO
2004063165, WO 2003072100, WO 2004060871, WO 2004005253, WO 2003097607, WO
2003035603, WO 2004000315, WO 2004000762, WO 2003074495, WO 2002070011, WO
2003084916, US 20040209936, WO 2003074050, WO 2003074051, WO 2003074052, JP
2003171275, WO 2003033493, WO 2003016291, WO 2002076957, WO 2002046154, WO
2002014291, WO 2001079197, WO 2003024395, WO 2002059098, WO 2002062774, WO
2002050048, WO 2002028434, WO 2001000603, WO 2001060807, WO 9728149, WO
2001034200, WO 9904815, WO 200125226, WO 2005097098; WO 2005097762; WO
2005097763.
[0005] Glucose lowering as a single approach does not overcome the macrovascular compli-cations associated with Type 2 diabetes and metabolic syndrome. Novel treatments of Type 2 diabetes and metabolic syndrome must therefore aim at lowering both the overt hypertriglyc-eridaemia associated with these syndromes as well as alleviation of hyperglycaemia. This indicates that research for compounds displaying various degree of PPAR-8 activation should lead to the discovery of efficacious triglyceride and/or cholesterol and/or glucose lowering drugs that have great potential in the treatment of diseases such as type 2 diabetes, dyslipide-mia, syndrome X (including the metabolic syndrome, i.e., impaired glucose tolerance, insulin resistance, hypertrigyceridaemia and/or obesity), cardiovascular diseases (including athero-sclerosis) and hypercholesteremia.

SUMMARY OF THE INVENTION
[0006] In an aspect, the present invention provides novel phenoxy-acetic acids or pharma-ceutically acceptable salts thereof that are useful as PPAR-8 activators.
[0007] In another aspect, the present invention provides novel pharmaceutical compositions comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of at least one of the compounds of the present invention or a pharmaceutically acceptable salt thereof.
[0008] In another aspect, the present invention provides a novel method of treating type 2 diabetes comprising administering to a patient in need thereof a therapeutically effective amount of at least one compound of the present invention or a pharmaceutically acceptable salt thereof.
[0009] In another aspect, the present invention provides a novel method of treating a disease comprising administering to a patient in need thereof a therapeutically effective amount of at least one compound of the present invention or a pharmaceutically acceptable salt thereof, wherein the disease is selected from dyslipidemia, syndrome X (including the metabolic syn-drome, e.g., hypertension, impaired glucose tolerance (IGT), insulin resistance, hypertri-gyceridaemia, and obesity), cardiovascular diseases (e.g., atherosclerosis, coronary artery dis-ease, and myocardial ischemia), hyperglycemia, hyperlipidemia, and hypercholesterolemia.
[0010] In another aspect, the present invention provides a novel method of treating a disease comprising administering to a patient in need thereof a therapeutically effective amount of at least one compound of the present invention or a pharmaceutically acceptable salt thereof, wherein the disease is selcted from non-insulin requiring Type 2 diabetes to insulin requiring Type 2 diabetes, decreasing apoptosis in mammalian cells (e.g., beta cells of Islets of Langer-hans), renal diseases (e.g., glomerulonephritis, glomerulosclerosis, nephrotic syndrome, and hypertensive nephrosclerosis), improving cognitive functions in dementia, treating diabetic complications, psoriasis, polycystic ovarian syndrome (PCOS), prevention and treatment of bone loss (e.g., osteoporosis), and lowering the bio-markers of atherosclerosis (e.g., c-reactive protein (CRP), TNF-(c, and IL-6).
[0011] In another aspect, the present invention provides novel compounds for use in ther-apy.
[0012] In another aspect, the present invention provides the use of novel compounds for the manufacture of a medicament for the treatment of type 2 diabetes.
[0013] These and other objects, which will become apparent during the following detailed description, have been achieved by the inventors' discovery that compounds of formula I:
R4c R 2 4b ~/
R4\

X \JJJ Xl R5d 5e I1 R
R

R5b R5a O
O OH
I
[0014] or pharmaceutically acceptable salts thereof, are PPAR-8 activators.
DESCRIPTION OF THE INVENTION
[0015] In a first embodiment, the present invention provides a novel compound of formula I:

R4c R2 R4b !
R4a ~/
~ II
X ~~ \JJJ Xi Sd ~ \/ I
R Rse Rl R5o ~ R3 Rsb R5a O
[0016] or a pharmaceutically acceptable salt thereof, wherein:
[0017] X is selected from 0, S, OCH2, and SCH2;
[0018] Xl is 0 or S;
[0019] Rl is selected from H, Cl_g alkyl, CZ_g alkenyl, aryl, heteroaryl,C3_1o cycloalkyl, and a heterocyclyl, wherein each Rl group is substituted with 0-4 Rla;
[0020] Rla, at each occurrence, is selected from S substituted with 0-1 Rlb, 0 substituted with 0-1 Rlb, halogen, NH2 substituted with 0-2 Rlb, -CN, NO2, Cl_6 a1ky1 substituted with 0-3 Rlb, C2_6 alkenyl substituted with 0-2 Rlb, C2_6 alkynyl substituted with 0-2 Rlb, aryl substi-tuted with 0-2 Rlb, heteroaryl substituted with 0-2 Rlb, C3_io cycloalkyl substituted with 0-2 Rlb, and heterocycle substituted with 0-2 Rlb;
[0021] Rlb, at each occurrence, is selected from S substituted with 0-1 Rl , 0 substituted with 0-1 Rl , halogen, methanesulfonyl, NH2 substituted with 0-2 Rl , -CN, NO2, Cl_6 alkyl substituted with 0-3 Rl , C2_6 alkenyl substituted with 0-2 Rl , aryl substituted with 0-2 Rl heteroaryl substituted with 0-2 Rl , C3_10 cycloalkyl substituted with 0-2 Rl , and a heterocy-cle substituted with 0-2 R";
[0022] Rl , at each occurrence, is selected from S substituted with 0-1 Rld, 0 substituted with 0-1 R'd, halogen, NH2 substituted with 0-2 Rid, -CN, NOz, Ci_6 alkyl substituted with 0-2 Rld, C2_6 alkenyl substituted with 0-2 Rld, aryl substituted with 0-2 Rld, heteroaryl substituted with 0-2 Rld, C3_1o cycloalkyl substituted with 0-2 Rld, and a heterocycle substituted with 0-2 Rld, , [0023] Rld, at each occurrence, is selected from OH, SH, S, 0, halogen, NH2, -CN, NOZ, Cl-6 alkyl, C2-6 alkenyl, aryl, CF3, and OCF3;
[0024] R 2 is selected from -C=C-RZa, -CH=CH-RZa, aryl substituted with 0-3 RZa, and het-eroaryl substituted with 0-3 R2a;
[0025] RZa, at each occurrence, is selected from S substituted with 0-1 R2b, 0 substituted with 0-1 RZb, halogen, NH2 substituted with 0-2 R 2b, -CN, NOZ, Cl-6 alkyl substituted with 0-2 R 2b, C2-6 alkenyl substituted with 0-2 RZb, aryl substituted with 0-2 RZb, heteroaryl substituted with 0-2 R 2b, C3-lo cycloalkyl substituted with 0-2 R 2b, and a heterocycle substituted with 0-2;
[0026] RZb, at each occurrence, is selected from S substituted with 0-1 R2o, 0 substituted with 0-1 RZ , halogen, methanesulfonyl, NH2 substituted with 0-2 R 2c, -CN, NOZ, Cl-6 alkyl substituted with 0-2 RZ , CZ-6 alkenyl substituted with 0-2 RZ , aryl substituted with 0-2 RZ , heteroaryl substituted with 0-2 RZ , C3-lo cycloalkyl substituted with 0-2 RZ
, and a heterocy-cle substituted with 0-2 R2o;
[0027] RZ , at each occurrence, is selected from S substituted with 0-1 RZd, 0 substituted with 0-1 RZd, halogen, NH2 substituted with 0-2 RZd, -CN, NOZ, Cl-6 alkyl substituted with 0-2 R 2d, C2-6 alkenyl substituted with 0-2 RZd, aryl substituted with 0-2 RZd, heteroaryl substituted with 0-2 RZd, C3-lo cycloalkyl substituted with 0-2 RZd, and a heterocycle substituted with 0-2 R 2d [0028] R2d, at each occurrence, is selected from OH, SH, S, 0, halogen, NH2, -CN, NOZ, Cl-6 alkyl, C2-6 alkenyl, aryl, CF3, and OCF3;
[0029] R3 is selected from halogen and Cl-6 alkyl substituted with 0-2 R3a;
[0030] R3a, at each occurrence, is selected from OH, 0, S, halogen, C(O)NH2, C(O)NH-Cl-4 alkyl, and C(O)N(Ci-4 alkyl)2;
[0031] alternatively, R3 and R 5e combine to form a 5, 6, or 7 membered ring consisting of carbon atoms and 0-2 heteroatoms selected from 0, N, and S(0)0-2 and there are 0-2 ring dou-ble bonds in the bridging portion formed by R3 and R 5e;
[0032] R4a, at each occurrence, is selected from H, halogen, and Cl-6 alkyl substituted with 0-2 R4d;
[0033] R4d, at each occurrence, is selected from OH, 0, halogen, NH2, NH-Cl-4 alkyl, and N(Ci-4 alkyl)z, [0034] R4b, at each occurrence, is selected from H, halogen, and Cl_6 alkyl substituted with 0-2 R4e;
[0035] R4e, at each occurrence, is selected from OH, 0, halogen, NH2, NH-Cl_4 alkyl, and N(Ci_4 alkyl)2;
[0036] R4o, at each occurrence, is selected from H, halogen, and Cl_6 alkyl substituted with 0-2 R4f;
[0037] R4f, at each occurrence, is selected from OH, 0, halogen, NH2, NH-Cl_4 alkyl, and N(Ci_4 alkyl)z, [0038] R5a, at each occurrence, is selected from H, halogen, CH3, and CH2CH3;
[0039] R5b, at each occurrence, is selected from H, halogen, CH3, and CH2CH3;
[0040] R5o, at each occurrence, is selected from H, halogen, CH3, and CH2CH3;
[0041] R5d, at each occurrence, is selected from H, halogen, CH3, and CH2CH3;
and, [0042] R5e, at each occurrence, is selected from H, halogen, CH3, and CH2CH3.
[0043] In another embodiment, the present invention provides a novel compound of formula I or a pharmaceutically acceptable salt thereof, wherein:
[0044] X is selected from 0, S, OCH2, and SCH2;
[0045] Xl is 0 or S;
[0046] R' is selected from H, Cl_g alkyl, CZ_g alkenyl, aryl, 5-10 membered heteroaryl con-sisting of carbon atoms and 1-4 heteroatoms selected from 0, N, and S(O)0-2, C3-io cycloalkyl, and a 3-8 membered heterocycle consisting of carbon atoms and 1-3 heteroatoms selected from 0, N, and S(O)o_Z, wherein each Rl group is substituted with 0-4 Rla;
[0047] Rla, at each occurrence, is selected from OH substituted with 0-1 Rlb, SH substituted with 0-1 Rlb, S, 0, halogen, NH2 substituted with 0-2 R'b, -CN, NOZ, Cl_6 alkyl substituted with 0-3 Rlb, C2_6 alkenyl substituted with 0-2 Rlb, C2_6 alkynyl substituted with 0-2 Rlb, aryl substituted with 0-2 Rlb, 5-10 membered heteroaryl substituted with 0-2 Rlb and consisting of carbon atoms and 1-4 heteroatoms selected from 0, N, and S(0)0-2, C3-io cycloalkyl substi-tuted with 0-2 Rlb, and a 3-8 membered heterocycle substituted with 0-2 Rlb and consisting of carbon atoms and 1-3 heteroatoms selected from 0, N, and S(O)o_Z, [0048] Rlb, at each occurrence, is selected from OH substituted with 0-1 Rl , SH substituted with 0-1 Rl , S, 0, halogen, methanesulfonyl, NH2 substituted with 0-2 Rl , -CN, NOZ, Cl-6 alkyl substituted with 0-3 Rl , CZ-6 alkenyl substituted with 0-2 Rl , aryl substituted with 0-2 Rl , 5-10 membered heteroaryl substituted with 0-2 Rl and consisting of carbon atoms and 1-4 heteroatoms selected from 0, N, and S(O)o-2, C3-io cycloalkyl substituted with 0-2 Rl , and a 3-8 membered heterocycle substituted with 0-2 Rl and consisting of carbon atoms and 1-3 heteroatoms selected from 0, N, and S(O)o-Z, [0049] Rl , at each occurrence, is selected from OH substituted with 0-1 Rld, SH substituted with 0-1 Rld, S, 0, halogen, NH2 substituted with 0-2 Rld, -CN, NOZ, Cl-6 alkyl substituted with 0-2 Rld, CZ-6 alkenyl substituted with 0-2 Rld, aryl substituted with 0-2 Rld, 5-10 mem-bered heteroaryl substituted with 0-2 Rld and consisting of carbon atoms and 1-4 heteroatoms selected from 0, N, and S(O)o-2, C3-io cycloalkyl substituted with 0-2 Rld, and a 3-8 mem-bered heterocycle substituted with 0-2 Rld and consisting of carbon atoms and 1-3 heteroa-toms selected from 0, N, and S(O)o-z, [0050] Rld, at each occurrence, is selected from OH, SH, S, 0, halogen, NH2, -CN, NOZ, Cl-6 alkyl, C2-6 alkenyl, aryl, CF3, and OCF3;
[0051] R 2 is selected from -C=C-RZa, -CH=CH-RZa substituted with 0-2 R 2a, aryl substituted with 0-3 RZa, and 5-10 membered heteroaryl substituted with 0-3 R 2a and consisting of carbon atoms and 1-4 heteroatoms selected from 0, N, and S(O)o-Z, [0052] R2a, at each occurrence, is selected from OH substituted with 0-1 R2b, SH substituted with 0-1 R 2b, S, 0, halogen, NH2 substituted with 0-2 R 2b, -CN, NOZ, Cl-6 alkyl substituted with 0-2 R 2b, CZ-6 alkenyl substituted with 0-2 RZb, aryl substituted with 0-2 RZb, 5-10 mem-bered heteroaryl substituted with 0-2 R 2b and consisting of carbon atoms and 1-4 heteroatoms selected from 0, N, and S(O)0-2, C3-io cycloalkyl substituted with 0-2 R2b, and a 3-8 mem-bered heterocycle substituted with 0-2 R 2b and consisting of carbon atoms and 1-3 heteroa-toms selected from 0, N, and S(O)o-Z, [0053] R2b, at each occurrence, is selected from OH substituted with 0-1 RZ , SH substituted with 0-1 R2o, S, 0 substituted with 0-1 R2 , halogen, methanesulfonyl, NH2 substituted with 0-2 RZ , -CN, NOZ, Cl-6 alkyl substituted with 0-2 RZ , CZ-6 alkenyl substituted with 0-2 R2o, aryl substituted with 0-2 RZ , 5-10 membered heteroaryl substituted with 0-2 RZ
and consisting of carbon atoms and 1-4 heteroatoms selected from 0, N, and S(O)0-2, C3-io cycloalkyl substi-tuted with 0-2 RZ , and a 3-8 membered heterocycle substituted with 0-2 RZ
and consisting of carbon atoms and 1-3 heteroatoms selected from 0, N, and S(O)0-2, [0054] RZ , at each occurrence, is selected from OH substituted with 0-1 RZd, SH substituted with 0-1 RZd, S, 0, halogen, NH2 substituted with 0-2 RZd, -CN, NOZ, Cl-6 alkyl substituted with 0-2 RZd, CZ-6 alkenyl substituted with 0-2 RZd, aryl substituted with 0-2 RZd, 5-10 mem-bered heteroaryl substituted with 0-2 R 2d and consisting of carbon atoms and 1-4 heteroatoms selected from 0, N, and S(O)o-2, C3-io cycloalkyl substituted with 0-2 RZd, and a 3-8 mem-bered heterocycle substituted with 0-2 RZd and consisting of carbon atoms and 1-3 heteroa-toms selected from 0, N, and S(O)o-Z, [0055] RZd, at each occurrence, is selected from OH, SH, S, 0, halogen, NH2, -CN, NOZ, Cl-6 alkyl, CZ-6 alkenyl, aryl, CF3, and OCF3;
[0056] R3 is selected from halogen and Cl-6 alkyl substituted with 0-2 R3a;
[0057] R3a, at each occurrence, is selected from OH, 0, S, halogen, C(O)NHZ, C(O)NH-Cl-4 alkyl, and C(O)N(Cl-4 alkyl)2;
[0058] alternatively, R3 and R5e combine to form a 5, 6, or 7 membered ring consisting of carbon atoms and 0-2 heteroatoms selected from 0, N, and S(0)0-2 and there are 0-2 ring dou-ble bonds in the bridging portion formed by R3 and Rse;
[0059] R4a, at each occurrence, is selected from H, halogen, and Cl-6 alkyl substituted with 0-2 R4d;
[0060] R4d, at each occurrence, is selected from OH, 0, halogen, NH2, NH-Cl-4 alkyl, and N(Ci-4 alkyl)z, [0061] R4b, at each occurrence, is selected from H, halogen, and Cl-6 alkyl substituted with 0-2 R4e;
[0062] R4e, at each occurrence, is selected from OH, 0, halogen, NH2, NH-Cl-4 alkyl, and N(Ci-4 alkyl)2;
[0063] R4o, at each occurrence, is selected from H, halogen, and Cl-6 alkyl substituted with 0-2 R4f;
[0064] R4f, at each occurrence, is selected from OH, 0, halogen, NH2, NH-Cl-4 alkyl, and N(Ci-4 alkyl)z, [0065] R5a, at each occurrence, is selected from H, halogen, CH3, and CH2CH3;
[0066] R5b, at each occurrence, is selected from H, halogen, CH3, and CH2CH3;
[0067] R5o, at each occurrence, is selected from H, halogen, CH3, and CH2CH3;
[0068] R5d, at each occurrence, is selected from H, halogen, CH3, and CH2CH3;
and, [0069] R5e, at each occurrence, is selected from H, halogen, CH3, and CH2CH3.
[0070] In another embodiment, the present invention provides a novel compound of formula I or a pharmaceutically acceptable salt thereof, wherein:
[0071] X is selected from 0, S, OCH2, and SCH2;
[0072] Xl is 0 or S;
[0073] Rl is selected from H, Cl_g alkyl, CZ_g alkenyl, aryl, 5-10 membered heteroaryl con-sisting of carbon atoms and 1-4 heteroatoms selected from 0, N, and S(O)o-2, C3-io cycloalkyl, and a 3-8 membered heterocycle consisting of carbon atoms and 1-3 heteroatoms selected from 0, N, and S(O)o_Z, wherein each Rl group is substituted with 0-4 Rla;
[0074] Rla, at each occurrence, is selected from OH substituted with 0-1 Rlb, SH substituted with 0-1 Rlb, S, 0, halogen, NH2 substituted with 0-2 Rlb, -CN, NOZ, Cl_6 alkyl substituted with 0-2 Rlb, C2_6 alkenyl substituted with 0-2 Rlb, C2_6 alkynyl substituted with 0-2 Rlb, aryl substituted with 0-2 Rlb, 5-10 membered heteroaryl substituted with 0-2 Rlb and consisting of carbon atoms and 1-4 heteroatoms selected from 0, N, and S(0)0-2, C3-io cycloalkyl substi-tuted with 0-2 Rlb, and a 3-8 membered heterocycle substituted with 0-2 Rlb and consisting of carbon atoms and 1-3 heteroatoms selected from 0, N, and S(0)0-2, [0075] Rlb, at each occurrence, is selected from OH substituted with 0-1 Rl , SH substituted with 0-1 Rl , S, 0, halogen, NH2 substituted with 0-2 Rl , -CN, NOZ, Cl_6 alkyl substituted with 0-2 Rl , C2_6 alkenyl substituted with 0-2 R' , aryl substituted with 0-2 R' , 5-10 mem-bered heteroaryl substituted with 0-2 Rl and consisting of carbon atoms and 1-4 heteroatoms selected from 0, N, and S(O)0-2, C3-io cycloalkyl substituted with 0-2 Rl , and a 3-8 mem-bered heterocycle substituted with 0-2 Rl and consisting of carbon atoms and 1-3 heteroa-toms selected from 0, N, and S(O)o_Z, [0076] Rl , at each occurrence, is selected from OH substituted with 0-1 Rld, SH substituted with 0-1 Rld, S, 0, halogen, NH2 substituted with 0-2 Rld, -CN, NOZ, Cl_6 alkyl substituted with 0-2 Rld, CZ-6 alkenyl substituted with 0-2 Rld, aryl substituted with 0-2 Rld, 5-10 mem-bered heteroaryl substituted with 0-2 Rld and consisting of carbon atoms and 1-4 heteroatoms selected from 0, N, and S(O)0-2, C3-io cycloalkyl substituted with 0-2 Rld, and a 3-8 mem-bered heterocycle substituted with 0-2 Rld and consisting of carbon atoms and 1-3 heteroa-toms selected from 0, N, and S(O)o-Z, [0077] Rld, at each occurrence, is selected from OH, SH, S, 0, halogen, NH2, -CN, NOZ, Cl-6 alkyl, CZ-6 alkenyl, aryl, CF3, and OCF3;
[0078] R 2 is selected from -C=C-RZa, -CH=CH-RZa substituted with 0-2 RZa, aryl substituted with 0-3 RZa, and 5-10 membered heteroaryl substituted with 0-3 R2a and consisting of carbon atoms and 1-4 heteroatoms selected from 0, N, and S(O)o-Z, [0079] R2a, at each occurrence, is selected from OH substituted with 0-1 R2b, SH substituted with 0-1 R 2b, S, 0, halogen, NH2 substituted with 0-2 R 2b, -CN, NOZ, Cl-6 alkyl substituted with 0-2 R 2b, CZ-6 alkenyl substituted with 0-2 RZb, aryl substituted with 0-2 RZb, 5-10 mem-bered heteroaryl substituted with 0-2 RZb and consisting of carbon atoms and 1-4 heteroatoms selected from 0, N, and S(O)o-2, C3-io cycloalkyl substituted with 0-2 R 2b, and a 3-8 mem-bered heterocycle substituted with 0-2 R 2b and consisting of carbon atoms and 1-3 heteroa-toms selected from 0, N, and S(O)o-Z, [0080] R2b, at each occurrence, is selected from OH substituted with 0-1 RZ , SH substituted with 0-1 R2o, S, 0, halogen, NH2 substituted with 0-2 RZ , -CN, NOZ, Cl-6 alkyl substituted with 0-2 RZ , CZ-6 alkenyl substituted with 0-2 RZ , aryl substituted with 0-2 RZ , 5-10 mem-bered heteroaryl substituted with 0-2 RZ and consisting of carbon atoms and 1-4 heteroatoms selected from 0, N, and S(O)0-2, C3-io cycloalkyl substituted with 0-2 RZ , and a 3-8 mem-bered heterocycle substituted with 0-2 RZ and consisting of carbon atoms and 1-3 heteroa-toms selected from 0, N, and S(O)o-Z, [0081] RZ , at each occurrence, is selected from OH substituted with 0-1 RZd, SH substituted with 0-1 RZd, S, 0, halogen, NH2 substituted with 0-2 R 2d, -CN, NOZ, Cl-6 alkyl substituted with 0-2 RZd, CZ-6 alkenyl substituted with 0-2 RZd, aryl substituted with 0-2 RZd, 5-10 mem-bered heteroaryl substituted with 0-2 RZd and consisting of carbon atoms and 1-4 heteroatoms selected from 0, N, and S(O)0-2, C3-io cycloalkyl substituted with 0-2 RZd, and a 3-8 mem-bered heterocycle substituted with 0-2 RZd and consisting of carbon atoms and 1-3 heteroa-toms selected from 0, N, and S(O)o-Z, [0082] RZd, at each occurrence, is selected from OH, SH, S, 0, halogen, NH2, -CN, NOZ, Cl-6 alkyl, C2-6 alkenyl, aryl, CF3, and OCF3;
[0083] R3 is selected from halogen and Cl-6 alkyl substituted with 0-2 R3a;
[0084] R3a, at each occurrence, is selected from OH, 0, S, halogen, C(O)NH2, C(O)NH-Cl-4 alkyl, and C(O)N(Ci-4 alkyl)z, [0085] alternatively, R3 and R5e combine to form a 5, 6, or 7 membered ring consisting of carbon atoms and 0-2 heteroatoms selected from 0, N, and S(O)0-2 and there are 0-2 ring dou-ble bonds in the bridging portion formed by R3 and Rse;
[0086] R4a, at each occurrence, is selected from H, halogen, and Cl-6 alkyl substituted with 0-2 R4d;
[0087] R4d, at each occurrence, is selected from OH, 0, halogen, NH2, NH-Cl-4 alkyl, and N(Ci-4 alkyl)z, [0088] R4b, at each occurrence, is selected from H, halogen, and Cl-6 alkyl substituted with 0-2 R4e;
[0089] R4e, at each occurrence, is selected from OH, 0, halogen, NH2, NH-Cl-4 alkyl, and N(Ci-4 alkyl)z, [0090] R4o, at each occurrence, is selected from H, halogen, and Cl-6 alkyl substituted with 0-2 R4f;
[0091] R4f, at each occurrence, is selected from OH, 0, halogen, NH2, NH-Cl-4 alkyl, and N(Ci-4 alkyl)z, [0092] R5a, at each occurrence, is selected from H, halogen, CH3, and CH2CH3;
[0093] R$b, at each occurrence, is selected from H, halogen, CH3, and CH2CH3;
[0094] R5o, at each occurrence, is selected from H, halogen, CH3, and CH2CH3;
[0095] R5d, at each occurrence, is selected from H, halogen, CH3, and CH2CH3;
and, [0096] R5e, at each occurrence, is selected from H, halogen, CH3, and CH2CH3.
[0097] In a embodiment, the present invention provides a novel compound of formula Ia:

4b OP, R4c R4a ~
Rsd Ri / RSe I

Rsb R5a O
O OH
Ia.
[0098] or a pharmaceutically acceptable salt thereof.
[0099] In another embodiment, the present invention provides a novel compound of formula II:
R2a II

R4b R4c I

R4a 1 Rsd / R5e Rl R5o \ R3 Rsb Rsa O
O OH
II
[00100] or a pharmaceutically acceptable salt thereof, wherein:
[00101] Rl is H, Cl_g alkyl, heteroaryl, and C3_10 cycloalkyl, wherein each Rl group is substi-tuted with 0-4 RIa;
[00102] Rla, at each occurrence, is selected from Cl-6 alkyl substituted with 0-3 Rlb; C2-6 al-kynyl substituted with 0-2 Rlb; aryl substituted with 0-2 Rlb, heteroaryl substituted with 0-2 Rlb, C3-10 cycloalkyl substituted with 0-2 Rlb, and a heterocycle substituted with 0-2 Rlb;
[00103] Rlb, at each occurrence, is selected from OH substituted with 0-1 Rl , SH substituted with 0-1 Rl , Cl, F, NH2 substituted with 0-2 Rl , -CN, NOZ, methanesulfonyl, Cl-4 alkyl sub-stituted with 0-3 Rl , CZ-4 alkenyl substituted with 0-2 Rl , aryl substituted with 0-2 Rl , het-eroaryl substituted with 0-2 Rl , C3-6 cycloalkyl substituted with 0-2 Rl , and a heterocycle substituted with 0-2 Rl ;
[00104] Rl , at each occurrence, is selected from OH, SH, Cl, F, NH2, -CN, NOZ, Cl-4 alkyl, and C2-4 alkenyl, aryl substituted with 0-2 Rld, heteroaryl substituted with 0-2 Rld and, C3-6 cycloalkyl substituted with 0-2 Rld, and a heterocycle substituted with 0-2 Rla;
[00105] Rld, at each occurrence, is selected from OH, SH, Cl, F, NH2, -CN, NOZ, Cl-4 alkyl, and CZ-4 alkenyl;
[00106] RZa is selected from Cl-6 alkyl substituted with 0-2 R2b, aryl substituted with 0-2 RZb, and heteroaryl substituted with 0-2 RZb;
[00107] R2b, at each occurrence, is selected from OH substituted with 0-1 RZ , SH substituted with 0-1 R 2c, Cl, F, NH2 substituted with 0-2 R 2c, -CN, NOZ, methanesulfonyl, Cl-4 alkyl sub-stituted with 0-2 RZ , CZ-4 alkenyl substituted with 0-2 RZ , aryl substituted with 0-2 R 2c, het-eroaryl substituted with 0-2 RZ , C3-6 cycloalkyl substituted with 0-2 RZ , and a heterocycle substituted with 0-2 R2 ;
[00108] RZ , at each occurrence, is selected from OH, SH, Cl, F, NH2, -CN, NOZ, Cl-4 alkyl, CZ-4 alkenyl, aryl substituted with 0-2 RZd, and heteroaryl substituted with 0-2 RZd;
[00109] RZd, at each occurrence, is selected from OH, SH, Cl, F, NH2, -CN, NOZ, Cl-4 alkyl, and C2-4 alkenyl;
[00110] R3 is selected from Cl, F, CH3, and CH2CH3;
[00111] alternatively, R3 and R5e combine to form a 5, 6, or 7 membered ring consisting of carbon atoms and 0-2 heteroatoms selected from 0, N, and S(O)0-2 and there are 0-2 ring dou-ble bonds in the bridging portion formed by R3 and Rse;
[00112] R4a, at each occurrence, is selected from H, Cl, F, and CH3;
[00113] R4b, at each occurrence, is selected from H, Cl, F, and CH3;
[00114] R4o, at each occurrence, is selected from H, Cl, F, and CH3;
[00115] R5a, at each occurrence, is selected from H, Cl, F, and CH3;
[00116] R5b, at each occurrence, is selected from H, Cl, F, and CH3;
[00117] R5o, at each occurrence, is selected from H, Cl, F, and CH3;
[00118] R5d, at each occurrence, is selected from H, Cl, F, and CH3; and, [00119] R5e, at each occurrence, is selected from H, Cl, F, and CH3.
[00120] In another embodiment, the present invention provides a novel compound of formula II or a pharmaceutically acceptable salt thereof, wherein:
[00121] Rl is H, Cl-g alkyl, 5-10 membered heteroaryl consisting of carbon atoms and 1-4 heteroatoms selected from 0, N, and SOO-2, and C3-10 cycloalkyl, wherein each Rl group is substituted with 0-4 Rla;
[00122] Rla, at each occurrence, is selected from Cl-6 alkyl substituted with 0-3 Rlb; CZ-6 al-kynyl substituted with 0-2 Rlb; aryl substituted with 0-2 Rlb, 5-10 membered heteroaryl sub-stituted with 0-2 Rlb and consisting of carbon atoms and 1-4 heteroatoms selected from 0, N, and SOO-2, C3-10 cycloalkyl substituted with 0-2 Rlb, and a 3-8 membered heterocycle substi-tuted with 0-2 Rlb and consisting of carbon atoms and 1-2 heteroatoms selected from 0, N, and S(O)o-z, [00123] R'b, at each occurrence, is selected from OH substituted with 0-1 Rl , SH substituted with 0-1 Rl , Cl, F, NH2 substituted with 0-2 Rl , -CN, NOZ, methanesulfonyl, Cl-4 alkyl sub-stituted with 0-3 Rl , CZ-4 alkenyl substituted with 0-2 Rl , aryl substituted with 0-2 Rl , 5-10 membered heteroaryl substituted with 0-2 Rl and consisting of carbon atoms and 1-4 heteroa-toms selected from 0, N, and SOO-2, C3-6 cycloalkyl substituted with 0-2 Rl , and a 3-6 membered heterocycle substituted with 0-2 R' and consisting of carbon atoms and 1-2 het-eroatoms selected from 0, N, and S(O)0-2, [00124] Rl , at each occurrence, is selected from OH, SH, Cl, F, NH2, -CN, NOZ, Cl-4 alkyl, and C2-4 alkenyl, aryl substituted with 0-2 Rld, 5-10 membered heteroaryl substituted with 0-2 Rld and consisting of carbon atoms and 1-4 heteroatoms selected from 0, N, and SOO-2, C3-6 cycloalkyl substituted with 0-2 Rld, and a 3-6 membered heterocycle substituted with 0-2 Rla and consisting of carbon atoms and 1-2 heteroatoms selected from 0, N, and S(O)o-Z, [00125] Rld, at each occurrence, is selected from OH, SH, Cl, F, NH2, -CN, NOZ, Cl-4 alkyl, and C2-4 alkenyl;
[00126] R 2a is selected from Cl-6 alkyl substituted with 0-2 R 2b, aryl substituted with 0-2 R 2b, and 5-10 membered heteroaryl substituted with 0-2 RZb and consisting of carbon atoms and 1-4 heteroatoms selected from 0, N, and S(O)o-Z, [00127] R2b, at each occurrence, is selected from OH substituted with 0-1 RZ , SH substituted with 0-1 R 2c, Cl, F, NH2 substituted with 0-2 R 2c, -CN, NOZ, methanesulfonyl, Cl-4 alkyl sub-stituted with 0-2 RZ , CZ-4 alkenyl substituted with 0-2 RZ , aryl substituted with 0-2 RZ , 5-10 membered heteroaryl substituted with 0-2 RZ and consisting of carbon atoms and 1-4 heteroa-toms selected from 0, N, and S(O)o-Z, C3-6 cycloalkyl substituted with 0-2 RZ
, and a 3-6 membered heterocycle substituted with 0-2 RZ and consisting of carbon atoms and 1-2 het-eroatoms selected from 0, N, and S(O)0-2, [00128] RZ , at each occurrence, is selected from OH, SH, Cl, F, NH2, -CN, NOZ, Cl-4 alkyl, CZ-4 alkenyl, aryl substituted with 0-2 R2d, and 5-10 membered heteroaryl substituted with 0-2 RZd and consisting of carbon atoms and 1-4 heteroatoms selected from 0, N, and S(O)0-2, [00129] RZd, at each occurrence, is selected from OH, SH, Cl, F, NH2, -CN, NOZ, Cl-4 alkyl, and CZ-4 alkenyl;
[00130] R3 is selected from Cl, F, CH3, and CH2CH3;
[00131] alternatively, R3 and R5e combine to form a 5, 6, or 7 membered ring consisting of carbon atoms and 0-2 heteroatoms selected from 0, N, and S(O)0-2 and there are 0-2 ring dou-ble bonds in the bridging portion formed by R3 and Rse;
[00132] R4a, at each occurrence, is selected from H, Cl, F, and CH3;
[00133] R4b, at each occurrence, is selected from H, Cl, F, and CH3;
[00134] R4o, at each occurrence, is selected from H, Cl, F, and CH3;
[00135] R5a, at each occurrence, is selected from H, Cl, F, and CH3;
[00136] R5b, at each occurrence, is selected from H, Cl, F, and CH3;
[00137] R5o, at each occurrence, is selected from H, Cl, F, and CH3;
[00138] R5d, at each occurrence, is selected from H, Cl, F, and CH3; and, [00139] R5e, at each occurrence, is selected from H, Cl, F, and CH3.
[00140] In another embodiment, the present invention provides a novel compound of formula Ilor a pharmaceutically acceptable salt thereof, wherein:
[00141] R' is H or Ci-4 alkyl substituted with 1-4 Rla;
[00142] Rla, at each occurrence, is selected from aryl substituted with 0-2 Rlb, 5-10 mem-bered heteroaryl substituted with 0-2 Rlb and consisting of carbon atoms and 1-4 heteroatoms selected from 0, N, and S(O)0-2, C3-io cycloalkyl substituted with 0-2 Rlb, and a 3-8 mem-bered heterocycle substituted with 0-2 Rlb and consisting of carbon atoms and 1-2 heteroa-toms selected from 0, N, and S(O)o-Z, [00143] Rlb, at each occurrence, is selected from OH substituted with 0-1 Rl , SH substituted with 0-1 Rl , Cl, F, NH2 substituted with 0-2 Rl , -CN, NOZ, Cl-4 alkyl substituted with 0-2 Rl , C2-4 alkenyl substituted with 0-2 Rl , aryl substituted with 0-2 Rl , 5-10 membered het-eroaryl substituted with 0-2 Rl and consisting of carbon atoms and 1-4 heteroatoms selected from 0, N, and S(O)o-Z, C3-6 cycloalkyl substituted with 0-2 Rl , and a 3-6 membered hetero-cycle substituted with 0-2 Rl and consisting of carbon atoms and 1-2 heteroatoms selected from 0, N, and S(O)o-Z, [00144] Rl , at each occurrence, is selected from OH, SH, Cl, F, NH2, -CN, NOZ, Cl-4 alkyl, and CZ-4 alkenyl, aryl substituted with 0-2 Rld, 5-10 membered heteroaryl substituted with 0-2 R'd and consisting of carbon atoms and 1-4 heteroatoms selected from 0, N, and S(O)0-2, C3-6 cycloalkyl substituted with 0-2 Rld, and a 3-6 membered heterocycle substituted with 0-2 Rla and consisting of carbon atoms and 1-2 heteroatoms selected from 0, N, and S(O)o-Z, [00145] Rld, at each occurrence, is selected from OH, SH, Cl, F, NH2, -CN, NOZ, Cl-4 alkyl, and C2-4 alkenyl;
[00146] R2a is selected from Cl-6 alkyl substituted with 0-2 R2b, aryl substituted with 0-2 RZb, and 5-10 membered heteroaryl substituted with 0-2 R 2b and consisting of carbon atoms and 1-4 heteroatoms selected from 0, N, and S(O)o-Z, [00147] R2b, at each occurrence, is selected from OH substituted with 0-1 RZ , SH substituted with 0-1 R 2c, Cl, F, NH2 substituted with 0-2 R 2c, -CN, NOZ, Cl-4 alkyl substituted with 0-2 RZ , C2-4 alkenyl substituted with 0-2 RZ , aryl substituted with 0-2 RZ , 5-10 membered het-eroaryl substituted with 0-2 RZ and consisting of carbon atoms and 1-4 heteroatoms selected from 0, N, and S(O)o-2, C3-6 cycloalkyl substituted with 0-2 R2o, and a 3-6 membered hetero-cycle substituted with 0-2 R2o and consisting of carbon atoms and 1-2 heteroatoms selected from 0, N, and S(O)0-2, [00148] R2o, at each occurrence, is selected from OH, SH, Cl, F, NH2, -CN, NO2, Cl-~ alkyl, C2-4 alkenyl, aryl substituted with 0-2 R2d, and 5-10 membered heteroaryl substituted with 0-2 R2d and consisting of carbon atoms and 1-4 heteroatoms selected from 0, N, and S(O)0-2, [00149] R2d, at each occurrence, is selected from OH, SH, Cl, F, NH2, -CN, NO2, Cl-4 alkyl, and C2-4 alkenyl;
[00150] R3 is selected from Cl, F, CH3, and CH2CH3;
[00151] alternatively, R3 and R5e combine to form a 5, 6, or 7 membered ring consisting of carbon atoms and 0-2 heteroatoms selected from 0, N, and S(0)0-2 and there are 0-2 ring dou-ble bonds in the bridging portion formed by R3 and Rse;
[00152] R4a, at each occurrence, is selected from H, Cl, F, and CH3;
[00153] R4b, at each occurrence, is selected from H, Cl, F, and CH3;
[00154] R4o, at each occurrence, is selected from H, Cl, F, and CH3;
[00155] R5a, at each occurrence, is selected from H, Cl, F, and CH3;
[00156] R5b, at each occurrence, is selected from H, Cl, F, and CH3;
[00157] R5o, at each occurrence, is selected from H, Cl, F, and CH3;
[00158] R5d, at each occurrence, is selected from H, Cl, F, and CH3; and, [00159] R5e, at each occurrence, is selected from H, Cl, F, and CH3.
[00160] In another embodiment, the present invention provides a novel compound of formula IIa:
R2a X

O
0 RSe IOH R3 / Xl IIa [00161] or a pharmaceutically acceptable salt thereof, wherein:
[00162] Rl is H, Cl-6 alkyl, aryl, heteroaryl, and C3_10 cycloalkyl, wherein each Rl group is substituted with 0-1 Rla;
[00163] Rla, at each occurrence, is selected from C1-6 alkyl substituted with 0-3 Rlb; C2-6 al-kynyl substituted with 0-2 Rlb; aryl substituted with 0-2 Rlb, heteroaryl substituted with 0-2 Rlb and, C5-6 cycloalkyl substituted with 0-2 Rlb, and a heterocycle substituted with 0-2 Rlb and;
[00164] Rlb, at each occurrence, is selected from OH, SH, Cl, F, NHZ, -CN, NOZ, methanesul-fonyl, Cl-4 alkyl substituted with 0-3 Rl , CZ-4 alkenyl substituted with 0-2 Rl , aryl substituted with 0-2 Rl , heteroaryl substituted with 0-2 Rl , C$-6 cycloalkyl substituted with 0-2 Rl , and a heterocycle substituted with 0-2 Rl ;
[00165] Rl , at each occurrence, is selected from OH, SH, Cl, F, NHZ, -CN, NOZ, Cl-4 alkyl, and CZ-4 alkenyl, aryl substituted with 0-2 Rld, heteroaryl substituted with 0-2 Rld, Cs_6 cycloalkyl substituted with 0-2 Rld, and a heterocycle substituted with 0-2 Rla;
[00166] Rld, at each occurrence, is selected from OH, SH, Cl, F, NHZ, -CN, NOZ, Cl-4 alkyl, and CZ-4 alkenyl;
[00167] R 2a is selected from Cl-6 alkyl substituted with 0-2 R 2b, aryl substituted with 0-2 R 2b, and heteroaryl substituted with 0-2 R2b;
[00168] R2b, at each occurrence, is selected from OH substituted with 0-1 R2c, SH, Cl, F, NHZ, -CN, NOZ, methanesulfonyl, Cl-4 alkyl, CZ-4 alkenyl, aryl, heteroaryl, C5-6 cycloalkyl, and a heterocycle;
[00169] RZ , at each occurrence, is Cl-4 alkyl;
[00170] R3 is selected from Cl, F, CH3, and CH2CH3; and, [00171] alternatively, R3 and R5e combine to form a 5, 6, or 7 membered ring consisting of carbon atoms and 0-2 heteroatoms selected from 0, N, and S(O)0-2 and there are 0-2 ring dou-ble bonds in the bridging portion formed by R3 and Rse [00172] In another embodiment, the present invention provides a novel compound of formula IIa or a pharmaceutically acceptable salt thereof, wherein:
[00173] Rl is H, Cl-6 alkyl, aryl, 5-6 membered heteroaryl consisting of carbon atoms and 1-4 heteroatoms selected from 0, N, and S(O)0-2, and C3-10 cycloalkyl, wherein each Rl group is substituted with 0-1 Rla;
[00174] Rla, at each occurrence, is selected from Cl-6 alkyl substituted with 0-3 Rlb; C2-6 al-kynyl substituted with 0-2 Rlb; aryl substituted with 0-2 Rlb, 5-6 membered heteroaryl substi-tuted with 0-2 Rlb and consisting of carbon atoms and 1-2 heteroatoms selected from 0, N, and S(O)o-Z, C5-6 cycloalkyl substituted with 0-2 Rlb, and a 5-6 membered heterocycle substi-tuted with 0-2 Rlb and consisting of carbon atoms and 1-2 heteroatoms selected from 0, N, and S(O)o-z, [00175] Rlb, at each occurrence, is selected from OH, SH, Cl, F, NH2, -CN, NOZ, methanesul-fonyl, Cl-4 alkyl substituted with 0-3 Rl , CZ-4 alkenyl substituted with 0-2 Rl , aryl substituted with 0-2 Rl , 5-6 membered heteroaryl substituted with 0-2 Rl and consisting of carbon at-oms and 1-2 heteroatoms selected from 0, N, and S(O)o-Z, C5-6 cycloalkyl substituted with 0-2 Rl , and a 5-6 membered heterocycle substituted with 0-2 Rl and consisting of carbon atoms and 1-2 heteroatoms selected from 0, N, and S(O)0_2, [00176] Rl , at each occurrence, is selected from OH, SH, Cl, F, NH2, -CN, NOZ, Cl-4 alkyl, and CZ-4 alkenyl, aryl substituted with 0-2 Rld, 5-6 membered heteroaryl substituted with 0-2 Rld and consisting of carbon atoms and 1-2 heteroatoms selected from 0, N, and S(O)0-2, C5-6 cycloalkyl substituted with 0-2 R'd, and a 5-6 membered heterocycle substituted with 0-2 Rla and consisting of carbon atoms and 1-2 heteroatoms selected from 0, N, and S(O)o-Z, [00177] Rld, at each occurrence, is selected from OH, SH, Cl, F, NH2, -CN, NOZ, Cl-4 alkyl, and C2-4 alkenyl;
[00178] R 2a is selected from Cl-6 alkyl substituted with 0-2 RZb, aryl substituted with 0-2 R 2b, and 5-6 membered heteroaryl substituted with 0-2 R2b and consisting of carbon atoms and 1-2 heteroatoms selected from 0, N, and S(O)o-Z, [00179] R2b, at each occurrence, is selected from OH substituted with 0-1 RZ , SH, Cl, F, NH2, -CN, NOZ, methanesulfonyl, Cl-4 alkyl, CZ-4 alkenyl, aryl, 5-6 membered heteroaryl con-sisting of carbon atoms and 1-2 heteroatoms selected from 0, N, and S(O)0-2õ
C5-6 cycloalkyl, and a 5-6 membered heterocycle and consisting of carbon atoms and 1-2 heteroatoms selected from 0, N, and S(O)o-Z, [00180] RZ , at each occurrence, is Cl-4 alkyl;
[00181] R3 is selected from Cl, F, CH3, and CH2CH3; and, [00182] alternatively, R3 and R5e combine to form a 5, 6, or 7 membered ring consisting of carbon atoms and 0-2 heteroatoms selected from 0, N, and S(O)0-2 and there are 0-2 ring dou-ble bonds in the bridging portion formed by R3 and Rse [00183] In another embodiment, the present invention provides a novel compound of formula IIa or a pharmaceutically acceptable salt thereof, wherein:
[00184] Rl is H or Cl-4 alkyl substituted with 1 Rla;
[00185] Rla, at each occurrence, is selected from aryl substituted with 0-2 Rlb, 5-6 membered heteroaryl substituted with 0-2 Rlb and consisting of carbon atoms and 1-2 heteroatoms se-lected from 0, N, and S(O)o-Z, C5-6 cycloalkyl substituted with 0-2 Rlb, and a 5-6 membered heterocycle substituted with 0-2 Rlb and consisting of carbon atoms and 1-2 heteroatoms se-lected from 0, N, and S(O)0-2, [00186] Rlb, at each occurrence, is selected from OH, SH, Cl, F, NH2, -CN, NOZ, Cl-4 alkyl substituted with 0-2 Rl , CZ-4 alkenyl substituted with 0-2 Rl , aryl substituted with 0-2 Rl , 5-6 membered heteroaryl substituted with 0-2 Rl and consisting of carbon atoms and 1-2 het-eroatoms selected from 0, N, and S(O)o-z, C5-6 cycloalkyl substituted with 0-2 Rl , and a 5-6 membered heterocycle substituted with 0-2 R' and consisting of carbon atoms and 1-2 het-eroatoms selected from 0, N, and S(O)0-2, [00187] Rl , at each occurrence, is selected from OH, SH, Cl, F, NH2, -CN, NOZ, Cl-4 alkyl, and C2-4 alkenyl, aryl substituted with 0-2 Rld, 5-6 membered heteroaryl substituted with 0-2 Rld and consisting of carbon atoms and 1-2 heteroatoms selected from 0, N, and S(O)o-2, C5-6 cycloalkyl substituted with 0-2 R'd, and a 5-6 membered heterocycle substituted with 0-2 R'a and consisting of carbon atoms and 1-2 heteroatoms selected from 0, N, and S(O)o-Z, [00188] Rld, at each occurrence, is selected from OH, SH, Cl, F, NH2, -CN, NOZ, Cl_4 alkyl, and C2-4 alkenyl;
[00189] R 2a is selected from Cl-6 alkyl substituted with 0-2 RZb, aryl substituted with 0-2 R 2b, and 5-6 membered heteroaryl substituted with 0-2 R 2b and consisting of carbon atoms and 1-2 heteroatoms selected from 0, N, and S(O)o-Z, [00190] RZb, at each occurrence, is selected from OH, SH, Cl, F, NH2, -CN, NOZ, Cl-4 alkyl, CZ-4 alkenyl, aryl, 5-6 membered heteroaryl consisting of carbon atoms and 1-2 heteroatoms selected from 0, N, and S(O)0-2õ C5-6 cycloalkyl, and a 5-6 membered heterocycle and con-sisting of carbon atoms and 1-2 heteroatoms selected from 0, N, and S(0)0-2, [00191] R3 is selected from Cl, F, CH3, and CH2CH3; and, [00192] alternatively, R3 and R5e combine to form a 5, 6, or 7 membered ring consisting of carbon atoms and 0-2 heteroatoms selected from 0, N, and S(O)0-2 and there are 0-2 ring dou-ble bonds in the bridging portion formed by R3 and Rse [00193] In another embodiment, the present invention provides a novel compound of formula IIa or a pharmaceutically acceptable salt thereof, wherein:
[00194] Rl is H, Cl-6 alkyl, aryl, heteroaryl, C3-10 cycloalkyl, wherein each Rl group is substi-tuted with 0-1 R";
[00195] Rla, at each occurrence, is selected from Cl-4 alkyl substituted with 0-3 Rlb; CZ-6 al-kynyl substituted with 0-1 Rib, aryl substituted with 0-1 Rlb, heteroaryl substituted with 0-1 Rlb, C5-6 cycloalkyl substituted with 0-1 Rlb, and a heterocycle substituted with 0-1 Rlb;
[00196] Rlb, at each occurrence, is selected from Cl, F, methanesulfonyl, and Cl-4 alkyl sub-stituted with 0-3 R", and;
[00197] R' , at each occurrence, is selected from Cl, F and a heterocycle ;
[00198] R 2a is selected from Cl-6 alkyl substituted with 0-2 RZb, aryl substituted with 0-2 R 2b, and heteroaryl substituted with 0-2 R2b;
[00199] RZb, at each occurrence, is selected from OH optionally substituted with Cl-4 alkyl, Cl, F, methanesulfonyl, aryl, heteroaryl, C5-6 cycloalkyl, and a heterocycle ;
[00200] R3 is selected from Cl, F, CH3, and CH2CH3..
[00201] In another embodiment, the present invention provides a novel compound of formula IIa or a pharmaceutically acceptable salt thereof, wherein:
[00202] Rl is H, Cl-6 alkyl, aryl, 5-6 membered heteroaryl consisting of carbon atoms and 1-2 heteroatoms selected from 0 and N; C3-10 cycloalkyl, wherein each Rl group is substituted with 0-1 Rla;
[00203] Rla, at each occurrence, is selected from Cl_4 alkyl substituted with 0-3 Rlb; C2_6 al-kynyl substituted with 0-1 Rlb aryl substituted with 0-1 Rlb, 5-6 membered heteroaryl substi-tuted with 0-1 Rlb and consisting of carbon atoms and 1-2 heteroatoms selected from 0 and N, C5_6 cycloalkyl substituted with 0-1 Rlb, and a 5-6 membered heterocycle substituted with 0-1 Rib;
[00204] Rlb, at each occurrence, is selected from Cl, F, methanesulfonyl, and Cl_4 alkyl sub-stituted with 0-3 R", and;
[00205] Rl , at each occurrence, is selected from Cl, F and a 5-6 membered heterocycle con-sisting of carbon atoms and 1-2 heteroatoms selected from 0 and N;
[00206] R2a is selected from Cl_6 alkyl substituted with 0-2 R2b, aryl substituted with 0-2 R2b, and 5-6 membered heteroaryl substituted with 0-2 R2b and consisting of carbon atoms and 1-2 heteroatoms selected from 0 and N;
[00207] R2b, at each occurrence, is selected from OH optionally substituted with Cl_4 alkyl, Cl, F, methanesulfonyl, aryl, 5-6 membered heteroaryl consisting of carbon atoms and 1-2 heteroatoms selected from 0 and N, C5_6 cycloalkyl, and a 5-6 membered heterocycle con-sisting of carbon atoms and 1-2 heteroatoms selected from 0 and N;
[00208] R3 is selected from Cl, F, CH3, and CH2CH3.
[00209] In another embodiment, the present invention provides a novel compound of formula IIb R2a X

O
O
OH R3 ~ Xl IIb or a pharmaceutically acceptable salt thereof.
[00210] In another embodiment, the present invention provides a novel compound of formula IIb, wherein Rl is Cl_6 alkyl.
[00211] In another embodiment, the present invention provides a novel compound of formula IIb, wherein R 2a is Cl_4 alkyl substituted with a heterocycle.
[00212] In another embodiment, the present invention provides a novel compound of formula IIb, wherein R 2a is Cl_4 alkyl substituted with morpholinyl.
[00213] In another embodiment, the present invention provides a novel compound of formula IIb, wherein R3 is selected from Cl and CH3.
[00214] In another embodiment, the present invention provides a novel compound of formula IIb, wherein X is selected from S and SCH2 [00215] In another embodiment, the present invention provides a novel compound of formula IIb, wherein X is S.
[00216] In another embodiment, the present invention provides a novel compound of formula IIb, wherein X is SCH2.
[00217] In another embodiment, the present invention provides a novel compound of formula IIb, wherein Xl is O.
[00218] In another embodiment, the present invention provides a novel compound of formula IIb, wherein Xl is S.
[00219] In another embodiment, the present invention provides a novel compound of formula IIb, wherein: Rl is aryl substituted with 0-1 Rla; wherein Rla, at each occurrence, is selected from OH, SH, Cl, F, NHZ, -CN, NOZ, Cl_4 alkyl.
[00220] In another embodiment, the present invention provides a novel compound of formula IIb, wherein Rl is Cl_6 alkyl substituted with Rla; and wherein Rla is aryl substituted with 0-1 Rlb; and wherein Rlb is selected from OH, SH, Cl, F, NHZ, -CN, NOZ, Cl_4 alkyl.
[00221] In another embodiment, the present invention provides a novel compound of formula IIb, wherein: Rl is Cl_6 alkyl substituted with R'a, wherein R'a is heteroaryl substituted with 0-1 Rlb; and wherein Rlb is selected from OH, SH, Cl, F, NHZ, -CN, NOZ, Cl_4 alkyl.
[00222] In another embodiment, the present invention provides a novel compound of formula IIb, wherein: Rl is Cl_6 alkyl substituted with Rla, wherein Rla is heterocyclyl substituted with 0-1 Rlb; and wherein Rlb is selected from OH, SH, Cl, F, NHZ, -CN, NOZ, Cl_4 alkyl.
[00223] In another embodiment, the present invention provides a novel compound of formula Ilb, wherein: Rl is Cl_6 alkyl substituted with Rla, wherein Rla is C5_6 cycloalkyl substituted with 0-2 Rlb; and wherein Rlb is selected from OH, SH, Cl, F, NH2, -CN, NOZ, Cl_4 alkyl.
[00224] In another embodiment, the present invention provides a novel compound of formula Ilb, wherein: R 2a is aryl substituted with RZb; wherein R 2b is selected from OH, SH, Cl, F, NH2, -CN, NOZ, Cl_4 alkyl.
[00225] In another embodiment, the present invention provides a novel compound of formula Ilb, wherein: R 2a is Cl_6 alkyl substituted with RZb; wherein R 2b is selected from aryl substi-tuted with RZ ; and wherein RZ is selected from OH, SH, Cl, F, NH2, -CN, NOZ, Cl_4 alkyl.
[00226] In another embodiment, the present invention provides a novel compound of formula Ilb, wherein: R 2a is Cl_6 alkyl substituted with RZb; wherein R 2b is selected from heteroaryl substituted with RZ ; and wherein RZ is selected from OH, SH, Cl, F, NH2, -CN, NOZ, Cl_4 alkyl.
[00227] In another embodiment, the present invention provides a novel compound selected from:
[00228] {2-Chloro-4-[3-(4-chloro-phenylethynyl)-5-(3-piperidin-1-yl-propoxy)-phenyl-sulfanyl] -phenoxy } -acetic acid;
[00229] { 2-Methyl-4-[3-(3-morpholin-4-yl-propoxy)-5-phenylethynyl-phenylsulfanyl]-phenoxy } -acetic acid;
[00230] { 2-Chloro-4-[3-(4-chloro-phenylethynyl)-5-(3-morpholin-4-yl-propoxy)-phenyl-sulfanyl] -phenoxy } -acetic acid;
[00231] { 2-Chloro-4-[3-(4-chloro-phenylethynyl)-5-(4-morpholin-4-ylmethyl-benzyloxy)-phenylsulfanyl] -phenoxy } -acetic acid;
[00232] {2-Chloro-4-[3-(4-chloro-phenylethynyl)-5-(1-methyl-piperidin-4-ylmethoxy)-phenylsulfanyl]-phenoxy } -acetic acid;
[00233] {2-Methyl-4-[3-(3-morpholin-4-yl-propoxy)-5-(3-phenyl-prop-1-ynyl)-phenyl-sulfanyl] -phenoxy } -acetic acid;
[00234] {4-[3-(4-Fluoro-benzyloxy)-5-(3-morpholin-4-yl-prop-1-ynyl)-phenylsulfanyl]-2-methyl-phenoxy } -acetic acid;
[00235] {4-[3-Cyclohexylmethoxy-5-(3-morpholin-4-yl-prop-1-ynyl)-phenylsulfanyl]-2-methyl-phenoxy } -acetic acid;
[00236] {4-[3-Isobutoxy-5-(3-morpholin-4-yl-prop-1-ynyl)-phenylsulfanyl]-2-methyl-phenoxy } -acetic acid;
[00237] {4-[3-(4-Chloro-benzyloxy)-5-(3-morpholin-4-yl-prop-1-ynyl)-phenylsulfanyl]-2-methyl-phenoxy } -acetic acid;
[00238] {2-Chloro-4-[3-(4-chloro-phenylethynyl)-5-hydroxy-phenylsulfanyl]-phenoxy}-acetic acid;
[00239] {4-[3-But-2-ynyloxy-5-(3-morpholin-4-yl-prop-1-ynyl)-phenylsulfanyl]-2-methyl-phenoxy } -acetic acid;
[00240] { 2-Methyl-4-[3-(2-morpholin-4-yl-ethoxy)-5-phenylethynyl-phenylsulfanyl]-phenoxy } -acetic acid;
[00241] {2-Chloro-4-[3-(3-methoxy-prop-1-ynyl)-5-(3-morpholin-4-yl-propoxy)-phenyl-sulfanyl] -phenoxy } -acetic acid;
[00242] {2-Chloro-4-[3-(3-morpholin-4-yl-propoxy)-5-pent-l-ynyl-phenylsulfanyl]-phenoxy } -acetic acid;
[00243] {2-Methyl-4-[3-(3-morpholin-4-yl-propoxy)-5-(3-phenyl-prop-1-ynyl)-benzyl-sulfanyl] -phenoxy } -acetic acid;
[00244] {4-[3-(4-Fluoro-benzyloxy)-5-(3-morpholin-4-yl-prop-1yny1)-benzylsulfanyl]-2-methyl-phenoxy}-acetic acid; and, [00245] {2-Methyl-4-[3-(3-morpholin-4-yl-ethoxy)-5-(3-phenyl-prop-1-ynyl)-benzyl-sulfanyl] -phenoxy } -acetic acid;
[00246] or a pharmaceutically acceptable salt thereof.
[00247] In another embodiment, the present invention provides a novel compound selected from:
[00248] {4-[3-Cyclohexylmethoxy-5-(4-methanesulfonyl-phenylethynyl)-phenylsulfanyl]-2-methyl-phenoxy } -acetic acid;
[00249] {4-[3-Cyclopentylmethoxy-5-(4-methanesulfonyl-phenylethynyl)-phenylsulfanyl]-2-methyl-phenoxy } -acetic acid;
[00250] {4-[3-Isobutoxy-5-(4-methanesulfonyl-phenylethynyl)-phenylsulfanyl]-2-methyl-phenoxy}-acetic acid ;
[00251] {4-[3-[2-(4-Chloro-phenyl)-ethoxy]-5-(4-methanesulfonyl-phenylethynyl)-phenyl-sulfanyl] -2-methyl-phenoxy } -acetic acid;
[00252] {4-[3-[2-(4-Chloro-phenyl)-ethoxy]-5-(3-morpholin-4-yl-prop-1-ynyl)-phenyl-sulfanyl] -2-methyl-phenoxy } -acetic acid;
[00253] {4-[3-[2-(4-Chloro-phenyl)-ethoxy]-5-(4-hydroxymethyl-phenylethynyl)-phenyl-sulfanyl] -2-methyl-phenoxy } -acetic acid;
[00254] {4-[3-(2-Ethyl-butoxy)-5-phenylethynyl-phenylsulfanyl]-2-methyl-phenoxy}-acetic acid;
[00255] [4-(3-Cyclopentyloxy-5-phenylethynyl-phenylsulfanyl)-2-methyl-phenoxy]-acetic acid;
[00256] {4-[3-(4-Fluoro-phenylethynyl)-5-(4-methanesulfonyl-benzyloxy)-phenylsulfanyl]-2-methyl-phenoxy } -acetic acid;
[00257] [4-(3-Cyclopentylmethoxy-5-phenylethynyl-phenylsulfanyl)-2-methyl-phenoxy]-acetic acid;
[00258] {4-[3-(2-Cyclohexyl-ethoxy)-5-phenylethynyl-phenylsulfanyl]-2-methyl-phenoxy}-acetic acid;
[00259] {4-[3-(2-Ethyl-butoxy)-5-(3-morpholin-4-yl-prop-1-ynyl)-phenylsulfanyl]-2-methyl-phenoxy } -acetic acid;
[00260] {4-[3-Cyclopentyloxy-5-(3-morpholin-4-yl-prop-1-ynyl)-phenylsulfanyl]-2-methyl-phenoxy } -acetic acid;
[00261] {4-[3-(2-Cyclohexyl-ethoxy)-5-(3-morpholin-4-yl-prop-1-ynyl)-phenylsulfanyl]-2-methyl-phenoxy } -acetic acid;
[00262] {4-[3-Cyclopentylmethoxy-5-(3-morpholin-4-yl-prop-1-ynyl)-phenylsulfanyl]-2-methyl-phenoxy } -acetic acid;
[00263] {4-[3-Cyclopentylmethoxy-5-(3-morpholin-4-yl-prop-1-ynyl)-phenylsulfanyl]-2-methyl-phenoxy } -acetic;
[00264] {4-[3-Isobutoxy-5-(3-morpholin-4-yl-prop-1-ynyl)-benzylsulfanyl]-2-methyl-phenoxy } -acetic acid;
[00265] [4-(3-Isobutoxy-5-phenylethynyl-benzylsulfanyl)-2-methyl-phenoxy]-acetic acid;
[00266] {4-[3-Isobutoxy-5-(4-methanesulfonyl-phenylethynyl)-benzylsulfanyl]-2-methyl-phenoxy } -acetic acid;
[00267] { 4-[3-(4-Methanesulfonyl-phenylethynyl)-5-(5-trifluoromethyl-pyridin-2-yloxy)-phenylsulfanyl] -2-methyl-phenoxy } -acetic acid;
[00268] {4-[3-(4-Methanesulfonyl-phenylethynyl)-5-(3-trifluoromethyl-pyridin-2-yloxy)-phenylsulfanyl] -2-methyl-phenoxy } -acetic acid;
[00269] {2-Methyl-4-[3-(3-morpholin-4-yl-prop-1-ynyl)-5-(3-trifluoromethyl-pyridin-2-yloxy)-phenylsulfanyl]-phenoxy}-acetic acid;
[00270] {2-Methyl-4-[3-(3-morpholin-4-yl-prop-1-ynyl)-5-(5-trifluoromethyl-pyridin-2-yloxy)-phenylsulfanyl]-phenoxy}-acetic acid;
[00271] {2-Methyl-4-[3-(3-morpholin-4-yl-prop-1-ynyl)-5-(3-trifluoromethyl-phenoxy)-phenylsulfanyl] -phenoxy } -acetic acid;
[00272] { 4-[3-(4-Methanesulfonyl-phenylethynyl)-5-(3-trifluoromethyl-phenoxy)-phenyl-sulfanyl]-2-methyl-phenoxy}-acetic acid; and [00273] { 2-Methyl-4-[3-phenylethynyl-5-(5-trifluoromethyl-pyridin-2-yloxy) -phenyl-sulfanyl] -phenoxy } -acetic acid, [00274] or a pharmaceutically acceptable salt thereof.
[00275] In another embodiment, the present invention provides a novel compound of formula III:

R2a ~

R4b R4c ~ I

X \ X1 R4a I
R5d R5e R' Rsb Rsa 0 [00276] or a pharmaceutically acceptable salt thereof, wherein:
[00277] R' is CI-4 alkyl substituted with 1-2 Rla;
[00278] Rla, at each occurrence, is selected from aryl substituted with 0-2 Rlb, heteroaryl sub-stituted with 0-2 Rlb, C3_1o cycloalkyl substituted with 0-2 Rlb, and a heterocycle substituted with 0-2 Rib;
[00279] Rlb, at each occurrence, is selected from OH substituted with 0-1 Rl , SH substituted with 0-1 Rl , Cl, F, NH2 substituted with 0-2 Rl , -CN, NO2, CI-4 alkyl substituted with 0-2 Rl , C2_4 alkenyl substituted with 0-2 Rl , aryl substituted with 0-2 Rl , heteroaryl substituted with 0-2 Rl , C3_6 cycloalkyl substituted with 0-2 Rl , and a heterocycle substituted with 0-2 RlO=
, [00280] Rl , at each occurrence, is selected from OH, SH, Cl, F, NH2, -CN, NO2, CI-4 alkyl, and C2_4 alkenyl, aryl substituted with 0-2 Rld, heteroaryl substituted with 0-2 Rld, C3_6 cycloalkyl substituted with 0-2 Rld, and a heterocycle substituted with 0-2 Rla;
[00281] Rld, at each occurrence, is selected from OH, SH, Cl, F, NH2, -CN, NO2, CI-4 alkyl, and C2_4 alkenyl;
[00282] R2a is selected from aryl substituted with 0-2 R2b and heteroaryl substituted with 0-2 R2b =
, [00283] R2b, at each occurrence, is selected from OH substituted with 0-1 R2o, SH substituted with 0-1 R 2c, Cl, F, NH2 substituted with 0-2 R 2c, -CN, NO2, CI-4 alkyl substituted with 0-2 RZ , CZ-4 alkenyl substituted with 0-2 RZ , aryl substituted with 0-2 RZ , heteroaryl substituted with 0-2 RZ , C3-6 cycloalkyl substituted with 0-2 R2o, and a heterocycle substituted with 0-2 RZO=
, [00284] RZ , at each occurrence, is selected from OH, SH, Cl, F, NH2, -CN, NO2, Cl-~ alkyl, CZ-4 alkenyl, aryl substituted with 0-2 R2d, and heteroaryl substituted with 0-2 RZd;
[00285] RZd, at each occurrence, is selected from OH, SH, Cl, F, NH2, -CN, NOZ, Cl-4 alkyl, and C2-4 alkenyl;
[00286] R3 is selected from Cl, F, CH3, and CH2CH3;
[00287] alternatively, R3 and R5e combine to form a 5, 6, or 7 membered ring consisting of carbon atoms and 0-2 heteroatoms selected from 0, N, and S(O)0-2 and there are 0-2 ring dou-ble bonds in the bridging portion formed by R3 and Rse;
[00288] R4a, at each occurrence, is selected from H, Cl, F, and CH3;
[00289] R4b, at each occurrence, is selected from H, Cl, F, and CH3;
[00290] R4o, at each occurrence, is selected from H, Cl, F, and CH3;
[00291] R5a, at each occurrence, is selected from H, Cl, F, and CH3;
[00292] R5b, at each occurrence, is selected from H, Cl, F, and CH3;
[00293] R5o, at each occurrence, is selected from H, Cl, F, and CH3;
[00294] R5d, at each occurrence, is selected from H, Cl, F, and CH3; and, [00295] R5e, at each occurrence, is selected from H, Cl, F, and CH3.
[00296] In another embodiment, the present invention provides a novel compound of formula III or a pharmaceutically acceptable salt thereof, wherein:
[00297] R' is Ci-4 alkyl substituted with 1-2 Rla;
[00298] Rla, at each occurrence, is selected from aryl substituted with 0-2 R'b, 5-10 mem-bered heteroaryl substituted with 0-2 Rlb and consisting of carbon atoms and 1-4 heteroatoms selected from 0, N, and S(O)0-2, C3-io cycloalkyl substituted with 0-2 Rlb, and a 3-8 mem-bered heterocycle substituted with 0-2 Rlb and consisting of carbon atoms and 1-2 heteroa-toms selected from 0, N, and S(O)o-Z, [00299] Rlb, at each occurrence, is selected from OH substituted with 0-1 Rl , SH substituted with 0-1 Rl , Cl, F, NH2 substituted with 0-2 Rl , -CN, NOZ, Cl-4 alkyl substituted with 0-2 Rl , CZ-4 alkenyl substituted with 0-2 Rl , aryl substituted with 0-2 Rl , 5-10 membered het-eroaryl substituted with 0-2 Rl and consisting of carbon atoms and 1-4 heteroatoms selected from 0, N, and S(O)o-Z, C3-6 cycloalkyl substituted with 0-2 Rl , and a 3-6 membered hetero-cycle substituted with 0-2 Rl and consisting of carbon atoms and 1-2 heteroatoms selected from 0, N, and S(O)o-Z, [00300] Rl , at each occurrence, is selected from OH, SH, Cl, F, NH2, -CN, NOZ, Cl-4 alkyl, and C2-4 alkenyl, aryl substituted with 0-2 Rld, 5-10 membered heteroaryl substituted with 0-2 Rld and consisting of carbon atoms and 1-4 heteroatoms selected from 0, N, and S(O)0-2, C3-6 cycloalkyl substituted with 0-2 Rld, and a 3-6 membered heterocycle substituted with 0-2 Rla and consisting of carbon atoms and 1-2 heteroatoms selected from 0, N, and S(O)o-Z, [00301] Rld, at each occurrence, is selected from OH, SH, Cl, F, NH2, -CN, NOZ, Cl-4 alkyl, and CZ-4 alkenyl;
[00302] R 2a is selected from aryl substituted with 0-2 R 2b and 5-10 membered heteroaryl sub-stituted with 0-2 RZb and consisting of carbon atoms and 1-4 heteroatoms selected from 0, N, and S(O)o-Z, [00303] R2b, at each occurrence, is selected from OH substituted with 0-1 RZ , SH substituted with 0-1 R 2c, Cl, F, NH2 substituted with 0-2 R 2c, -CN, NOZ, Cl-4 alkyl substituted with 0-2 RZ , C2-4 alkenyl substituted with 0-2 RZ , aryl substituted with 0-2 RZ , 5-10 membered het-eroaryl substituted with 0-2 RZ and consisting of carbon atoms and 1-4 heteroatoms selected from 0, N, and S(O)o-Z, C3-6 cycloalkyl substituted with 0-2 RZ , and a 3-6 membered hetero-cycle substituted with 0-2 RZ and consisting of carbon atoms and 1-2 heteroatoms selected from 0, N, and S(O)o-Z, [00304] RZ , at each occurrence, is selected from OH, SH, Cl, F, NH2, -CN, NOZ, Cl-4 alkyl, CZ-4 alkenyl, aryl substituted with 0-2 R2d, and 5-10 membered heteroaryl substituted with 0-2 RZd and consisting of carbon atoms and 1-4 heteroatoms selected from 0, N, and S(O)0-2, [00305] RZd, at each occurrence, is selected from OH, SH, Cl, F, NH2, -CN, NOZ, Cl_4 alkyl, and C2-4 alkenyl;
[00306] R3 is selected from Cl, F, CH3, and CH2CH3;
[00307] alternatively, R3 and R5e combine to form a 5, 6, or 7 membered ring consisting of carbon atoms and 0-2 heteroatoms selected from 0, N, and S(O)0-2 and there are 0-2 ring dou-ble bonds in the bridging portion formed by R3 and Rse;
[00308] R4a, at each occurrence, is selected from H, Cl, F, and CH3;
[00309] R4b, at each occurrence, is selected from H, Cl, F, and CH3;
[00310] R4o, at each occurrence, is selected from H, Cl, F, and CH3;
[00311] R5a, at each occurrence, is selected from H, Cl, F, and CH3;
[00312] R5b, at each occurrence, is selected from H, Cl, F, and CH3;
[00313] R5o, at each occurrence, is selected from H, Cl, F, and CH3;
[00314] RSd, at each occurrence, is selected from H, Cl, F, and CH3; and, [00315] R5e, at each occurrence, is selected from H, Cl, F, and CH3.
[00316] In another embodiment, the present invention provides a novel compound of formula IIIa X
R2a O I ~
IOH 3 / Xl qr~
R' IIIa [00317] or a pharmaceutically acceptable salt thereof, wherein:
[00318] Rla, at each occurrence, is selected from aryl substituted with 0-2 Rlb, heteroaryl sub-stituted with 0-2 Rlb, C5-6 cycloalkyl substituted with 0-2 Rlb, and a heterocycle substituted with 0-2 Rlb;
[00319] Rlb, at each occurrence, is selected from OH, SH, Cl, F, NH2, -CN, NO2, Cl_4 alkyl substituted with 0-2 Rl , C2-4 alkenyl substituted with 0-2 Rl , aryl substituted with 0-2 Rl heteroaryl substituted with 0-2 Rl , C5-6 cycloalkyl substituted with 0-2 Rl , and a heterocycle substituted with 0-2 R";
[00320] Rl , at each occurrence, is selected from OH, SH, Cl, F, NH2, -CN, NO2, Cl-4 alkyl, and C2-4 alkenyl, aryl substituted with 0-2 Rld, heteroaryl substituted with 0-2 Rld, C3-6 cycloalkyl substituted with 0-2 Rld, and a heterocycle substituted with 0-2 Rla;
[00321] RZa is selected from aryl substituted with 0-2 R 2b and heteroaryl substituted with 0-2 R 2b and; and, [00322] RZb, at each occurrence, is selected from OH, SH, Cl, F, NH2, -CN, NOZ, Cl-4 alkyl, CZ-4 alkenyl, aryl, heteroaryl, C$-6 cycloalkyl, and a heterocycle.
[00323] In another embodiment, the present invention provides a novel compound of formula IIIa or a pharmaceutically acceptable salt thereof, wherein:
[00324] Rla, at each occurrence, is selected from aryl substituted with 0-2 Rlb, 5-6 membered heteroaryl substituted with 0-2 Rlb and consisting of carbon atoms and 1-2 heteroatoms se-lected from 0, N, and S(O)o-Z, C5-6 cycloalkyl substituted with 0-2 Rlb, and a 5-6 membered heterocycle substituted with 0-2 Rlb and consisting of carbon atoms and 1-2 heteroatoms se-lected from 0, N, and S(O)o-Z, [00325] Rlb, at each occurrence, is selected from OH, SH, Cl, F, NH2, -CN, NOZ, Cl-4 alkyl substituted with 0-2 Rl , CZ-4 alkenyl substituted with 0-2 Rl , aryl substituted with 0-2 Rl , 5-6 membered heteroaryl substituted with 0-2 Rl and consisting of carbon atoms and 1-2 het-eroatoms selected from 0, N, and S(O)o-z, C5-6 cycloalkyl substituted with 0-2 Rl , and a 5-6 membered heterocycle substituted with 0-2 Rl and consisting of carbon atoms and 1-2 het-eroatoms selected from 0, N, and S(O)0-2, [00326] R' , at each occurrence, is selected from OH, SH, Cl, F, NH2, -CN, NOZ, Cl-4 alkyl, and CZ-4 alkenyl, aryl substituted with 0-2 Rld, 5-6 membered heteroaryl substituted with 0-2 Rld and consisting of carbon atoms and 1-2 heteroatoms selected from 0, N, and S(O)o-2, C3-6 cycloalkyl substituted with 0-2 Rld, and a 3-6 membered heterocycle substituted with 0-2 Rla and consisting of carbon atoms and 1-2 heteroatoms selected from 0, N, and S(O)o-Z, [00327] R2a is selected from aryl substituted with 0-2 R2b and 5-6 membered heteroaryl sub-stituted with 0-2 R 2b and consisting of carbon atoms and 1-2 heteroatoms selected from 0, N, and S(O)o-Z; and, [00328] RZb, at each occurrence, is selected from OH, SH, Cl, F, NH2, -CN, NOZ, Cl_4 alkyl, CZ-4 alkenyl, aryl, 5-6 membered heteroaryl consisting of carbon atoms and 1-2 heteroatoms selected from 0, N, and S(O)o-2, C5-6 cycloalkyl, and a 5-6 membered heterocycle and consist-ing of carbon atoms and 1-2 heteroatoms selected from 0, N, and S(O)o-Z.
[00329] In another embodiment, the present invention provides a novel compound of formula Ia, wherein:
[00330] Rl is Cl-4 alkyl substituted with 1-2 Rla;
[00331] Rla, at each occurrence, is selected from aryl substituted with 0-2 Rlb, heteroaryl sub-stituted with 0-2 Rlb, C3-io cycloalkyl substituted with 0-2 Rlb, and a heterocycle substituted with 0-2 Rlb;
[00332] Rlb, at each occurrence, is selected from OH substituted with 0-1 Rl , SH substituted with 0-1 Rl , Cl, F, NH2 substituted with 0-2 Rl , -CN, NOZ, Cl-4 alkyl substituted with 0-2 Rl , C2-4 alkenyl substituted with 0-2 Rl , aryl substituted with 0-2 Rl , heteroaryl substituted with 0-2 Rl , C3-6 cycloalkyl substituted with 0-2 Rl , and a heterocycle substituted with 0-2 RlO=
, [00333] Rl , at each occurrence, is selected from OH, SH, Cl, F, NH2, -CN, NOZ, Cl-4 alkyl, and CZ-4 alkenyl, aryl substituted with 0-2 Rld, heteroaryl substituted with 0-2 Rld, C3_6 cycloalkyl substituted with 0-2 Rld, and a heterocycle substituted with 0-2 Rla;
[00334] Rld, at each occurrence, is selected from OH, SH, Cl, F, NH2, -CN, NOZ, Cl-4 alkyl, and CZ-4 alkenyl;
[00335] R2 is aryl substituted with 0-3 R2a or heteroaryl substituted with 0-2 R2a;
[00336] R2a, at each occurrence, is selected from OH substituted with 0-1 RZb, SH substituted with 0-1 R 2b, Cl, F, NH2 substituted with 0-2 R 2b, -CN, NOZ, Cl-4 alkyl substituted with 0-2 R 2b, C2-6 alkenyl substituted with 0-2 RZb, aryl substituted with 0-2 RZb, heteroaryl substituted with 0-2 R 2b, C3-6 cycloalkyl substituted with 0-2 R 2b, and a heterocycle substituted with 0-2 RZb =
, [00337] R2b, at each occurrence, is selected from OH, SH, Cl, F, NH2, -CN, NOZ, Cl_4 alkyl, and, C2-4 alkenyl;
[00338] R3 is selected from Cl, F, CH3, and CH2CH3;
[00339] alternatively, R3 and R5e combine to form a 5, 6, or 7 membered ring consisting of carbon atoms and 0-2 heteroatoms selected from 0, N, and S(O)0-2 and there are 0-2 ring dou-ble bonds in the bridging portion formed by R3 and Rse;
[00340] R4a, at each occurrence, is selected from H, Cl, F, and CH3;
[00341] R4b, at each occurrence, is selected from H, Cl, F, and CH3;
[00342] R4o, at each occurrence, is selected from H, Cl, F, and CH3;
[00343] R5a, at each occurrence, is selected from H, Cl, F, and CH3;
[00344] R5b, at each occurrence, is selected from H, Cl, F, and CH3;
[00345] R5o, at each occurrence, is selected from H, Cl, F, and CH3;
[00346] R5d, at each occurrence, is selected from H, Cl, F, and CH3; and, [00347] R5e, at each occurrence, is selected from H, Cl, F, and CH3.
[00348] In another embodiment, the present invention provides a novel compound of formula Ia, wherein:
[00349] R' is Ci-4 alkyl substituted with 1-2 Rla;
[00350] Rla, at each occurrence, is selected from aryl substituted with 0-2 Rlb, 5-10 mem-bered heteroaryl substituted with 0-2 Rlb and consisting of carbon atoms and 1-4 heteroatoms selected from 0, N, and S(O)0-2, C3-io cycloalkyl substituted with 0-2 Rlb, and a 3-8 mem-bered heterocycle substituted with 0-2 Rlb and consisting of carbon atoms and 1-2 heteroa-toms selected from 0, N, and S(O)o-Z, [00351] Rlb, at each occurrence, is selected from OH substituted with 0-1 Rl , SH substituted with 0-1 Rl , Cl, F, NH2 substituted with 0-2 Rl , -CN, NOZ, Cl-4 alkyl substituted with 0-2 R' , C2-4 alkenyl substituted with 0-2 R' , aryl substituted with 0-2 Rl , 5-10 membered het-eroaryl substituted with 0-2 Rl and consisting of carbon atoms and 1-4 heteroatoms selected from 0, N, and S(O)o-Z, C3-6 cycloalkyl substituted with 0-2 Rl , and a 3-6 membered hetero-cycle substituted with 0-2 Rl and consisting of carbon atoms and 1-2 heteroatoms selected from 0, N, and S(O)o-Z, [00352] Rl , at each occurrence, is selected from OH, SH, Cl, F, NH2, -CN, NOZ, Cl-4 alkyl, and C2-4 alkenyl, aryl substituted with 0-2 Rld, 5-10 membered heteroaryl substituted with 0-2 Rld and consisting of carbon atoms and 1-4 heteroatoms selected from 0, N, and S(O)o-z, C3-6 cycloalkyl substituted with 0-2 Rld, and a 3-6 membered heterocycle substituted with 0-2 Rla and consisting of carbon atoms and 1-2 heteroatoms selected from 0, N, and S(O)o-Z, [00353] Rld, at each occurrence, is selected from OH, SH, Cl, F, NH2, -CN, NOZ, Cl_4 alkyl, and C2-4 alkenyl;
[00354] R 2 is aryl substituted with 0-3 RZa or 5-10 membered heteroaryl substituted with 0-2 R 2a and consisting of carbon atoms and 1-4 heteroatoms selected from 0, N, and S(O)0-2, [00355] R2a, at each occurrence, is selected from OH substituted with 0-1 R2b, SH substituted with 0-1 RZb, Cl, F, NH2 substituted with 0-2 R 2b, -CN, NO2, Cl-4 alkyl substituted with 0-2 RZb, C2-6 alkenyl substituted with 0-2 RZb, aryl substituted with 0-2 RZb, 5-10 membered het-eroaryl substituted with 0-2 R 2b and consisting of carbon atoms and 1-4 heteroatoms selected from 0, N, and S(O)o-Z, C3-6 cycloalkyl substituted with 0-2 RZb, and a 3-6 membered hetero-cycle substituted with 0-2 R 2b and consisting of carbon atoms and 1-2 heteroatoms selected from 0, N, and S(O)o-Z, [00356] RZb, at each occurrence, is selected from OH, SH, Cl, F, NH2, -CN, NOZ, Cl-4 alkyl, and, C2-4 alkenyl;
[00357] R3 is selected from Cl, F, CH3, and CH2CH3;
[00358] alternatively, R3 and R5e combine to form a 5, 6, or 7 membered ring consisting of carbon atoms and 0-2 heteroatoms selected from 0, N, and S(0)0-2 and there are 0-2 ring dou-ble bonds in the bridging portion formed by R3 and Rse;
[00359] R4a, at each occurrence, is selected from H, Cl, F, and CH3;
[00360] R4b, at each occurrence, is selected from H, Cl, F, and CH3;
[00361] R4o, at each occurrence, is selected from H, Cl, F, and CH3;
[00362] R5a, at each occurrence, is selected from H, Cl, F, and CH3;
[00363] RSb, at each occurrence, is selected from H, Cl, F, and CH3;
[00364] R5o, at each occurrence, is selected from H, Cl, F, and CH3;
[00365] R5d, at each occurrence, is selected from H, Cl, F, and CH3; and, [00366] R5e, at each occurrence, is selected from H, Cl, F, and CH3.
[00367] In another embodiment, the present invention provides a novel compound of formula Ib:
X RZ
O\~
O
IOH R3 Xi i R
Ib [00368] or a pharmaceutically acceptable salt thereof, wherein:
[00369] R' is Cl-4 alkyl substituted with 1 Rla;
[00370] Rla, at each occurrence, is selected from aryl substituted with 0-2 Rlb, 5-6 membered heteroaryl substituted with 0-2 Rlb and consisting of carbon atoms and 1-2 heteroatoms se-lected from 0, N, and S(O)o-Z, C5-6 cycloalkyl substituted with 0-2 Rlb, and a 5-6 membered heterocycle substituted with 0-2 Rlb and consisting of carbon atoms and 1-2 heteroatoms se-lected from 0, N, and S(O)0-2, [00371] Rlb, at each occurrence, is selected from OH, SH, Cl, F, NH2, -CN, NOZ, Cl-4 alkyl substituted with 0-2 Rl , CZ_4 alkenyl substituted with 0-2 Rl , aryl substituted with 0-2 Rl , 5-6 membered heteroaryl substituted with 0-2 Rl and consisting of carbon atoms and 1-2 het-eroatoms selected from 0, N, and S(O)o-z, C5-6 cycloalkyl substituted with 0-2 Rl , and a 5-6 membered heterocycle substituted with 0-2 Rl and consisting of carbon atoms and 1-2 het-eroatoms selected from 0, N, and S(O)0-2, [00372] Rl , at each occurrence, is selected from OH, SH, Cl, F, NH2, -CN, NOZ, Cl-4 alkyl, and C2-4 alkenyl, aryl substituted with 0-2 Rld, 5-6 membered heteroaryl substituted with 0-2 Rld and consisting of carbon atoms and 1-2 heteroatoms selected from 0, N, and S(O)0-2, C3-6 cycloalkyl substituted with 0-2 Rld, and a 3-6 membered heterocycle substituted with 0-2 Rla and consisting of carbon atoms and 1-2 heteroatoms selected from 0, N, and S(O)o-Z, [00373] R2 is aryl substituted with 0-2 R 2a or 5-6 membered heteroaryl substituted with 0-2 R 2a and consisting of carbon atoms and 1-2 heteroatoms selected from 0, N, and S(O)0-2, and, [00374] R2a, at each occurrence, is selected from OH substituted with 0-1 R2b, SH substituted with 0-1 R 2b, Cl, F, NH2 substituted with 0-2 R 2b, -CN, NOZ, Cl-4 alkyl substituted with 0-2 R 2b, C2-6 alkenyl substituted with 0-2 R 2b, aryl substituted with 0-2 RZb, 5-6 membered het-eroaryl substituted with 0-2 R 2b and consisting of carbon atoms and 1-2 heteroatoms selected from 0, N, and S(O)o_Z, C5_6 cycloalkyl substituted with 0-2 R 2b, and a 5-6 membered hetero-cycle substituted with 0-2 R 2b and consisting of carbon atoms and 1-2 heteroatoms selected from 0, N, and S(O)o_Z.
[00375] In another embodiment, the present invention provides a novel compound pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a compound of the present invention or a pharmaceutically acceptable salt thereof.
[00376] In another embodiment, the present invention provides a novel method of treating type 2 diabetes, comprising: administering a therapeutically effective amount of a compound of the present invention or a pharmaceutically acceptable salt thereof.
[00377] In another embodiment, the present invention provides a method of treating a disease comprising administering to a patient in need thereof a therapeutically effective amount of a compound of the present invention or a pharmaceutically acceptable salt thereof, wherein the disease is selected from dyslipidemia, syndrome X (including the metabolic syndrome, e.g., hypertension, impaired glucose tolerance (IGT), insulin resistance, hypertrigyceridaemia, and obesity), cardiovascular diseases (e.g., atherosclerosis and related diseases, including mortal-ity reduction, coronary artery diseases, coronary heart diseases, heart attack, myocardial ischemia, myocardial infarct, coronary infarct, transient ischemic attack (TIA), and stroke), hyperglycemia, hyperlipidemia, hypercholesterolemia, and hyperinsulinemia.
[00378] In another embodiment, the present invention provides a method of treating a disease comprising administering to a patient in need thereof a therapeutically effective amount of at least one compound of the present invention or a pharmaceutically acceptable salt thereof, wherein the disease is selcted from non-insulin requiring Type 2 diabetes to insulin requiring Type 2 diabetes, decreasing apoptosis in mammalian cells (e.g., beta cells of Islets of Langerhans), renal diseases (e.g., glomerulonephritis, glomerulosclerosis, nephrotic syndrome, and hypertensive nephrosclerosis), improving cognitive functions in dementia, treating diabetic complications, psoriasis, polycystic ovarian syndrome (PCOS), prevention and treatment of bone loss (e.g. osteoporosis), and lowering the bio-markers of atherosclerosis (e.g., c-reactive protein (CRP), TNF-(c, and IL-6).
[00379] In another embodiment, the present invention provides a novel process for the prepa-ration of the compounds of the present invention or stereoisomers or pharmaceutically accept-able salts thereof.
[00380] In another embodiment, the present compounds are administered in combination with one or more further pharmacologically active substances selected from antiobesity agents, ap-petite regulating agents, antidiabetics, antihypertensive agents, agents for the treatment of complications resulting from or associated with diabetes, and agents for the treatment of com-plications and disorders resulting from or associated with obesity.
[00381] Suitable additional substances may be selected from CART (cocaine amphetamine regulated transcript) agonists, NPY (neuropeptide Y) antagonists, MC4 (melanocortin 4) ago-nists, orexin antagonists, TNF (tumor necrosis factor) agonists, CRF
(corticotropin releasing factor) agonists, CRF BP (corticotropin releasing factor binding protein) antagonists, uro-cortin agonists, (33 agonists, MSH (melanocyte-stimulating hormone) agonists, MCH
(melanocyte-concentrating hormone) antagonists, CCK (cholecystokinin) agonists, serotonin re-uptake inhibitors, serotonin and noradrenaline re-uptake inhibitors, mixed serotonin and noradrenergic compounds, 5HT (serotonin) agonists, bombesin agonists, galanin antagonists, growth hormone, growth hormone releasing compounds, TRH (thyreotropin releasing hor-mone) agonists, UCP 2 or 3 (uncoupling protein 2 or 3) modulators, leptin agonists, DA ago-nists (bromocriptin, doprexin), lipase/amylase inhibitors, RXR (retinoid X
receptor) modula-tors or TR (3 agonists.
[00382] Suitable antiobesity agents include leptin, dexamphetamine, amphetamine, fenflura-mine, dexfenfluramine, sibutramine, orlistat, mazindol, and phentermine.
[00383] Suitable antidiabetics include insulin, orally active hypoglycaemic agents, and GLP-1 (glucagon like peptide-1) derivatives (see WO 98/08871).
[00384] Orally active hypoglycaemic agents preferably include sulphonylureas, biguanides, meglitinides, glucosidase inhibitors, glucagon antagonists (see W099/01423), GLP-1 ago-nists, potassium channel openers (see WO 97/26265 and WO 99/03861), DPP-IV
(dipeptidyl peptidase-IV) inhibitors, inhibitors of hepatic enzymes involved in stimulation of gluconeo-genesis and/or glycogenolysis, glucose uptake modulators, compounds modifying the lipid metabolism (e.g., antihyperlipidemic agents and antilipidemic agents), compounds lowering food intake, RXR agonists, agents acting on the ATP-dependent potassium channel of the (3-cells, and thiazolidinediones (e.g., troglitazone, ciglitazone, pioglitazone and rosiglitazone).
[00385] Agents to be administered in combination with compounds of the present invention also include sulphonylureas (e.g., tolbutamide, glibenclamide, glipizide, and glicazide), biguanides (e.g., metformin), meglitinides (e.g., repaglinide and senaglinide), oc-glucosidase inhibitors (e.g., miglitol and acarbose), an agent acting on the ATP-dependent potassium channel of the (3-cells (e.g., the above sulphonylureas and repaglinide), and nateglinide.
[00386] Antihyperlipidemic or antilipidemic agents include apolipoprotein A-I
Milano, cho-lestyramine, colestipol, clofibrate, gemfibrozil, fenofibrate, bezafibrate, tesaglitazar, muragli-tazar, EML-4156, LY-518674, LY-519818, MK-767, torcetrapib, atorvastatin, fluvastatin, lovastatin, pravastatin, simvastatin, cerivastin, rosuvastatin, pitavastatin, acipimox, ezetimibe, probucol, dextrothyroxine and nicotinic acid.
[00387] In another embodiment the present compounds are administered in combination with more than one of the above-mentioned compounds (e.g, in combination with a sulphonylurea and metformin, a sulphonylurea and acarbose, repaglinide and metformin, insulin and a sul-phonylurea, insulin and metformin, or insulin and lovastatin).
[00388] Examples of ntihypertensive agents include (3-blockers (e.g, alprenolol, atenolol, ti-molol, pindolol, propranolol, and metoprolol), ACE (angiotensin converting enzyme) inhibi-tors (e.g., benazepril, captopril, enalapril, fosinopril, lisinopril, quinapril and ramipril), cal-cium channel blockers (e.g., nifedipine, felodipine, nicardipine, isradipine, nimodipine, dilti-azem and verapamil), and oc-blockers (e.g., doxazosin, urapidil, prazosin and terazosin).
[00389] It should be understood that any suitable combination of the compounds according to the invention with one or more of the above-mentioned compounds and optionally one or more further pharmacologically active substances are considered to be within the scope of the present invention.
[00390] It is preferred that the compounds of the present invention have a solubility in water of at least 0.1 mg/L as determined at 25 C and pH 7Ø More preferably the solubility is at least 0.5 mg/L. Even more preferably the solubility is at least 1 mg/L. Still more preferably, the solu-bility is at least 2 mg/L. Further preferably the solubility is at least 10 mg/L. Even further pref-erably the solubility is at least 50 mg/L. Still further preferably the solubility is at least 200 mg/L.
[00391] It is preferred that compounds of the present invention have an IC50 value of less than 5 m as determined by the PPAR transient transactivation assay. More preferably the IC50 value is less than 1 m. Even more preferably the IC5o value is less than 500 nM. Still more preferably the IC5o value is less than 100 nM. Further preferably the IC50 value is less than 50 nM. Even further preferably the IC50 value is less than 25 nM. Still further preferably the IC50 value is less than 10 nM. Even still further preferably the IC5o value is less than 5 nM.
[00392] It is preferred that the compounds of the present invention have a molecular weight of less than 1000 g/mol. More preferably the molecular weight is less than 750 g/mol. Even more preferably the molecular weight is less than 600 g/mol. Still more preferably, the mo-lecular weight is less than 550 g/mol. Further preferably the molecular weight is less than 500 g/mol. Even further preferably the molecular weight is less than 400 g/mol.
[00393] It is preferred that compounds of the present invention are ionized at pH 7.4.
[00394] It is preferred that the compounds of the present invention have only one ionized carboxylic acid group at a pH of from 5.5-9. More preferably the compounds have only one ionized carboxylic acid group at a pH of from 6-8. Even more preferably the compounds have only one ionized carboxylic acid group at a pH of from 6.5-7.5. Still more preferably, the compounds have only one ionized carboxylic acid group at pH 7.4.
[00395] It is preferred that the compounds of the present invention are zwitter-ionic with one ionized amine group and one ionized carboxylic acid group at a pH of from 5.5-9. More pref-erably the compounds are zwitter-ionic with one ionized amine group and one ionized car-boxylic acid group at a pH of from 6-8. Even more preferably the compounds are zwitter-ionic with one ionized amine group and one ionized carboxylic acid group at a pH of from 6.5-7.5. Still more preferably, the compounds are zwitter-ionic with one ionized amine group and one ionized carboxylic acid group at pH 7.4.

PHARMACEUTICAL COMPOSITIONS
[00396] The compounds of the invention may be administered alone or in combination with pharmaceutically acceptable carriers or excipients, in either single or multiple doses. The pharmaceutical compositions of the present invention may be formulated with pharmaceuti-cally acceptable carriers or diluents as well as any other known adjuvants and excipients in accordance with conventional techniques such as those disclosed in Remington:
The Science and Practice of Pharmacy, 19th Edition, Gennaro, Ed., Mack Publishing Co., Easton, PA, 1995. The compositions may appear in conventional forms, which include capsules, tablets, aerosols, solutions, suspensions, andtopical applications.
[00397] Typical compositions include a compound of the present invention a pharmaceuti-cally acceptable acid addition salt thereof, associated with a pharmaceutically acceptable excipient, which may be a carrier or a diluent or be diluted by a carrier, or enclosed within a carrier, which can be in the form of a capsule, sachet, paper, or other container. In making the compositions, conventional techniques for the preparation of pharmaceutical compositions may be used. For example, the active compound will usually be mixed with a carrier, or diluted by a carrier, or enclosed within a carrier which may be in the form of a ampoule, capsule, sachet, paper, or other container. When the carrier serves as a diluent, it may be solid, semi-solid, or liquid material which acts as a vehicle, excipient, or medium for the active compound. The active compound can be adsorbed on a granular solid container for example in a sachet. Some examples of suitable carriers are water, salt solutions, alcohols, polyethylene glycols, polyhydroxyethoxylated castor oil, peanut oil, olive oil, gelatine, lactose, terra alba, sucrose, cyclodextrin, amylose, magnesium stearate, talc, gelatin, agar, pectin, acacia, stearic acid or lower alkyl ethers of cellulose, silicic acid, fatty acids, fatty acid amines, fatty acid monoglycerides and diglycerides, pentaerythritol fatty acid esters, polyoxyethylene, hydroxymethylcellulose and polyvinylpyrrolidone. Similarly, the carrier or diluent may include any sustained release material known in the art, such as glyceryl monostearate or glyceryl distearate, alone or mixed with a wax. The formulations may also include wetting agents, emulsifying and suspending agents, preserving agents, sweetening agents or flavouring agents. The formulations of the invention may be formulated so as to provide quick, sustained, or delayed release of the active ingredient after administration to the patient by employing procedures well known in the art.
[00398] The pharmaceutical compositions can be sterilized and mixed, if desired, with auxil-iary agents, emulsifiers, salt for influencing osmotic pressure, buffers and/or colouring sub-stances and the like, which do not deleteriously react with the active compounds.
[00399] The route of administration may be any route, which effectively transports the active compound to the appropriate or desired site of action, such as oral, nasal, pulmonary, trans-dermal or parenteral e.g. rectal, depot, subcutaneous, intravenous, intraurethral, intramuscu-lar, intranasal, ophthalmic solution or an ointment, the oral route being preferred.
[00400] If a solid carrier is used for oral administration, the preparation may be tabletted, placed in a hard gelatin capsule in powder or pellet form or it can be in the form of a troche or lozenge.
If a liquid carrier is used, the preparation may be in the form of a syrup, emulsion, soft gelatin capsule or sterile injectable liquid such as an aqueous or non-aqueous liquid suspension or solution.
[00401] For nasal administration, the preparation may contain a compound of formula I dis-solved or suspended in a liquid carrier, in particular an aqueous carrier, for aerosol application.
The carrier may contain additives such as solubilizing agents, e.g. propylene glycol, surfactants, absorption enhancers such as lecithin (phosphatidylcholine) or cyclodextrin, or preservatives such as parabenes.
[00402] For parenteral application, particularly suitable are injectable solutions or suspen-sions, preferably aqueous solutions with the active compound dissolved in polyhydroxylated castor oil.
[00403] Tablets, dragees, or capsules having talc and/or a carbohydrate carrier or binder or the like are particularly suitable for oral application. Preferable carriers for tablets, dragees, or capsules include lactose, corn starch, and/or potato starch. A syrup or elixir can be used in cases where a sweetened vehicle can be employed.
[00404] If desired, the pharmaceutical composition of the invention may comprise a compound of the present invention in combination with further pharmacologically active substances such as those described in the foregoing.
[00405] The compounds of the invention may be administered to a mammal, especially a human in need of such treatment, prevention, elimination, alleviation or amelioration of diseases related to the regulation of blood sugar. Mammals also include animals, both domestic animals, e.g. household pets, and non-domestic animals such as wildlife.
[00406] The compounds of the present invention are expected to be effective over a wide dosage range. A typical oral dosage is in the range of from about 0.001 to about 100 mg/kg body weight per day, preferably from about 0.01 to about 50 mg/kg body weight per day, and more preferred from about 0.05 to about 10 mg/kg body weight per day administered in one or more dosages such as 1 to 3 dosages. The exact dosage will depend upon the frequency and mode of administration, the sex, age, weight and general condition of the subject treated, the nature and severity of the condition treated and any concomitant diseases to be treated and other factors evident to those skilled in the art.
[00407] The formulations may conveniently be presented in unit dosage form by methods known to those skilled in the art. A typical unit dosage form for oral administration one or more times per day such as 1 to 3 times per day may contain of from 0.05 to about 1000 mg, preferably from about 0.1 to about 500 mg, and more preferred from about 0.5 mg to about 200 mg.

DEFINITIONS
[00408] All references described herein are incorporated in there entirety by reference.
[00409] "Substituted" signifies that one or more hydrogen atoms are replaced by the desig-nated substituent. Only pharmaceutically stable compounds are intended to be covered.
[00410] When examples of definitions are provided, the definition is not meant to be limited to the specific examples.
[00411] The present invention includes all isotopes of atoms occurring in the present com-pounds. Isotopes include those atoms having the same atomic number but different mass numbers. By way of general example and without limitation, isotopes of hydrogen include tritium and deuterium. Isotopes of carbon include C-13 and C-14.
[00412] When 0 or S is listed as a substituent, oxo and sulfo, respectively, it is intended that a carbon atom be replaced by either the 0 or S. For example if alkyl were substituted by 0, then an ether would be formed. Preferably heteroatom-heteroatom bonds such as 0-0, O-S, O-N, S-S, and S-N are not formed.
[00413] "Alkyl" includes both straight chain and branched alkyl groups having the designated number of carbon atoms (e.g., 1, 2, 3, 4, 5, 6, 7, or 8). Examples of alkyl groups include methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl, t-butyl, 2-methyl-butyl, and 2-ethyl-butyl.
[00414] "Alkenyl" includes both straight chain and branched alkenyll groups having the des-ignated number of carbon atoms (e.g., 2, 3, 4, 5, 6, 7, or 8). Examples of alkenyl groups in-clude ethenyl, 1-propenyl, 2-propenyl, 1-butenyl, 2-butenyl, and 2-methyl-butenyl.
[00415] "Alkynyl" includes both straight chain and branched alkynyl groups having the des-ignated number of carbon atoms (e.g., 2, 3, 4, 5, 6, 7, or 8). Examples of alkynyl groups in-clude ethynyl, 1-propynyl, 2-propynyl, 1-butynyl, 2-butynyl, and 2-methyl-butynyl.
[00416] "Aryl" includes phenyl, naphthyl, fluorene, anthracene, phenanthrenyl, azulenyl, and a partially saturated bicyclic carbocyclic ring. The partially saturated bicyclic carbocyclic ring consists of 8, 9, 10, 11, or 12 carbon atoms, preferably 8, 9, or 10 carbon atoms. Exam-ples of partially saturated bicyclic carbocyclic rings include 1,2,3,4-tetrahydronaphthyl, in-danyl, indenyl, 1,2,40c,5,8,8a-hexahydronaphtyl, and 1,3oc-dihydropentalene. A
preferred aryl group is phenyl.
[00417] "Cycloalkyl" means a ring having the number of designated carbon atoms and hav-ing only single bonds between the carbon atoms. Examples of cycloalkyl include, but are not limited to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cycloheptyl.
Preferred cycloalkyl groups are cyclopentyl and cyclohexyl.
[00418] "Heteroaryl" signifies a mono-, bi-, or tricyclic ring consisting of carbon atoms and from one heteroatom to 5, wherein the heteroatom is selected from oxygen, nitrogen, and sul-phur. If sulphur is present, then it can be mono- or di-oxidized. If a nitrogen is present, then it can be N, NH, or substituted N. The heterocycle can be attached via a carbon or nitrogen atom, unless linking the nitrogen atom would lead to a quaternary nitrogen. If the heteroaryl is bicyclic, then one or both of the rings may have a heteroatom(s) present.
If the heteroaryl is tricyclic, then one, two, or all three of the rings may have a heteroatom(s) present. If the het-erocycle is monocyclic, then this ring is aromatic (e.g., fully unsaturated).
If the heteroaryl is bicyclic or tricyclic, then at least one ring is aromatic.
[00419] Examples of "heteroaryl" are pyrrolyl (e.g. pyrrol-1-yl, pyrrol-2-yl, pyrrol-3-yl), fu-ranyl (e.g. furan-2-yl, furan-3-yl), thienyl (e.g. thien-2-yl, thien-3-yl), oxazolyl (e.g. oxazol-2-yl, oxazol-4-yl, oxazol-5-yl), thiazolyl (e.g. thiazol-2-yl, thiazol-4-yl, thiazol-5-yl), imidazolyl (e.g. imidazol-2-yl, imidazol-4-yl, imidazol-5-yl), pyrazolyl (e.g. pyrazol-l-yl, pyrazol-3-yl, pyrazol-5-yl), isoxazolyl (e.g. isoxazol-3-yl, isoxazol-4-yl, isoxazol-5-yl), isothiazolyl (e.g.
isothiazol-3-yl, isothiazol-4-yl, isothiazol-5-yl), 1,2,3-triazolyl (e.g.
1,2,3-triazol-1-yl, 1,2,3-triazol-4-yl, 1,2,3-triazol-5-yl), 1,2,4-triazolyl (e.g. 1,2,4-triazol-1-yl, 1,2,4-triazol-3-yl, 1,2,4-triazol-5-yl), 1,2,3-oxadiazolyl (e.g. 1,2,3-oxadiazol-4-yl, 1,2,3-oxadiazol-5-yl), 1,2,4-oxa-diazolyl (e.g. 1,2,4-oxadiazol-3-yl, 1,2,4-oxadiazol-5-yl), 1,2,5-oxadiazolyl (e.g. 1,2,5-oxa-diazol-3-yl, 1,2,5-oxadiazol-4-yl), 1,3,4-oxadiazolyl (e.g. 1,3,4-oxadiazol-2-yl, 1,3,4-oxadia-zol-5-yl), 1,2,3-thiadiazolyl (e.g. 1,2,3-thiadiazol-4-yl, 1,2,3-thiadiazol-5-yl), 1,2,4-thiadia-zolyl (e.g. 1,2,4-thiadiazol-3-yl, 1,2,4-thiadiazol-5-yl), 1,2,5-thiadiazolyl (e.g. 1,2,5-thiadia-zol-3-yl, 1,2,5-thiadiazol-4-yl), 1,3,4-thiadiazolyl (e.g. 1,3,4-thiadiazol-2-yl, 1,3,4-thiadiazol-5-yl), tetrazolyl (e.g. tetrazol-1-yl, tetrazol-5-yl), pyranyl (e.g. pyran-2-yl), pyridinyl (e.g.
pyridine-2-yl, pyridine-3-yl, pyridine-4-yl), pyridazinyl (e.g. pyridazin-2-yl, pyridazin-3-yl), pyrimidinyl (e.g. pyrimidin-2-yl, pyrimidin-4-yl, pyrimidin-5-yl), pyrazinyl, 1,2,3-triazinyl, 1,2,4-triazinyl, 1,3,5-triazinyl, thiadiazinyl, azepinyl, azecinyl, indolyl (e.g. indol-1-yl, indol-2-yl, indol-3-yl, indol-5-yl), isoindolyl, benzofuranyl (e.g. benzo[b]furan-2-yl, benzo[b]furan-3-yl, benzo[b]furan-5-yl, benzo[c]furan-2-yl, benzo[c]furan-3-yl, benzo[c]furan-5-yl), benzo-thienyl (e.g. benzo[b]thien-2-yl, benzo[b]thien-3-yl, benzo[b]thien-5-yl, benzo[c]thien-2-yl, benzo[c]thien-3-yl, benzo[c]thien-5-yl), indazolyl (e.g. indazol-l-yl, indazol-3-yl, indazol-5-yl), indolizinyl (e.g. indolizin-1-yl, indolizin-3-yl), benzopyranyl (e.g.
benzo[b]pyran-3-yl, benzo[b]pyran-6-yl, benzo[c]pyran-1-yl, benzo[c]pyran-7-yl), benzimidazolyl (e.g. benzimi-dazol-1-yl, benzimidazol-2-yl, benzimidazol-5-yl), benzothiazolyl (e.g.
benzothiazol-2-yl, benzothiazol-5-yl), benzisothiazolyl, benzoxazolyl, benzisoxazolyl, benzoxazinyl, benzotria-zolyl, naphthyridinyl (e.g. 1,8-naphthyridin-2-yl, 1,7-naphthyridin-2-yl, 1,6-naphthyridin-2-yl), phthalazinyl (e.g. phthalazin-l-yl, phthalazin-5-yl), pteridinyl, purinyl (e.g. purin-2-yl, purin-6-yl, purin-7-yl, purin-8-yl, purin-9-yl), quinazolinyl (e.g. quinazolin-2-yl, quinazolin-4-yl, quinazolin-6-yl), cinnolinyl, quinoliny (e.g. quinolin-2-yl, quinolin-3-yl, quinolin-4-yl, quinolin-6-yl), isoquinolinyl (e.g. isoquinolin-l-yl, isoquinolin-3-yl, isoquinolin-4-yl), qui-noxalinyl (e.g. quinoxalin-2-yl, quinoxalin-5-yl), pyrrolopyridinyl (e.g.
pyrrolo[2,3-b]pyridi-nyl, pyrrolo[2,3-c]pyridinyl, pyrrolo[3,2-c]pyridinyl), furopyridinyl (e.g.
furo[2,3-b]pyridinyl, furo[2,3-c]pyridinyl, furo[3,2-c]pyridinyl), thienopyridinyl (e.g. thieno[2,3-b]pyridinyl, thi-eno[2,3-c]pyridinyl, thieno[3,2-c]pyridinyl), imidazopyridinyl (e.g.
imidazo[4,5-b]pyridinyl, imidazo[4,5-c]pyridinyl, imidazo[1,5-a]pyridinyl, imidazo[1,2-a]pyridinyl), imidazopyrimidi-nyl (e.g. imidazo[1,2-a]pyrimidinyl, imidazo[3,4-a]pyrimidinyl), pyrazolopyridinyl (e.g. pyra-zolo[3,4-b]pyridinyl, pyrazolo[3,4-c]pyridinyl, pyrazolo[1,5-a]pyridinyl), pyrazolopyrimidi-nyl (e.g. pyrazolo[1,5-a]pyrimidinyl, pyrazolo[3,4-d]pyrimidinyl), thiazolopyridinyl (e.g. thi-azolo[3,2-d]pyridinyl), thiazolopyrimidinyl (e.g. thiazolo[5,4-d]pyrimidinyl), imdazothiazolyl (e.g. imidazo[2,1-b]thiazolyl), triazolopyridinyl (e.g. triazolo[4,5-b]pyridinyl), triazolopyrimi-dinyl (e.g. 8-azapurinyl), carbazolyl (e.g. carbazol-2-yl, carbazol-3-yl, carbazol-9-yl), phen-oxazinyl (e.g. phenoxazin-l0-yl), phenazinyl (e.g. phenazin-5-yl), acridinyl (e.g. acridin-9-yl, acridin-l0-yl), phenothiazinyl (e.g. phenothiazin-l0-yl), carbolinyl (e.g.
pyrido[3,4-b]indol-l-yl, pyrido[3,4-b]indol-3-yl), phenanthrolinyl (e.g. phenanthrolin-5-yl), pyrrolinyl, pyrazolinyl, imidazolinyl (e.g. 4,5-dihydroimidazol-2-yl, 4,5-dihydroimidazol-1-yl), indolinyl (e.g. 2,3-dihydroindol-l-yl, 2,3-dihydroindol-5-yl), dihydrobenzofuranyl (e.g. 2,3-dihydrobenzo-[b]furan-2-yl, 2,3-dihydrobenzo[b]furan-4-yl), dihydrobenzothienyl (e.g. 2,3-dihydrobenzo-[b]thien-2-yl, 2,3-dihydrobenzo[b]thien-5-yl), 4,5,6,7-tetrahydrobenzo[b]furan-5-yl), dihy-drobenzopyranyl (e.g. 3,4-dihydrobenzo[b]pyran-3-yl, 3,4-dihydrobenzo[b]pyran-6-yl, 3,4-dihydrobenzo[c]pyran-1-yl, dihydrobenzo[c]pyran-7-yl), oxazolinyl (e.g. 4,5-dihydrooxazol-2-yl, 4,5-dihydrooxazol-4-yl, 4,5-dihydrooxazol-5-yl), isoxazolinyl, oxazepinyl, tetrahydro-indazolyl (e.g. 4,5,6,7-tetrahydroindazol-1-yl, 4,5,6,7-tetrahydroindazol-3-yl, 4,5,6,7-tetrahy-droindazol-4-yl, 4,5,6,7-tetrahydroindazol-6-yl), tetrahydrobenzimidazolyl (e.g. 4,5,6,7-tetrahydrobenzimidazol-1-yl, 4,5,6,7-tetrahydrobenzimidazol-5-yl), tetrahydroimidazo[4,5-c]pyridyl (e.g. 4,5,6,7-tetrahydroimidazo[4,5-c]pyrid-1-yl, 4,5,6,7-tetrahydroimidazo[4,5-c]pyrid-5-yl, 4,5,6,7-tetrahydroimidazo[4,5-c]pyrid-6-yl), tetrahydroquinolinyl (e.g. 1,2,3,4-tetrahydroquinolinyl, 5,6,7,8-tetrahydroquinolinyl), tetrahydroisoquinolinyl (e.g. 1,2,3,4-tetra-hydroisoquinolinyl, 5,6,7,8-tetrahydroisoquinolinyl), tetrahydroquinoxalinyl (e.g. 1,2,3,4-te-trahydroquinoxalinyl, 5,6,7,8-tetrahydroquinoxalinyl), spiro[isoquinoline-3,1'-cyclohexan]-1-yl, spiro[piperidine-4,1'-benzo[c]thiophen]-1-yl, spiro[piperidine-4,1'-benzo[c]furan]-1-yl, spiro[piperidine-4,3'-benzo[b]furan]-1-yl, spiro[piperidine-4,3'-coumarin]-1-yl. A preferred heteroaryl is pyridinyl.
[00420] Other examples of "heteroaryl" are furyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, tri-azolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, isothiazolyl, isoxazolyl, oxazolyl, oxa-diazolyl, thiadiazolyl, quinolyl, isoquinolyl, quinazolinyl, quinoxalinnyl, indolyl, benzimida-zolyl, benzofuranyl, benzothienyl, pteridinyl and purinyl.
[00421] "Heterocyclyl" or "heterocycle" (heterocycle) signifies a mono-, bi-, or tricyclic ring consisting of carbon atoms and from one heteroatom to 4, wherein the heteroatom is selected from oxygen, nitrogen, and sulphur. If sulphur is present, then it can be S, S(O), or S(O)Z. If nitrogen is present, then it can be N, NH, substituted N, or N-oxide. The heterocycle is a satu-rated or partially saturated ring. From 0-2 CH2 groups of the heterocycle can be replaced by C(O). The heterocycle can be attached via a carbon or nitrogen atom, unless linking the ni-trogen atom would lead to a quaternary nitrogen. If the heterocycle is bicyclic, then one or both of the rings may have a heteroatom(s) present. If the heterocycle is tricyclic, then one, two, or all three of the rings may have a heteroatom(s) present.
[00422] Examples of "heterocycle" are aziridinyl (e.g. aziridin-l-yl), azetidinyl (e.g. azetidin-1-yl, azetidin-3-yl), oxetanyl, pyrrolidinyl (e.g. pyrrolidin-1-yl, pyrrolidin-2-yl, pyrrolidin-3-yl), imidazolidinyl (e.g. imidazolidin-1-yl, imidazolidin-2-yl, imidazolidin-4-yl), oxazolidinyl (e.g. oxazolidin-2-yl, oxazolidin-3-yl, oxazolidin-4-yl), thiazolidinyl (e.g.
thiazolidin-2-yl, thiazolidin-3-yl, thiazolidin-4-yl), isothiazolidinyl, piperidinyl (e.g.
piperidin-1-yl, piperidin-2-yl, piperidin-3-yl, piperidin-4-yl), homopiperidinyl (e.g. homopiperidin-l-yl, homopiperi-din-2-yl, homopiperidin-3-yl, homopiperidin-4-yl), piperazinyl (e.g. piperazin-1-yl, piperazin-2-yl), morpholinyl (e.g. morpholin-2-yl, morpholin-3-yl, morpholin-4-yl), thiomorpholinyl (e.g. thiomorpholin-2-yl, thiomorpholin-3-yl, thiomorpholin-4-yl), 1-oxo-thiomorpholinyl, 1,1-dioxo-thiomorpholinyl, tetrahydrofuranyl (e.g. tetrahydrofuran-2-yl, tetrahydrofuran-3-yl), tetrahydrothienyl, tetrahydro-l,l-dioxothienyl, tetrahydropyranyl (e.g. 2-tetrahydropyra-nyl), tetrahydrothiopyranyl (e.g. 2-tetrahydrothiopyranyl), 1,4-dioxanyl, 1,3-dioxanyl, octa-hydroindolyl (e.g. octahydroindol-l-yl, octahydroindol-2-yl, octahydroindol-3-yl, octahydro-indol-5-yl), decahydroquinolinyl (e.g. decahydroquinolin-l-yl, decahydroquinolin-2-yl, deca-hydroquinolin-3-yl, decahydroquinolin-4-yl, decahydroquinolin-6-yl), decahydroquinoxalinyl (e.g. decahydroquinoxalin-l-yl, decahydroquinoxalin-2-yl, decahydroquinoxalin-6-yl), 3-aza-bicyclo[3.2.2]nonyl, 2-azabicyclo[2.2.1]heptyl, 3-azabicyclo[3.1.0]hexyl, 2,5-diazabicyclo-[2.2.1]heptyl, atropinyl, tropinyl, quinuclidinyl, 1,4-diazabicyclo[2.2.2]octanyl, 1,4-dioxa-spiro[4.5]decanyl (e.g. 1,4-dioxaspiro[4.5]decan-2-yl, 1,4-dioxaspiro[4.5]decan-7-yl), 1,4-dioxa-8-azaspiro[4.5]decanyl (e.g. 1,4-dioxa-8-azaspiro[4.5]decan-2-yl, 1,4-dioxa-8-aza-spiro[4.5]decan-8-yl), 8-azaspiro[4.5]decanyl (e.g. 8-azaspiro[4.5]decan-l-yl, 8-azaspiro-[4.5]decan-8-yl), 2-azaspiro[5.5]undecanyl (e.g. 2-azaspiro[5.5]undecan-2-yl), 2,8-diaza-spiro[4.5]decanyl (e.g. 2,8-diazaspiro[4.5]decan-2-yl, 2,8-diazaspiro[4.5]decan-8-yl), 2,8-diazaspiro[5.5]undecanyl (e.g. 2,8-diazaspiro[5.5]undecan-2-yl), 1,3,8-triazaspiro[4.5]decanyl (e.g. 1,3,8-triazaspiro[4.5]decan-l-yl, 1,3,8-triazaspiro[4.5]decan-3-yl, and 1,3,8-triazaspi-ro[4.5]decan-8-yl).
[00423] Preferred examples of "heterocycle" are pyrrolidinyl, pyrrolinyl, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothiophenyl, dihydrothiophenyl, imidzolidinyl, imidazolinyl, pyra-zolidinyl, pyrazolinyl, oxazolidinyl, oxazoline, isoxazolidinyl, isoxazoline, thioxazolidinyl, thioxazoline, isothioxazolidinyl, isothioxazoline, triazolidinyl, triazolinyl, tetrazolidinyl, tetrazolinyl, tetrahydropyranyl, dihydropyranyl, pyran, piperidinyl, piperazinyl, homopiperaz-inyl, morpholinyl. Preferred heterocycle groups are piperidinyl and morpholinyl.
[00424] "Therapeutically effective amount" is intended to include an amount of a compound of the present invention that is effective when administered alone or in combination to acti-vate glucokinase.
[00425] "Treating" or "treatment" cover the treatment of a disease-state in a mammal, par-ticularly in a human, and include: (a) preventing the disease-state from occurring in a mam-mal, in particular, when such mammal is predisposed to the disease-state but has not yet been diagnosed as having it; (b) inhibiting the disease-state, e.g., arresting or slowing its develop-ment; and/or (c) relieving the disease-state, e.g., causing regression of the disease state itself or some symptom of the disease state.
[00426] Pharmaceutically acceptable include pharmaceutically acceptable acid addition salts, pharmaceutically acceptable base addition salts, pharmaceutically acceptable metal salts, am-monium salts, and alkylated ammonium salts. Acid addition salts include salts of inorganic acids as well as organic acids. Representative examples of suitable inorganic acids include hydrochloric, hydrobromic, hydroiodic, phosphoric, sulfuric, and nitric acids.
Representative examples of suitable organic acids include formic, acetic, trichloroacetic, trifluoroacetic, propionic, benzoic, cinnamic, citric, fumaric, glycolic, lactic, maleic, malic, malonic, man-delic, oxalic, picric, pyruvic, salicylic, succinic, methanesulfonic, ethanesulfonic, tartaric, ascorbic, pamoic, bismethylene salicylic, ethanedisulfonic, gluconic, citraconic, aspartic, stearic, palmitic, EDTA, glycolic, p-aminobenzoic, glutamic, benzenesulfonic, p-toluene-sulfonic acids, sulphates, nitrates, phosphates, perchlorates, borates, acetates, benzoates, hy-droxynaphthoates, glycerophosphates, and ketoglutarates. Further examples of pharmaceuti-cally acceptable inorganic or organic acid addition salts include the pharmaceutically accept-able salts listed in J. Pharm. Sci. 1977, 66, 2, which is incorporated herein by reference. Ex-amples of metal salts include lithium, sodium, potassium, magnesium, zinc, and calcium salts.
Examples of amines and organic amines include ammonium, methylamine, dimethylamine, trimethylamine, ethylamine, diethylamine, propylamine, butylamine, tetramethylamine, etha-nolamine, diethanolamine, triethanolamine, meglumine, ethylenediamine, choline, N,N'-dibenzylethylenediamine, N-benzylphenylethylamine, N-methyl-D-glucamine, and guanidine.
Examples of cationic amino acids include lysine, arginine, and histidine.
[00427] The pharmaceutically acceptable salts are prepared by reacting the compound of formula I with 1 to 4 equivalents of a base such as sodium hydroxide, sodium methoxide, so-dium hydride, potassium t-butoxide, calcium hydroxide, and magnesium hydroxide, in sol-vents such as ether, THF, methanol, t-butanol, dioxane, isopropanol, ethanol etc. Mixture of solvents may be used. Organic bases such as lysine, arginine, diethanolamine, choline, guandine and their derivatives etc. may also be used. Alternatively, acid addition salts wher-ever applicable are prepared by treatment with acids such as hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, phosphoric acid, p-toluenesulphonic acid, methanesulfonic acid, acetic acid, citric acid, maleic acid salicylic acid, hydroxynaphthoic acid, ascorbic acid, palmitic acid, succinic acid, benzoic acid, benzenesulfonic acid, and tartaric acid in solvents such as ethyl acetate, ether, alcohols, acetone, THF, dioxane etc. Mixture of solvents may also be used.
[00428] The stereoisomers of the compounds forming part of this invention may be prepared by using reactants in their single enantiomeric form in the process wherever possible or by conducting the reaction in the presence of reagents or catalysts in their single enantiomer form or by resolving the mixture of stereoisomers by conventional methods. Some of the preferred methods include use of microbial resolution, enzymatic resolution, resolving the diastereo-meric salts formed with chiral acids such as mandelic acid, camphorsulfonic acid, tartaric acid, and lactic acid wherever applicable or chiral bases such as brucine, (R)-or (S)-phenyl-ethylamine, cinchona alkaloids and their derivatives. Commonly used methods are compiled by Jaques et al in "Enantiomers, Racemates and Resolution" (Wiley Interscience, 1981).
More specifically a compound of the present invention may be converted to a 1:1 mixture of diastereomeric amides by treating with chiral amines, aminoacids, aminoalcohols derived from aminoacids; conventional reaction conditions may be employed to convert acid into an amide; the diastereomers may be separated either by fractional crystallization or chromatog-raphy and the stereoisomers of compound of formula I may be prepared by hydrolysing the pure diastereomeric amide.
[00429] The invention also encompasses prodrugs of the present compounds, which on ad-ministration undergo chemical conversion by metabolic processes before becoming active pharmacological substances. In general, such prodrugs will be functional derivatives of the present compounds, which are readily convertible in vivo into a compound of the present in-vention. Conventional procedures for the selection and preparation of suitable prodrug de-rivatives are described, for example, in "Design of Prodrugs", ed. H.
Bundgaard, Elsevier, 1985.
[00430] This invention will be better understood from the following examples, which are for purposes of illustration and are not intended to limit the invention defined in the claims which follow thereafter.

EXAMPLES
[00431] All reactions involving air-sensitive reagents were performed under nitrogen using syringe-septum cap techniques. The glassware was dried by heating with a heat-gun. MgSO4 was used to dry solutions. Solvents were removed in vacuo by rotary evaporation. Melting points were recorded on a Btichi 535. Bruker AMX 400 and Bruker DRX 300 instruments were used to record 1H NMR spectra at 400 and 300 MHz, respectively, with tetramethylsi-lane (TMS) as internal standard. Coupling constants (J) are given in Hz.
[00432] Materials [00433] Test compounds were synthesized or when commercially available they were pur-chased from Aldrich, Specs, Maybridge, or Bionet. For the synthesized compounds, the pro-cedure for synthesis and measured characteristics of the compound are stated in the example.
All compounds for which no synthesis procedure is stated in the examples are commercially available and have been purchased or were prepared by standard methods described in the lit-erature.
[00434] A general procedure may be as follows:
Scheme 1:
Br Br R4b / R4c R4b Rac X~" I I
R5d R5e R d X R4a OH X Raa O
s I
R5d \ R5e RI
#Rf)b #R'5b 5e R5o R3 R5~ O R5o R3 R5c I ~ R3 R5'~ O R5a R5bO

O O
Ralk O ~ O ~
Raik Raik R 4~ R4c R2 I R b R4c X O
R5d Raa I X O
5e RI
#,~b 5e R' R 5d R4a #nR5b R5c R3 R5a 0 RSc R3 a O R2a r R2a O O R2: I~I or Ralk Scheme 2:

Br R2 R45 / R4 R45 R4c I
X c Rd RSe X \ OH X 4 OH
\ R ~ A R5e #r:Z Raa R5~ R
R R / I
R5a Q RS I R ~ RJc RSt~ / R' ~ RSa RS R a O O
O O

Rau, I I
Rau Rauk R45 R4c R4b R4c / I

X \ O X I
Jd R4aI R4a R \ RSe R7 ~ RSd #R5L) 5e R

I /R5c RJ RSt~O R3RJ R~ R2a RJa O III Rza I I
O J~ i O ~OH R2: or Rau, Scheme 3:
R' Br R2 e R4b Rao R Ra- ( R4b Ra~
I
X~H x O
X 0 sci R-~. I X O
::p: F;sd R RRi d Rd - -Rsc Rd R5e Rsc Rs Rsa O Rs R d 0 R5 O R5b R O
O O O O ~
O O ~ O OH
Rau. I
Rau. Rau"
Rz~
R2~
R2: III ~~
[00435] The synthetic intermediate of formula I with R1 = H, R2 =Br and a carboxylic ester group e.g. [4-(3-Bromo-5-hydroxy-phenylsulfanyl)-2-methyl-phenoxy]-acetic acid ethyl ace-tate can be converted via a classical Mitsunobu reaction or a reaction can be performed be-tween the phenol and an alkyl halides (or an alkyle mesylate, triflate, tosylate or alike) to a new intermediate of formula I where X1-R1 forms a ether or thioether group and R = Br. The new intermediate can be converted via a classical Sonogashira, Heck or Suzuki coupling pro-tocol to a new intermediate where R2 is -C=C-RZa, -CH=CH-RZa or a substituted or non sub-stituted aryl or heteroaryl. It is also possible to perform the reaction in the opposite way by first performing the Sonogashira, Heck or Suzuki coupling followed by the ether forming re-action as described above. The claimed compounds can also be performed as described for [4-(3-Bromo-5-cyclopropylmethoxy-phenylsulfanyl)-2-methyl-phenoxy]-acetic acid ethyl ester by con-densing e.g. 1,3-dibromo-5-cyclopropylmethoxy-benzene or another substituted dibromo-phenyle ether with (4-Mercapto-2-methyl-phenoxy)-acetic acid ethyl ester or another substi-tuted mercaptobezene. The intermediates formed can be converted to the claimed compounds by a classical ester hydrolyses reaction from the respective esters of I
(scheme 1-3).
[00436] General procedure (A) [00437] HPLC systems [00438] HPLC method A
[00439] The RP-purification was performed on a Gilson system (4 Gilson 306 pumps, Gilson 155 detector, Gilson reodyne manual injection, Gilson 811C mixer and a Gilson 202 fraction collector) using a Phenomenex RP synergi-MAX column (3 m, 30 mm x 250 mm) with gra-dient elution, 5 % to 100 % solvent B (acetonitrile) in solvent A (water) within 40 min, 60 mL/min, detection at 210 nm, room temperature. The pooled fractions were either evaporated to dryness in vacuo, or evaporated in vacuo until the MeCN is removed, and then frozen and freeze dried.
[00440] HPLC method B
[00441] The RP-purification was performed on a Gilson system (3 Gilson 306 pumps, Gilson 170 DAD detector and a Gilson 215 liquid-handler) using a Waters X-terra RP
(10 m, 30 mm x 150 mm) with gradient elution, 5% to 95% solvent B (0.05% TFA in acetonitrile) in solvent A (0.05% TFA in water) within 15 min, 40 mL/min, detection at 210 nm, room tem-perature. The pooled fractions were either evaporated to dryness in vacuo or evaporated in vacuo until the MeCN is removed and then frozen and freeze dried.
[00442] HPLC-MS (System 1) [00443] The RP-analysis was performed on an Agilent HPLC system (1100 degasser, 1100 pump, 1100 injector and a 1100 DAD) fitted with an Agilent MS detector system Model VL
(MW 0-1000) and a S.E.D.E.R.E Model Sedex 55 ELS detector system using a Waters X-terra MS C18 column (5 m, 3.0 mm x 50 mm) with gradient elution, 5% to 95%
solvent B
(0.05% TFA in acetonitrile) in solvent A (0.05% TFA in water) within 3 min, 2.7 mL/min.
[00444] Thin layer chromatography was performed on Merck DC-Alufolien, silica gel 60 F254 and components were visualized by UV254. Flash chromatography was performed using silica gel Merck 60 size 0.04-0-063 mm and a Quad 12/25 flash system.

3,5-dibromophenol was prepared as described by Yang, et al., Synth Commun;
2003, 33, 19, 3317-3326.
[00445] Intermediates [00446] [4-(3-Bromo-5-hydroxy-benzylsulfanyl)-2-methyl-phenoxy]-acetic acid ethyl ester OH
Br A
S
[00447] Step A: tert-Butyl-(3,5-dibromo-phenoxy)-dimethyl-silane H
H3C. /'~3 0,S~ CH3 Br Br [00448] 3,5-Dibromophenol (59.6 mmol; 15 g) and imidazole (65.5 mmol; 4.5 g) were dis-solved in dichloromethane (150 mL) and tert-butyl-dimethylsilylchloride (65,5 mmol; 9,9 g) was added. The reaction mixture was stirred at room temperature for 16 hours, diluted with diethyl ether, and filtered. The organic solution was washed with saturated ammonium chlo-ride, saturated sodium hydrogen carbonate, and water and dried and evaporated to dryness.
Yield: 22 g. HPLC-MS: m/z: 366.9 (M+); Rt: 3.09 min.
[00449] Step B: 3-Bromo-5-(tert-butyl-dimethyl-silanyloxy)-benzaldehyde H3C, Y~H3 ~ \
Br ~ O
H
[00450] tert-Butyl-(3,5-dibromo-phenoxy)-dimethyl-silane (22 g; 60.08 mmol) was dissolved in THF (200 mL) in a dried reaction flask under an atmosphere of nitrogen. The mixture was cooled to -78 C and n-BuLi (1.6 N in hexane; 41.25 mL; 66.09 mmol) was added while the temperature was kept between -60 and -78 C. The mixture was stirred for 15 min. and DMF
(4.83 g; 66.08 mmol) was added. The reaction mixture was stirred for 1 h and methanol (5 mL) followed by saturated ammonium chloride was added. Etyl acetate (200 mL) was added and the organic phase was separated from the aqueous phase. The organic phase was washed with water, dried, and evaporated to dryness. The crude product was purified by flash chro-matography (heptane: dichloromethane (1:1). Yield 7 g. HPLC-MS: m/z: 317.0 (M+1); Rt:
2.7 min.
[00451] Step C: [3-Bromo-5-(tert-butyl-dimethyl-silanyloxy)-phenyl]-methanol H P3 ~

3 , .Si CH3 I \
Br OH
[00452] 3-Bromo-5-(tert-butyl-dimethyl-silanyloxy)-benzaldehyde (7 g, 22.2 mmol) was dis-solved in THF and sodium borohydride (0.92 g; 24.4 mmol) waas added. The reaction mix-ture was stirred at room temperature for 2 h and water was added, and the reaction mixture was partly avaporated to strip off THF. Ethyl acetate was added and the phases separated.
The organic phase was washed with water, dried, and evaporated to dryness.
Yield: 6.4 g;
HPLC-MS: m/z: 317.0 (M+); Rt: 2.37 min.
[00453] Step D: {4-[3-Bromo-5-(tert-butyl-dimethyl-silanyloxy)-benzylsulfanyl]-2-methyl-phenoxy}-acetic acid ethyl ester aSI, ~ \
Br S
0-1, O
I___IO O
[00454] [3-Bromo-5-(tert-butyl-dimethyl-silanyloxy)-phenyl] -methanol (6.4 g;
20.17 mmol) and (4-mercapto-2-methyl-phenoxy)-acetic acid ethyl ester (5.02 g; 22.19 mmol) were dis-solved in THF (200 mL). Tributylphosphine (8.15 g; 40.34 mmol) and 1,1'-(azodicarbonyl)-dipiperidine (10.17 g; 40.34 mmol) were added, and the reaction mixture was stirred for 14 h at room temperature. Water and ethyl acetate were added to the reaction mixture. The phases were separated. The organic phase was washed with water, dried, and evaporated. The crude product was purified by flash chromatography (heptane: dichloromethane (1:1)).
Yield: 8 g;
80%. HPLC-MS: m/z: 527.0 (M+l); Rt: 3.10 min.
[00455] Step E: [4-(3-Bromo-5-hydroxy-benzylsulfanyl)-2-methyl-phenoxy] -acetic acid ethyl ester OH
Br S
A

~OO
[00456] {4-[3-Bromo-5-(tert-butyl-dimethyl-silanyloxy)-benzylsulfanyl]-2-methyl-phenoxy}-acetic acid ethyl ester 7 g, 13.3 mmol) was dissolved in THF under an atmosphere of nitrogen. Tetrabutylammonium fluoride 1 N in THF (15 mL) was added, and the reaction mixture was stirred at 60 C for 2h. Saturated sodium carbonate and water were added to-gether with ethyl acetate, and the organic phase was separated. The organic phase was washed with water, dried, and evaporated to dryness. Yield: 3.2 g. HPLC-MS:
m/z: 435.4 (M+Na); Rt: 2.22 min.
[00457] [4-(3-Bromo-5-hydroxy-phenylsulfanyl)-2-chloro-phenoxy]-acetic acid ethyl acetate Br S O

I
CI
O OI
[00458] (2-Chloro-4-mercapto-phenoxy)-acetic acid ethyl ester (3 g; 12,16 mmol), dibromo-phenol (3,67 g; 14,59 mmol), tris(dibenzylideneacetone)dipalladium (0) (0.45 g; 0.49 mmol), and 1,1'-bis-(diphenylphosphineo)ferrocenE (0.40 g; 0.73 mmol) were added to a dry reaction flask under an atmosphere of nitrogen. Triethylamine (6,74 mL, 48,64 mmol) and NMP (10 mL) were added, and the reaction mixture was stirred in a microwave oven for 1 h at 100 C.
The reaction mixture was extracted with ethyl acetate, and the ethyl acetate phase was washed twice with a 5% aqueous citric acid solution. The organic phase was dried and evaporated in vacuo. The crude reaction product was purified by flash chromatography (dichloromethane -> dichlormethane: ethyl acetate (1:1)). Yield 1.8 g. HPLC-MS: m/z: 441.2 (M+Na); Rt:
2.34 min.
[00459] [4-(3-Bromo-5-hydroxy-phenylsulfanyl)-2-methyl-phenoxy]-acetic acid ethyl ace-tate Br i I
S ~ OH
o O O
[00460] (2-Methyl-4-mercapto-phenoxy)-acetic acid ethyl ester (6 g; 26,51 mmol), dibromo-phenol (8,68 g; 34,47 mmol), tris(dibenzylideneacetone)dipalladium (0) (0.97 g; 1,06 mmol), and 1,1'-bis-(diphenylphosphineo)ferrocene (0.88 g; 1,59 mmol) were added to a dry reaction flask under an atmosphere of nitrogen. Triethylamine (10.73 mL, 106 mmol) and NMP (20 mL) were added, and the reaction mixture was stirred in a microwave oven for 1 h at 105 C.
A 5% aqueous citric acid solution (150 mL) was added to the reaction mixture, which was extracted with ethyl acetate (4 X 100 mL). The pooled organic phases were washed twice with water (30 mL), dried and evaporated in vacuo. The crude reaction product was purified by flash chromatography (heptane: ethyl acetate (10:1 -> 7:3). Yield 6,5 g.
HPLC-MS: m/z:
397.3 (M+); Rt: 2,33 min.
[00461] {4-[3-Bromo-5-(3-morpholin-4-yl-propoxy)-phenylsulfanyl]-2-chloro-phenoxy}-acetic acid ethyl ester Br S \ O~~
\~1O
CI
O
O~ O
'CH3 [00462] [4-(3-Bromo-5-hydroxy-phenylsulfanyl)-2-chloro-phenoxy]-acetic acid ethyl acetate (1.7 g; 4.07 mmol), N-(3-hydroxypropyl)morpholine (0.59 g; 4.07 mmol) and tributyl-phosphine (1.8 g; 7.33 mmol) were dissolved in THF (100 mL) in a dried reaction flask under an atmosphere of nitrogen. 1,1'-(Azodicarbonyl)dipiperidine (1.85 g; 7,33 mmol) dissolved in THF (50 mL) was added to the reaction mixture, which was stirred at room temperature for 16 h. The reaction mixture was evaporated to dryness and purified by flash chromatography (ethyl acetate: heptane). Yield: 1.1 g. HPLC-MS: m/z: 544.0 (M+); Rt: 1.78 min.
[00463] {2-Chloro-4-[3-(4-chloro-phenylethynyl)-5-hydroxy-phenylsulfanyl]-phenoxy}-acetic acid ethyl ester ci ~~
S \~
~I OH
~ L cl O
O~O
'CH3 [00464] [4-(3-Bromo-5-hydroxy-phenylsulfanyl)-2-chloro-phenoxy]-acetic acid ethyl acetate (1.1 g; 2.63 mmol), 4-chlorophenylacetylene (1.08 g; 7.9 mmol), bis(triphenylphosphine)-palladium (II) chloride (0.15 g; 0.21 mmol) and copper iodide (0.03 g; 0.16 mmol) were dis-solved in a mixture of triethylamine (5 mL) and DMF (5 mL) under an atmosphere of nitro-gen. The reaction mixture was reacted in a microwave oven at 100 C for lh. The reaction mixture was evaporated to dryness and portioned between 5% aqueous citric acid and ethyl acetate. The organic phase was dried and evaporated to dryness. The crude product was puri-fied by flash chromatography (ethyl acetate: heptane 1:3). Yield: 1.1 g. HPLC-MS: m/z:
473.3 (M+); Rt: 2.76 min.
[00465] [4-(3-hydroxy-5-phenylethynyl-phenylsulfanyl)-2-methyl-phenoxy]-acetic acid ethyl ester OH
\ I
S
[00466] [4-(3-Bromo-5-hydroxy-phenylsulfanyl)-2-methyl-phenoxy]-acetic acid ethyl acetate (3 g; 7.55 mmol), 3-phenyl-l-propyn (2.63 g; 22.65 mmol), bis(triphenylphosphine)palladium (11) chloride (0.42 g; 0.60 mmol) and copper iodide (0.086 g; 0.45 mmol) were dissolved in a mixture of triethylamine (3 mL) and DMF (6 mL) under an atmosphere of nitrogen. The reac-tion mixture was reacted in a microwave oven at 100 C for 11h. The reaction mixture was evaporated to dryness, and portioned between 5% aqueous citric acid and ethyl acetate. The organic phase was dried and evaporated to dryness. The crude product was purified by prepa-rative HPLC method A. Yield: 1.4 g. HPLC-MS: m/z: 433.3 (M+); Rt: min.
[00467] [4-(3-Hydroxy-5-phenylethynyl-phenylsulfanyl)-2-methyl-phenoxy]-acetic acid ethyl ester I I

S OH
O

OO
[00468] [4-(3-Bromo-5-hydroxy-phenylsulfanyl)-2-methyl-phenoxy]-acetic acid ethyl acetate (2.3 g; 5.79 mmol), phenylacetylene (1.9 mL; 17.4 mmol), bis(triphenylphosphine)palladium (11) chloride (0.33 g; 0.46 mmol) and copper iodide (0.07 g; 0.35 mmol) were dissolved in a mixture of triethylamine (7 mL) and DMF (8 mL) under an atmosphere of nitrogen. The reac-tion mixture was reacted in a microwave oven at 100 C for lh. The reaction mixture was evaporated to dryness, and 5% aqueous citric acid and ethyl acetate was added.
The organic phase was separated, dried and evaporated to dryness. The crude product was purified by flash chromatography (ethyl acetate: heptane 1:10 -> 1:3). Yield: 1.2 g. HPLC-MS: m/z: 419 (M+); Rt: 2.52 min.
[00469] {4-[3-Hydroxy-5-(3-morpholin-4-yl-prop-1-ynyl)-phenylsulfanyl]-2-methyl-phenoxy}-acetic acid ethyl ester CoJ

\\ / OH

H3C'00 [00470] [4-(3-Bromo-5-hydroxy-phenylsulfanyl)-2-methyl-phenoxy]-acetic acid ethyl acetate (3 g; 7.55 mmol), 4-prop-2-ynyl-morpholine (2.8 g; 22.65 mmol), bis(triphenylphosphine)-palladium (11) chloride (0.42 g; 0.60 mmol) and copper iodide (0.09 g; 0.45 mmol) were dis-solved in a mixture of triethylamine (7 mL) and DMF (8 mL) under an atmosphere of nitro-gen. The reaction mixture was reacted in a microwave oven at 100 C for 1.5 h.
The reaction mixture was purified by preparative HPLC (method A). Yield: 1.4 g. HPLC-MS:
m/z: 442.4 (M+); Rt: 1.54 min.
[00471] {4-[3-Hydroxy-5-(3-morpholin-4-yl-prop-1-ynyl)-benzylsulfanyl]-2-methyl-phenoxy}-acetic acid ethyl ester OH
ON

~_CH, H3C'00 [00472] [4-(3-Bromo-5-hydroxy-benzylsulfanyl)-2-methyl-phenoxy]-acetic acid ethyl ester (2.3 g; 5.6 mmol), 4-prop-2-ynyl-morpholine (2.1 g; 16.8 mmol), bis(triphenylphosphine)-palladium (11) chloride (0.31 g; 0.45 mmol) and copper iodide (0.06 g; 0.34 mmol) were dis-solved in a mixture of triethylamine (5 mL) and DMF (10 mL) under an atmosphere of nitro-gen. The reaction mixture was reacted in a microwave oven at 100 C for lh.
The reaction mixture was purified by preparative HPLC (method A). Yield: 0.9 g. HPLC-MS:
m/z: 456.1 (M+); Rt: 1.53 min.
[00473] {4-[3-Hydroxy-5-(3-phenyl-prop-1-ynyl)-benzylsulfanyl]-2-methyl-phenoxy}-acetic acid ethyl ester OH

O

H3C'OO
[00474] [4-(3-Bromo-5-hydroxy-benzylsulfanyl)-2-methyl-phenoxy]-acetic acid ethyl ester (2 g; 4.9 mmol), 3-phenyl-l-propyn (1.7 g; 14.6 mmol), bis(triphenylphosphine)palladium (II) chloride (0.27 g; 0.39 mmol) and copper iodide (0.056 g; 0.29 mmol) were dissolved in a mixture of triethylamine (5 mL) and DMF (10 mL) under an atmosphere of nitrogen. The re-action mixture was reacted in a microwave oven at 100 C for lh. Further 3-phenyl-l-propyn (1.7 g; 14.6 mmol) was added and the reaction mixture was reacted in a microwave oven at 100 C for further lh. The reaction mixture was purified by preparative HPLC
(method A).
Yield: 0.8 g. HPLC-MS: m/z: 434.6 (M+1); Rt: 2.43 min.
[00475] {4- [3-Bromo-5-cyclohexylmethoxy-phenylsulfanyl)-2-methyl-phenoxy] -acetic acid ethyl ester ra Br ~ O
~ /

I ~ O

y r O
[00476] [4-(3-Bromo-5-hydroxy-phenylsulfanyl)-2-methyl-phenoxy]-acetic acid ethyl acetate ester (0.23 g; 0.58 mmol), cyclohexyl-methanol (80 l; 0.64 mmol) and tributylphosphine (0.21 mL; 0.87 mmol) were dissolved in THF (10 mL) in a dried reaction flask under an at-mosphere of nitrogen. 1,1'-(Azodicarbonyl)dipiperidine (0.22 g; 0,87 mmol) dissolved in THF (10 mL) was added to the reaction mixture, which was stirred at room temperature for 2 days. The reaction mixture was filtered, evaporated to dryness and purified by flash chroma-tography (ethyl acetate: heptane 1:1). Yield: 100 mg. HPLC-MS: m/z: 493.4 (M)+; Rt: 3.17 min.
[00477] {4- [3-Bromo-5-cyclopentylmethoxy-phenylsulfanyl)-2-methyl-phenoxy] -acetic acid ethyl ester Br / I

S \ O
I ~ ~ ~
CH3 ~ul O

O O
[00478] 1,3-Dibromo-5-cyclopentylmethoxy-benzene.
[00479] 3,5-Dibromophenol (5.0 g; 19.8 mmol), cyclopentane-methanol (2.0 g;
19.9 mmol) and tributylphosphine (8.8 mL; 35.7 mmol) were dissolved in dry THF (250 mL) in a dried reaction flask under an atmosphere of nitrogen. 1,1'-(Azodicarbonyl)dipiperidine (9.01 g;
35.7 mmol) dissolved in dry THF (150 mL) was added to the reaction mixture, which was stirred at room temperature for 16 hours. The reaction mixture was filtered, evaporated to dryness and purified by flash chromatography (heptane -> ethyl acetate:
heptane 2:3). Yield:
5.68 g; 86 %.
[00480] [4-(3-Bromo-5-cyclopentylmethoxy-phenylsulfanyl)-2-methyl-phenoxy]-acetic acid ethyl ester.
[00481] 1,3-Dibromo-5-cyclopentylmethoxy-benzene (2.9 g; 8.6 mmol), (4-Mercapto-2-methyl-phenoxy) -acetic acid ethyl ester (1.5 g; 6.6 mmol), tris(dibenzylideneacetone)-dipalladium(0) (0.18g, 0.20 mmol) and 1,1'-bis(diphenylphosphino)-ferrocen (0.22 g; 0.40 mmol) was added to a dried microwave flask under an atmosphere of nitrogene.
The reaction flask was sealed and dry NMP (10 mL) and TEA (3,7 mL; 26.5 mmol) was added through the septum. The reaction flask was reacted in a microwave oven at 140 C for lh.
Ethyl acetate (30 mL) and aqueous 5% citric acid (30 mL) was added to the reaction mixture and the phases were separated. The aqueous phase was extracted with ethyl acetate (30 mL X 2) and the pooled organic phases were dried (MgSO4) and evaporated to dryness. The reaction mixture was purified by flash chromatography (heptane -> heptane: ethyl acetate (9:11/2). Yield: 1.45 g (46%). HPLC-MS: m/z: 479.8 (M)+; Rt: 3.18 min.
[00482] {4-[3-Bromo-5-isobutoxy-phenylsulfanyl)-2-methyl-phenoxy]-acetic acid ethyl ester Br / I

S \ O
Y
O

O~O
[00483] {4-[3-Bromo-5-isobutoxy-phenylsulfanyl)-2-methyl-phenoxy]-acetic acid ethyl ester was prepared as described for {4-[3-Bromo-5-cyclopentylmethoxy-phenylsulfanyl)-2-methyl-phenoxy]-acetic acid ethyl ester. Yield: 45%. HPLC-MS: m/z:. 454.8 (M+H)+; Rt:
3.07 min.
[00484] (4-{ 3-Bromo-5-[2-(4-chloro-phenyl)-ethoxy]-phenylsulfanyl}-2-methyl-phenoxy)-acetic acid ethyl ester Br \ CI
S O

O
[00485] (4-{ 3-Bromo-5-[2-(4-chloro-phenyl)-ethoxy]-phenylsulfanyl}-2-methyl-phenoxy)-acetic acid ethyl ester was prepared as described for {4-[3-Bromo-5-cyclopentylmethoxy-phenylsulfanyl)-2-methyl-phenoxy]-acetic acid ethyl ester. Yield: 25%. HPLC-MS:
m/z:.537.1 (M+2); Rt: 3.11 min.
[00486] { 4- [3-Bromo-5-(2-ethyl-butoxy)-phenylsulfanyl] -2-methyl-phenoxy } -acetic acid ethyl ester Br S ~ Q~CH3 I ~. H3C

L, CH3 [00487] {4-[3-Bromo-5-(2-ethyl-butoxy)-phenylsulfanyl]-2-methyl-phenoxy}-acetic acid ethyl ester was prepared as described for {4-[3-Bromo-5-cyclopentylmethoxy-phenyl-sulfanyl)-2-methyl-phenoxy]-acetic acid ethyl ester. Yield: 63%. HPLC-MS:
m/z:. 481.0 (M)+; Rt: 3.20 min.
[00488] [4-(3-Bromo-5-cyclopentyloxy-phenylsulfanyl)-2-methyl-phenoxy]-acetic acid ethyl ester Br O

O_~ O
[00489] [4-(3-Bromo-5-cyclopentyloxy-phenylsulfanyl)-2-methyl-phenoxy]-acetic acid ethyl ester was prepared as described for {4-[3-Bromo-5-cyclopentylmethoxy-phenylsulfanyl)-2-methyl-phenoxy]-acetic acid ethyl ester. Yield: 51%. HPLC-MS: m/z:.565.0 (M)+;
Rt: 3.04 min.
[00490] {4-[3-Bromo-5-(4-methanesulfonyl-benzyloxy)-phenylsulfanyl]-2-methyl-phenoxy}-acetic acid ethyl ester Br / I
O
S \ O

pS'CHs O
OO
L, CH3 [00491] {4-[3-Bromo-5-(4-methanesulfonyl-benzyloxy)-phenylsulfanyl]-2-methyl-phenoxy}-acetic acid ethyl ester was prepared as described for {4-[3-Bromo-5-cyclopentylmethoxy-phenylsulfanyl)-2-methyl-phenoxy]-acetic acid ethyl ester. Yield: 9%. HPLC-MS:
m/z: 565.2 (M)+; Rt: 2.58 min.
[00492] { 4- [3-Bromo-5-(2-cyclohexyl-ethoxy)-phenylsulfanyl] -2-methyl-phenoxy } -acetic acid ethyl ester Br S \ 0 ~ CH3 O

O~ OI
'CH3 [00493] {4-[3-Bromo-5-(2-cyclohexyl-ethoxy)-phenylsulfanyl]-2-methyl-phenoxy}-acetic acid ethyl ester was prepared as described for {4-[3-Bromo-5-cyclopentylmethoxy-phenyl-sulfanyl)-2-methyl-phenoxy]-acetic acid ethyl ester. Yield: 51%. HPLC-MS:
m/z:. 508.8 (M+H)+; Rt: 3.33 min.
[00494] {4-[3-Bromo-5-(3-trifluoromethyl-pyridin-2-yloxy)-phenylsulfanyl]-2-methyl-phenoxy}-acetic acid ethyl ester Br / I

S \ O F
N'~ I FF

O
O~OI
'CH3 [00495] 2-(3,5-Dibromo-phenoxy)-3-trifluoromethyl-pyridine.
[00496] 3,5-Dibromophenol (2.0 g; 7.9 mmol), 2-chloro-3-triflouropyridine (1.4 g; 7.9 mmol), potassium hydroxide (0.45 g; 7.9 mmol) and DMSO (40 mL) was added to a reaction flask under an atmosphere of nitrogen. The reaction mixture was reacted at 110 C for 6 h.
The reaction mixture was cooled to room temperature and ethyl acetate (30 ml) and water (120 mL) was added. The organic phase was separated form the aqueous phase and the aque-ous phase was extracted with ethyl acetate (30 mL X 4). The combined organic phases were dried, evaporated to dryness and purified by flash chromatography (heptane ->
ethyl acetate:
heptane 1:8). Yield: 2.23 g; 71 %. HPLC-MS: m/z: 397.9 (M)+; Rt: 2.58 min.
[00497] {4-[3-Bromo-5-(3-trifluoromethyl-pyridin-2-yloxy)-phenylsulfanyl]-2-methyl-phenoxy}-acetic acid ethyl ester [00498] 2-(3,5-Dibromo-phenoxy)-3-trifluoromethyl-pyridine (2.05 g; 5.17 mmol) and (4-Mercapto-2-methyl-phenoxy) -acetic acid ethyl ester (0.9 g; 4.0 mmol) was condensed to give the title product applying the procedure described for {4-[3-Bromo-5-cyclopentylmethoxy-phenylsulfanyl)-2-methyl-phenoxy]-acetic acid ethyl ester. The crude product was purified by flash chromatography (heptane -> ethyl acetate: heptane 2:9). Yield 1.26 g (58%). HPLC-MS: m/z: 544.3 (M+2); Rt: 2.77 min.
[00499] {4-[3-Bromo-5-(5-trifluoromethyl-pyridin-2-yloxy)-phenylsulfanyl]-2-methyl-phenoxy}-acetic acid ethyl ester Br / I

S \ O
N
TF
O
F F
O O
[00500] 2-(3,5-Dibromo-phenoxy)-5-trifluoromethyl-pyridine.
[00501] The title product was prepared as described for 2-(3,5-Dibromo-phenoxy)-3-tri-fluoromethyl-pyridine Yield: 70%; HPLC-MS: m/z: 397.7 (M)+; Rt 2.60 min.
[00502] {4-[3-Bromo-5-(5-trifluoromethyl-pyridin-2-yloxy)-phenylsulfanyl]-2-methyl-phenoxy}-acetic acid ethyl ester [00503] 2-(3,5-Dibromo-phenoxy)-5-trifluoromethyl-pyridine (2.5 g; 6.3 mmol) and (4-Mercapto-2-methyl-phenoxy) -acetic acid ethyl ester (1.1 g; 4.9 mmol) was condensed to give the title product applying the procedure described for {4-[3-Bromo-5-cyclopentylmethoxy-phenylsulfanyl)-2-methyl-phenoxy]-acetic acid ethyl ester. The crude product was purified by flash chromatography (heptane -> ethyl acetate: heptane 2:9). Yield 1.4 g (53%). HPLC-MS:
m/z: 544.3 (M+2); Rt: 2.80 min.
[00504] {4-[3-Bromo-5-(3-trifluoromethyl-phenoxy)-phenylsulfanyl]-2-methyl-phenoxy}-acetic acid ethyl ester Br S ~ O
I
F
O F F

O~O
[00505] 1,3-Dibromo-5-(3-trifluoromethyl-phenoxy)-benzene.
[00506] 3,5-Dibromophenol (4.1 g; 16.2 mmol), 3-(triflouromethyl)-phenylboronic acid (6.2 g; 32.4 mmol), Cu(II) acetate (2.9 g; 16.2 mmol), TEA (5.6 mL; 40.5 mmol) and dichloro-methane (150 mL) and molecular sieves (2 ml) was added to a reaction flask the reaction mix-ture was stirred for 7 days. Further 3-(triflouromethyl)-phenylboronic acid (6.2 g; 32.4 mmol) was added and the reaction mixture stirred for 1 day. Further 3-(triflouromethyl)-phenyl-boronic acid (6.2 g; 32.4 mmol) and TEA (5.6 mL; 40.5 mmol) was added and the reaction mixture stirred for 1 day. 5% Aqueous citric acid (150 mL) was added and the two phases were separated. The aqueous phase was extracted with dichloromethane (50 mL X
2) and the organic phases were pooled, dried and evaporated to dryness. The crude product purified by flash chromatography (heptane -> ethyl acetate: heptane 1:9). Yield: 1.86 g;
HPLC-MS: m/z:
397. (M+H)+; Rt: 2.78 min.
[00507] {4-[3-Bromo-5-(3-trifluoromethyl-phenoxy)-phenylsulfanyl]-2-methyl-phenoxy}-acetic acid ethyl ester [00508] 1,3-Dibromo-5-(3-trifluoromethyl-phenoxy)-benzene (1.35 g; 3.4 mmol) and (4-Mercapto-2-methyl-phenoxy) -acetic acid ethyl ester (0.7 g; 3.1 mmol) was condensed to give the title product applying the procedure described for {4-[3-Bromo-5-cyclopentylmethoxy-phenylsulfanyl)-2-methyl-phenoxy]-acetic acid ethyl ester. The crude product was purified by preparative HPLC (Method A) followed by flash chromatography (dichloromethane:
heptane 3:7). Yield 0.5 g. HPLC-MS: m/z: 541.3 (M)+; Rt: 3.03 min.
[00509] [4-(3-Bromo-5-cyclopropylmethoxy-benzylsulfanyl)-2-methyl-phenoxy]-acetic acid ethyl ester Br ~ O
S

O_~O
[00510] [4-(3-Bromo-5-hydroxy-benzylsulfanyl)-2-methyl-phenoxy]-acetic acid ethyl ester (1.0 g; 2.43 mmol), cyclopropylcarbinol (175 mg; 2.43 mmol) and tributylphosphine (1.07 mL; 4.38 mmol) was dissolved in THF (100 mL) in a dried reaction flask under an atmos-phere of nitrogen. 1,1'-(Azodicarbonyl)dipiperidine (1.1 g; 4,38 mmol) dissolved in THF (20 mL) was added to the reaction mixture, which was stirred at room temperature for 16 hours.
The reaction mixture was filtered, evaporated to dryness and purified by flash chromatogra-phy (ethyl acetate: heptane 1:9 -> 2:3). Yield: 980 mg; 86%; HPLC-MS: mlz:
465.0 (M)+; Rt:
2.74 min.
[00511] [4-(3-Bromo-5-cyclopropylmethoxy-phenylsulfanyl)-2-methyl-phenoxy]-acetic acid ethyl ester Br / I
S \ 0"7 V

O
O~O
L
[00512] Step A: 1,3-Dibromo-5-cyclopropylmethoxy-benzene [00513] 3,5-Dibromo-phenol (5g; 19.9 mmol), cyclopropylcarbinol (1.4 g; 19.9 mmol) and tributylphosphine (8.8 mL; 35.7 mmol) were dissolved in THF (500 mL) in a dried reaction flask under an atmosphere of nitrogen. 1,1'-(Azodicarbonyl)dipiperidine (9.0 g; 35,7 mmol) dissolved in THF (100 mL) was added to the reaction mixture, which was stirred at room temperature for 16 hours. The reaction mixture was partly evaporated, filtered, evaporated to dryness and purified by flash chromatography (ethyl acetate: heptane 0:1 ->
1:10). Yield: 5.45 g; 90%.
[00514] Step B: [4-(3-Bromo-5-cyclopropylmethoxy-phenylsulfanyl)-2-methyl-phenoxy]-acetic acid ethyl ester [00515] 1,3-Dibromo-5-cyclopropylmethoxy-benzene (5.27 g; 17,23 mmol), (4-Mercapto-2-methyl-phenoxy) -acetic acid ethyl ester (3g; 13.26 mmol), tris(dibenzylideneacetone)dipal-ladium (0) (0.36 g; 0,40 mmol), and 1,1'-bis-(diphenylphosphineo)ferrocene (0.44 g; 0,80 mmol) was added to a dry reaction flask under an atmosphere of nitrogen.
Triethylamine (7.45 mL) and NMP (8 mL) was added, and the reaction mixture was stirred in a microwave oven for 1 h at 140 C. A 5% aqueous citric acid solution (150 mL) was added to the reaction mixture, which was extracted with ethyl acetate (4 X 100 mL). The pooled organic phases were dried and evaporated in vacuo. The crude reaction product was purified by flash chroma-tography (heptane: ethyl acetate (20:1 -> 7:3). Yield 2.8 g; 47%). HPLC-MS:
m/z: 451.0 (M+); Rt: 2.85 min [00516] [4-(3-Bromo-5-isobutoxy-phenylsulfanyl)-2,5-dimethyl-phenoxy]-acetic acid ethyl ester Br / I

S \ O'_~
O

O~O
[00517] Step Al: 1,3-Dibromo-5-isobutoxy-benzene [00518] Potassium hydroxide (15.9g; 284 mmol) was dissolved in water (300 ml) and 3,5-dibromo-phenol (47g; 188.5 mmol) was added. Benzyl tributylammoniumchloride (17.7g;
56.8 mmol) and toluene (200 ml) was added and the reaction mixture was heated to 85 C.

Bromoethylpropan (32.3 g; 325.7 mmol) was added over 5 hours and the reaction mixture was stirred at 85 C for additional 16 h. The reaction mixture was cooled to room temperature and the phases were separated. Toluene (100 ml) was added to the organic phase which was washed with 0.2 N aqueous HCl (200 ml X 2) and water (200 ml X 2). The organic phase was evaporated to give the crude product which was purified by distillation (0.7.mm Hg; Bp: 98 C); Yield: 43 g (colourless oil).
[00519] Step A2: (4-Mercapto-2,5-dimethyl-phenoxy)-acetic acid ethyl ester [00520] (4-Mercapto-2,5-dimethyl-phenoxy)-acetic acid ethyl ester was prepared as de-scribed for 2,6-difluoro-4-mercapto-phenoxy)acetic acid methyl ester (compound 21) in Eur.
J. Med. Chem, 1995, 30, 403 (Kawashima, M. S.) except that (4-chlorosulfonyl-2,5-dimethyl-phenoxy)-acetic acid ethyl ester was reduced with 4 eq. of zn (dust) in a mixture of konc. sul-furic acid and ethanol at 80 C.
[00521] Step B: [4-(3-Bromo-5-isobutoxy-phenylsulfanyl)-2,5-dimethyl-phenoxy]-acetic acid ethyl ester [00522] 1,3-Dibromo-5-isobutoxy-benzene (1.66 g; 5.4 mmol), (4-Mercapto-2,5-dimethyl-phenoxy)-acetic acid ethyl ester (1.0 g; 4.1 mmol), tris(dibenzylideneacetone)dipalladium (0) (0.11 g; 0,12 mmol), and 1,1'-bis-(diphenylphosphineo)ferrocene (0.14 g; 0,25 mmol) were added to a dry reaction flask under an atmosphere of nitrogen. Triethylamine (2.3 mL) and NMP (10 mL) was added, and the reaction mixture was stirred in a microwave oven for 1 h at 140 C. A 5% aqueous citric acid solution (150 mL) was added to the reaction mixture, which was extracted with ethyl acetate (4 X 100 mL). The pooled organic phases were dried and evaporated in vacuo. The crude reaction product was purified by flash chromatography (hep-tane: ethyl acetate (10:1 -> 1:1). Yield: 1.3 g; 67%. HPLC-MS: m/z: 467.0 (M+); Rt: 3.10 min [00523] [4-(3-Bromo-5-isobutoxy-phenoxy)-2-methyl-phenoxy] -acetic acid methyl ester Br I
O \ O_ O

OO
[00524] Step A: 3-Bromo-5-isobutoxy-phenylboronic acid [00525] 1,3-Dibromo-5-isobutoxy-benzene (1. g; 3.3 mmol) was dissolved in dry THF (30 ml) in a dry reaction under stirring. The reaction mixture was cooled to -70 C and n-BuLi (2M; 2.44 ml) was added. The reaction mixture was stirred for 15 min. and triisobutylborate (1.50 ml; 6.5 mmol) was added at -70 C. The temperature was raised to -30 C
and stirred for 11/2 hour followed by a temperature increase to room temperature. The reaction mixture was quenched with saturated aqueous sodium hydrogen carbonate (about 3 ml) and evaporated to dryness. The crude product was purified by prep HPLC (method B). Yield: 430 mg; 49 %.
HPLC-MS: m/z: 272.9 (M+); Rt: 2.08 min [00526] Step B: [4-(3-Bromo-5-isobutoxy-phenoxy)-2-methyl-phenoxy]-acetic acid methyl ester [00527] (4-Hydroxy-2-methyl-phenoxy) -acetic acid methyl ester ( 215 mg; 1.1 mmol), 3-Bromo-5-isobutoxy-phenylboronic acid (523.4; 1.9 mmol), copper(II) acetate (199 mg; 1.1 mmol), crushed molsieves (about lg) and triethylamine (0.46 ml; 3.3 mmol) was dissolved in dichloromethane (40 ml) and stirred over night. The reaction mixture was filtered through celite and evaporated to dryness. The crude product was purified by preperative HPLC
(method B). Yield: 300 mg; 65%. HPLC-MS: m/z: 423.5 (M+); Rt: 2.71 min [00528] Example 1 [00529] {2-Chloro-4-[3-(4-chloro-phenylethynyl)-5-(3-piperidin-1-yl-propoxy)-phenyl-sulfanyl] -phenoxy } -acetic acid ci ~~
S \~ \
iO-'--N

ti ~ cl O

O~OH
[00530] Step A: {2-Chloro-4-[3-(4-chloro-phenylethynyl)-5-(3-piperidin-1-yl-propoxy)-phenylsulfanyl]-phenoxy}-acetic acid ethyl ester [00531] [ { 2-Chloro-4-[3-(4-chloro-phenylethynyl)-5-hydroxy-phenylsulfanyl]-phenoxy } -acetic acid ethyl ester (0.4 g; 0.85 mmol), 3-piperidin-l-yl-propan-l-ol (0.12 g; 0.85 mmol) and tributylphosphine (0.37 mL; 1.5 mmol) were dissolved in THF (50 mL) in a dried reac-tion flask under an atmosphere of nitrogen. 1,1'-(Azodicarbonyl)dipiperidine (0.38 g; 1,5 mmol) dissolved in THF (25 mL) was added to the reaction mixture, which was stirred at room temperature for 16 h. The reaction mixture was evaporated to dryness and 5% aqueous citric acid and ethyl acetate was added. The organic phase was separated, dried, evaporated to dryness, and purified by prep HPLC (method A). Yield: 275 mg. HPLC-MS: m/z:
598.0 (M+); Rt: 2.3 min.
[00532] Step B: {2-Chloro-4-[3-(4-chloro-phenylethynyl)-5-(3-piperidin-1-yl-propoxy)-phenylsulfanyl] -phenoxy } -acetic acid [00533] {2-Chloro-4-[3-(4-chloro-phenylethynyl)-5-(3-piperidin-1-yl-propoxy)-phenyl-sulfanyl]-phenoxy}-acetic acid ethyl ester (275 mg; 0.46 mmol) was dissolved in ethanol (15 mL) and aqueous 1N sodium hydroxide (3 mL) was added. The reaction mixture was stirred for 16 h, acidified with 5% aqueous citric acid, and extracted with ethyl acetate. The organic phase was dried and evaporated to dryness. Yield: 200 mg. HPLC-MS: mlz: 570.0 (M+); Rt:
2.07 min.
[00534] Example 2 [00535] { 2-Methyl-4-[3-(3-morpholin-4-yl-propoxy)-5-phenylethynyl-phenylsulfanyl]-phenoxy } -acetic acid ~1~
O

O
O~OH
[00536] Step A: {2-Methyl-4-[3-(3-morpholin-4-yl-propoxy)-5-phenylethynyl-phenyl-sulfanyl]-phenoxy}-acetic acid ethyl ester [00537] [4-(3-Hydroxy-5-phenylethynyl-phenylsulfanyl)-2-methyl-phenoxy]-acetic acid ethyl ester (0.25 g; 0.60 mmol), 3-morpholin-4-yl-propan-l-ol (0.12 g; 0.84 mmol) and tribu-tylphosphine (0.27 mL; 1.08 mmol) were dissolved in THF (20 mL) in a dried reaction flask under an atmosphere of nitrogen. 1,1'-(Azodicarbonyl)dipiperidine (0.27 g;
1,08 mmol) dis-solved in THF (10 mL) was added to the reaction mixture, which was stirred at room tempera-ture for 16 h. The reaction mixture was evaporated to dryness, acetonitrile added, and the mixture filtered. The solution was purified by prep HPLC (method A). Yield:
150 mg.
HPLC-MS: m/z: 546.6 (M+H); Rt: 2.08 min.
[00538] Step B: {2-Methyl-4-[3-(3-morpholin-4-yl-propoxy)-5-phenylethynyl-phenyl-sulfanyl] -phenoxy } -acetic acid [00539] { 2-Methyl-4-[3-(3-morpholin-4-yl-propoxy)-5-phenylethynyl-phenylsulfanyl]-phenoxy}-acetic acid ethyl ester (150 mg; 0.28 mmol) was dissolved in ethanol (15 mL), and aqueous 1N sodium hydroxide (3 mL) was added. The reaction mixture was stirred for 16 h, acidified with 1N aqueous hydrochloric acid, and extracted with ethyl acetate.
The organic phase was dried and evaporated to dryness. Yield: 110 mg. HPLC-MS: mlz: 518.1 (M+H);
Rt: 1.86 min.
[00540] Example 3 [00541] { 2-Chloro-4-[3-(4-chloro-phenylethynyl)-5-(3-morpholin-4-yl-propoxy)-phenyl-sulfanyl] -phenoxy } -acetic acid a I I

S N~
~O
/ CI
O
O~OH
[00542] Step A: {2-Chloro-4-[3-(4-chloro-phenylethynyl)-5-(3-morpholin-4-yl-propoxy)-phenylsulfanyl]-phenoxy}-acetic acid ethyl ester [00543] [ { 2-Chloro-4- [3-(4-chloro-phenylethynyl)-5-hydroxy-phenylsulfanyl] -phenoxy } -acetic acid ethyl ester (293 mg; 0.62 mmol) was dissolved in THF (15 mL) in a dried reaction flask under an atmosphere of nitrogen. 3-morpholin-4-yl-propan-l-ol (75 mg;
0.52 mmol) and tributylphosphine (0.23 mL; 0.93 mmol) was added followed by 1,1'-(Azodicarbonyl)-dipiperidine (0.38 g; 1,5 mmol) dissolved in THF (10 mL). The reaction mixture was stirred at room temperature for 16 h, filtered and evaporated in vacuo. The crude product was puri-fied by prep. HPLC (method B). Yield: 200 mg. HPLC-MS: m/z: 600.4 (M+); Rt:
2.2 min.
[00544] Step B: {2-Chloro-4-[3-(4-chloro-phenylethynyl)-5-(3-morpholin-4-yl-propoxy)-phenylsulfanyl] -phenoxy } -acetic acid [00545] { 2-Chloro-4-[3-(4-chloro-phenylethynyl)-5-(3-morpholin-4-yl-propoxy)-phenyl-sulfanyl]-phenoxy}-acetic acid ethyl ester (200 mg; 0.33 mmol) was dissolved in ethanol (10 mL), and aqueous 1N sodium hydroxide (3 mL) was added. The reaction mixture was stirred for 16 h, acidified with 1N aqueous hydrochloric acid, and extracted with ethyl acetate. The organic phase was dried, evaporated to dryness, and purified by prep. HPLC
(method A).
Yield: 46 mg. HPLC-MS: m/z: 572.3 (M+); Rt: 2.03 min.
[00546] Example 4 [00547] { 2-Chloro-4-[3-(4-chloro-phenylethynyl)-5-(4-morpholin-4-ylmethyl-benzyloxy)-phenylsulfanyl] -phenoxy } -acetic acid cl I I

s o ~ O
I~ CI I i NJ
O

OOH
[00548] Step A: {2-Chloro-4-[3-(4-chloro-phenylethynyl)-5-(4-morpholin-4-ylmethyl-benzyloxy)-phenylsulfanyl]-phenoxy}-acetic acid ethyl ester [00549] {2-Chloro-4-[3-(4-chloro-phenylethynyl)-5-hydroxy-phenylsulfanyl]-phenoxy}-acetic acid ethyl ester (274 mg; 0.58 mmol) was dissolved in THF (15 mL) in a dried reaction flask under an atmosphere of nitrogen. (4-Morpholin-4-ylmethyl-phenyl)-methanol (100 mg;
0.48 mmol) and tributylphosphine (0.21 mL; 0.87 mmol) was added followed by 1,1'-(Azodi-carbonyl)dipiperidine (0.22 g; 0.87 mmol) dissolved in THF (10 mL). The reaction mixture was stirred at room temperature for 5 h, filtered and evaporated in vacuo. The crude product was purified by prep. HPLC (method A). Yield: 250 mg. HPLC-MS: m/z: 663.0 (M+H); Rt:
2.47 min.
[00550] Step B: {2-Chloro-4-[3-(4-chloro-phenylethynyl)-5-(4-morpholin-4-ylmethyl-benzyloxy)-phenylsulfanyl]-phenoxy}-acetic acid [00551] { 2-Chloro-4-[3-(4-chloro-phenylethynyl)-5-(4-morpholin-4-ylmethyl-benzyloxy)-phenylsulfanyl]-phenoxy}-acetic acid ethyl ester (250 mg; 0.38 mmol) was dissolved in etha-nol (10 mL), and aqueous 1N sodium hydroxide (5 mL) was added. The reaction mixture was stirred for 16 h, acidified with 1N aqueous hydrochloric acid, and extracted with ethyl acetate.
The organic phase was dried, evaporated to dryness and purified by prep. HPLC
(method A).
Yield: 32 mg. HPLC-MS: mlz: 634.5 (M+); Rt: 2.21 min.
[00552] Example 5 [00553] {2-Chloro-4-[3-(4-chloro-phenylethynyl)-5-(1-methyl-piperidin-4-ylmethoxy)-phenylsulfanyl] -phenoxy } -acetic acid CI

~~
s ~~ \
i I O

N
CI
O
O~OH
[00554] Step A: {2-Chloro-4-[3-(4-chloro-phenylethynyl)-5-(1-methyl-piperidin-4-yl-methoxy)-phenylsulfanyl]-phenoxy}-acetic acid ethyl ester [00555] {2-Chloro-4-[3-(4-chloro-phenylethynyl)-5-hydroxyl-phenylsullfanyl]-phenoxy}-acetic acid ethyl ester (274 mg; 0.58 mmol) was dissolved in THF (15 mL) in a dried reaction flask under an atmosphere of nitrogen. 1-(Methyl-piperidin-4-yl)-methanol (100 mg; 0.48 mmol) and tributylphosphine (0.21 mL; 0.87 mmol) were added followed by 1,1'-(Azodi-carbonyl)dipiperidine (0.22 g; 0.87 mmol) dissolved in THF (10 mL). The reaction mixture was stirred at room temperature for 5 h, filtered, and evaporated in vacuo.
The crude product was purified by prep. HPLC (method B). Yield: 250 mg. HPLC-MS: m/z: 663.0 (M+H); Rt:
2.47 min.
[00556] Step B: {2-Chloro-4-[3-(4-chloro-phenylethynyl)-5-(1-methyl-piperidin-ylmethoxy)-phenylsulfanyl] -phenoxy } -acetic acid [00557] {2-Chloro-4-[3-(4-chloro-phenylethynyl)-5-(1-methyl-piperidin-4-ylmethoxy)-phenylsulfanyl]-phenoxy}-acetic acid ethyl ester (60 mg; 0.10 mmol) was dissolved in etha-nol (7 mL), and aqueous 1N sodium hydroxide (3 mL) was added. The reaction mixture was stirred for 16 h, acidified with 1N aqueous hydrochloric acid, and extracted with ethyl acetate.
The organic phase was dried, evaporated to dryness and purified by prep. HPLC
(method B).
Yield: 20 mg. HPLC-MS: mlz: 556.5 (M+); Rt: 2.10 min.
[00558] Example 6 [00559] {2-Methyl-4-[3-(3-morpholin-4-yl-propoxy)-5-(3-phenyl-prop-1-ynyl)-phenyl-sulfanyl] -phenoxy } -acetic acid J

O
s O

OOH
[00560] Step A: {2-Methyl-4-[3-(3-morpholin-4-yl-propoxy)-5-(3-phenyl-prop-1-ynyl)-phenylsulfanyl]-phenoxy}-acetic acid ethyl ester [00561] {4-[3-Hydroxy-5-(3-phenyl-prop-1-ynyl)-phenylsulfanyl]-2-methyl-phenoxy}-acetic acid ethyl ester (200 mg; 0.46 mmol), 3-morpholin-4-yl-propan-l-ol (101 mg;
0.69 mmol), tributylphosphine (0.28 mL; 1.39 mmol) and 1,1'-(azodicarbonyl)dipiperidine (0.35 g; 1.39 mmol) were dissolved in THF (15 mL) in a dried reaction flask under an atmosphere of nitro-gen. After stirring for 1 h the reaction mixture was purified by prep. HPLC
(method A).
Yield: 200 mg. HPLC-MS: m/z: 560.5 (M+H); Rt: 2.07 min.
[00562] Step B: {2-Methyl-4-[3-(3-morpholin-4-yl-propoxy)-5-(3-phenyl-prop-1-ynyl)-phenylsulfanyl] -phenoxy } -acetic acid [00563] {2-Methyl-4-[3-(3-morpholin-4-yl-propoxy)-5-(3-phenyl-prop-1-ynyl)-phenyl-sulfanyl]-phenoxy}-acetic acid ethyl ester (200 mg; 0.36 mmol) was dissolved in ethanol (20 mL), and aqueous 1 N sodium hydroxide (3 mL) was added. The reaction mixture was stirred for 1 h, acidified with 1 N aqueous hydrochloric acid, and extracted with ethyl acetate. The organic phase was dried and evaporated to dryness. Yield: 150 mg. HPLC-MS:
m/z: 532.1 (M+); Rt: 1.87 min.
[00564] Example 7 [00565] {4-[3-(4-Fluoro-benzyloxy)-5-(3-morpholin-4-yl-prop-1-ynyl)-phenylsulfanyl]-2-methyl-phenoxy } -acetic acid F

O / N~
~ ~
~ /

O

O), OH
[00566] Step A: {4-[3-(4-Fluoro-benzyloxy)-5-(3-morpholin-4-yl-prop-1-ynyl)-phenyl-sulfanyl]-2-methyl-phenoxy}-acetic acid ethyl ester [00567] {4-[3-Hydroxy-5-(3-morpholin-4-yl-prop-1-ynyl)-phenylsulfanyl]-2-methyl-phenoxy}-acetic acid ethyl ester (200 mg; 0.45 mmol), 4-flourobenzylalcohol (85.7 mg; 0.68 mmol), tributylphosphine (0.27 mL; 1.36 mmol) and 1,1'-(azodicarbonyl)dipiperidine (0.34 g; 1.36 mmol) were dissolved in THF (15 mL) in a dried reaction flask under an atmosphere of nitrogen. After stirring for 1 h the reaction mixture was purified by prep.
HPLC (method A). Yield: 200 mg. HPLC-MS: m/z: 550.3 (M+H); Rt: 2.00 min.
[00568] Step B: {4-[3-(4-Fluoro-benzyloxy)-5-(3-morpholin-4-yl-prop-1-ynyl)-phenyl-sulfanyl] -2-methyl-phenoxy } -acetic acid [00569] {4-[3-(4-Fluoro-benzyloxy)-5-(3-morpholin-4-yl-prop-1-ynyl)-phenylsulfanyl]-2-methyl-phenoxy}-acetic acid ethyl ester (200 mg; 0.36 mmol) was dissolved in ethanol (20 mL), and aqueous 1 N sodium hydroxide (3 mL) was added. The reaction mixture was stirred for 1 h, acidified with 1 N aqueous hydrochloric acid, and extracted with ethyl acetate. The organic phase was dried and evaporated to dryness. Yield: 170 mg. HPLC-MS:
m/z: 522.1 (M+); Rt: 1.77 min.
[00570] Example 8 [00571] {4-[3-Cyclohexylmethoxy-5-(3-morpholin-4-yl-prop-1-ynyl)-phenylsulfanyl]-2-methyl-phenoxy } -acetic acid _ Yo N

O'OH
[00572] Step A: {4-[3-Cyclohexylmethoxy-5-(3-morpholin-4-yl-prop-1-ynyl)-phenyl-sulfanyl]-2-methyl-phenoxy}-acetic acid ethyl ester [00573] {4-[3-Hydroxy-5-(3-morpholin-4-yl-prop-1-ynyl)-phenylsulfanyl]-2-methyl-phenoxy}-acetic acid ethyl ester (200 mg; 0.45 mmol), cyclohexylmethanol (77.6 mg; 0.68 mmol), tributylphosphine (0.27 mL; 1.36 mmol) and 1,1'-(azodicarbonyl)dipiperidine (0.34 g;
1.36 mmol) were dissolved in THF (15 mL) in a dried reaction flask under an atmosphere of nitrogen. After stirring for 1 h the reaction mixture was purified by prep.
HPLC (method A).
Yield: 200 mg. HPLC-MS: m/z: 538.1 (M+H); Rt: 2.24 min.
[00574] Step B: {4-[3-Cyclohexylmethoxy-5-(3-morpholin-4-yl-prop-1-ynyl)-phenyl-sulfanyl] -2-methyl-phenoxy } -acetic acid [00575] {4-[3-Cyclohexylmethoxy-5-(3-morpholin-4-yl-prop-1-ynyl)-phenylsulfanyl]-2-methyl-phenoxy}-acetic acid ethyl ester (200 mg; 0.37 mmol) was dissolved in ethanol (20 mL), and aqueous 1 N sodium hydroxide (3 mL) was added. The reaction mixture was stirred for 1 h, acidified with 1 N aqueous hydrochloric acid, and extracted with ethyl acetate. The organic phase was dried and evaporated to dryness. Yield: 180 mg. HPLC-MS:
m/z: 510.1 (M+); Rt: 1.98 min.
[00576] Example 9 [00577] {4-[3-Isobutoxy-5-(3-morpholin-4-yl-prop-1-ynyl)-phenylsulfanyl]-2-methyl-phenoxy } -acetic acid r O
NJ
II

S O"-r CH3 ~ CH3 OOH
[00578] Step A: {4-[3-Isobutoxy-5-(3-morpholin-4-yl-prop-1-ynyl)-phenylsulfanyl]-2-methyl-phenoxy}-acetic acid ethyl ester [00579] {4-[3-Hydroxy-5-(3-morpholin-4-yl-prop-1-ynyl)-phenylsulfanyl]-2-methyl-phenoxy}-acetic acid ethyl ester (250 mg; 0.57 mmol), 2-methyl-propan-l-ol (0.078 mL;
0.85 mmol) and tributylphosphine (0.31 mL; 1.25 mmol) were dissolved in THF
(15 mL) in a dried reaction flask under an atmosphere of nitrogen. 1,1'-(Azodicarbonyl)dipiperidine (0.31 g; 1.25 mmol) was dissolved in THF (10 mL) and added to the reaction mixture.
After stir-ring for 16 h the reaction mixture was evaporated to dryness and purified by prep. HPLC
(method B). Yield: 200 mg. HPLC-MS: m/z: 498.1 (M+); Rt: 2.03 min [00580] Step B: {4-[3-Isobutoxy-5-(3-morpholin-4-yl-prop-1-ynyl)-phenylsulfanyl]-2-methyl-phenoxy } -acetic acid [00581] {4-[3-Isobutoxy-5-(3-morpholin-4-yl-prop-1-ynyl)-phenylsulfanyl]-2-methyl-phenoxy}-acetic acid ethyl ester (140 mg; 0.28 mmol) was dissolved in ethanol (15 mL), and aqueous 1 N sodium hydroxide (3 mL) was added. The reaction mixture was stirred for 1 h, acidified with 1 N aqueous hydrochloric acid, and extracted with ethyl acetate. The organic phase was dried and evaporated to dryness. Yield: 130 mg. HPLC-MS: m/z: 470.0 (M+); Rt:
1.76 min. 6H(400 MHz; CDC13) 1.00 (d, 6H), 1.98-2.09 (m, 1H), 2.27 (s, 3H), 3.13-3.29 (m, 2H), 3.43-3.57 (m, 2H), 3.66 (d, 2H), 3.92-4.09 (m, 4H), 4.12 (s, 2H), 4.71 (s, 2H), 6.55 (m, 1H), 6.71-6.75 (m, 2H), 6.79 (m, 1H), 7.25-7.29 (m, 1H), 7.30 (m, 1H).
[00582] Example 10 [00583] {4-[3-(4-Chloro-benzyloxy)-5-(3-morpholin-4-yl-prop-1-ynyl)-phenylsulfanyl]-2-methyl-phenoxy } -acetic acid D
N

II
S O'_'IaCI
OOH
[00584] Step A: {4-[3-(4-Chloro-benzyloxy)-5-(3-morpholin-4-yl-prop-1-ynyl)-phenylsulfanyl]-2-methyl-phenoxy}-acetic acid ethyl ester [00585] 4-[3-Hydroxy-5-(3-morpholin-4-yl-prop-1-ynyl)-phenylsulfanyl]-2-methyl-phenoxy}-acetic acid ethyl ester (250 mg; 0.57 mmol), 4-(chloro-phenyl)-methanol (0.12 mg;
0.85 mmol) and tributylphosphine (0.31 mL; 1.25 mmol) were dissolved in THF
(15 mL) in a dried reaction flask under an atmosphere of nitrogen. 1,1'-(Azodicarbonyl)dipiperidine (0.31 g; 1.25 mmol) was dissolved in THF (10 mL) and added to the reaction mixture.
After stir-ring for 16 h the reaction mixture was evaporated to dryness and purified by prep. HPLC
(method B). Yield: 200 mg. HPLC-MS: m/z: 566.1 (M+); Rt: 2.13 min.
[00586] Step B: {4-[3-(4-Chloro-benzyloxy)-5-(3-morpholin-4-yl-prop-1-ynyl)-phenyl-sulfanyl] -2-methyl-phenoxy } -acetic acid { 4-[3-(4-Chloro-benzyloxy)-5-(3-morpholin-4-yl-prop-1-ynyl)-phenylsulfanyl] -methyl-phenoxy}-acetic acid ethyl ester (140 mg; 0.28 mmol) was dissolved in ethanol (15 mL), and aqueous 1 N sodium hydroxide (3 mL) was added. The reaction mixture was stirred for 1 h, acidified with 1 N aqueous hydrochloric acid, and extracted with ethyl acetate. The organic phase was dried and evaporated to dryness. Yield: 180 mg. HPLC-MS:
m/z: 538.0 (M+); Rt: 1.84 min. 64400 MHz; CDC13) 2.27 (s, 3H), 3.15-3.30 (m, 2H), 3.45 (d, 2H), 3.99-4.06 (m, 2H), 4.13-4.22 (m, 4H), 4.73 (s, 2H), 4.96 (s, 2H), 6.57-6.60 (m, 1H), 6.74 (d, 1H), 6.76-6.81 (m, 2H), 7.25-7.31 (m, 4H), 7.32-7.36 (m, 2H).
[00587] Example 11 [00588] {2-Chloro-4-[3-(4-chloro-phenylethynyl)-5-hydroxy-phenylsulfanyl]-phenoxy}-acetic acid ci S~ \
~~

OH
cl O
O;OH
[00589] {2-Chloro-4-[3-(4-chloro-phenylethynyl)-5-hydroxy-phenylsulfanyl]-phenoxy}-acetic acid ethyl ester (50 mg; 0.11 mmol) was dissolved in ethanol (6 mL), and aqueous 1 N
sodium hydroxide (3 mL) was added. The reaction mixture was stirred for 1 h, acidified with 1 N aqueous hydrochloric acid, and extracted with ethyl acetate. The organic phase was dried and evaporated to dryness and purified by prep. HPLC (method B). Yield: 36 mg.
HPLC-MS: mlz: 445.1 (M+); Rt: 2.44 min.
[00590] Example 12 [00591] {4-[3-But-2-ynyloxy-5-(3-morpholin-4-yl-prop-1-ynyl)-phenylsulfanyl]-2-methyl-phenoxy } -acetic acid N J

S O
O
OOH
[00592] Step A: {4-[3-But-2-ynyloxy-5-(3-morpholin-4-yl-prop-1-ynyl)-phenylsulfanyl]-2-methyl-phenoxy}-acetic acid ethyl ester [00593] 4-[3-Hydroxy-5-(3-morpholin-4-yl-prop-1-ynyl)-phenylsulfanyl]-2-methyl-phenoxy}-acetic acid ethyl ester (250 mg; 0.57 mmol), 2-butyn-l-ol (0.064 mL;
0.85 mmol) and tributylphosphine (0.31 mL; 1.25 mmol) were dissolved in THF (15 mL) in a dried reac-tion flask under an atmosphere of nitrogen. 1,1'-(Azodicarbonyl)dipiperidine (0.31 g; 1.25 mmol) was dissolved in THF (10 mL) and added to the reaction mixture. After stirring for 16 h the reaction mixture was evaporated to dryness and purified by prep. HPLC
(method B).
Yield: 150 mg. HPLC-MS: mlz: 494.0 (M+); Rt: 1.87 min.
[00594] Step B: {4-[3-But-2-ynyloxy-5-(3-morpholin-4-yl-prop-1-ynyl)-phenylsulfanyl]-2-methyl-phenoxy } -acetic acid [00595] {4-[3-But-2-ynyloxy-5-(3-morpholin-4-yl-prop-1-ynyl)-phenylsulfanyl]-2-methyl-phenoxy}-acetic acid ethyl ester (150 mg; 0.30 mmol) was dissolved in ethanol (15 mL), and aqueous 1 N sodium hydroxide (3 mL) was added. The reaction mixture was stirred for 1 h, acidified with 1 N aqueous hydrochloric acid, and extracted with ethyl acetate. The organic phase was dried and evaporated to dryness. Yield: 140 mg. HPLC-MS: m/z: 466.0 (M+); Rt:
1.60 min.
[00596] Example 13 [00597] { 2-Methyl-4-[3-(2-morpholin-4-yl-ethoxy)-5-phenylethynyl-phenylsulfanyl]-phenoxy } -acetic acid I I
rO
S O---__iN__) O
O~OH
[00598] Step A: {2-Methyl-4-[3-(2-morpholin-4-yl-ethoxy)-5-phenylethynyl-phenyl-sulfanyl]-phenoxy}-acetic acid ethyl ester [00599] [4-(3-Hydroxy-5-phenylethynyl-phenylsulfanyl)-2-methyl-phenoxy]-acetic acid ethyl ester (200 mg; 0.48 mmol), 2-morpholin-4-yl-ethanol (0.22 g; 0.67 mmol) and tributyl-phosphine (0.24 mL; 0.96 mmol) were dissolved in THF (15 mL) in a dried reaction flask un-der an atmosphere of nitrogen. 1,1'-(Azodicarbonyl)dipiperidine (0.24 g; 0.96 mmol) was dissolved in THF (10 mL) and added to the reaction mixture. After stirring for 16 h the reac-tion mixture was evaporated to dryness and purified by flash chromatography (ethyl acetate:
heptane (1:3 ---> 1:9). Yield: 150 mg. HPLC-MS: m/z: 532.6 (M+H); Rt: 2.07 min.
[00600] Step B: {2-Methyl-4-[3-(2-morpholin-4-yl-ethoxy)-5-phenylethynyl-phenylsulfanyl]-phenoxy } -acetic acid [00601] { 2-Methyl-4-[3-(2-morpholin-4-yl-ethoxy)-5-phenylethynyl-phenylsulfanyl]-phenoxy}-acetic acid ethyl ester (150 mg; 0.30 mmol) was dissolved in ethanol (15 mL), and aqueous 1 N sodium hydroxide (3 mL) was added. The reaction mixture was stirred for 1 h, acidified with 1 N aqueous hydrochloric acid, and extracted with ethyl acetate. The organic phase was dried and evaporated to dryness. Yield: 140 mg. HPLC-MS: mlz: 504.1 (M+); Rt:
1.80 min.
[00602] Example 14 [00603] {2-Chloro-4-[3-(3-methoxy-prop-1-ynyl)-5-(3-morpholin-4-yl-propoxy)-phenyl-sulfanyl] -phenoxy } -acetic acid I I

S \ O~ ~O
Ci O
O_~ OH
[00604] Step A: {2-Chloro-4-[3-(3-methoxy-prop-1-ynyl)-5-(3-morpholin-4-yl-propoxy)-phenylsulfanyl]-phenoxy}-acetic acid ethyl ester [00605] {4-[3-Bromo-5-(3-morpholin-4-yl-propoxy)-phenylsulfanyl]-2-chloro-phenoxy}-acetic acid ethyl ester (0.2 g; 0.37 mmol), 3-methoxy-propyne (0.10 g; 1.47 mmol), bis(triphenylphosphine) palladium (II) chloride (21 mg; 0.029 mmol) and copper iodide (4.2 mg; 0.022 mmol) were dissolved in a mixture of triethylamine (2 mL) and DMF (2 mL) under an atmosphere of nitrogen. The reaction mixture was reacted in a microwave oven at 150 C

for lh. The reaction mixture was evaporated to dryness and extracted with ethyl acetate from a aqueous 5% citric acid solution. The crude product was dried, evaporated to dryness and purified by preparative HPLC (method B). Yield: 160 mg. HPLC-MS: m/z: 534.1 (M+); Rt:
1.79 min.
[00606] Step B: {2-Chloro-4-[3-(3-methoxy-prop-1-ynyl)-5-(3-morpholin-4-yl-propoxy)-phenylsulfanyl] -phenoxy } -acetic acid [00607] {2-Chloro-4-[3-(3-methoxy-prop-1-ynyl)-5-(3-morpholin-4-yl-propoxy)-phenyl-sulfanyl]-phenoxy}-acetic acid ethyl ester (150 mg; 0.30 mmol) was dissolved in ethanol (10 mL), and aqueous 1 N sodium hydroxide (3 mL) was added. The reaction mixture was stirred for 1 h, acidified with 1 N aqueous hydrochloric acid, and extracted with ethyl acetate. The organic phase was dried, and evaporated to dryness and purified by preparative HPLC
(method B). Yield: 50 mg. HPLC-MS: m/z: 506.0 (M+); Rt: 1.56 min. 6H(400 MHz;
CDC13) 2.06-2.15 (m, 2H), 2.82-2.92 (m, 2H), 3.15-3.23 (m, 2H), 3.45 (s, 3H), 3.56 (d, 2H), 3.78(t, 2H), 3.95-4.03 (m, 4H), 4.30 (s, 2H), 4.89 (s, 2H), 5.91-5.94(m, 1H), 6.63-6.66 (m, 1H), 6.93 (d, 1H), 7.01-7.03 (m, 1H), 7.40 (dd, 1H), 7.58 (d, 1H).
[00608] Example 15 [00609] {2-Chloro-4-[3-(3-morpholin-4-yl-propoxy)-5-pent-l-ynyl-phenylsulfanyl]-phenoxy } -acetic acid II

S ON
~
~1~
O
CI
O
O'~OH
[00610] Step A: {2-Chloro-4-[3-(3-morpholin-4-yl-propoxy)-5-pent-l-ynyl-phenylsulfanyl]-phenoxy}-acetic acid ethyl ester [00611] {4-[3-Bromo-5-(3-morpholin-4-yl-propoxy)-phenylsulfanyl]-2-chloro-phenoxy}-acetic acid ethyl ester (0.2 g; 0.37 mmol), 1-pentyne (0.10 g; 1.47 mmol), bis(triphenyl-phosphine)palladium (11) chloride (21 mg; 0.029 mmol) and copper iodide (4.2 mg; 0.022 mmol) were dissolved in a mixture of triethylamine (2 mL) and DMF (2 mL) under an atmos-phere of nitrogen. The reaction mixture was reacted in a microwave oven at 150 C for lh.
The reaction mixture was evaporated to dryness and extracted with ethyl acetate from a aque-ous 5% citric acid solution. The crude product was dried, evaporated to dryness and purified by preparative HPLC (method B). Yield: 120 mg. HPLC-MS: m/z: 532.0 (M+); Rt:
2.02 min.
[00612] Step B: {2-Chloro-4-[3-(3-morpholin-4-yl-propoxy)-5-pent-l-ynyl-phenylsulfanyl]-phenoxy}-acetic acid [00613] {2-Chloro-4-[3-(3-morpholin-4-yl-propoxy)-5-pent-l-ynyl-phenylsulfanyl]-phenoxy}-acetic acid ethyl ester (150 mg; 0.30 mmol) was dissolved in ethanol (10 mL), and aqueous 1 N sodium hydroxide (3 mL) was added. The reaction mixture was stirred for 1 h, acidified with 1 N aqueous hydrochloric acid, and extracted with ethyl acetate. The organic phase was dried, and evaporated to dryness and purified by preparative HPLC
(method B).
Yield: 70 mg. HPLC-MS: mlz: 504.1 (M+); Rt: 1.81 min.
[00614] Example 16 [00615] {2-Methyl-4-[3-(3-morpholin-4-yl-propoxy)-5-(3-phenyl-prop-1-ynyl)-benzyl-sulfanyl] -phenoxy } -acetic acid \
oJ

s ~~

\ CH3 [00616] Step A: {2-Methyl-4-[3-(3-morpholin-4-yl-propoxy)-5-(3-phenyl-prop-1-ynyl)-benzylsulfanyl]-phenoxy}-acetic acid ethyl ester [00617] {4-[3-Hydroxy-5-(3-phenyl-prop-1-ynyl)-benzylsulfanyl]-2-methyl-phenoxy}-acetic acid ethyl ester (200 mg; 0.45 mmol), 3-morpholin-4-yl-propan-l-ol (97.6 mg;
0.67 mmol), tributylphosphine (0.27 mg; 1.34 mmol) and 1,1'-(Azodicarbonyl)dipiperidine (0.34 g; 1.34 mmol) were dissolved in THF (20 mL) in a dried reaction flask under an atmosphere of nitro-gen. The reaction mixture was stirred for lh and purified by prep. HPLC
(method A). Yield:
200 mg. HPLC-MS: m/z: 574.3 (M+H); Rt: 2.07 min.
[00618] Step B: {2-Methyl-4-[3-(3-morpholin-4-yl-propoxy)-5-(3-phenyl-prop-1-ynyl)-benzylsulfanyl] -phenoxy } -acetic acid [00619] {2-Methyl-4-[3-(3-morpholin-4-yl-propoxy)-5-(3-phenyl-prop-1-ynyl)-benzyl-sulfanyl]-phenoxy}-acetic acid ethyl ester (150 mg; 0.30 mmol) was dissolved in ethanol (20 mL), and aqueous 1 N sodium hydroxide (3 mL) was added. The reaction mixture was stirred for 1 h, acidified with 1 N aqueous hydrochloric acid, and extracted with ethyl acetate. The organic phase was dried and evaporated to dryness. Yield: 190 mg. HPLC-MS:
m/z: 546.1 (M+); Rt: 1.85 min.
[00620] Example 17 [00621] {4-[3-(4-Fluoro-benzyloxy)-5-(3-morpholin-4-yl-prop-1yny1)-benzylsulfanyl]-2-methyl-phenoxy } -acetic acid F

O
N

~

O

HO~O
[00622] Step A: {4-[3-(4-Fluoro-benzyloxy)-5-(3-morpholin-4-yl-prop-lynyl)-benzyl-sulfanyl]-2-methyl-phenoxy}-acetic acid ethyl ester [00623] {4-[3-Hydroxy-5-(3-morpholin-4-yl-prop-1-ynyl)-benzylsulfanyl]-2-methyl-phenoxy}-acetic acid ethyl ester (250 mg; 0.55 mmol), 1-fluoro-4-methoxymethyl-benzene (103.8 mg; 0.82 mmol), tributylphosphine (0.33 mg; 1.65 mmol) and 1,1'-(azodicarbonyl)-dipiperidine (0.414 g; 1.65 mmol) were dissolved in THF (15 mL) in a dried reaction flask under an atmosphere of nitrogen. The reaction mixture was stirred for 16h and purified by prep. HPLC (method A). Yield: 160 mg. HPLC-MS: m/z: 564.1 (M+H); Rt: 1.99 min.
[00624] Step B: {4-[3-(4-Fluoro-benzyloxy)-5-(3-morpholin-4-yl-prop-1yny1)-benzyl-sulfanyl] -2-methyl-phenoxy } -acetic acid [00625] {4-[3-(4-Fluoro-benzyloxy)-5-(3-morpholin-4-yl-prop-1yny1)-benzylsulfanyl]-2-methyl-phenoxy}-acetic acid ethyl ester (150 mg; 0.30 mmol) was dissolved in ethanol (20 mL), and aqueous 1 N sodium hydroxide (3 mL) was added. The reaction mixture was stirred for 1 h, acidified with 1 N aqueous hydrochloric acid, and extracted with ethyl acetate. The organic phase was dried and evaporated to dryness. Yield: 190 mg. HPLC-MS:
m/z: 536.1 (M+); Rt: 1.76 min.
[00626] Example 18 [00627] {2-Methyl-4-[3-(3-morpholin-4-yl-ethoxy)-5-(3-phenyl-prop-1-ynyl)-benzyl-sulfanyl]-phenoxy}-acetic acid ~oI
O~/N~/
s O

Ho~f"o [00628] Step A: {2-Methyl-4-[3-(3-morpholin-4-yl-ethoxy)-5-(3-phenyl-prop-1-ynyl)-benzylsulfanyl]-phenoxy}-acetic acid ethyl ester [00629] {4-[3-Hydroxy-5-(3-phenyl-prop-1-ynyl)-benzylsulfanyl]-2-methyl-phenoxy}-acetic acid ethyl ester (250 mg; 0.56 mmol), 3-morpholin-4-yl-propan-l-ol (110.1 mg;
0.84 mmol), tributylphosphine (0.34 mL; 1.68 mmol) and 1,1'-(azodicarbonyl)dipiperidine (0.42 g; 1.68 mmol) were dissolved in THF (15 mL) in a dried reaction flask under an atmosphere of nitro-gen. After stirring for 2 h the reaction mixture was purified by prep. HPLC
(method A).
Yield: 50 mg. HPLC-MS: mlz: 560.2 (M+H); Rt: 2.03 min.
[00630] Step B: {2-Methyl-4-[3-(3-morpholin-4-yl-ethoxy)-5-(3-phenyl-prop-1-ynyl)-benzyl-sulfanyl]-phenoxy } -acetic acid [00631] {2-Methyl-4-[3-(3-morpholin-4-yl-ethoxy)-5-(3-phenyl-prop-1-ynyl)-benzyl-sulfanyl]-phenoxy}-acetic acid ethyl ester (50 mg; 0.09 mmol) was dissolved in ethanol (10 mL), and aqueous 1 N sodium hydroxide (2 mL) was added. The reaction mixture was stirred for 16 h, acidified with 1 N aqueous hydrochloric acid and extracted with dichloromethane.
The organic phase was dried and evaporated to dryness. Yield: 45 mg. HPLC-MS:
m/z:
532.1 (M+); Rt: 1.79 min.
[00632] Example 19 [00633] {4-[3-Cyclohexylmethoxy-5-(4-methanesulfonyl-phenylethynyl)-phenylsulfanyl]-2-methyl-phenoxy}-acetic acid 0=S=0 II
S ~~ \

/ I O,0 HO~O
[00634] Step A: {4-[3-Cyclohexylmethoxy-5-(4-methanesulfonyl-phenylethynyl)-phenyl-sulfanyl]-2-methyl-phenoxy}-acetic acid ethyl ester [00635] [4-(3-Bromo-5-cyclohexylmethoxy-phenylsulfanyl)-2-methyl-phenoxy]-acetic acid ethyl acetate (0.1 g; 0.203 mmol), 1 -Ethynyl-4-methanesulfonyl-benzene (0.109 g; 0.61 mmol), bis(triphenylphosphine)palladium (II) chloride (11.4 mg; 0.016 mmol) and copper io-dide (2.3 mg; 0.06 mmol) were dissolved in a mixture of triethylamine (2 mL) and DMF (2 mL) under an atmosphere of nitrogen. The reaction mixture was reacted in a microwave oven at 120 C for lh. Water and dichloromethane was added to the reaction mixture and the phases were separated and washed with water. The organic phase was dried and evaporated to dryness. The crude product was purified by prep. HPLC (Metode A). Yield: 90 mg. HPLC-MS: mlz: 593.5 (M+H)+; Rt: 3.04 min.
[00636] Step B: {4-[3-Cyclohexylmethoxy-5-(4-methanesulfonyl-phenylethynyl)-phenyl-sulfanyl] -2-methyl-phenoxy } -acetic acid [00637] {4-[3-Cyclohexylmethoxy-5-(4-methanesulfonyl-phenylethynyl)-phenylsulfanyl]-2-methyl-phenoxy}-acetic acid ethyl ester (120 mg; 0.202 mmol) was dissolved in ethanol (50 mL), and aqueous 1 N sodium hydroxide (2 mL) was added. The reaction mixture was stirred for 30 min, acidified with 1 N aqueous hydrochloric acid and extracted with dichloromethane.
The organic phase was dried and evaporated to dryness. Yield: 90 mg. HPLC-MS:
m/z: 565.3 (M+H)+; Rt: 2.81 min.
[00638] Example 20 [00639] {4-[3-Cyclopentylmethoxy-5-(4-methanesulfonyl-phenylethynyl)-phenylsulfanyl]-2-methyl-phenoxy } -acetic acid ~
o=s=o 1~_10_ s 0 o'Co [00640] Step A: {4-[3-Cyclopentylmethoxy-5-(4-methanesulfonyl-phenylethynyl)-phenyl-sulfanyl]-2-methyl-phenoxy}-acetic acid ethyl ester [00641] [4-(3-Bromo-5-cyclopentylmethoxy-phenylsulfanyl)-2-methyl-phenoxy]-acetic acid ethyl acetate (0.24 g; 0.50 mmol), 1 -Ethynyl-4-methanesulfonyl-benzene (0.271 g; 1.5 mmol), bis(triphenylphosphine)palladium (11) chloride (28.11 mg; 0.04 mmol) and copper iodide (5.7 mg; 0.03 mmol) were dissolved in a mixture of triethylamine (5 mL) and DMF (5 mL) under an atmosphere of nitrogen. The reaction mixture was reacted in a microwave oven at 120 C
for lh. Water and dichloromethane was added to the reaction mixture and the phases were separated and washed with water. The organic phase was dried and evaporated to dryness.
The crude product was purified by prep. HPLC (Metode A). Yield: 180 mg. HPLC-MS: m/z:
579.4 (M+H)+; Rt: 3.00 min.
[00642] Step B: {4-[3-Cyclopentylmethoxy-5-(4-methanesulfonyl-phenylethynyl)-phenyl-sulfanyl] -2-methyl-phenoxy } -acetic acid [00643] {4-[3-Cyclopentylmethoxy-5-(4-methanesulfonyl-phenylethynyl)-phenylsulfanyl]-2-methyl-phenoxy}-acetic acid ethyl ester (120 mg; 0.202 mmol) was dissolved in ethanol (50 mL), and aqueous 1 N sodium hydroxide (2 mL) was added. The reaction mixture was stirred for 30 min, acidified with 1 N aqueous hydrochloric acid and extracted with dichloromethane.
The organic phase was dried and evaporated to dryness. Yield: 100 mg. HPLC-MS:
m/z:
551.5 (M+H)+; Rt: 2.69 min.
[00644] Example 21 [00645] {4-[3-Isobutoxy-5-(4-methanesulfonyl-phenylethynyl)-phenylsulfanyl]-2-methyl-phenoxy } -acetic acid o=s=o ~~
s o I~ ~

oo [00646] Step A: {4-[3-Isobutoxy-5-(4-methanesulfonyl-phenylethynyl)-phenylsulfanyl]-2-methyl-phenoxy}-acetic acid ethyl ester [00647] The title product was prepared as described for {4-[3-Cyclopentylmethoxy-5-(4-methanesulfonyl-phenylethynyl)-phenylsulfanyl]-2-methyl-phenoxy}-acetic acid ethyl ester.
The crude product was purified by prep. HPLC (method B). Yield: 52%. HPLC-MS:
m/z:
552.7 (M)+; Rt: 2.88 min.
[00648] Step B: {4-[3-Isobutoxy-5-(4-methanesulfonyl-phenylethynyl)-phenylsulfanyl]-2-methyl-phenoxy } -acetic acid [00649] {4-[3-Isobutoxy-5-(4-methanesulfonyl-phenylethynyl)-phenylsulfanyl]-2-methyl-phenoxy}-acetic acid ethyl ester (190 mg; 0.34 mmol) was dissolved in ethanol (10 mL), and aqueous 1 N sodium hydroxide (3 mL) was added. The reaction mixture was stirred for 16 h.

acidified with 1 N aqueous hydrochloric acid and extracted with ethyl acetate.
The organic phase was dried and evaporated to dryness and purified by prep HPLC (method B). Yield:
110 mg (61%). HPLC-MS: mlz: 525.1 (M+H)+; Rt: 2.55 min.
[00650] Example 22 [00651] {4-[3-[2-(4-Chloro-phenyl)-ethoxy]-5-(4-methanesulfonyl-phenylethynyl)-phenylsulfanyl] -2-methyl-phenoxy } -acetic acid O=S=O
I ~ C
II

/ - V~~
S~~o ~
I ~ CH3 O
O~OH
[00652] Step A: {4-[3-[2-(4-Chloro-phenyl)-ethoxy]-5-(4-methanesulfonyl-phenylethynyl)-phenylsulfanyl]-2-methyl-phenoxy}-acetic acid ethyl ester [00653] The title product was prepared as described for {4-[3-Cyclopentylmethoxy-5-(4-methanesulfonyl-phenylethynyl)-phenylsulfanyl]-2-methyl-phenoxy}-acetic acid ethyl ester.
The crude product was purified by prep. HPLC (method B). Yield: 64 %. HPLC-MS:
m/z:
635.4 (M+H)+; Rt: 2.92 min.
[00654] Step B: {4-[3-[2-(4-Chloro-phenyl)-ethoxy]-5-(4-methanesulfonyl-phenylethynyl)-phenylsulfanyl] -2-methyl-phenoxy } -acetic acid [00655] {4-[3-[2-(4-Chloro-phenyl)-ethoxy]-5-(4-methanesulfonyl-phenylethynyl)-phenyl-sulfanyl]-2-methyl-phenoxy}-acetic acid ethyl ester (190 mg; 0.30 mmol) was dissolved in ethanol (15 mL), and aqueous 1 N sodium hydroxide (3 mL) was added. The reaction mix-ture was stirred for 16 h. acidified with 1 N aqueous hydrochloric acid and extracted with ethyl acetate. The organic phase was dried and evaporated to dryness and purified by prep HPLC (method B). Yield: 160 mg (89%). HPLC-MS: m/z: 607.1 (M+H)+; Rt: 2.82 min.
[00656] Example 23 [00657] {4-[3-[2-(4-Chloro-phenyl)-ethoxy]-5-(3-morpholin-4-yl-prop-1-ynyl)-phenyl-sulfanyl] -2-methyl-phenoxy } -acetic acid ON

CI
[00658] Step A: {4-[3-[2-(4-Chloro-phenyl)-ethoxy]-5-(3-morpholin-4-yl-prop-1-ynyl)-phenylsulfanyl]-2-methyl-phenoxy}-acetic acid ethyl ester [00659] (4-{ 3-Bromo-5-[2-(4-chloro-phenyl)-ethoxy]-phenylsulfanyl}-2-methyl-phenoxy)-acetic acid ethyl ester (300 mg; 0.56 mmol), 4-prop-2-ynyl-morpholine (280,4 mg; 2.2 mmol), bis(triphenylphosphine) palladium (11) chloride (31.4 mg; 0.045 mmol) and copper iodide (6.4 mg; 0.034 mmol) were dissolved in a mixture of triethylamine (2 mL) and DMF (2 mL) under an atmosphere of nitrogen. The reaction mixture was reacted in a microwave oven at 110 C
for 1.5 h. The reaction mixture was evaporated to dryness, and 5% aqueous citric acid (30 mL) and ethyl acetate (30 mL) was added. The two phases were separated and the aqueous phase was extracted with ethyl acetate (30 mL). The combined organic phases were dried and evaporated to dryness and purified by preparative HPLC (method B). Yield: 300 mg; 92%.
HPLC-MS: m/z: 580.7 (M+H)+; Rt: 2.16 min.
[00660] Step B: {4-[3-[2-(4-Chloro-phenyl)-ethoxy]-5-(3-morpholin-4-yl-prop-l-ynyl)-phenylsulfanyl] -2-methyl-phenoxy } -acetic acid { 4- [3- [2-(4-Chloro-phenyl)-ethoxy] -5-(3-morpholin-4-yl-prop-1-ynyl)-phenylsulfanyl] -2-methyl-phenoxy}-acetic acid ethyl ester (190 mg; 0.30 mmol) was dissolved in ethanol (25 mL), and aqueous 1 N sodium hydroxide (5 mL) was added. The reaction mixture was stirred for 16 h. acidified with 1 N aqueous hydrochloric acid and extracted with ethyl acetate. The organic phase was dried and evaporated to dryness, redissolved in dichloromethane and evaporated to dryness. Yield: 250 mg (87%). HPLC-MS: m/z: 552.8 (M+H)+; Rt:
1.90 min.
[00661] Example 24 [00662] {4-[3-[2-(4-Chloro-phenyl)-ethoxy]-5-(4-hydroxymethyl-phenylethynyl)-phenyl-sulfanyl] -2-methyl-phenoxy } -acetic acid HO
s~ /

CI
IIO

/ I

O OH
[00663] Step A: {4-[3-[2-(4-Chloro-phenyl)-ethoxy]-5-(4-hydroxymethyl-phenylethynyl)-phenylsulfanyl]-2-methyl-phenoxy}-acetic acid ethyl ester [00664] (4-{ 3-Bromo-5-[2-(4-chloro-phenyl)-ethoxy]-phenylsulfanyl}-2-methyl-phenoxy)-acetic acid ethyl ester (270 mg; 0.46 mmol), (4-ethynyl-phenyl)-methanol (296 mg; 2.2 mmol), bis(triphenylphosphine) palladium (11) chloride (31.4 mg; 0.045 mmol) and copper iodide (6.4 mg; 0.034 mmol) were dissolved in a mixture of triethylamine (2 mL) and DMF (2 mL) under an atmosphere of nitrogen. The reaction mixture was reacted in a microwave oven at 110 C for 1.5 h. The reaction mixture was evaporated to dryness, and 5%
aqueous citric acid (30 mL) and ethyl acetate (30 mL) was added. The two phases were separated and the aqueous phase was extracted with ethyl acetate (30 mL). The combined organic phases were dried and evaporated to dryness and purified by preparative HPLC (method B).
Yield: 270 mg (83%). HPLC-MS: m/z: 587.1 (M+H)+; Rt: 2.96 min.
[00665] Step B: {4-[3-[2-(4-Chloro-phenyl)-ethoxy]-5-(4-hydroxymethyl-phenylethynyl)-phenylsulfanyl] -2-methyl-phenoxy } -acetic acid [00666] { 4-[3-[2-(4-Chloro-phenyl)-ethoxy]-5-(4-hydroxymethyl-phenylethynyl)-phenyl-sulfanyl]-2-methyl-phenoxy}-acetic acid ethyl ester (270 mg; 0.46 mmol) was dissolved in ethanol (15 mL), and aqueous 1 N sodium hydroxide (3 mL) was added. The reaction mix-ture was stirred for 16 h. acidified with 1 N aqueous hydrochloric acid and extracted with ethyl acetate. The organic phase was dried, evaporated to dryness and purified by prep HPLC
(method B). Yield: 218 mg (85%). HPLC-MS: m/z: 559.1 (M+H)+; Rt: 2.61 min.
[00667] Example 25 [00668] {4-[3-(2-Ethyl-butoxy)-5-phenylethynyl-phenylsulfanyl]-2-methyl-phenoxy}-acetic acid O
[00669] Step A: {4-[3-(2-Ethyl-butoxy)-5-phenylethynyl-phenylsulfanyl]-2-methyl-phenoxy}-acetic acid ethyl ester [00670] The title product was prepared from {4-[3-Bromo-5-(2-ethyl-butoxy)-phenyl-sulfanyl]-2-methyl-phenoxy}-acetic acid ethyl ester (200 mg; 0.42 mmol), (phenyl acetylene (170 mg; 1.66 mmol) applying the procedure described for {4-[3-[2-(4-Chloro-phenyl)-ethoxy]-5-(4-hydroxymethyl-phenylethynyl)-phenylsulfanyl]-2-methyl-phenoxy}-acetic acid ethyl ester. The crude product was purified by preparative HPLC (method B).
Yield: 170 mg (82%). HPLC-MS: m/z: 502.9 (M)+; Rt: 3.32 min.
[00671] Step B: {4-[3-(2-Ethyl-butoxy)-5-phenylethynyl-phenylsulfanyl]-2-methyl-phen-oxy}-acetic acid [00672] {4-[3-(2-Ethyl-butoxy)-5-phenylethynyl-phenylsulfanyl]-2-methyl-phenoxy}-acetic acid ethyl ester (270 mg; 0.46 mmol) was dissolved in ethanol (10 mL), and aqueous 1 N so-dium hydroxide (3 mL) was added. The reaction mixture was stirred for 16 h.
acidified with 1 N aqueous hydrochloric acid and extracted with ethyl acetate. The organic phase was dried, evaporated to dryness and purified by prep HPLC (method B). Yield: 128 mg (80%). HPLC-MS: mlz: 475.1 (M+H)+; Rt: 3.06 min.
[00673] Example 26 [00674] [4-(3-Cyclopentyloxy-5-phenylethynyl-phenylsulfanyl)-2-methyl-phenoxy]-acetic acid I I

n s O/~' O
O~OH
[00675] Step A: [4-(3-Cyclopentyloxy-5-phenylethynyl-phenylsulfanyl)-2-methyl-phenoxy]-acetic acid ethyl ester [00676] The title product was prepared from [4-(3-Bromo-5-cyclopentyloxy-phenylsulfanyl)-2-methyl-phenoxy]-acetic acid ethyl ester (250 mg; 0.54 mmol), (phenyl acetylene (110 mg;
1.07 mmol) applying the procedure described for {4-[3-[2-(4-Chloro-phenyl)-ethoxy]-5-(4-hydroxymethyl-phenylethynyl)-phenylsulfanyl]-2-methyl-phenoxy}-acetic acid ethyl ester.
The crude product was purified by preparative HPLC (method B). Yield: 186 mg (70%).
HPLC-MS: m/z: 487.1 (M+H)+; Rt: 3.17 min.
[00677] Step B: [4-(3-Cyclopentyloxy-5-phenylethynyl-phenylsulfanyl)-2-methyl-phenoxy]-acetic acid [00678] { [4-(3-Cyclopentyloxy-5-phenylethynyl-phenylsulfanyl)-2-methyl-phenoxy]-acetic acid ethyl ester (270 mg; 0.46 mmol) was dissolved in ethanol (10 mL), and aqueous 1 N so-dium hydroxide (3 mL) was added. The reaction mixture was stirred for 16 h.
acidified with 1 N aqueous hydrochloric acid and extracted with ethyl acetate. The organic phase was dried, evaporated to dryness and purified by prep HPLC (method B). Yield: 120 mg (69%). HPLC-MS: m/z: 459.1 (M+H)+; Rt: 2.86 min.
[00679] Example 27 [00680] {4-[3-(4-Fluoro-phenylethynyl)-5-(4-methanesulfonyl-benzyloxy)-phenylsulfanyl]-2-methyl-phenoxy } -acetic acid F

/
II
/

pS'OH3 O
O~OH
[00681] Step A: {4-[3-(4-Fluoro-phenylethynyl)-5-(4-methanesulfonyl-benzyloxy)-phenyl-sulfanyl]-2-methyl-phenoxy}-acetic acid ethyl ester [00682] The title product was prepared from {4-[3-Bromo-5-(4-methanesulfonyl-benzyloxy)-phenylsulfanyl]-2-methyl-phenoxy}-acetic acid ethyl ester (335 mg; 0.59 mmol), 1-ethynyl-4-fluorobenzene (142.3 mg; 1.19 mmol) applying the procedure described for {4-[3-[2-(4-Chloro-phenyl)-ethoxy] -5- (4-hydroxymethyl-phenylethynyl)-phenylsulfanyl] -2-methyl-phenoxy}-acetic acid ethyl ester. The crude product was purified by preparative HPLC
(method B). Yield: 140 mg (39%). HPLC-MS: m/z: 605.5 (M+H)+; Rt: 2.80 min.
[00683] Step B: {4-[3-(4-Fluoro-phenylethynyl)-5-(4-methanesulfonyl-benzyloxy)-phenyl-sulfanyl] -2-methyl-phenoxy } -acetic acid [00684] {4-[3-(4-Fluoro-phenylethynyl)-5-(4-methanesulfonyl-benzyloxy)-phenylsulfanyl]-2-methyl-phenoxy}-acetic acid ethyl ester (270 mg; 0.46 mmol) was dissolved in ethanol (15 mL), and aqueous 1 N sodium hydroxide (3 mL) was added. The reaction mixture was stirred for 16 h. acidified with 1 N aqueous hydrochloric acid and extracted with ethyl acetate. The organic phase was dried, evaporated to dryness and purified by prep HPLC
(method B).
Yield: 113 mg (85%). HPLC-MS: m/z: 599.4 (M+Na); Rt: 2.50 min.
[00685] Example 28 [00686] [4-(3-Cyclopentylmethoxy-5-phenylethynyl-phenylsulfanyl)-2-methyl-phenoxy]-acetic acid s ~ CH3 O

OOH
[00687] Step A: [4-(3-Cyclopentylmethoxy-5-phenylethynyl-phenylsulfanyl)-2-methyl-phenoxy]-acetic acid ethyl ester [00688] The title product was prepared from [4-(3-Bromo-5-cyclopentyloxy-phenylsulfanyl)-2-methyl-phenoxy]-acetic acid ethyl ester (300 mg; 0.63 mmol), phenylacetylen (191.7 mg;
1.88 mmol) applying the procedure described for {4-[3-[2-(4-Chloro-phenyl)-ethoxy]-5-(4-hydroxymethyl-phenylethynyl)-phenylsulfanyl]-2-methyl-phenoxy}-acetic acid ethyl ester.
The crude product was purified by preparative HPLC (method B). Yield: 200 mg (64%).
HPLC-MS: m/z: 500.8 (M)+; Rt: 3.30 min.
[00689] Step B: [4-(3-Cyclopentylmethoxy-5-phenylethynyl-phenylsulfanyl)-2-methyl-phenoxy]-acetic acid [00690] { [4-(3-Cyclopentylmethoxy-5-phenylethynyl-phenylsulfanyl)-2-methyl-phenoxy]-acetic acid ethyl ester (200 mg; 0.40 mmol) was dissolved in THF (2 mL), ethanol (4 mL), and aqueous 1 N sodium hydroxide (3 mL) was added. The reaction mixture was stirred for 30 min. acidified with 1 N aqueous hydrochloric acid and extracted with ethyl acetate. The organic phase was dried and evaporated to dryness. Yield: 146 mg (78%). HPLC-MS: m/z:
472.9 (M)+; Rt: 3.03 min.
[00691] Example 29 [00692] {4-[3-(2-Cyclohexyl-ethoxy)-5-phenylethynyl-phenylsulfanyl]-2-methyl-phenoxy}-acetic acid ~I

\ \ \ O~
s O

OIOH
[00693] Step A: {4-[3-(2-Cyclohexyl-ethoxy)-5-phenylethynyl-phenylsulfanyl]-2-methyl-phenoxy}-acetic acid ethyl ester [00694] The title product was prepared from {4-[3-Bromo-5-(2-cyclohexyl-ethoxy)-phenylsulfanyl]-2-methyl-phenoxy}-acetic acid ethyl ester (300 mg; 0.58 mmol), phenylace-tylen (181.1 mg; 1.8 mmol) applying the procedure described for {4-[3-[2-(4-Chloro-phenyl)-ethoxy]-5-(4-hydroxymethyl-phenylethynyl)-phenylsulfanyl]-2-methyl-phenoxy}-acetic acid ethyl ester. The crude product was purified by preparative HPLC (method B).
Yield: 110 mg (33%). HPLC-MS: m/z: 529.6 (M+H)+; Rt: 3.38 min.
[00695] Step B: {4-[3-(2-Cyclohexyl-ethoxy)-5-phenylethynyl-phenylsulfanyl]-2-methyl-phenoxy } -acetic acid [00696] {4-[3-(2-Cyclohexyl-ethoxy)-5-phenylethynyl-phenylsulfanyl]-2-methyl-phenoxy}-acetic acid ethyl ester (110 mg; 0.208 mmol) was dissolved in THF (2 mL), ethanol (4 mL), and aqueous 1 N sodium hydroxide (3 mL) was added. The reaction mixture was stirred for 30 min. acidified with 1 N aqueous hydrochloric acid and extracted with ethyl acetate. The organic phase was dried and evaporated to dryness. Yield: 105 mg. HPLC-MS:
mlz: 500.1 (M)+; Rt: 3.20 min.
[00697] Example 30 [00698] {4-[3-(2-Ethyl-butoxy)-5-(3-morpholin-4-yl-prop-1-ynyl)-phenylsulfanyl]-2-methyl-phenoxy}-acetic acid O

s O~CH3 OIOH
[00699] Step A: {4-[3-(2-Ethyl-butoxy)-5-(3-morpholin-4-yl-prop-1-ynyl)-phenylsulfanyl]-2-methyl-phenoxy}-acetic acid ethyl ester [00700] The title product was prepared from 4-(3-Bromo-5-cyclopentyloxy-phenylsulfanyl)-2-methyl-phenoxy]-acetic acid ethyl ester (200 mg; 0.42 mmol) and 4-prop-2-ynyl-morpho-line (156,0 mg; 1,26 mmol) applying the procedure described for {4-[3-[2-(4-Chloro-phenyl)-ethoxy]-5-(4-hydroxymethyl-phenylethynyl)-phenylsulfanyl]-2-methyl-phenoxy}-acetic acid ethyl ester. The crude product was purified by preparative HPLC (method B).
Yield: 210 mg (95%). HPLC-MS: m/z: 526.2 (M+H)+; Rt: 2.23 min [00701] Step B: {4-[3-(2-Ethyl-butoxy)-5-(3-morpholin-4-yl-prop-1-ynyl)-phenylsulfanyl]-2-methyl-phenoxy } -acetic acid [00702] {4-[3-(2-Ethyl-butoxy)-5-(3-morpholin-4-yl-prop-1-ynyl)-phenylsulfanyl]-2-methyl-phenoxy}-acetic acid ethyl ester (210 mg; 0.40 mmol) was dissolved in ethanol (10 mL), and aqueous 1 N sodium hydroxide (3 mL) was added. The reaction mixture was stirred for 16 h.
acidified with 1 N aqueous hydrochloric acid and extracted with ethyl acetate.
The organic phase was dried and evaporated to dryness and purified by prep HPLC (method B). Yield:
144 mg (73%). HPLC-MS: mlz: 498.2 (M+H)+; Rt: 1.97 min.
[00703] Example 31 [00704] {4-[3-Cyclopentyloxy-5-(3-morpholin-4-yl-prop-1-ynyl)-phenylsulfanyl]-2-methyl-phenoxy } -acetic acid OII
S I O'o /

O

Of,OH
[00705] Step A: {4-[3-Cyclopentyloxy-5-(3-morpholin-4-yl-prop-1-ynyl)-phenylsulfanyl]-2-methyl-phenoxy}-acetic acid ethyl ester [00706] The title product was prepared from [4-(3-Bromo-5-cyclopentyloxy-phenylsulfanyl)-2-methyl-phenoxy]-acetic acid ethyl ester (250 mg; 0.54 mmol) and 4-prop-2-ynyl-morpho-line (134.48 mg; 1.07 mmol) applying the procedure described for {4-[3-[2-(4-Chloro-phenyl)-ethoxy] -5-(4-hydroxymethyl-phenylethynyl)-phenylsulfanyl] -2-methyl-phenoxy } -acetic acid ethyl ester. The crude product was purified by preparative HPLC
(method B).
Yield: 210 mg (95%). HPLC-MS: m/z: 510.2 (M+H)+; Rt: 2.03 min [00707] Step B: {4-[3-Cyclopentyloxy-5-(3-morpholin-4-yl-prop-1-ynyl)-phenylsulfanyl]-2-methyl-phenoxy } -acetic acid [00708] {4-[3-Cyclopentyloxy-5-(3-morpholin-4-yl-prop-1-ynyl)-phenylsulfanyl]-2-methyl-phenoxy}-acetic acid ethyl ester (160 mg; 0.31 mmol) was dissolved in ethanol (10 mL), and aqueous 1 N sodium hydroxide (3 mL) was added. The reaction mixture was stirred for 16 h.
acidified with 1 N aqueous hydrochloric acid and extracted with ethyl acetate.
The organic phase was dried and evaporated to dryness and purified by prep HPLC (method B). Yield:
105 mg (70%). HPLC-MS: mlz: 482.2 (M+H)+; Rt: 1.77 min.
[00709] Example 32 [00710] {4-[3-(2-Cyclohexyl-ethoxy)-5-(3-morpholin-4-yl-prop-1-ynyl)-phenylsulfanyl]-2-methyl-phenoxy } -acetic acid o \ q O' ~
S I~/~I

O
O),OH
[00711] Step A: {4-[3-(2-Cyclohexyl-ethoxy)-5-(3-morpholin-4-yl-prop-1-ynyl)-phenyl-sulfanyl]-2-methyl-phenoxy}-acetic acid ethyl ester [00712] The title product was prepared from {4-[3-Bromo-5-(2-cyclohexyl-ethoxy)-phenyl-sulfanyl]-2-methyl-phenoxy}-acetic acid ethyl ester (300 mg; 0.59 mmol) and 4-prop-2-ynyl-morpholine (222.0 mg; 1.77 mmol) applying the procedure described for {4-[3-[2-(4-Chloro-phenyl)-ethoxy] -5-(4-hydroxymethyl-phenylethynyl)-phenylsulfanyl] -2-methyl-phenoxy } -acetic acid ethyl ester. The crude product was purified by preparative HPLC
(method B).
Yield: 200 mg (30%). HPLC-MS: m/z: 551.8 (M)+; Rt: 2.35 min [00713] Step B: {4-[3-(2-Cyclohexyl-ethoxy)-5-(3-morpholin-4-yl-prop-1-ynyl)-phenyl-sulfanyl] -2-methyl-phenoxy } -acetic acid [00714] {4-[3-(2-Cyclohexyl-ethoxy)-5-(3-morpholin-4-yl-prop-1-ynyl)-phenylsulfanyl]-2-methyl-phenoxy}-acetic acid ethyl ester (200 mg; 0.36 mmol) was dissolved in THF (2 mL) and ethanol (4 mL), and aqueous 1 N sodium hydroxide (3 mL) was added. The reaction mix-ture was stirred for 30 min. acidified with 1 N aqueous hydrochloric acid and extracted with ethyl acetate. The organic phase was dried and evaporated to dryness. Yield:
107 mg (57%).
HPLC-MS: m/z: 523.9 (M)+; Rt: 2.06 min.
[00715] Example 33 [00716] {4-[3-Cyclopentylmethoxy-5-(3-morpholin-4-yl-prop-1-ynyl)-phenylsulfanyl]-2-methyl-phenoxy } -acetic acid O
NJ
II

S O' O

O),OH
[00717] Step A: {4-[3-(2-Cyclohexyl-ethoxy)-5-(3-morpholin-4-yl-prop-1-ynyl)-phenyl-sulfanyl]-2-methyl-phenoxy}-acetic acid ethyl ester [00718] The title product was prepared from {4-[3-Bromo-5-cyclopentylmethoxy-phenyl-sulfanyl)-2-methyl-phenoxy]-acetic acid ethyl ester (260 mg; 0.54 mmol) and 4-prop-2-ynyl-morpholine (203.6 mg; 1.63 mmol) applying the procedure described for {4-[3-[2-(4-Chloro-phenyl)-ethoxy] -5-(4-hydroxymethyl-phenylethynyl)-phenylsulfanyl] -2-methyl-phenoxy } -acetic acid ethyl ester. The crude product was purified by preparative HPLC
(method B).
Yield: 80 mg (28%). HPLC-MS: m/z: 523.9 (M)+; Rt: 2.19 min [00719] Step B: {4-[3-Cyclopentylmethoxy-5-(3-morpholin-4-yl-prop-1-ynyl)-phenyl-sulfanyl] -2-methyl-phenoxy } -acetic acid [00720] {4-[3-Cyclopentylmethoxy-5-(3-morpholin-4-yl-prop-1-ynyl)-phenylsulfanyl]-2-methyl-phenoxy}-acetic acid ethyl ester (80 mg; 0.15 mmol) was dissolved in THF (2 mL) and ethanol (4 mL), and aqueous 1 N sodium hydroxide (3 mL) was added. The reaction mix-ture was stirred for 30 min. acidified with 1 N aqueous hydrochloric acid and extracted with ethyl acetate. The organic phase was dried and evaporated to dryness. Yield:
43 mg (57%).
HPLC-MS: m/z: 495.8 (M)+; Rt: 1.92 min.
[00721] Example 34 [00722] {4-[3-Cyclopentylmethoxy-5-(3-morpholin-4-yl-prop-1-ynyl)-phenylsulfanyl]-2-methyl-phenoxy } -acetic O
LDN

O

HO~O
[00723] Step A: {4-[3-Cyclopentylmethoxy-5-(3-morpholin-4-yl-prop-1-ynyl)-phenyl-sulfanyl] -2-methyl-phenoxy } -acetic ethyl ester [00724] The title product was prepared from {4-[3-Hydroxy-5-(3-morpholin-4-yl-prop-l-ynyl)-benzylsulfanyl]-2-methyl-phenoxy}-acetic acid ethyl ester (350 mg; 0.77 mmol), cyclohexylmethanol (131.6 mg; 1.15 mmol), tributylphosphine (0.465 mg; 2.31 mmol) and 1,1'-(azodicarbonyl)dipiperidine (0.581 g; 2.31 mmol) were dissolved in THF
(50 mL) in a dried reaction flask under an atmosphere of nitrogen. The reaction mixture was stirred for 16h and purified by column chromatography; ethyl acetate: heptane (5:1).
Yield: 120 mg.
HPLC-MS: m/z: 552.1 (M+H)+; Rt: 2.19 min.
[00725] Step B: {4-[3-Cyclopentylmethoxy-5-(3-morpholin-4-yl-prop-1-ynyl)-phenyl-sulfanyl] -2-methyl-phenoxy } -acetic [00726] {4-[3-Cyclopentylmethoxy-5-(3-morpholin-4-yl-prop-1-ynyl)-phenylsulfanyl]-2-methyl-phenoxy}-acetic ethyl ester (120 mg; 0.22 mmol) was dissolved in THF (2 mL) and ethanol (8 mL), and aqueous 1 N sodium hydroxide (2 mL) was added. The reaction mixture was stirred for 16 h. acidified with 1 N aqueous hydrochloric acid and extracted with ethyl acetate. The organic phase was dried and evaporated to dryness. Yield: 110 mg (90%). HPLC-MS: mlz: 524.2 (M+H)+; Rt: 1.97 min.
[00727] Example 35 [00728] {4-[3-Isobutoxy-5-(3-morpholin-4-yl-prop-1-ynyl)-benzylsulfanyl]-2-methyl-phenoxy } -acetic acid CoJ

~
s oo [00729] Step A: {4-[3-Isobutoxy-5-(3-morpholin-4-yl-prop-1-ynyl)-benzylsulfanyl]-2-methyl-phenoxy}-acetic acid ethyl ester The title product was prepared from [4-(3-Bromo-5-isobutoxy-benzylsulfanyl)-2-methyl-phenoxy]-acetic acid ethyl ester (300 mg; 0.64 mmol) and 4-prop-2-ynyl-morpholine (221 mg; 2.6 mmol) applying the procedure described for {4-[3-[2-(4-Chloro-phenyl)-ethoxy]-5-(4-hydroxymethyl-phenylethynyl)-phenylsulfanyl]-2-methyl-phenoxy}-acetic acid ethyl ester.
The crude product was purified by preparative HPLC (method B). Yield: 140 mg (44%).
HPLC-MS: m/z: 511.9 (M)+; Rt: 2.00 min.
[00730] Step B: {4-[3-Isobutoxy-5-(3-morpholin-4-yl-prop-1-ynyl)-benzylsulfanyl]-2-methyl-phenoxy } -acetic acid { {4-[3-Isobutoxy-5-(3-morpholin-4-yl-prop-1- ynyl)-benzylsulfanyl]-2-methyl-phenoxy}-acetic acid ethyl ester (140 mg; 0.27 mmol) was dissolved in ethanol (15 mL), and aqueous 1 N sodium hydroxide (3 mL) was added. The reaction mixture was stirred for 16 h. acidified with 1 N aqueous hydrochloric acid and extracted with ethyl acetate. The organic phase was dried and evaporated to dryness, redissolved in dichloromethane and evaporated to dryness.
Yield: 113 mg (86%). HPLC-MS: m/z: 484.9 (M+H)+; Rt: 1.70 min. 6H(400 MHz;
CDC13) 1.03 (d, 6H), 2.04-2.12 (m, 1H), 2.24 (s, 3H), 2.90-3.30 (m, 2H), 3.40-3.70 (m, 2H), 3.71 (d, 2H), 3.74 (s, 2H), 3.95-4.05 (m, 4H), 4.17 (s, 2H), 4.69 (s, 2H), 6.14 (m, 1H), 6.53 (d, 1H), 6.77(dd, 1H), 6.81 (m, 1H), 6.89 (m, 1H), 7.23 (d, 1H).
[00731] Example 36 [00732] [4-(3-Isobutoxy-5-phenylethynyl-benzylsulfanyl)-2-methyl-phenoxy]-acetic acid C H
~
\ I CH3 O
s O

O~OH
[00733] Step A: [4-(3-Isobutoxy-5-phenylethynyl-benzylsulfanyl)-2-methyl-phenoxy]-acetic acid ethyl ester [00734] The title product was prepared from [4-(3-Bromo-5-isobutoxy-benzylsulfanyl)-2-methyl-phenoxy] -acetic acid ethyl ester (300 mg; 0.64 mmol) and phenylacetylen (262 mg;
2.6 mmol) applying the procedure described for {4-[3-[2-(4-Chloro-phenyl)-ethoxy]-5-(4-hydroxymethyl-phenylethynyl)-phenylsulfanyl]-2-methyl-phenoxy}-acetic acid ethyl ester.
The crude product was purified by preparative HPLC (method B). Yield: 130 mg (45%).
HPLC-MS: m/z: 489.1 (M+H)+; Rt: 3.01 min [00735] Step B: [4-(3-Isobutoxy-5-phenylethynyl-benzylsulfanyl)-2-methyl-phenoxy]-acetic acid [00736] [4-(3-Isobutoxy-5-phenylethynyl-benzylsulfanyl)-2-methyl-phenoxy]-acetic acid ethyl ester (130 mg; 0.27 mmol) was dissolved in ethanol (15 mL), and aqueous 1 N sodium hydroxide (3 mL) was added. The reaction mixture was stirred for 16 h.
acidified with 1 N
aqueous hydrochloric acid and extracted with ethyl acetate. The organic phase was dried and evaporated to dryness, redissolved in dichloromethane and evaporated to dryness. Yield: 120 mg (97%). HPLC-MS: m/z: 461.7 (M+H)+; Rt: 2.82 min.
[00737] Example 37 [00738] { 4-[3-Isobutoxy-5-(4-methanesulfonyl-phenylethynyl)-benzylsulfanyl]-2-methyl-phenoxy } -acetic acid H3C'S CH
CY
CiH3 s O~OH
[00739] Step A: [{4-[3-Isobutoxy-5-(4-methanesulfonyl-phenylethynyl)-benzylsulfanyl]-2-methyl-phenoxy}-acetic acid ethyl ester [00740] The title product was prepared from [4-(3-Bromo-5-isobutoxy-benzylsulfanyl)-2-methyl-phenoxy]-acetic acid ethyl ester (300 mg; 0.64 mmol) and 1-Ethynyl-4-methane-sulfonyl-benzene (347.0 mg; 1.93 mmol) applying the procedure described for {4-[3-[2-(4-Chloro-phenyl)-ethoxy] -5- (4-hydroxymethyl-phenylethynyl)-phenylsulfanyl] -2-methyl-phenoxy}-acetic acid ethyl ester. The crude product was purified by preparative HPLC
(method A). Yield: 260 mg (72%). HPLC-MS: m/z: 567.6 (M+H)+; Rt: 2.77 min [00741] Step B: {4-[3-Isobutoxy-5-(4-methanesulfonyl-phenylethynyl)-benzylsulfanyl]-2-methyl-phenoxy } -acetic acid.
[00742] {4-[3-Isobutoxy-5-(4-methanesulfonyl-phenylethynyl)-benzylsulfanyl]-2-methyl-phenoxy}-acetic acid ethyl ester (130 mg; 0.27 mmol) was dissolved in ethanol (15 mL), and aqueous 1 N sodium hydroxide (3 mL) was added. The reaction mixture was stirred for 16 h.
acidified with 1 N aqueous hydrochloric acid and extracted with ethyl acetate.
The organic phase was dried and evaporated to dryness, redissolved in dichloromethane and evaporated to dryness. Yield: 230 mg (%). HPLC-MS: m/z: 539.5 (M+H)+; Rt: 2.49 min.
[00743] Example 38 [00744] { 4-[3-(4-Methanesulfonyl-phenylethynyl)-5-(5-trifluoromethyl-pyridin-2-yloxy)-phenylsulfanyl] -2-methyl-phenoxy } -acetic acid O=S=O
I \

F
II F Jt' S~ I ~ 11 F
O

O
O~OH
[00745] Step A: {4-[3-(4-Methanesulfonyl-phenylethynyl)-5-(5-trifluoromethyl-pyridin-2-yloxy)-phenylsulfanyl]-2-methyl-phenoxy}-acetic acid ethyl ester [00746] The title product was prepared from {4-[3-Bromo-5-(5-trifluoromethyl-pyridin-2-yloxy)-phenylsulfanyl]-2-methyl-phenoxy}-acetic acid ethyl ester (250 mg; 0.46 mmol) and 1-Ethynyl-4-methanesulfonyl-benzene (249.2 mg; 1.38 mmol) applying the procedure de-scribed for {4-[3-[2-(4-Chloro-phenyl)-ethoxy]-5-(4-hydroxymethyl-phenylethynyl)-phenyl-sulfanyl]-2-methyl-phenoxy}-acetic acid ethyl ester. The crude product was purified by preparative HPLC (method B). Yield: 168 mg (57%). HPLC-MS: m/z: 642.1 (M+H)+;
Rt:
2.75 min [00747] Step B: {4-[3-(4-Methanesulfonyl-phenylethynyl)-5-(5-trifluoromethyl-pyridin-2-yloxy)-phenylsulfanyl]-2-methyl-phenoxy}-acetic acid.
[00748] { {4-[3-(4-Methanesulfonyl-phenylethynyl)-5-(5-trifluoromethyl-pyridin-2-yloxy)-phenylsulfanyl]-2-methyl-phenoxy}-acetic acid ethyl ester (168 mg; 0.26 mmol) was dis-solved in ethanol (15 mL), and aqueous 1 N sodium hydroxide (3 mL) was added.
The reac-tion mixture was stirred for 16 h. acidified with 1 N aqueous hydrochloric acid and extracted with ethyl acetate, dried and evaporated to dryness. The organic phase was purified by prepa-rative HPLC (method B). Yield: 120 mg (75%). HPLC-MS: m/z: 614.1 (M+H)+; Rt:
2.45 min.
[00749] Example 39 [00750] {4-[3-(4-Methanesulfonyl-phenylethynyl)-5-(3-trifluoromethyl-pyridin-2-yloxy)-phenylsulfanyl] -2-methyl-phenoxy } -acetic acid O-S-O

I \
II

N ) ~ ~
S O
F F

O
O~OH
[00751] Step A: {4-[3-(4-Methanesulfonyl-phenylethynyl)-5-(3-trifluoromethyl-pyridin-2-yloxy)-phenylsulfanyl]-2-methyl-phenoxy}-acetic acid ethyl ester [00752] The title product was prepared from {4-[3-Bromo-5-(3-trifluoromethyl-pyridin-2-yloxy)-phenylsulfanyl]-2-methyl-phenoxy}-acetic acid ethyl ester (250 mg; 0.46 mmol) and 1-Ethynyl-4-methanesulfonyl-benzene (249.2 mg; 1.38 mmol) applying the procedure de-scribed for {4-[3-[2-(4-Chloro-phenyl)-ethoxy]-5-(4-hydroxymethyl-phenylethynyl)-phenylsulfanyl]-2-methyl-phenoxy}-acetic acid ethyl ester. The crude product was purified by preparative HPLC (method B). Yield: 197 mg (67%). HPLC-MS: m/z: 642.4 (M+H)+;
Rt:

2.73 min [00753] Step B: {4-[3-(4-Methanesulfonyl-phenylethynyl)-5-(3-trifluoromethyl-pyridin-2-yloxy)-phenylsulfanyl]-2-methyl-phenoxy}-acetic acid.
[00754] {4-[3-(4-Methanesulfonyl-phenylethynyl)-5-(3-trifluoromethyl-pyridin-2-yloxy)-phenylsulfanyl]-2-methyl-phenoxy}-acetic acid ethyl ester (197 mg; 0.31 mmol) was dis-solved in ethanol (15 mL), and aqueous 1 N sodium hydroxide (3 mL) was added.
The reac-tion mixture was stirred for 16 h. acidified with 1 N aqueous hydrochloric acid and extracted with ethyl acetate, dried and evaporated to dryness. The organic phase was purified by prepa-rative HPLC (method B). Yield: 150 mg (80%). HPLC-MS: m/z: 614.4 (M+H)+; Rt:
2.42 min.
[00755] Example 40 [00756] {2-Methyl-4-[3-(3-morpholin-4-yl-prop-1-ynyl)-5-(3-trifluoromethyl-pyridin-2-yloxy)-phenylsulfanyl]-phenoxy}-acetic acid O

N~
F
F F
8 l O

O

O~OH
[00757] Step A: {2-Methyl-4-[3-(3-morpholin-4-yl-prop-1-ynyl)-5-(3-trifluoromethyl-pyridin-2-yloxy)-phenylsulfanyl]-phenoxy}-acetic acid ethyl ester [00758] The title product was prepared from {4-[3-Bromo-5-(3-trifluoromethyl-pyridin-2-yloxy)-phenylsulfanyl]-2-methyl-phenoxy}-acetic acid ethyl ester (250 mg; 0.46 mmol) and 4-prop-2-ynyl-morpholine (173.09 mg; 1.38 mmol) applying the procedure described for {4-[3- [2-(4-Chloro-phenyl)-ethoxy] -5- (4-hydroxymethyl-phenylethynyl)-phenylsulfanyl] -2-methyl-phenoxy}-acetic acid ethyl ester. The crude product was purified by preparative HPLC (method B). Yield: 262 mg (97%). HPLC-MS: m/z: 587.5 (M+H)+; Rt: 2.03 min [00759] Step B: {2-Methyl-4-[3-(3-morpholin-4-yl-prop-1-ynyl)-5-(3-trifluoromethyl-pyridin-2-yloxy)-phenylsulfanyl]-phenoxy}-acetic acid.
[00760] {2-Methyl-4-[3-(3-morpholin-4-yl-prop-1-ynyl)-5-(3-trifluoromethyl-pyridin-2-yloxy)-phenylsulfanyl]-phenoxy}-acetic acid ethyl ester (262 mg; 0.45 mmol) was dissolved in ethanol (15 mL), and aqueous 1 N sodium hydroxide (3 mL) was added. The reaction mix-ture was stirred for 16 h. acidified with 1 N aqueous hydrochloric acid and extracted with ethyl acetate, dried and evaporated to dryness. The organic phase was purified by preparative HPLC (method B). Yield: 178 mg (72%). HPLC-MS: m/z: 559.5 (M+H)+; Rt: 1.78 min.
[00761] Example 41 [00762] {2-Methyl-4-[3-(3-morpholin-4-yl-prop-1-ynyl)-5-(5-trifluoromethyl-pyridin-2-yloxy)-phenylsulfanyl]-phenoxy}-acetic acid ON

II F
N~ FF
s O

O

O'~ OH
[00763] Step A: {2-Methyl-4-[3-(3-morpholin-4-yl-prop-1-ynyl)-5-(5-trifluoromethyl-pyridin-2-yloxy)-phenylsulfanyl]-phenoxy}-acetic acid ethyl ester [00764] The title product was prepared from {4-[3-Bromo-5-(5-trifluoromethyl-pyridin-2-yloxy)-phenylsulfanyl]-2-methyl-phenoxy}-acetic acid ethyl ester (250 mg; 0.46 mmol) and 4-prop-2-ynyl-morpholine (173.09 mg; 1.38 mmol) applying the procedure described for {4-[3- [2-(4-Chloro-phenyl)-ethoxy] -5- (4-hydroxymethyl-phenylethynyl)-phenylsulfanyl] -2-methyl-phenoxy}-acetic acid ethyl ester. The crude product was purified by preparative HPLC (method B). Yield: 270 mg (100%). HPLC-MS: m/z: 587.5 (M+H)+; Rt: 2.03 min [00765] Step B: {2-Methyl-4-[3-(3-morpholin-4-yl-prop-1-ynyl)-5-(5-trifluoromethyl-pyridin-2-yloxy)-phenylsulfanyl]-phenoxy}-acetic acid.
[00766] {2-Methyl-4-[3-(3-morpholin-4-yl-prop-1-ynyl)-5-(5-trifluoromethyl-pyridin-2-yloxy)-phenylsulfanyl]-phenoxy}-acetic acid ethyl ester (262 mg; 0.45 mmol) was dissolved in ethanol (15 mL), and aqueous 1 N sodium hydroxide (3 mL) was added. The reaction mix-ture was stirred for 16 h. acidified with 1 N aqueous hydrochloric acid and extracted with ethyl acetate, dried and evaporated to dryness. The organic phase was purified by preparative HPLC (method B). Yield: 174 mg (68%). HPLC-MS: m/z: 559.5 (M+H)+; Rt: 1.81 min.
[00767] Example 42 [00768] {2-Methyl-4-[3-(3-morpholin-4-yl-prop-1-ynyl)-5-(3-trifluoromethyl-phenoxy)-phenylsulfanyl] -phenoxy } -acetic acid (o) F F
~ O~F
i I

S

OfOH
[00769] Step A: {2-Methyl-4-[3-(3-morpholin-4-yl-prop-1-ynyl)-5-(3-trifluoromethyl-phenoxy)-phenylsulfanyl]-phenoxy}-acetic acid ethyl ester [00770] The title product was prepared from {4-[3-Bromo-5-(3-trifluoromethyl-phenoxy)-phenylsulfanyl]-2-methyl-phenoxy}-acetic acid ethyl ester (230 mg; 0.43 mmol) and 4-prop-2-ynyl-morpholine (159.5 mg; 1.28 mmol) applying the procedure described for {4-[3-[2-(4-Chloro-phenyl)-ethoxy] -5- (4-hydroxymethyl-phenylethynyl)-phenylsulfanyl] -2-methyl-phenoxy}-acetic acid ethyl ester. The crude product was purified by preparative HPLC
(method A). Yield: 160 mg. HPLC-MS: m/z: 586.5 (M+H)+; Rt: 2.18 min [00771] Step B: {2-Methyl-4-[3-(3-morpholin-4-yl-prop-1-ynyl)-5-(3-trifluoromethyl-phenoxy)-phenylsulfanyl] -phenoxy } -acetic acid.
[00772] {2-Methyl-4-[3-(3-morpholin-4-yl-prop-1-ynyl)-5-(3-trifluoromethyl-phenoxy)-phenylsulfanyl]-phenoxy}-acetic acid ethyl ester (160 mg; 0.27 mmol) was dissolved in etha-nol (15 mL), and aqueous 1 N sodium hydroxide (3 mL) was added. The reaction mixture was stirred for 16 h. acidified with 1 N aqueous hydrochloric acid and extracted with ethyl acetate, dried and evaporated to dryness. The organic phase was purified by preparative HPLC
(method B). Yield: 128 mg (84%). HPLC-MS: m/z: 558.4 (M+H)+; Rt: 1.91 min.
6H(400 MHz; CDC13) 2.26 (s, 3H), 3.05-3.55 (m, 4H), 3.91-4.04 (m, 4H), 4.11 (s, 2H), 4.70 (s, 2H), 6.71-6.78 (m, 3H), 6.81-6.84 (m, 1H), 7.11-7.16 (m, 1H), 7.19-7.23 (m, 1H), 7.27-7.33 (m, 2H), 7.37-7.41 (m, 1H), 7.43-7.49 (m, 1H).
[00773] Example 43 [00774] {4-[3-(4-Methanesulfonyl-phenylethynyl)-5-(3-trifluoromethyl-phenoxy)-phenylsulfanyl] -2-methyl-phenoxy } -acetic acid H3C,S-~
O ~ I
F F
O \ F
~ /

O'~OH
[00775] Step A: {4-[3-(4-Methanesulfonyl-phenylethynyl)-5-(3-trifluoromethyl-phenoxy)-phenylsulfanyl]-2-methyl-phenoxy}-acetic acid ethyl ester [00776] The title product was prepared from {4-[3-Bromo-5-(3-trifluoromethyl-phenoxy)-phenylsulfanyl]-2-methyl-phenoxy}-acetic acid ethyl ester (230 mg; 0.43 mmol) and 1-Ethynyl-4-methanesulfonyl-benzene (229.7 mg; 1.28 mmol) applying the procedure described for {4-[3-[2-(4-Chloro-phenyl)-ethoxy]-5-(4-hydroxymethyl-phenylethynyl)-phenylsulfanyl]-2-methyl-phenoxy}-acetic acid ethyl ester. The crude product was purified by preparative HPLC (method A). Yield: 140 mg. HPLC-MS: m/z: 641.5 (M+H)+; Rt: 2.89 min [00777] Step B: {4-[3-(4-Methanesulfonyl-phenylethynyl)-5-(3-trifluoromethyl-phenoxy)-phenylsulfanyl] -2-methyl-phenoxy } -acetic acid.
[00778] {4-[3-(4-Methanesulfonyl-phenylethynyl)-5-(3-trifluoromethyl-phenoxy)-phenyl-sulfanyl]-2-methyl-phenoxy}-acetic acid ethyl ester (140 mg; 0.22 mmol) was dissolved in ethanol (15 mL), and aqueous 1 N sodium hydroxide (3 mL) was added. The reaction mixture was stirred for 16 h. acidified with 1 N aqueous hydrochloric acid and extracted with ethyl acetate, dried and evaporated to dryness. The organic phase was purified by preparative HPLC (method B). Yield: 100 mg (75%). HPLC-MS: m/z: 635.1 (M+Na); Rt: 2.62 min.
[00779] Example 44 [00780] { 2-Methyl-4-[3-phenylethynyl-5-(5-trifluoromethyl-pyridin-2-yloxy)-phenyl-sulfanyl] -phenoxy } -acetic acid Q

N F
O FF
S

O

OOH
[00781] Step A: {2-Methyl-4-[3-phenylethynyl-5-(5-trifluoromethyl-pyridin-2-yloxy)-phenylsulfanyl]-phenoxy}-acetic acid ethyl ester [00782] The title product was prepared from {4-[3-Bromo-5-(3-trifluoromethyl-phenoxy)-phenylsulfanyl]-2-methyl-phenoxy}-acetic acid ethyl ester (300 mg; 0.55 mmol) and phenylacetylene (113 mg; 1.11 mmol) applying the procedure described for {4-[3-[2-(4-Chloro-phenyl)-ethoxy] -5- (4-hydroxymethyl-phenylethynyl)-phenylsulfanyl] -2-methyl-phenoxy}-acetic acid ethyl ester. The crude product was purified by preparative HPLC
(method A). Yield: 150 mg. HPLC-MS: m/z: 564.5 (M+H)+; Rt: 3.00 min [00783] Step B: {2-Methyl-4-[3-phenylethynyl-5-(5-trifluoromethyl-pyridin-2-yloxy)-phenylsulfanyl] -phenoxy } -acetic acid.
[00784] { 2-Methyl-4-[3-phenylethynyl-5-(5-trifluoromethyl-pyridin-2-yloxy)-phenylsulfanyl]-phenoxy}-acetic acid ethyl ester (150 mg; 0.266 mmol) was dissolved in THF (2 mL) and ethanol (4 mL), and aqueous 1 N sodium hydroxide (3 mL) was added. The reaction mixture was stirred for 1/2 h. acidified with 5% aqueous citric acid and extracted with ethyl acetate, dried and evaporated to dryness. Yield: 100 mg (75%). HPLC-MS:
m/z: 535.7 (M)+; Rt: 2.78 min.
[00785] Example 45 [00786] {4-[3-Cyclopropylmethoxy-5-(3-morpholin-4-yl-prop-1-ynyl)-benzylsulfanyl]-2-methyl-phenoxy } -acetic acid ~N O
~/

S

O

O~OH
[00787] Step A: {4-[3-Cyclopropylmethoxy-5-(3-morpholin-4-yl-prop-1-ynyl)-benzyl-sulfanyl]-2-methyl-phenoxy}-acetic acid acid ethyl ester [00788] The title product was prepared from [4-(3-Bromo-5-cyclopropylmethoxy-benzylsulfanyl)-2-methyl-phenoxy]-acetic acid ethyl ester (200 mg; 0.43 mmol) and 4-prop-2-ynyl-morpholine (161 mg; 1.3 mmol) applying the procedure described for {4-[3-[2-(4-Chloro-phenyl)-ethoxy] -5- (4-hydroxymethyl-phenylethynyl)-phenylsulfanyl] -2-methyl-phenoxy}-acetic acid ethyl ester. The crude product was purified by preparative HPLC
(method B). Yield: 173 mg; 79%. HPLC-MS: m/z: 510.1 (M)+; Rt: 1.9 min.
[00789] Step B: {4-[3-Cyclopropylmethoxy-5-(3-morpholin-4-yl-prop-1-ynyl)-benzylsulfanyl] -2-methyl-phenoxy } -acetic acid [00790] {4-[3-Cyclopropylmethoxy-5-(3-morpholin-4-yl-prop-1-ynyl)-benzylsulfanyl]-2-methyl-phenoxy}-acetic acid acid ethyl ester (173 mg; 0.34 mmol) was dissolved in ethanol (15 mL), and aqueous 1 N sodium hydroxide (3 mL) was added. The reaction mixture was stirred for 16 h. acidified with 1 N aqueous hydrochloric acid and extracted with ethyl acetate.
The organic phase was dried and evaporated to dryness. Yield: 107 mg; 66%.
HPLC-MS:
m/z: 482.0 (M+H)+; Rt: 1.62 min.
[00791] Example 46 [00792] _{ 4-[3-Cyclopropylmethoxy-5-(3-morpholin-4-yl-prop-1-ynyl)-phenylsulfanyl]-2-methyl-phenoxy } -acetic acid cI
S O

~ CH3 O

O~OH
[00793] Step A: {4-[3-Cyclopropylmethoxy-5-(3-morpholin-4-yl-prop-1-ynyl)-phenyl-sulfanyl]-2-methyl-phenoxy}-acetic acid ethyl ester [00794] The title product was prepared from [4-(3-Bromo-5-cyclopropylmethoxy-phenyl-sulfanyl)-2-methyl-phenoxy]-acetic acid ethyl ester (250 mg; 0.55 mmol) and 4-prop-2-ynyl-morpholine (208 mg; 1.7 mmol) applying the procedure described for {4-[3-[2-(4-Chloro-phenyl)-ethoxy] -5-(4-hydroxymethyl-phenylethynyl)-phenylsulfanyl] -2-methyl-phenoxy } -acetic acid ethyl ester. The crude product was purified by preparative HPLC
(method B).
Yield: 205 mg; 75%. HPLC-MS: m/z: 496.1 (M+H)+; Rt: 2.04 min.
[00795] Step B: {4-[3-Cyclopropylmethoxy-5-(3-morpholin-4-yl-prop-1-ynyl)-phenylsulfanyl]-2-methyl-phenoxy}-acetic acid [00796] {4-[3-Cyclopropylmethoxy-5-(3-morpholin-4-yl-prop-1-ynyl)-phenylsulfanyl]-2-methyl-phenoxy}-acetic acid ethyl ester (205 mg; 0.41 mmol) was dissolved in ethanol (15 mL), and aqueous 1 N sodium hydroxide (3 mL) was added. The reaction mixture was stirred for 16 h. acidified with 1 N aqueous hydrochloric acid and extracted with ethyl acetate. The organic phase was dried and evaporated to dryness. Yield: 160 mg; 83%. HPLC-MS: m/z:
468.1 (M+H)+; Rt: 1.78 min.
[00797] Example 47 [00798] {4-[3-Isobutoxy-5-(3-morpholin-4-yl-prop-1-ynyl)-phenylsulfanyl]-2,5-dimethyl-phenoxy } -acetic acid O

S O~ 'CH3 ~ CH3 7CH3 O
O~OH
[00799] Step A: {4-[3-Isobutoxy-5-(3-morpholin-4-yl-prop-1-ynyl)-phenylsulfanyl]-2,5-dimethyl-phenoxy}-acetic acid ethyl ester [00800] The title product was prepared from [4-(3-Bromo-5-isobutoxy-phenylsulfanyl)-2,5-dimethyl-phenoxy]-acetic acid ethyl ester (400 mg; 0.86 mmol) and 4-prop-2-ynyl-morpholine (321.3 mg; 2.6 mmol) applying the procedure described for {4-[3-[2-(4-Chloro-phenyl)-ethoxy]-5-(4-hydroxymethyl-phenylethynyl)-phenylsulfanyl]-2-methyl-phenoxy } -acetic acid ethyl ester. The crude product was purified by preparative HPLC
(method B).
Yield: 350 mg; 80%. HPLC-MS: m/z: 512.2 (M+H)+; Rt: 2.09 min.
[00801] Step B: {4-[3-Isobutoxy-5-(3-morpholin-4-yl-prop-1-ynyl)-phenylsulfanyl]-2,5-dimethyl-phenoxy } -acetic acid [00802] {4-[3-Isobutoxy-5-(3-morpholin-4-yl-prop-1-ynyl)-phenylsulfanyl]-2,5-dimethyl-phenoxy}-acetic acid ethyl ester (350 mg; 0.68 mmol) was dissolved in ethanol (15 mL), and aqueous 1 N sodium hydroxide (3 mL) was added. The reaction mixture was stirred for 16 h.
acidified with 1 N aqueous hydrochloric acid and extracted with ethyl acetate.
The organic phase was dried and evaporated to dryness and purified by prep HPLC (method B). Yield:
250 mg; 76%. HPLC-MS: m/z: 484.6 (M+H)+; Rt: 1.87 min.
[00803] Example 48 {4-[3-Isobutoxy-5-(3-morpholin-4-yl-prop-1-ynyl)-phenoxy]-2-methyl-phenoxy}-acetic acid cI

O ~ O~7 'CH3 O
O~OH
[00804] Step A: {4-[3-Isobutoxy-5-(3-morpholin-4-yl-prop-1-ynyl)-phenoxy]-2-methyl-phenoxy}-acetic acid ethyl ester [00805] The title product was prepared from [4-(3-Bromo-5-isobutoxy-phenylsulfanyl)-2,5-dimethyl-phenoxy]-acetic acid ethyl ester (300 mg; 0.71 mmol) and 4-prop-2-ynyl-morpholine (266.1 mg; 2.1 mmol) applying the procedure described for {4-[3-[2-(4-Chloro-phenyl)-ethoxy] -5-(4-hydroxymethyl-phenylethynyl)-phenylsulfanyl] -2-methyl-phenoxy } -acetic acid ethyl ester. The crude product was purified by preparative HPLC
(method B).
Yield: 260 mg; 79%. HPLC-MS: m/z: 468.7 (M+H)+; Rt: 1.94 min [00806] Step B: {4-[3-Isobutoxy-5-(3-morpholin-4-yl-prop-1-ynyl)-phenoxy]-2-methyl-phenoxy } -acetic acid [00807] {4-[3-Isobutoxy-5-(3-morpholin-4-yl-prop-1-ynyl)-phenoxy]-2-methyl-phenoxy}-acetic acid ethyl ester (260 mg; 0.56 mmol) was dissolved in ethanol (15 mL), and aqueous 1 N sodium hydroxide (3 mL) was added. The reaction mixture was stirred for 16 h. acidified with 1 N aqueous hydrochloric acid and extracted with ethyl acetate. The organic phase was dried and evaporated to dryness and purified by prep HPLC (method B). Yield:
180 mg; 72%.
HPLC-MS: m/z: 454.6 (M+H)+; Rt: 1.77 min. 6H(400 MHz; CDC13) 1.01 (d, 6H), 2.02-2.10 (m, 1H), 2.28 (s, 3H), 3.10-3.55 (m, 4H), 3.68 (d, 2H), 3.93-4.07 (m, 4H), 4.10 (s, 2H), 4.67 (s, 2H), 6.47 (m, 1H), 6.57-6.59 (m, 1H), 6.66-6.69 (m, 1H), 6.71 (d, 1H), 6.79 (dd, 1H), 6.86 (d, 1H).

PHARMACOLOGICAL METHODS
IN VITRO PPAR-b ACTIVATION ACTIVITY
[00808] The PPAR transient transactivation assay is based on transient transfection into hu-man HEK293 cells of two plasmids encoding a chimeric test protein and a reporter protein respectively. The chimeric test protein is a fusion of the DNA binding domain (DBD) from the yeast GAL4 transcription factor to the ligand binding domain (LBD) of the human PPAR
proteins. The PPAR-LBD moiety harbored in addition to the ligand binding pocket also the native activation domain (activating function 2 = AF2) allowing the fusion protein to function as a PPAR ligand dependent transcription factor. The GAL4 DBD will direct the chimeric protein to bind only to Ga14 enhancers (of which none existed in HEK293 cells). The reporter plasmid contained a Ga14 enhancer driving the expression of the firefly luciferase protein.
After transfection, HEK293 cells expressed the GAL4-DBD-PPAR-LBD fusion protein. The fusion protein will in turn bind to the Ga14 enhancer controlling the luciferase expression, and do nothing in the absence of ligand. Upon addition to the cells of a PPAR
ligand luciferase protein will be produced in amounts corresponding to the activation of the PPAR protein.
The amount of luciferase protein is measured by light emission after addition of the appropri-ate substrate.

CELL CULTURE AND TRANSFECTION
[00809] HEK293 cells were grown in DMEM + 10% FCS. Cells were seeded in 96-well plates the day before transfection to give a confluency of 50-80 % at transfection. A total of 0,8 g DNA containing 0,64 g pMloc/yLBD, 0,1 g pCMV(3Gal, 0,08 g pGL2(Ga14)5 and 0,02 g pADVANTAGE was transfected per well using FuGene transfection reagent accord-ing to the manufacturers instructions (Roche). Cells were allowed to express protein for 48 h followed by addition of compound.
[00810] Plasmids: Human PPAR-8 was obtained by PCR amplification using cDNA
synthe-sized by reverse transcription of mRNA from human liver, adipose tissue and plancenta re-spectively. Amplified cDNAs were cloned into pCR2.1 and sequenced. The ligand binding domain (LBD) of each PPAR isoform was generated by PCR (PPAR8: aa 128 - C-terminus) and fused to the DNA binding domain (DBD) of the yeast transcription factor GAL4 by sub-cloning fragments in frame into the vector pMl (Sadowski et al. (1992), Gene 118, 137) gen-erating the plasmids pM1ocLBD, pM1yLBD and pM18. Ensuing fusions were verified by se-quencing. The reporter was constructed by inserting an oligonucleotide encoding five repeats of the GAL4 recognition sequence (5 x CGGAGTACTGTCCTCCG(AG)) (Webster et al.
(1988), Nucleic Acids Res. 16, 8192) into the vector pGL2 promotor (Promega) generating the plasmid pGL2(GAL4)5. pCMV(3Ga1 was purchased from Clontech and pADVANTAGE
was purchased from Promega.

IN VITRO TRANSACTIVATION ASSAY
[00811] Compounds: All compounds were dissolved in DMSO and diluted 1:1000 upon ad-dition to the cells. Compounds were tested in quadruple in concentrations ranging from 0.001 to 300 p.M. Cells were treated with compound for 24 h followed by luciferase assay. Each compound was tested in at least two separate experiments.
[00812] Luciferase assay: Medium including test compound was aspirated and 100 l PBS
incl. 1mM Mg++ and Ca++ were added to each well. The luciferase assay was performed using the LucLite kit according to the manufacturer's instructions (Packard Instruments).
Light emission was quantified by counting on a Packard LumiCounter. To measure (3-galactosidase activity 25 l supernatant from each transfection lysate was transferred to a new microplate. (3-Galactosidase assays were performed in the microwell plates using a kit from Promega and read in a Labsystems Ascent Multiscan reader. The 0-galactosidase data were used to normalize (transfection efficiency, cell growth etc.) the luciferase data.
STATISTICAL METHODS
[00813] The activity of a compound is calculated as fold induction compared to an untreated sample. For each compound the efficacy (maximal activity) is given as a relative activity compared to Wy14,643 for PPARoc, Rosiglitazone for PPARy and Carbacyclin for PPARS.
The EC50 is the concentration giving 50% of maximal observed activity. EC50 values were calculated via non-linear regression using GraphPad PRISM 3.02 (GraphPad Software, San Diego, Ca).
[00814] While the invention has been described and illustrated with reference to certain pre-ferred embodiments thereof, those skilled in the art will appreciate that various changes, modifications, and substitutions can be made therein without departing from the spirit and scope of the present invention. For example, effective dosages other than the preferred dos-ages as set forth herein may be applicable as a consequence of variations in the responsive-ness of the mammal being treated for PPAR-8 mediated disease(s). Likewise, the specific pharmacological responses observed may vary according to and depending on the particular active compound selected or whether there are present pharmaceutical carriers, as well as the type of formulation and mode of administration employed, and such expected variations or differences in the results are contemplated in accordance with the objects and practices of the present invention. Accordingly, the invention is not to be limited as by the appended claims.
[00815] The features disclosed in the foregoing description and/or in the claims may both separately ans in any combination thereof be material for realising the invention in diverse forms thereof.
[00816] Preferred features of the invention:
[00817] 1. A compound of formula I:
R4c R2 R4b /
R4a':"X~1"Xl ' X 1 R5d se 1 ~ R Rl R5o R3 R5b Rsa O

or a pharmaceutically acceptable salt thereof, wherein:
X is selected from 0, S, OCH2, and SCH2;

Xl is 0 or S;

Rl is selected from H, Cl_g alkyl, CZ_g alkenyl, aryl, heteroaryl,C3_10 cycloalkyl, and a hetero-cyclyl, wherein each Rl group is substituted with 0-4 Rla;

Rla, at each occurrence, is selected from S substituted with 0-1 Rlb, 0 substituted with 0-1 Rlb, halogen, NH2 substituted with 0-2 Rlb, -CN, NOZ, Cl_6 alkyl substituted with 0-3 Rlb, C2_6 alkenyl substituted with 0-2 Rlb, C2_6 alkynyl substituted with 0-2 Rlb, aryl substituted with 0-2 Rlb, heteroaryl substituted with 0-2 Rlb, C3_10 cycloalkyl substituted with 0-2 Rlb, and het-erocycle substituted with 0-2 Rlb;

Rlb, at each occurrence, is selected from S substituted with 0-1 Rl , 0 substituted with 0-1 Rl , halogen, methanesulfonyl, NH2 substituted with 0-2 Rl , -CN, NOZ, Cl_6 alkyl substituted with 0-3 Rl , C2_6 alkenyl substituted with 0-2 Rl , aryl substituted with 0-2 Rl , heteroaryl substituted with 0-2 Rl , C3_1o cycloalkyl substituted with 0-2 Rl , and a heterocycle substi-tuted with 0-2 R";

Rl , at each occurrence, is selected from S substituted with 0-1 Rld, 0 substituted with 0-1 'd, halogen, NH2 substituted with 0-2 R'd, -CN, NOZ, Cl_6 alkyl substituted with 0-2 Rld R , CZ_6 alkenyl substituted with 0-2 Rld, aryl substituted with 0-2 Rld, heteroaryl substituted with 0-2 Rld, C3_1o cycloalkyl substituted with 0-2 Rld, and a heterocycle substituted with 0-2 Rla;

Rld, at each occurrence, is selected from OH, SH, S, 0, halogen, NH2, -CN, NOZ, C1_6 alkyl, C2_6 alkenyl, aryl, CF3, and OCF3;

R2 is selected from -C=C-RZa, -CH=CH-RZa, aryl substituted with 0-3 RZa, and heteroaryl sub-stituted with 0-3 R2a;

RZa at each occurrence, is selected from S substituted with 0-1 R 2b, 0 substituted with 0-1 RZb, halogen, NHZ substituted with 0-2 RZb, -CN, NOZ, Cl_6 alkyl substituted with 0-2 RZb, C2_6 alkenyl substituted with 0-2 R 2b, aryl substituted with 0-2 RZb, heteroaryl substituted with 0-2 RZb, C3_1o cycloalkyl substituted with 0-2 R 2b, and a heterocycle substituted with 0-2;

RZb, at each occurrence, is selected from S substituted with 0-1 RZ , 0 substituted with 0-1 RZ , halogen, methanesulfonyl, NH2 substituted with 0-2 RZ , -CN, NOZ, Cl_6 alkyl substituted with 0-2 RZ , C2_6 alkenyl substituted with 0-2 RZ , aryl substituted with 0-2 RZ , heteroaryl substituted with 0-2 RZ , C3_1o cycloalkyl substituted with 0-2 RZ , and a heterocycle substi-tuted with 0-2 R2 ;

RZ , at each occurrence, is selected from S substituted with 0-1 RZd, 0 substituted with 0-1 RZd, halogen, NH2 substituted with 0-2 RZd, -CN, NOZ, Cl_6 alkyl substituted with 0-2 RZd, C2_6 alkenyl substituted with 0-2 RZd, aryl substituted with 0-2 RZd, heteroaryl substituted with 0-2 RZd, C3_1o cycloalkyl substituted with 0-2 RZd, and a heterocycle substituted with 0-2 RZd RZd, at each occurrence, is selected from OH, SH, S, 0, halogen, NH2, -CN, NOZ, Cl_6 alkyl, C2_6 alkenyl, aryl, CF3, and OCF3;

R3 is selected from halogen and Cl_6 alkyl substituted with 0-2 R3a;

R3a, at each occurrence, is selected from OH, 0, S, halogen, C(O)NH2, C(O)NH-Cl_4 alkyl, and C(O)N(Ci_4 alkyl)z, alternatively, R3 and R5e combine to form a 5, 6, or 7 membered ring consisting of carbon at-oms and 0-2 heteroatoms selected from 0, N, and S(O)o_Z and there are 0-2 ring double bonds in the bridging portion formed by R3 and Rse;

R4a at each occurrence, is selected from H, halogen, and Cl_6 alkyl substituted with 0-2 R4a;
R4d, at each occurrence, is selected from OH, 0, halogen, NH2, NH-Cl_4 alkyl, and N(Cl_4 al-kyl)2;

R4b, at each occurrence, is selected from H, halogen, and Cl-6 alkyl substituted with 0-2 R4e;
R4e, at each occurrence, is selected from OH, 0, halogen, NH2, NH-Cl-4 alkyl, and N(Cl-4 al-kyl)z, R4o, at each occurrence, is selected from H, halogen, and Cl-6 alkyl substituted with 0-2 R4f;
R4f, at each occurrence, is selected from OH, 0, halogen, NH2, NH-Cl-4 alkyl, and N(Cl-4 al-kyl)2;

RSa, at each occurrence, is selected from H, halogen, CH3, and CH2CH3;
R5b, at each occurrence, is selected from H, halogen, CH3, and CH2CH3;
RS , at each occurrence, is selected from H, halogen, CH3, and CH2CH3;

RSd, at each occurrence, is selected from H, halogen, CH3, and CH2CH3; and, R5e, at each occurrence, is selected from H, halogen, CH3, and CH2CH3.
[00818] 2. A compound of clause 1 wherein:

X is selected from 0, S, OCHZ, and SCH2;
Xl is 0 or S;

Rl is selected from H, Cl-g alkyl, CZ-g alkenyl, aryl, 5-10 membered heteroaryl consisting of carbon atoms and 1-4 heteroatoms selected from 0, N, and S(O)0-2, C3-io cycloalkyl, and a 3-8 membered heterocycle consisting of carbon atoms and 1-3 heteroatoms selected from 0, N, and S(O)o-Z, wherein each Rl group is substituted with 0-4 Rla;

Rla, at each occurrence, is selected from OH substituted with 0-1 Rlb, SH
substituted with 0-1 Rlb, S, 0, halogen, NH2 substituted with 0-2 Rlb, -CN, NOZ, Cl-6 alkyl substituted with 0-3 Rlb, C2-6 alkenyl substituted with 0-2 Rlb, CZ-6 alkynyl substituted with 0-2 Rlb, aryl substi-tuted with 0-2 Rlb, 5-10 membered heteroaryl substituted with 0-2 Rlb and consisting of car-bon atoms and 1-4 heteroatoms selected from 0, N, and S(O)o-2, C3-10 cycloalkyl substituted with 0-2 Rlb, and a 3-8 membered heterocycle substituted with 0-2 Rlb and consisting of car-bon atoms and 1-3 heteroatoms selected from 0, N, and S(O)o-Z, Rlb, at each occurrence, is selected from OH substituted with 0-1 Rl , SH
substituted with 0-1 Rl , S, 0, halogen, methanesulfonyl, NH2 substituted with 0-2 Rl , -CN, NOZ, Cl-6 alkyl sub-stituted with 0-3 Rl , CZ-6 alkenyl substituted with 0-2 Rl , aryl substituted with 0-2 Rl , 5-10 membered heteroaryl substituted with 0-2 Rl and consisting of carbon atoms and 1-4 heteroa-toms selected from 0, N, and S(O)o-2, C3-i0 cycloalkyl substituted with 0-2 Rl , and a 3-8 membered heterocycle substituted with 0-2 Rl and consisting of carbon atoms and 1-3 het-eroatoms selected from 0, N, and S(O)0-2, Rl , at each occurrence, is selected from OH substituted with 0-1 Rld, SH
substituted with 0-1 Rld, S, 0, halogen, NH2 substituted with 0-2 Rld, -CN, NOZ, Cl-6 alkyl substituted with 0-2 Rld, C2-6 alkenyl substituted with 0-2 Rld, aryl substituted with 0-2 Rld, 5-10 membered het-eroaryl substituted with 0-2 Rld and consisting of carbon atoms and 1-4 heteroatoms selected from 0, N, and S(O)o-2, C3-i0 cycloalkyl substituted with 0-2 R'd, and a 3-8 membered hetero-cycle substituted with 0-2 Rld and consisting of carbon atoms and 1-3 heteroatoms selected from 0, N, and S(O)o-Z, Rld, at each occurrence, is selected from OH, SH, S, 0, halogen, NH2, -CN, NOZ, Cl-6 alkyl, C2-6 alkenyl, aryl, CF3, and OCF3;

RZ is selected from -C=C-RZa, -CH=CH-RZa substituted with 0-2 RZa, aryl substituted with 0-3 RZa, and 5-10 membered heteroaryl substituted with 0-3 R 2a and consisting of carbon atoms and 1-4 heteroatoms selected from 0, N, and S(O)0_2, RZa, at each occurrence, is selected from OH substituted with 0-1 R 2b, SH
substituted with 0-1 RZb, S, 0, halogen, NH2 substituted with 0-2 R 2b, -CN, NOZ, Cl-6 alkyl substituted with 0-2 RZb, C2-6 alkenyl substituted with 0-2 RZb, aryl substituted with 0-2 RZb, 5-10 membered het-eroaryl substituted with 0-2 R 2b and consisting of carbon atoms and 1-4 heteroatoms selected from 0, N, and S(O)o-2, C3-io cycloalkyl substituted with 0-2 RZb, and a 3-8 membered hetero-cycle substituted with 0-2 R 2b and consisting of carbon atoms and 1-3 heteroatoms selected from 0, N, and S(O)o-Z, R 2b, at each occurrence, is selected from OH substituted with 0-1 RZ , SH
substituted with 0-1 RZ , S, 0 substituted with 0-1 RZ , halogen, methanesulfonyl, NH2 substituted with 0-2 RZ , -CN, NOZ, Cl-6 alkyl substituted with 0-2 RZ , CZ-6 alkenyl substituted with 0-2 RZ , aryl substi-tuted with 0-2 RZ , 5-10 membered heteroaryl substituted with 0-2 RZ and consisting of car-bon atoms and 1-4 heteroatoms selected from 0, N, and S(O)0-2, C3-io cycloalkyl substituted with 0-2 RZ , and a 3-8 membered heterocycle substituted with 0-2 RZ and consisting of car-bon atoms and 1-3 heteroatoms selected from 0, N, and S(O)0_2, RZ , at each occurrence, is selected from OH substituted with 0-1 R 2d, SH
substituted with 0-1 RZd, S, 0, halogen, NH2 substituted with 0-2 RZd, -CN, NOZ, Cl-6 alkyl substituted with 0-2 RZd, C2-6 alkenyl substituted with 0-2 RZd, aryl substituted with 0-2 RZd, 5-10 membered het-eroaryl substituted with 0-2 R2d and consisting of carbon atoms and 1-4 heteroatoms selected from 0, N, and S(O)o-2, C3-io cycloalkyl substituted with 0-2 RZd, and a 3-8 membered hetero-cycle substituted with 0-2 RZd and consisting of carbon atoms and 1-3 heteroatoms selected from 0, N, and S(O)o-Z, RZd, at each occurrence, is selected from OH, SH, S, 0, halogen, NH2, -CN, NOZ, Cl-6 alkyl, C2-6 alkenyl, aryl, CF3, and OCF3;

R3 is selected from halogen and Cl_6 alkyl substituted with 0-2 R3a;

R3a, at each occurrence, is selected from OH, 0, S, halogen, C(O)NH2, C(O)NH-Cl_~ alkyl, and C(O)N(Ci_4 alkyl)z, alternatively, R3 and R5e combine to form a 5, 6, or 7 membered ring consisting of carbon at-oms and 0-2 heteroatoms selected from 0, N, and S(O)o_Z and there are 0-2 ring double bonds in the bridging portion formed by R3 and R 5e;

R4a at each occurrence, is selected from H, halogen, and Cl_6 alkyl substituted with 0-2 R4a;
R4d, at each occurrence, is selected from OH, 0, halogen, NH2, NH-Cl_4 alkyl, and N(Cl_4 al-kyl)z, R4b, at each occurrence, is selected from H, halogen, and Cl_6 alkyl substituted with 0-2 R4e;
R4e, at each occurrence, is selected from OH, 0, halogen, NH2, NH-Cl_4 alkyl, and N(Cl_4 al-kyl)2;
R4o, at each occurrence, is selected from H, halogen, and Cl_6 alkyl substituted with 0-2 R4f;
R4f, at each occurrence, is selected from OH, 0, halogen, NH2, NH-Cl_4 alkyl, and N(Cl_4 al-kyl)2;
R5a, at each occurrence, is selected from H, halogen, CH3, and CH2CH3;
RSb, at each occurrence, is selected from H, halogen, CH3, and CH2CH3;
RS , at each occurrence, is selected from H, halogen, CH3, and CH2CH3;

RSd, at each occurrence, is selected from H, halogen, CH3, and CH2CH3; and, R5e, at each occurrence, is selected from H, halogen, CH3, and CH2CH3.
[00819] 3. A compound of clause 1 or 2 wherein:
X is selected from 0, S, OCH2, and SCH2;

X1 is O or S;

Rl is selected from H, Cl_g alkyl, CZ_g alkenyl, aryl, 5-10 membered heteroaryl consisting of carbon atoms and 1-4 heteroatoms selected from 0, N, and S(O)0-2, C3-io cycloalkyl, and a 3-8 membered heterocycle consisting of carbon atoms and 1-3 heteroatoms selected from 0, N, and S(O)o_Z, wherein each Rl group is substituted with 0-4 Rla;

Rla, at each occurrence, is selected from OH substituted with 0-1 Rlb, SH
substituted with 0-1 Rlb, S, 0, halogen, NH2 substituted with 0-2 Rlb, -CN, NOZ, Cl_6 alkyl substituted with 0-2 R , aryl substi-'b, C2_6 alkenyl substituted with 0-2 R'b, C2_6 alkynyl substituted with 0-2 Rlb tuted with 0-2 Rlb, 5-10 membered heteroaryl substituted with 0-2 Rlb and consisting of car-bon atoms and 1-4 heteroatoms selected from 0, N, and S(O)0-2, C3-io cycloalkyl substituted with 0-2 Rlb, and a 3-8 membered heterocycle substituted with 0-2 Rlb and consisting of car-bon atoms and 1-3 heteroatoms selected from 0, N, and S(O)0-2, Rlb, at each occurrence, is selected from OH substituted with 0-1 Rl , SH
substituted with 0-1 Rl , S, 0, halogen, NH2 substituted with 0-2 Rl , -CN, NOZ, Cl_6 alkyl substituted with 0-2 Rl , C2_6 alkenyl substituted with 0-2 Rl , aryl substituted with 0-2 Rl , 5-10 membered het-eroaryl substituted with 0-2 Rl and consisting of carbon atoms and 1-4 heteroatoms selected from 0, N, and S(O)o-2, C3-io cycloalkyl substituted with 0-2 Rl , and a 3-8 membered hetero-cycle substituted with 0-2 R" and consisting of carbon atoms and 1-3 heteroatoms selected from 0, N, and S(O)o-Z, Rl , at each occurrence, is selected from OH substituted with 0-1 Rld, SH
substituted with 0-1 Rld, S, 0, halogen, NH2 substituted with 0-2 Rld, -CN, NOZ, Cl-6 alkyl substituted with 0-2 Rld, C2-6 alkenyl substituted with 0-2 Rld, aryl substituted with 0-2 Rld, 5-10 membered het-eroaryl substituted with 0-2 Rld and consisting of carbon atoms and 1-4 heteroatoms selected from 0, N, and S(O)o-2, C3-io cycloalkyl substituted with 0-2 Rld, and a 3-8 membered hetero-cycle substituted with 0-2 Rld and consisting of carbon atoms and 1-3 heteroatoms selected from 0, N, and S(O)o-Z, Rld, at each occurrence, is selected from OH, SH, S, 0, halogen, NH2, -CN, NOZ, Cl-6 alkyl, C2-6 alkenyl, aryl, CF3, and OCF3;

R 2 is selected from -C=C-RZa, -CH=CH-RZa substituted with 0-2 RZa, aryl substituted with 0-3 R 2a, and 5-10 membered heteroaryl substituted with 0-3 R 2a and consisting of carbon atoms and 1-4 heteroatoms selected from 0, N, and S(O)0_2, R2a , at each occurrence, is selected from OH substituted with 0-1 RZb, SH
substituted with 0-1 R 2b, S, 0, halogen, NH2 substituted with 0-2 R 2b, -CN, NOZ, Cl-6 alkyl substituted with 0-2 R 2b, C2-6 alkenyl substituted with 0-2 RZb, aryl substituted with 0-2 RZb, 5-10 membered het-eroaryl substituted with 0-2 R 2b and consisting of carbon atoms and 1-4 heteroatoms selected from 0, N, and S(O)0-2, C3-io cycloalkyl substituted with 0-2 R 2b, and a 3-8 membered hetero-cycle substituted with 0-2 R 2b and consisting of carbon atoms and 1-3 heteroatoms selected from 0, N, and S(O)o-Z, RZb, at each occurrence, is selected from OH substituted with 0-1 RZ , SH
substituted with 0-1 RZ , S, 0, halogen, NH2 substituted with 0-2 R 2c, -CN, NOZ, Cl-6 alkyl substituted with 0-2 RZ , C2-6 alkenyl substituted with 0-2 RZ , aryl substituted with 0-2 RZ , 5-10 membered het-eroaryl substituted with 0-2 RZ and consisting of carbon atoms and 1-4 heteroatoms selected from 0, N, and S(O)o-2, C3-io cycloalkyl substituted with 0-2 R2o, and a 3-8 membered hetero-cycle substituted with 0-2 RZ and consisting of carbon atoms and 1-3 heteroatoms selected from 0, N, and S(O)o-Z, RZ , at each occurrence, is selected from OH substituted with 0-1 RZd, SH
substituted with 0-1 RZd, S, 0, halogen, NH2 substituted with 0-2 RZd, -CN, NOZ, Cl-6 alkyl substituted with 0-2 RZd, C2-6 alkenyl substituted with 0-2 RZd, aryl substituted with 0-2 RZd, 5-10 membered het-eroaryl substituted with 0-2 RZd and consisting of carbon atoms and 1-4 heteroatoms selected from 0, N, and S(O)o-2, C3-io cycloalkyl substituted with 0-2 RZd, and a 3-8 membered hetero-cycle substituted with 0-2 RZd and consisting of carbon atoms and 1-3 heteroatoms selected from 0, N, and S(O)o-Z, RZd, at each occurrence, is selected from OH, SH, S, 0, halogen, NH2, -CN, NOZ, Cl-6 alkyl, C2-6 alkenyl, aryl, CF3, and OCF3;
R3 is selected from halogen and Cl-6 alkyl substituted with 0-2 R3a;

R3a, at each occurrence, is selected from OH, 0, S, halogen, C(O)NH2, C(O)NH-Cl-4 alkyl, and C(O)N(Ci-4 alkyl)z, alternatively, R3 and R5e combine to form a 5, 6, or 7 membered ring consisting of carbon at-oms and 0-2 heteroatoms selected from 0, N, and S(O)o-Z and there are 0-2 ring double bonds in the bridging portion formed by R3 and Rse;

R4a, at each occurrence, is selected from H, halogen, and Cl-6 alkyl substituted with 0-2 R4a;
R4d, at each occurrence, is selected from OH, 0, halogen, NH2, NH-Cl-4 alkyl, and N(Cl-4 al-kyl)2;

R4b, at each occurrence, is selected from H, halogen, and Cl-6 alkyl substituted with 0-2 R4e;

R4e, at each occurrence, is selected from OH, 0, halogen, NH2, NH-Cl_4 alkyl, and N(Cl_4 al-kyl)2;

R4o, at each occurrence, is selected from H, halogen, and Cl_6 alkyl substituted with 0-2 R4f;
R4f, at each occurrence, is selected from OH, 0, halogen, NH2, NH-Cl_4 alkyl, and N(Cl_4 al-kyl)2;

RSa, at each occurrence, is selected from H, halogen, CH3, and CH2CH3;
RSb, at each occurrence, is selected from H, halogen, CH3, and CH2CH3;
RS , at each occurrence, is selected from H, halogen, CH3, and CH2CH3;
R5d, at each occurrence, is selected from H, halogen, CH3, and CH2CH3; and, RSe, at each occurrence, is selected from H, halogen, CH3, and CH2CH3.
[00820] 4. A compound of any of the preceding clauses 1-3, wherein the compound is of for-mula Ia:

RZ
R4b R4c ~

X ~ X1 R4a 1 RSd Ri R5e I
R5o \ R3 Rsb RSa O
OH
O

Ia.
or a pharmaceutically acceptable salt thereof.
[00821] 5. A compound of clause 1, wherein the compound is of formula 11:
R2a ll R4b R4c I

R4a 1 Rsd / R5e Rl R5o \ R3 Rsb Rsa O
OH

II
or a pharmaceutically acceptable salt thereof, wherein:

R' is H, Cl_g alkyl, heteroaryl, and C3_10 cycloalkyl, wherein each R' group is substituted with 0-4 R1a;

Rla, at each occurrence, is selected from Cl_6 alkyl substituted with 0-3 Rlb;
C2_6 alkynyl sub-stituted with 0-2 R'b; aryl substituted with 0-2 R'b, heteroaryl substituted with 0-2 Rlb, C3_10 cycloalkyl substituted with 0-2 Rlb, and a heterocycle substituted with 0-2 R'b;

Rlb, at each occurrence, is selected from OH substituted with 0-1 Rl , SH
substituted with 0-1 Rl , Cl, F, NH2 substituted with 0-2 Rl , -CN, NO2, methanesulfonyl, Cl_4 alkyl substituted with 0-3 Rl , C2_4 alkenyl substituted with 0-2 Rl , aryl substituted with 0-2 Rl , heteroaryl substituted with 0-2 Rl , C3_6 cycloalkyl substituted with 0-2 Rl , and a heterocycle substituted with 0-2 R";

Rl , at each occurrence, is selected from OH, SH, Cl, F, NH2, -CN, NOZ, Cl_4 alkyl, and C2_4 alkenyl, aryl substituted with 0-2 Rld, heteroaryl substituted with 0-2 Rld and, C3_6 cycloalkyl substituted with 0-2 Rld, and a heterocycle substituted with 0-2 Rla;

Rld, at each occurrence, is selected from OH, SH, Cl, F, NH2, -CN, NOZ, Cl_4 alkyl, and C2_4 alkenyl;

RZa is selected from Cl_6 alkyl substituted with 0-2 RZb, aryl substituted with 0-2 R2b , and het-eroaryl substituted with 0-2 RZb;

RZb, at each occurrence, is selected from OH substituted with 0-1 RZ , SH
substituted with 0-1 RZ , Cl, F, NH2 substituted with 0-2 RZ , -CN, NOZ, methanesulfonyl, Cl_4 alkyl substituted with 0-2 RZ , C2_4 alkenyl substituted with 0-2 RZ , aryl substituted with 0-2 RZ , heteroaryl substituted with 0-2 RZ , C3_6 cycloalkyl substituted with 0-2 RZ , and a heterocycle substituted with 0-2 R2 ;

RZ , at each occurrence, is selected from OH, SH, Cl, F, NH2, -CN, NOZ, Cl_4 alkyl, C2_4 al-kenyl, aryl substituted with 0-2 RZd, and heteroaryl substituted with 0-2 RZd;

R 2d, at each occurrence, is selected from OH, SH, Cl, F, NH2, -CN, NOZ, Cl_4 alkyl, and C2_4 alkenyl;

R3 is selected from Cl, F, CH3, and CH2CH3;
alternatively, R3 and R5e combine to form a 5, 6, or 7 membered ring consisting of carbon at-oms and 0-2 heteroatoms selected from 0, N, and S(O)o_Z and there are 0-2 ring double bonds in the bridging portion formed by R3 and Rse;

R4a, at each occurrence, is selected from H, Cl, F, and CH3;

R4b, at each occurrence, is selected from H, Cl, F, and CH3;

R4o, at each occurrence, is selected from H, Cl, F, and CH3;
RSa, at each occurrence, is selected from H, Cl, F, and CH3;
Rsb, at each occurrence, is selected from H, Cl, F, and CH3;
RS , at each occurrence, is selected from H, Cl, F, and CH3;

RSd, at each occurrence, is selected from H, Cl, F, and CH3; and, Rse, at each occurrence, is selected from H, Cl, F, and CH3.
[00822] 6. A compound of clause 5 wherein:

Rl is H, Cl-g alkyl, 5-10 membered heteroaryl consisting of carbon atoms and 1-4 heteroatoms selected from 0, N, and S(O)0-2, and C3_10 cycloalkyl, wherein each Rl group is substituted with 0-4 Rla;

Rla, at each occurrence, is selected from Cl-6 alkyl substituted with 0-3 Rlb;
CZ-6 alkynyl sub-stituted with 0-2 Rlb; aryl substituted with 0-2 Rlb, 5-10 membered heteroaryl substituted with 0-2 Rlb and consisting of carbon atoms and 1-4 heteroatoms selected from 0, N, and S(O)o-Z, C3-10 cycloalkyl substituted with 0-2 Rlb, and a 3-8 membered heterocycle substituted with 0-2 Rlb and consisting of carbon atoms and 1-2 heteroatoms selected from 0, N, and S(O)Q-Z;
Rlb, at each occurrence, is selected from OH substituted with 0-1 Rl , SH
substituted with 0-1 Rl , Cl, F, NH2 substituted with 0-2 Rl , -CN, NOZ, methanesulfonyl, Cl-4 alkyl substituted with 0-3 Rl , CZ-4 alkenyl substituted with 0-2 Rl , aryl substituted with 0-2 Rl , 5-10 mem-bered heteroaryl substituted with 0-2 Rl and consisting of carbon atoms and 1-4 heteroatoms selected from 0, N, and S(O)0-2, C3-6 cycloalkyl substituted with 0-2 Rl , and a 3-6 membered heterocycle substituted with 0-2 Rl and consisting of carbon atoms and 1-2 heteroatoms se-lected from 0, N, and S(O)0-2, Rl , at each occurrence, is selected from OH, SH, Cl, F, NH2, -CN, NOZ, Cl-4 alkyl, and CZ-4 alkenyl, aryl substituted with 0-2 Rld, 5-10 membered heteroaryl substituted with 0-2 Rld and consisting of carbon atoms and 1-4 heteroatoms selected from 0, N, and S(O)o-Z, C3-6 cycloal-kyl substituted with 0-2 Rld, and a 3-6 membered heterocycle substituted with 0-2 Rld and consisting of carbon atoms and 1-2 heteroatoms selected from 0, N, and S(O)o-Z, Rld, at each occurrence, is selected from OH, SH, Cl, F, NH2, -CN, NOZ, Cl-4 alkyl, and CZ-4 alkenyl;

R 2a is selected from Cl-6 alkyl substituted with 0-2 R 2b, aryl substituted with 0-2 R 2b, and 5-10 membered heteroaryl substituted with 0-2 R 2b and consisting of carbon atoms and 1-4 heteroa-toms selected from 0, N, and S(O)o-Z, RZb, at each occurrence, is selected from OH substituted with 0-1 RZ , SH
substituted with 0-1 RZ , Cl, F, NH2 substituted with 0-2 RZ , -CN, NOZ, methanesulfonyl, Cl-4 alkyl substituted with 0-2 R 2c, CZ-4 alkenyl substituted with 0-2 RZ , aryl substituted with 0-2 RZ , 5-10 mem-bered heteroaryl substituted with 0-2 RZ and consisting of carbon atoms and 1-4 heteroatoms selected from 0, N, and S(O)0-2, C3-6 cycloalkyl substituted with 0-2 RZ , and a 3-6 membered heterocycle substituted with 0-2 R2o and consisting of carbon atoms and 1-2 heteroatoms se-lected from 0, N, and S(O)0_2, RZ , at each occurrence, is selected from OH, SH, Cl, F, NH2, -CN, NOZ, Cl-4 alkyl, C2-4 al-kenyl, aryl substituted with 0-2 RZd, and 5-10 membered heteroaryl substituted with 0-2 RZd and consisting of carbon atoms and 1-4 heteroatoms selected from 0, N, and S(O)o-Z, RZd, at each occurrence, is selected from OH, SH, Cl, F, NH2, -CN, NOZ, Cl_4 alkyl, and C2_4 alkenyl;

R3 is selected from Cl, F, CH3, and CH2CH3;
alternatively, R3 and R5e combine to form a 5, 6, or 7 membered ring consisting of carbon at-oms and 0-2 heteroatoms selected from 0, N, and S(O)o_Z and there are 0-2 ring double bonds in the bridging portion formed by R3 and Rse;

R4a, at each occurrence, is selected from H, Cl, F, and CH3;
R4b, at each occurrence, is selected from H, Cl, F, and CH3;
R4o, at each occurrence, is selected from H, Cl, F, and CH3;
RSa, at each occurrence, is selected from H, Cl, F, and CH3;
RSb, at each occurrence, is selected from H, Cl, F, and CH3;
R5o, at each occurrence, is selected from H, Cl, F, and CH3;

RSd, at each occurrence, is selected from H, Cl, F, and CH3; and, RSe, at each occurrence, is selected from H, Cl, F, and CH3.
[00823] 7. A compound of clause 5 or 6, wherein:
R' is H or Ci_4 alkyl substituted with 1-4 Rla;

Rla, at each occurrence, is selected from aryl substituted with 0-2 Rlb, 5-10 membered het-eroaryl substituted with 0-2 Rlb and consisting of carbon atoms and 1-4 heteroatoms selected from 0, N, and S(O)o-2, C3-i0 cycloalkyl substituted with 0-2 Rlb, and a 3-8 membered hetero-cycle substituted with 0-2 Rlb and consisting of carbon atoms and 1-2 heteroatoms selected from 0, N, and S(O)o-Z, Rlb, at each occurrence, is selected from OH substituted with 0-1 R", SH
substituted with 0-1 Rl , Cl, F, NH2 substituted with 0-2 Rl , -CN, NOZ, Cl-4 alkyl substituted with 0-2 Rlc, CZ-4 alkenyl substituted with 0-2 Rl , aryl substituted with 0-2 Rl , 5-10 membered heteroaryl sub-stituted with 0-2 Rl and consisting of carbon atoms and 1-4 heteroatoms selected from 0, N, and S(O)o-Z, C3-6 cycloalkyl substituted with 0-2 Rl , and a 3-6 membered heterocycle substi-tuted with 0-2 Rl and consisting of carbon atoms and 1-2 heteroatoms selected from 0, N, and S(O)o-z, Rl , at each occurrence, is selected from OH, SH, Cl, F, NH2, -CN, NOZ, Cl-4 alkyl, and CZ-4 alkenyl, aryl substituted with 0-2 Rld, 5-10 membered heteroaryl substituted with 0-2 Rld and consisting of carbon atoms and 1-4 heteroatoms selected from 0, N, and S(O)o-Z, C3-6 cycloal-kyl substituted with 0-2 Rld, and a 3-6 membered heterocycle substituted with 0-2 Rld and consisting of carbon atoms and 1-2 heteroatoms selected from 0, N, and S(O)o-Z, Rld, at each occurrence, is selected from OH, SH, Cl, F, NH2, -CN, NOZ, Cl-4 alkyl, and CZ-4 alkenyl;

R 2a is selected from Cl-6 alkyl substituted with 0-2 R2b, aryl substituted with 0-2 R2b, and 5-10 membered heteroaryl substituted with 0-2 R 2b and consisting of carbon atoms and 1-4 heteroa-toms selected from 0, N, and S(O)o-Z, R 2b, at each occurrence, is selected from OH substituted with 0-1 RZ , SH
substituted with 0-1 RZ , Cl, F, NH2 substituted with 0-2 RZ , -CN, NOZ, Cl-4 alkyl substituted with 0-2 RZ , CZ-4 alkenyl substituted with 0-2 RZ , aryl substituted with 0-2 RZ , 5-10 membered heteroaryl sub-stituted with 0-2 RZ and consisting of carbon atoms and 1-4 heteroatoms selected from 0, N, and S(O)o_Z, C3_6 cycloalkyl substituted with 0-2 RZ, , and a 3-6 membered heterocycle substi-tuted with 0-2 RZ and consisting of carbon atoms and 1-2 heteroatoms selected from 0, N, and S(O)o_z, RZ , at each occurrence, is selected from OH, SH, Cl, F, NH2, -CN, NOZ, Cl_4 alkyl, C2_4 al-kenyl, aryl substituted with 0-2 RZd, and 5-10 membered heteroaryl substituted with 0-2 RZd and consisting of carbon atoms and 1-4 heteroatoms selected from 0, N, and S(O)o_Z, RZd, at each occurrence, is selected from OH, SH, Cl, F, NH2, -CN, NOZ, Cl_4 alkyl, and C2_4 alkenyl;

R3 is selected from Cl, F, CH3, and CH2CH3;

alternatively, R3 and R5e combine to form a 5, 6, or 7 membered ring consisting of carbon at-oms and 0-2 heteroatoms selected from 0, N, and S(O)o_Z and there are 0-2 ring double bonds in the bridging portion formed by R3 and Rse;

R4a, at each occurrence, is selected from H, Cl, F, and CH3;
R4b, at each occurrence, is selected from H, Cl, F, and CH3;
R4o, at each occurrence, is selected from H, Cl, F, and CH3;
RSa, at each occurrence, is selected from H, Cl, F, and CH3;

RSb, at each occurrence, is selected from H, Cl, F, and CH3;
RS , at each occurrence, is selected from H, Cl, F, and CH3;

RSd, at each occurrence, is selected from H, Cl, F, and CH3; and, RSe, at each occurrence, is selected from H, Cl, F, and CH3.
[00824] 8. A compound of clause 5, wherein the compound is of formula IIa:
R2a X
O
0 R5e OH R3 / Xl IIa or a pharmaceutically acceptable salt thereof, wherein:

R' is H, Cl_6 alkyl, aryl, heteroaryl, and C3_1o cycloalkyl, wherein each Rl group is substituted with 0-1 Rla;

Rla, at each occurrence, is selected from Cl_6 alkyl substituted with 0-3 Rlb;
C2_6 alkynyl sub-stituted with 0-2 Rlb; aryl substituted with 0-2 Rlb, heteroaryl substituted with 0-2 Rlb and, C5_ 6 cycloalkyl substituted with 0-2 R'b, and a heterocycle substituted with 0-2 Rlb and;

Rlb, at each occurrence, is selected from OH, SH, Cl, F, NH2, -CN, NO2, methanesulfonyl, Cl_ 4 alkyl substituted with 0-3 Rl , C2_4 alkenyl substituted with 0-2 Rl , aryl substituted with 0-2 Rl , heteroaryl substituted with 0-2 Rl , C5_6 cycloalkyl substituted with 0-2 Rl , and a hetero-cycle substituted with 0-2 Ri ;

Rl , at each occurrence, is selected from OH, SH, Cl, F, NH2, -CN, NO2, Cl_4 alkyl, and C2_4 alkenyl, aryl substituted with 0-2 Rld, heteroaryl substituted with 0-2 Rld, C5_6 cycloalkyl sub-stituted with 0-2 R'd, and a heterocycle substituted with 0-2 R'a;

Rld, at each occurrence, is selected from OH, SH, Cl, F, NH2, -CN, NOZ, Cl_4 alkyl, and C2_4 alkenyl;

R 2a is selected from Cl_6 alkyl substituted with 0-2 R2b, aryl substituted with 0-2 R2b, and het-eroaryl substituted with 0-2 RZb;

R 2b, at each occurrence, is selected from OH substituted with 0-1 R 2c, SH, Cl, F, NH2, -CN, NOZ, methanesulfonyl, Cl_4 alkyl, C2_4 alkenyl, aryl, heteroaryl, C5_6 cycloalkyl, and a hetero-cycle;
RZ , at each occurrence, is Cl_4 alkyl;

R3 is selected from Cl, F, CH3, and CH2CH3; and, alternatively, R3 and R5e combine to form a 5, 6, or 7 membered ring consisting of carbon at-oms and 0-2 heteroatoms selected from 0, N, and S(O)o_Z and there are 0-2 ring double bonds in the bridging portion formed by R3 and Rse [00825] 9. A compound of clause 8 wherein:
Rl is H, Cl_6 alkyl, aryl, 5-6 membered heteroaryl consisting of carbon atoms and 1-4 heteroa-toms selected from 0, N, and S(O)o_Z, and C3_10 cycloalkyl, wherein each Rl group is substi-tuted with 0-1 Rla;

Rla, at each occurrence, is selected from Cl_6 alkyl substituted with 0-3 Rlb;
C2_6 alkynyl sub-stituted with 0-2 Rlb; aryl substituted with 0-2 Rlb, 5-6 membered heteroaryl substituted with 0-2 Rlb and consisting of carbon atoms and 1-2 heteroatoms selected from 0, N, and S(O)o_Z, C5_6 cycloalkyl substituted with 0-2 Rlb, and a 5-6 membered heterocycle substituted with 0-2 Rlb and consisting of carbon atoms and 1-2 heteroatoms selected from 0, N, and S(O)0_2, Rlb, at each occurrence, is selected from OH, SH, Cl, F, NH2, -CN, NOZ, methanesulfonyl, Cl-4 alkyl substituted with 0-3 Rl , CZ-4 alkenyl substituted with 0-2 Rl , aryl substituted with 0-2 Rl , 5-6 membered heteroaryl substituted with 0-2 Rl and consisting of carbon atoms and 1-2 heteroatoms selected from 0, N, and S(O)o-2, C5-6 cycloalkyl substituted with 0-2 Rl , and a 5-6 membered heterocycle substituted with 0-2 Rl and consisting of carbon atoms and 1-2 het-eroatoms selected from 0, N, and S(O)0_2, Rl , at each occurrence, is selected from OH, SH, Cl, F, NH2, -CN, NOZ, Cl-4 alkyl, and CZ-4 alkenyl, aryl substituted with 0-2 Rld, 5-6 membered heteroaryl substituted with 0-2 Rld and consisting of carbon atoms and 1-2 heteroatoms selected from 0, N, and S(O)o-Z, C5-6 cycloal-kyl substituted with 0-2 Rld, and a 5-6 membered heterocycle substituted with 0-2 Rld and consisting of carbon atoms and 1-2 heteroatoms selected from 0, N, and S(O)o-Z, Rld, at each occurrence, is selected from OH, SH, Cl, F, NH2, -CN, NOZ, Cl-4 alkyl, and CZ-4 alkenyl;

R 2a is selected from Cl-6 alkyl substituted with 0-2 R 2b, aryl substituted with 0-2 R 2b, and 5-6 membered heteroaryl substituted with 0-2 R 2b and consisting of carbon atoms and 1-2 heteroa-toms selected from 0, N, and S(O)o-Z, R 2b, at each occurrence, is selected from OH substituted with 0-1 R 2c, SH, Cl, F, NH2, -CN, NOZ, methanesulfonyl, Cl-4 alkyl, CZ-4 alkenyl, aryl, 5-6 membered heteroaryl consisting of carbon atoms and 1-2 heteroatoms selected from 0, N, and S(O)0-2õ C5-6 cycloalkyl, and a 5-6 membered heterocycle and consisting of carbon atoms and 1-2 heteroatoms selected from 0, N, and S(O)o-Z, RZ , at each occurrence, is Cl-4 alkyl;

R3 is selected from Cl, F, CH3, and CH2CH3; and, alternatively, R3 and R5e combine to form a 5, 6, or 7 membered ring consisting of carbon at-oms and 0-2 heteroatoms selected from 0, N, and S(O)o-Z and there are 0-2 ring double bonds in the bridging portion formed by R3 and Rse [00826] 10. A compound of clause 8 or 9 wherein:
R' is H or Ci-4 alkyl substituted with 1 Rla;

Rla, at each occurrence, is selected from aryl substituted with 0-2 Rlb, 5-6 membered het-eroaryl substituted with 0-2 Rlb and consisting of carbon atoms and 1-2 heteroatoms selected from 0, N, and S(O)o-Z, C5-6 cycloalkyl substituted with 0-2 Rlb, and a 5-6 membered hetero-cycle substituted with 0-2 Rlb and consisting of carbon atoms and 1-2 heteroatoms selected from 0, N, and S(O)o-Z, Rlb, at each occurrence, is selected from OH, SH, Cl, F, NH2, -CN, NOZ, Cl-4 alkyl substituted with 0-2 Rl , CZ-4 alkenyl substituted with 0-2 Rl , aryl substituted with 0-2 Rl , 5-6 mem-bered heteroaryl substituted with 0-2 Rl and consisting of carbon atoms and 1-2 heteroatoms selected from 0, N, and S(O)o-2, C5-6 cycloalkyl substituted with 0-2 Rl , and a 5-6 membered heterocycle substituted with 0-2 R' and consisting of carbon atoms and 1-2 heteroatoms se-lected from 0, N, and S(O)0-2, Rl , at each occurrence, is selected from OH, SH, Cl, F, NH2, -CN, NOZ, Cl-4 alkyl, and CZ-4 alkenyl, aryl substituted with 0-2 Rld, 5-6 membered heteroaryl substituted with 0-2 Rld and consisting of carbon atoms and 1-2 heteroatoms selected from 0, N, and S(O)o-Z, C5-6 cycloal-kyl substituted with 0-2 Rld, and a 5-6 membered heterocycle substituted with 0-2 Rld and consisting of carbon atoms and 1-2 heteroatoms selected from 0, N, and S(O)o-Z;

Rld, at each occurrence, is selected from OH, SH, Cl, F, NH2, -CN, NOZ, Cl-4 alkyl, and CZ-4 alkenyl;

RZa is selected from Cl_6 alkyl substituted with 0-2 R 2b, aryl substituted with 0-2 R 2b, and 5-6 membered heteroaryl substituted with 0-2 R 2b and consisting of carbon atoms and 1-2 heteroa-toms selected from 0, N, and S(O)o_Z, RZb, at each occurrence, is selected from OH, SH, Cl, F, NH2, -CN, NOZ, Cl_4 alkyl, C2_4 al-kenyl, aryl, 5-6 membered heteroaryl consisting of carbon atoms and 1-2 heteroatoms selected from 0, N, and S(O)o_Zõ C5_6 cycloalkyl, and a 5-6 membered heterocycle and consisting of carbon atoms and 1-2 heteroatoms selected from 0, N, and S(O)0_2, R3 is selected from Cl, F, CH3, and CH2CH3; and, alternatively, R3 and R5e combine to form a 5, 6, or 7 membered ring consisting of carbon at-oms and 0-2 heteroatoms selected from 0, N, and S(O)o_Z and there are 0-2 ring double bonds in the bridging portion formed by R3 and Rse [00827] 11. A compound of clause 8 wherein:

Rl is H, Cl_6 alkyl, aryl, 5-6 membered heteroaryl consisting of carbon atoms and 1-2 heteroa-toms selected from 0 and N; C3_10 cycloalkyl, wherein each R' group is substituted with 0-1 Rla;

Rla, at each occurrence, is selected from Cl_4 alkyl substituted with 0-3 Rlb;
C2_6 alkynyl sub-stituted with 0-1 R'b aryl substituted with 0-1 R'b, heteroaryl substituted with 0-1 Rlb, C5_6 cycloalkyl substituted with 0-1 R'b, and a heterocycle substituted with 0-1 R'b;

Rlb, at each occurrence, is selected from Cl, F, methanesulfonyl, and Cl_4 alkyl substituted with 0-3 Rl , and;

Rl , at each occurrence, is selected from Cl, F and a heterocycle ;

RZa is selected from Cl_6 alkyl substituted with 0-2 R 2b, aryl substituted with 0-2 R 2b, and het-eroaryl substituted with 0-2 R2b;

RZb, at each occurrence, is selected from OH optionally substituted with Cl_~
alkyl, Cl, F, methanesulfonyl, aryl, heteroaryl, C5_6 cycloalkyl, and a heterocycle ;

R3 is selected from Cl, F, CH3, and CH2CH3..
[00828] 12. A compound of clause 11 wherein:
Rl is H, Cl_6 alkyl, aryl, 5-6 membered heteroaryl consisting of carbon atoms and 1-2 heteroa-toms selected from 0 and N; C3_10 cycloalkyl, wherein each Rl group is substituted with 0-1 Rla, Rla, at each occurrence, is selected from Cl_4 alkyl substituted with 0-3 Rlb;
C2_6 alkynyl sub-stituted with 0-1 Rlb aryl substituted with 0-1 Rlb, 5-6 membered heteroaryl substituted with 0-1 Rlb and consisting of carbon atoms and 1-2 heteroatoms selected from 0 and N, C5_6 cycloalkyl substituted with 0-1 Rlb, and a 5-6 membered heterocycle substituted with 0-1 Rlb;

Rlb, at each occurrence, is selected from Cl, F, methanesulfonyl, and Cl_4 alkyl substituted with 0-3 Rl , and;

Rl , at each occurrence, is selected from Cl, F and a 5-6 membered heterocycle consisting of carbon atoms and 1-2 heteroatoms selected from 0 and N;

R 2a is selected from Cl_6 alkyl substituted with 0-2 R 2b, aryl substituted with 0-2 R 2b, and 5-6 membered heteroaryl substituted with 0-2 R 2b and consisting of carbon atoms and 1-2 heteroa-toms selected from 0 and N;

R2b, at each occurrence, is selected from OH optionally substituted with Cl_4 alkyl, Cl, F, methanesulfonyl, aryl, 5-6 membered heteroaryl consisting of carbon atoms and 1-2 heteroa-toms selected from 0 and N, C5_6 cycloalkyl, and a 5-6 membered heterocycle consisting of carbon atoms and 1-2 heteroatoms selected from 0 and N;

R3 is selected from Cl, F, CH3, and CH2CH3.
[00829] 13. A compound of clause 12 wherein Rl is Cl_4 alkyl substituted with 1 Rla [00830] 14. A compound of clause 5, wherein the compound is of of formula IIb R2a X
O
O
OH R3 ~ Xl IIb or a pharmaceutically acceptable salt thereof.
[00831] 15. A compound of clause 14 wherein R2a is selected from aryl substituted with 0-2 R2b and 5-6 membered heteroaryl substituted with 0-2 R2b and consisting of carbon atoms and 1-2 heteroatoms selected from 0, N, and S(O)0_2.
[00832] 16. A compound of clause 14, wherein Rl is Cl_6 alkyl.
[00833] 17. A compound of clause 14, wherein R2a is Cl_4 alkyl substituted with a heterocy-cle.
[00834] 18. A compound of clause 14, wherein the R2a is Cl_4 alkyl substituted with mor-pholinyl.
[00835] 19. A compound of clause 14, wherein R3 is selected from Cl and CH3.
[00836] 20. A compound of clause 14, wherein X is selected from S and SCH2 [00837] 21. A compound of clause 14, wherein X is S.
[00838] 22. A compound of clause 14, wherein X is O.
[00839] 23. A compound of clause 14, wherein X is SCH2.
[00840] 24. A compound of clause 14, wherein Xl is O.
[00841] 25. A compound of clause 14, wherein Rl is aryl substituted with 0-1 Rla; wherein Rla, at each occurrence, is selected from OH, SH, Cl, F, NH2, -CN, NOZ, Cl_4 alkyl.
[00842] 26. A compound of clause 14, wherein ein Rl is Cl_6 alkyl substituted with Rla; and wherein Rla is aryl substituted with 0-1 Rlb; and wherein Rlb is selected from OH, SH, Cl, F, NHZ, -CN, NOZ, Cl_4 alkyl.
[00843] 27. A compound of clause 14, wherein Rl is Cl_6 alkyl substituted with Rla, wherein Rla is heteroaryl substituted with 0-1 Rlb; and wherein Rlb is selected from OH, SH, Cl, F, NHZ, -CN, NOZ, Cl_4 alkyl.
[00844] 28. A compound of clause 14, wherein R' is Cl_6 alkyl substituted with R'a, wherein Rla is heterocyclyl substituted with 0-1 Rlb; and wherein Rlb is selected from OH, SH, Cl, F, NH2, -CN, NOZ, Cl_4 alkyl.
[00845] 29. A compound of clause 14, wherein Rl is Cl_6 alkyl substituted with Rla, wherein Rla is C5_6 cycloalkyl substituted with 0-2 Rlb; and wherein Rlb is selected from OH, SH, Cl, F, NHZ, -CN, NO2, Cl_4 alkyl.
[00846] 30. A compound of clause 14, wherein RZa is aryl substituted with RZb;
wherein R 2b is selected from OH, SH, Cl, F, NH2, -CN, NOZ, Cl_4 alkyl.
[00847] 31. A compound of clause 14, wherein R 2a is Cl_6 alkyl substituted with RZb; wherein R 2b is selected from aryl substituted with RZ ; and wherein RZ is selected from OH, SH, Cl, F, NH2, -CN, NOZ, Cl_4 alkyl.
[00848] 32. A compound of clause 14, wherein R2a is Cl_6 alkyl substituted with RZb; wherein R 2b is selected from heteroaryl substituted with RZ ; and wherein RZ is selected from OH, SH, Cl, F, NH2, -CN, NOZ, Cl_4 alkyl.
[00849] 33. A compound of clause 1, wherein the compound is selected from: .
{ 2-Chloro-4-[3- (4-chloro-phenylethynyl)-5- (3-piperidin-1-yl-propoxy)-phenylsulfanyl] -phenoxy } -acetic acid;
{ 2-Methyl-4- [3-(3-morpholin-4-yl-propoxy)-5-phenylethynyl-phenylsulfanyl] -phenoxy } -acetic acid;
{ 2-Chloro-4-[3-(4-chloro-phenylethynyl)-5-(3-morpholin-4-yl-propoxy)-phenylsulfanyl] -phenoxy } -acetic acid;
{ 2-Chloro-4-[3-(4-chloro-phenylethynyl)-5-(4-morpholin-4-ylmethyl-benzyloxy)-phenyl-sulfanyl]-phenoxy } -acetic acid;
{ 2-Chloro-4-[3-(4-chloro-phenylethynyl)-5-(1-methyl-piperidin-4-ylmethoxy)-phenyl-sulfanyl] -phenoxy } -acetic acid;
{ 2-Methyl-4- [3-(3-morpholin-4-yl-propoxy)-5-(3-phenyl-prop-1-ynyl)-phenylsulfanyl] -phenoxy } -acetic acid;
{ 4- [3-(4-Fluoro-benzyloxy)-5-(3-morpholin-4-yl-prop-1-ynyl)-phenylsulfanyl]-2-methyl-phenoxy } -acetic acid;
{ 4- [3-Cyclohexylmethoxy-5-(3-morpholin-4-yl-prop-1-ynyl)-phenylsulfanyl] -2-methyl-phenoxy } -acetic acid;

{4- [3-Isobutoxy-5-(3-morpholin-4-yl-prop-l-ynyl)-phenylsulfanyl] -2-methyl-phenoxy } -acetic acid;
{ 4- [3-(4-Chloro-benzyloxy)-5-(3-morpholin-4-yl-prop-1-ynyl)-phenylsulfanyl] -2-methyl-phenoxy } -acetic acid;
{2-Chloro-4-[3-(4-chloro-phenylethynyl)-5-hydroxy-phenylsulfanyl]-phenoxy}-acetic acid;
{ 4- [3-But-2-ynyloxy-5-(3-morpholin-4-yl-prop-1-ynyl)-phenylsulfanyl] -2-methyl-phenoxy } -acetic acid;
{ 2-Methyl-4- [3-(2-morpholin-4-yl-ethoxy)-5-phenylethynyl-phenylsulfanyl] -phenoxy } -acetic acid;
{2-Chloro-4-[3-(3-methoxy-prop-1-ynyl)-5-(3-morpholin-4-yl-propoxy)-phenylsulfanyl]-phenoxy } -acetic acid;
{ 2-Chloro-4-[3-(3-morpholin-4-yl-propoxy)-5-pent-l-ynyl-phenylsulfanyl] -phenoxy } -acetic acid;
{ 2-Methyl-4-[3-(3-morpholin-4-yl-propoxy)-5-(3-phenyl-prop-1-ynyl)-benzylsulfanyl] -phenoxy } -acetic acid;
{ 4- [3-(4-Fluoro-benzyloxy)-5-(3-morpholin-4-yl-prop-1 ynyl)-benzylsulfanyl] -2-methyl-phenoxy}-acetic acid; and, { 2-Methyl-4- [3-(3-morpholin-4-yl-ethoxy)-5-(3-phenyl-prop-1-ynyl)-benzylsulfanyl] -phenoxy } -acetic acid;
or a pharmaceutically acceptable salt thereof.
[00850] 34. A compound of clause 1, wherein the compound is selected from: .
{ 4- [3-Cyclohexylmethoxy-5-(4-methanesulfonyl-phenylethynyl)-phenylsulfanyl] -2-methyl-phenoxy } -acetic acid;
{4-[3-Cyclopentylmethoxy-5-(4-methanesulfonyl-phenylethynyl)-phenylsulfanyl]-2-methyl-phenoxy } -acetic acid;
{ 4- [3-Isobutoxy-5-(4-methanesulfonyl-phenylethynyl)-phenylsulfanyl] -2-methyl-phenoxy } -acetic acid ;
{ 4- [3- [2-(4-Chloro-phenyl)-ethoxy] -5-(4-methanesulfonyl-phenylethynyl)-phenylsulfanyl] -2-methyl-phenoxy } -acetic acid;

{4- [3- [2-(4-Chloro-phenyl)-ethoxy] -5-(3-morpholin-4-yl-prop-l-ynyl)-phenylsulfanyl] -2-methyl-phenoxy } -acetic acid;
{ 4- [3- [2-(4-Chloro-phenyl)-ethoxy] -5-(4-hydroxymethyl-phenylethynyl)-phenylsulfanyl] -2-methyl-phenoxy } -acetic acid;
{4-[3-(2-Ethyl-butoxy)-5-phenylethynyl-phenylsulfanyl]-2-methyl-phenoxy}-acetic acid;
[4-(3-Cyclopentyloxy-5-phenylethynyl-phenylsulfanyl)-2-methyl-phenoxy]-acetic acid;
{ 4- [3-(4-Fluoro-phenylethynyl)-5-(4-methanesulfonyl-benzyloxy)-phenylsulfanyl] -2-methyl-phenoxy } -acetic acid;
[4-(3-Cyclopentylmethoxy-5-phenylethynyl-phenylsulfanyl)-2-methyl-phenoxy]-acetic acid;
{4-[3-(2-Cyclohexyl-ethoxy)-5-phenylethynyl-phenylsulfanyl]-2-methyl-phenoxy}-acetic acid;
{ 4- [3-(2-Ethyl-butoxy)-5-(3-morpholin-4-yl-prop-1-ynyl)-phenylsulfanyl] -2-methyl-phenoxy } -acetic acid;
{ 4-[3-Cyclopentyloxy-5-(3-morpholin-4-yl-prop-1-ynyl)-phenylsulfanyl] -2-methyl-phenoxy } -acetic acid;
{ 4- [3-(2-Cyclohexyl-ethoxy)-5-(3-morpholin-4-yl-prop-1-ynyl)-phenylsulfanyl]
-2-methyl-phenoxy } -acetic acid;
{ 4- [3-Cyclopentylmethoxy-5-(3-morpholin-4-yl-prop-1-ynyl)-phenylsulfanyl] -2-methyl-phenoxy } -acetic acid;
{4-[3-Cyclopentylmethoxy-5-(3-morpholin-4-yl-prop-1-ynyl)-phenylsulfanyl]-2-methyl-phenoxy } -acetic;
{ 4- [3-Isobutoxy-5-(3-morpholin-4-yl-prop-1-ynyl)-benzylsulfanyl] -2-methyl-phenoxy } -acetic acid;
[4-(3-Isobutoxy-5-phenylethynyl-benzylsulfanyl)-2-methyl-phenoxy]-acetic acid;
{4-[3-Isobutoxy-5-(4-methanesulfonyl-phenylethynyl)-benzylsulfanyl]-2-methyl-phenoxy}-acetic acid;
{ 4- [3-(4-Methanesulfonyl-phenylethynyl)-5-(5-trifluoromethyl-pyridin-2-yloxy)-phenylsulfanyl] -2-methyl-phenoxy } -acetic acid;
{ 4- [3-(4-Methanesulfonyl-phenylethynyl)-5-(3-trifluoromethyl-pyridin-2-yloxy)-phenylsulfanyl] -2-methyl-phenoxy } -acetic acid;

{ 2-Methyl-4- [3-(3-morpholin-4-yl-prop-l-ynyl)-5- (3-trifluoromethyl-pyridin-2-yloxy)-phenylsulfanyl] -phenoxy } -acetic acid;
{ 2-Methyl-4- [3-(3-morpholin-4-yl-prop-1-ynyl)-5- (5-trifluoromethyl-pyridin-2-yloxy)-phenylsulfanyl] -phenoxy } -acetic acid;
{2-Methyl-4-[3-(3-morpholin-4-yl-prop-1-ynyl)-5-(3-trifluoromethyl-phenoxy)-phenylsulfanyl] -phenoxy } -acetic acid;
{ 4- [3-(4-Methanesulfonyl-phenylethynyl)-5-(3-trifluoromethyl-phenoxy)-phenylsulfanyl] -2-methyl-phenoxy } -acetic acid; and { 2-Methyl-4- [3-phenylethynyl-5- (5-trifluoromethyl-pyridin-2-yloxy)-phenylsulfanyl] -phenoxy } -acetic acid, or a pharmaceutically acceptable salt thereof.
[00851] 35. A compound of clause 1, wherein the compound is of formula formula III:
R2a R4b R4c R4a I
/ R5e R' R 5d R5o R3 Rsb Rsa O
O OH

or a pharmaceutically acceptable salt thereof, wherein:
RI is Ci_4 alkyl substituted with 1-2 Rla;

Rla, at each occurrence, is selected from aryl substituted with 0-2 Rlb, heteroaryl substituted with 0-2 Rlb, C3_1o cycloalkyl substituted with 0-2 Rlb, and a heterocycle substituted with 0-2 Rlb=
, Rlb, at each occurrence, is selected from OH substituted with 0-1 Rl , SH
substituted with 0-1 Rl , Cl, F, NH2 substituted with 0-2 Rl , -CN, NOZ, Cl_4 alkyl substituted with 0-2 Rl , C2_4 alkenyl substituted with 0-2 Rl , aryl substituted with 0-2 Rl , heteroaryl substituted with 0-2 Rl , C3_6 cycloalkyl substituted with 0-2 R", and a heterocycle substituted with 0-2 Ri ;

Rl , at each occurrence, is selected from OH, SH, Cl, F, NH2, -CN, NOZ, Cl_4 alkyl, and C2_4 alkenyl, aryl substituted with 0-2 Rld, heteroaryl substituted with 0-2 Rld, C3_6 cycloalkyl sub-stituted with 0-2 Rld, and a heterocycle substituted with 0-2 Rla;

Rld, at each occurrence, is selected from OH, SH, Cl, F, NHZ, -CN, NOZ, Cl_4 alkyl, and C2_4 alkenyl;

R 2a is selected from aryl substituted with 0-2 R 2b and heteroaryl substituted with 0-2 RZb;

RZb, at each occurrence, is selected from OH substituted with 0-1 RZ , SH
substituted with 0-1 RZ , Cl, F, NH2 substituted with 0-2 RZ , -CN, NOZ, Cl_4 alkyl substituted with 0-2 RZ , C2_4 alkenyl substituted with 0-2 RZ , aryl substituted with 0-2 RZ , heteroaryl substituted with 0-2 RZ , C3_6 cycloalkyl substituted with 0-2 RZ , and a heterocycle substituted with 0-2 R 2c;

RZ , at each occurrence, is selected from OH, SH, Cl, F, NH2, -CN, NOZ, Cl_4 alkyl, C2_4 al-kenyl, aryl substituted with 0-2 RZd, and heteroaryl substituted with 0-2 R2d;

RZd, at each occurrence, is selected from OH, SH, Cl, F, NH2, -CN, NOZ, Cl_4 alkyl, and C2_4 alkenyl;

R3 is selected from Cl, F, CH3, and CH2CH3;

alternatively, R3 and R5e combine to form a 5, 6, or 7 membered ring consisting of carbon at-oms and 0-2 heteroatoms selected from 0, N, and S(O)o-Z and there are 0-2 ring double bonds in the bridging portion formed by R3 and R 5e;

R4a, at each occurrence, is selected from H, Cl, F, and CH3;
R4b, at each occurrence, is selected from H, Cl, F, and CH3;
R4o, at each occurrence, is selected from H, Cl, F, and CH3;

RSa, at each occurrence, is selected from H, Cl, F, and CH3;
R5b, at each occurrence, is selected from H, Cl, F, and CH3;
RS , at each occurrence, is selected from H, Cl, F, and CH3;

RSd, at each occurrence, is selected from H, Cl, F, and CH3; and, R5e, at each occurrence, is selected from H, Cl, F, and CH3.
[00852] 36. A compound of clause 35, wherein:

RI is Ci-4 alkyl substituted with 1-2 R'a;
Rla, at each occurrence, is selected from aryl substituted with 0-2 Rlb, 5-10 membered het-eroaryl substituted with 0-2 Rlb and consisting of carbon atoms and 1-4 heteroatoms selected from 0, N, and S(O)o-2, C3-10 cycloalkyl substituted with 0-2 Rlb, and a 3-8 membered hetero-cycle substituted with 0-2 R1b and consisting of carbon atoms and 1-2 heteroatoms selected from 0, N, and S(O)o-Z, Rlb, at each occurrence, is selected from OH substituted with 0-1 Rl , SH
substituted with 0-1 Rl , Cl, F, NH2 substituted with 0-2 Rl , -CN, NOZ, Cl_4 alkyl substituted with 0-2 Rl , C2_4 alkenyl substituted with 0-2 Rl , aryl substituted with 0-2 Rl , 5-10 membered heteroaryl sub-stituted with 0-2 Rl and consisting of carbon atoms and 1-4 heteroatoms selected from 0, N, and S(O)o_Z, C3_6 cycloalkyl substituted with 0-2 Rl , and a 3-6 membered heterocycle substi-tuted with 0-2 Rl and consisting of carbon atoms and 1-2 heteroatoms selected from 0, N, and S(O)o_z, Rl , at each occurrence, is selected from OH, SH, Cl, F, NH2, -CN, NOZ, Cl_4 alkyl, and C2_4 alkenyl, aryl substituted with 0-2 Rld, 5-10 membered heteroaryl substituted with 0-2 Rld and consisting of carbon atoms and 1-4 heteroatoms selected from 0, N, and S(O)o_Z, C3_6 cycloal-kyl substituted with 0-2 Rld, and a 3-6 membered heterocycle substituted with 0-2 Rld and consisting of carbon atoms and 1-2 heteroatoms selected from 0, N, and S(O)o_Z, Rld, at each occurrence, is selected from OH, SH, Cl, F, NH2, -CN, NOZ, Cl_4 alkyl, and C2_4 alkenyl;

RZa is selected from aryl substituted with 0-2 RZb and 5-10 membered heteroaryl substituted with 0-2 R 2b and consisting of carbon atoms and 1-4 heteroatoms selected from 0, N, and S(O)0-z;

RZb, at each occurrence, is selected from OH substituted with 0-1 RZ , SH
substituted with 0-1 RZ , Cl, F, NH2 substituted with 0-2 R2o, -CN, NOZ, Cl_4 alkyl substituted with 0-2 R2 , C2_4 alkenyl substituted with 0-2 RZ , aryl substituted with 0-2 RZ , 5-10 membered heteroaryl sub-stituted with 0-2 RZ and consisting of carbon atoms and 1-4 heteroatoms selected from 0, N, and S(O)o_Z, C3_6 cycloalkyl substituted with 0-2 RZ , and a 3-6 membered heterocycle substi-tuted with 0-2 RZ and consisting of carbon atoms and 1-2 heteroatoms selected from 0, N, and S(O)o_z, RZ , at each occurrence, is selected from OH, SH, Cl, F, NH2, -CN, NOZ, Cl_4 alkyl, C2_4 al-kenyl, aryl substituted with 0-2 RZd, and 5-10 membered heteroaryl substituted with 0-2 RZd and consisting of carbon atoms and 1-4 heteroatoms selected from 0, N, and S(O)o_Z, RZd, at each occurrence, is selected from OH, SH, Cl, F, NH2, -CN, NOZ, Cl_4 alkyl, and C2_4 alkenyl;

R3 is selected from Cl, F, CH3, and CH2CH3;

alternatively, R3 and R5e combine to form a 5, 6, or 7 membered ring consisting of carbon at-oms and 0-2 heteroatoms selected from 0, N, and S(O)o_Z and there are 0-2 ring double bonds in the bridging portion formed by R3 and Rse;

R4a, at each occurrence, is selected from H, Cl, F, and CH3;
R4b, at each occurrence, is selected from H, Cl, F, and CH3;
R4o, at each occurrence, is selected from H, Cl, F, and CH3;
R5a, at each occurrence, is selected from H, Cl, F, and CH3;

RSb, at each occurrence, is selected from H, Cl, F, and CH3;
RS , at each occurrence, is selected from H, Cl, F, and CH3;
R5d, at each occurrence, is selected from H, Cl, F, and CH3; and, RSe, at each occurrence, is selected from H, Cl, F, and CH3.
[00853] 37. A compound of clause 35, wherein the compound is of formula formula IIIa X
R2a O
qr~
OH R3 , Xl IIIa or a pharmaceutically acceptable salt thereof, wherein:

Rla, at each occurrence, is selected from aryl substituted with 0-2 Rlb, heteroaryl substituted with 0-2 R'b, C5_6 cycloalkyl substituted with 0-2 R'b, and a heterocycle substituted with 0-2 Rlb=
, Rlb, at each occurrence, is selected from OH, SH, Cl, F, NH2, -CN, NOZ, Cl_4 alkyl substituted with 0-2 Rl , CZ_4 alkenyl substituted with 0-2 Rl , aryl substituted with 0-2 Rl , heteroaryl substituted with 0-2 Rl , C5_6 cycloalkyl substituted with 0-2 R' , and a heterocycle substituted with 0-2 R";

Rl , at each occurrence, is selected from OH, SH, Cl, F, NH2, -CN, NOZ, Cl_4 alkyl, and CZ_4 alkenyl, aryl substituted with 0-2 Rld, heteroaryl substituted with 0-2 Rld, C3_6 cycloalkyl sub-stituted with 0-2 Rld, and a heterocycle substituted with 0-2 Rla;

RZa is selected from aryl substituted with 0-2 RZb and heteroaryl substituted with 0-2 RZb and;
and, R 2b, at each occurrence, is selected from OH, SH, Cl, F, NH2, -CN, NOZ, Cl_4 alkyl, C2_4 al-kenyl, aryl, heteroaryl, C5_6 cycloalkyl, and a heterocycle.
[00854] 38. A compound of clause 37 wherein:
Rla, at each occurrence, is selected from aryl substituted with 0-2 Rlb, 5-6 membered het-eroaryl substituted with 0-2 Rlb and consisting of carbon atoms and 1-2 heteroatoms selected from 0, N, and S(O)o-Z, C5-6 cycloalkyl substituted with 0-2 Rlb, and a 5-6 membered hetero-cycle substituted with 0-2 Rlb and consisting of carbon atoms and 1-2 heteroatoms selected from 0, N, and S(O)o-Z, Rlb, at each occurrence, is selected from OH, SH, Cl, F, NH2, -CN, NOZ, Cl-4 alkyl substituted with 0-2 Rl , CZ-4 alkenyl substituted with 0-2 Rl , aryl substituted with 0-2 Rl , 5-6 mem-bered heteroaryl substituted with 0-2 Rl and consisting of carbon atoms and 1-2 heteroatoms selected from 0, N, and S(O)o-2, C5-6 cycloalkyl substituted with 0-2 Rl , and a 5-6 membered heterocycle substituted with 0-2 Rl and consisting of carbon atoms and 1-2 heteroatoms se-lected from 0, N, and S(O)o-Z, Rl , at each occurrence, is selected from OH, SH, Cl, F, NH2, -CN, NOZ, Cl-4 alkyl, and CZ-4 alkenyl, aryl substituted with 0-2 Rld, 5-6 membered heteroaryl substituted with 0-2 Rld and consisting of carbon atoms and 1-2 heteroatoms selected from 0, N, and S(O)o-Z, C3-6 cycloal-kyl substituted with 0-2 Rld, and a 3-6 membered heterocycle substituted with 0-2 Rld and consisting of carbon atoms and 1-2 heteroatoms selected from 0, N, and S(O)o-Z, R 2a is selected from aryl substituted with 0-2 RZb and 5-6 membered heteroaryl substituted with 0-2 RZb and consisting of carbon atoms and 1-2 heteroatoms selected from 0, N, and S(O)o_Z, and, R 2b, at each occurrence, is selected from OH, SH, Cl, F, NH2, -CN, NOZ, Cl-4 alkyl, C2-4 al-kenyl, aryl, 5-6 membered heteroaryl consisting of carbon atoms and 1-2 heteroatoms selected from 0, N, and S(O)o-Z, C5-6 cycloalkyl, and a 5-6 membered heterocycle and consisting of carbon atoms and 1-2 heteroatoms selected from 0, N, and S(0)0-2.
[00855] 39. A compound of clause 4, wherein:

RI is Ci-4 alkyl substituted with 1-2 Rla;

Rla, at each occurrence, is selected from aryl substituted with 0-2 Rlb, heteroaryl substituted with 0-2 Rlb, C3_1o cycloalkyl substituted with 0-2 Rlb, and a heterocycle substituted with 0-2 Rlb=
, Rlb, at each occurrence, is selected from OH substituted with 0-1 Rl , SH
substituted with 0-1 Rl , Cl, F, NH2 substituted with 0-2 Rl , -CN, NOZ, Cl_4 alkyl substituted with 0-2 Rl , C2_4 alkenyl substituted with 0-2 Rl , aryl substituted with 0-2 Rl , heteroaryl substituted with 0-2 Rl , C3_6 cycloalkyl substituted with 0-2 R", and a heterocycle substituted with 0-2 Ri ;

Rl , at each occurrence, is selected from OH, SH, Cl, F, NH2, -CN, NOZ, Cl_4 alkyl, and C2_4 alkenyl, aryl substituted with 0-2 Rld, heteroaryl substituted with 0-2 Rld, C3_6 cycloalkyl sub-stituted with 0-2 Rld, and a heterocycle substituted with 0-2 Rla;

Rld, at each occurrence, is selected from OH, SH, Cl, F, NHZ, -CN, NOZ, Cl_4 alkyl, and C2_4 alkenyl;

R 2 is aryl substituted with 0-3 R 2a or heteroaryl substituted with 0-2 R 2a;

RZa, at each occurrence, is selected from OH substituted with 0-1 RZb, SH
substituted with 0-1 RZb, Cl, F, NH2 substituted with 0-2 RZb, -CN, NOZ, Cl_4 alkyl substituted with 0-2 RZb, C2_6 alkenyl substituted with 0-2 R 2b, aryl substituted with 0-2 RZb, heteroaryl substituted with 0-2 RZb, C3_6 cycloalkyl substituted with 0-2 R 2b, and a heterocycle substituted with 0-2 RZb;

RZb, at each occurrence, is selected from OH, SH, Cl, F, NH2, -CN, NOZ, Cl_4 alkyl, and, C2_4 alkenyl;

R3 is selected from Cl, F, CH3, and CH2CH3;

alternatively, R3 and R5e combine to form a 5, 6, or 7 membered ring consisting of carbon at-oms and 0-2 heteroatoms selected from 0, N, and S(O)o-Z and there are 0-2 ring double bonds in the bridging portion formed by R3 and Rse;

R4a, at each occurrence, is selected from H, Cl, F, and CH3;
R4b, at each occurrence, is selected from H, Cl, F, and CH3;
R4o, at each occurrence, is selected from H, Cl, F, and CH3;
RSa, at each occurrence, is selected from H, Cl, F, and CH3;
RSb, at each occurrence, is selected from H, Cl, F, and CH3;
RS , at each occurrence, is selected from H, Cl, F, and CH3;

RSd, at each occurrence, is selected from H, Cl, F, and CH3; and, R5e, at each occurrence, is selected from H, Cl, F, and CH3.
[00856] 40. A compound of clause 39, wherein:
RI is Ci-4 alkyl substituted with 1-2 Rla;

Rla, at each occurrence, is selected from aryl substituted with 0-2 Rlb, 5-10 membered het-eroaryl substituted with 0-2 Rlb and consisting of carbon atoms and 1-4 heteroatoms selected from 0, N, and S(O)o-2, C3-10 cycloalkyl substituted with 0-2 Rlb, and a 3-8 membered hetero-cycle substituted with 0-2 Rlb and consisting of carbon atoms and 1-2 heteroatoms selected from 0, N, and S(O)o-Z, Rlb, at each occurrence, is selected from OH substituted with 0-1 Rl , SH
substituted with 0-1 Rl , Cl, F, NH2 substituted with 0-2 Rl , -CN, NOZ, Cl_4 alkyl substituted with 0-2 Rl , C2_4 alkenyl substituted with 0-2 Rl , aryl substituted with 0-2 Rl , 5-10 membered heteroaryl sub-stituted with 0-2 Rl and consisting of carbon atoms and 1-4 heteroatoms selected from 0, N, and S(O)o_Z, C3_6 cycloalkyl substituted with 0-2 Rl , and a 3-6 membered heterocycle substi-tuted with 0-2 Rl and consisting of carbon atoms and 1-2 heteroatoms selected from 0, N, and S(O)o_z, Rl , at each occurrence, is selected from OH, SH, Cl, F, NH2, -CN, NOZ, Cl_4 alkyl, and C2_4 alkenyl, aryl substituted with 0-2 Rld, 5-10 membered heteroaryl substituted with 0-2 Rld and consisting of carbon atoms and 1-4 heteroatoms selected from 0, N, and S(O)o_Z, C3_6 cycloal-kyl substituted with 0-2 Rld, and a 3-6 membered heterocycle substituted with 0-2 Rld and consisting of carbon atoms and 1-2 heteroatoms selected from 0, N, and S(O)o_Z, Rld, at each occurrence, is selected from OH, SH, Cl, F, NH2, -CN, NOZ, Cl_4 alkyl, and C2_4 alkenyl;

R 2 is aryl substituted with 0-3 R 2a or 5-10 membered heteroaryl substituted with 0-2 R 2a and consisting of carbon atoms and 1-4 heteroatoms selected from 0, N, and S(O)o_Z, R 2a, at each occurrence, is selected from OH substituted with 0-1 R 2b, SH
substituted with 0-1 RZb, Cl, F, NH2 substituted with 0-2 RZb, -CN, NOZ, Cl_4 alkyl substituted with 0-2 RZb, C2_6 alkenyl substituted with 0-2 R 2b, aryl substituted with 0-2 RZb, 5-10 membered heteroaryl sub-stituted with 0-2 R2b and consisting of carbon atoms and 1-4 heteroatoms selected from 0, N, and S(O)o_Z, C3_6 cycloalkyl substituted with 0-2 R 2b, and a 3-6 membered heterocycle substi-tuted with 0-2 R 2b and consisting of carbon atoms and 1-2 heteroatoms selected from 0, N, and S(O)o_z, R 2b, at each occurrence, is selected from OH, SH, Cl, F, NH2, -CN, NOZ, Cl_4 alkyl, and, C2_4 alkenyl;

R3 is selected from Cl, F, CH3, and CH2CH3;

alternatively, R3 and R5e combine to form a 5, 6, or 7 membered ring consisting of carbon at-oms and 0-2 heteroatoms selected from 0, N, and S(O)o_Z and there are 0-2 ring double bonds in the bridging portion formed by R3 and Rse;

R4a, at each occurrence, is selected from H, Cl, F, and CH3;
R4b, at each occurrence, is selected from H, Cl, F, and CH3;
R4o, at each occurrence, is selected from H, Cl, F, and CH3;
Rsa, at each occurrence, is selected from H, Cl, F, and CH3;
R5b, at each occurrence, is selected from H, Cl, F, and CH3;
RS , at each occurrence, is selected from H, Cl, F, and CH3;

RSd, at each occurrence, is selected from H, Cl, F, and CH3; and, RSe, at each occurrence, is selected from H, Cl, F, and CH3.
[00857] 41. A compound of clause 40, wherein the compound is of formula Ib:
X RZ
O\~
'~ _O
IOH 3 Xi Rl~
Ib or a pharmaceutically acceptable salt thereof, wherein:

RI is Ci-4 alkyl substituted with 1 Rla;

Rla, at each occurrence, is selected from aryl substituted with 0-2 Rlb, 5-6 membered het-eroaryl substituted with 0-2 Rlb and consisting of carbon atoms and 1-2 heteroatoms selected from 0, N, and SOO-2, C5-6 cycloalkyl substituted with 0-2 Rlb, and a 5-6 membered hetero-cycle substituted with 0-2 Rlb and consisting of carbon atoms and 1-2 heteroatoms selected from 0, N, and S(O)o-Z, Rlb, at each occurrence, is selected from OH, SH, Cl, F, NH2, -CN, NOZ, Cl-4 alkyl substituted with 0-2 Rl , CZ-4 alkenyl substituted with 0-2 Rl , aryl substituted with 0-2 Rl , 5-6 mem-bered heteroaryl substituted with 0-2 Rl and consisting of carbon atoms and 1-2 heteroatoms selected from 0, N, and SOO-2, C5-6 cycloalkyl substituted with 0-2 Rl , and a 5-6 membered heterocycle substituted with 0-2 Rl and consisting of carbon atoms and 1-2 heteroatoms se-lected from 0, N, and S(O)0-2, Rl , at each occurrence, is selected from OH, SH, Cl, F, NH2, -CN, NOZ, Cl-4 alkyl, and CZ-4 alkenyl, aryl substituted with 0-2 Rld, 5-6 membered heteroaryl substituted with 0-2 Rld and consisting of carbon atoms and 1-2 heteroatoms selected from 0, N, and SOO-2, C3-6 cycloal-kyl substituted with 0-2 Rld, and a 3-6 membered heterocycle substituted with 0-2 Rld and consisting of carbon atoms and 1-2 heteroatoms selected from 0, N, and S(O)o-Z, R 2 is aryl substituted with 0-2 R 2a or 5-6 membered heteroaryl substituted with 0-2 R 2a and consisting of carbon atoms and 1-2 heteroatoms selected from 0, N, and S(O)o-Z, and, RZa at each occurrence, is selected from OH substituted with 0-1 R 2b, SH
substituted with 0-1 RZb, Cl, F, NH2 substituted with 0-2 RZb, -CN, NOZ, Cl-4 alkyl substituted with 0-2 RZb, CZ-6 alkenyl substituted with 0-2 R 2b, aryl substituted with 0-2 RZb, 5-6 membered heteroaryl sub-stituted with 0-2 R 2b and consisting of carbon atoms and 1-2 heteroatoms selected from 0, N, and SOO-2, C5-6 cycloalkyl substituted with 0-2 R 2b, and a 5-6 membered heterocycle substi-tuted with 0-2 RZb and consisting of carbon atoms and 1-2 heteroatoms selected from 0, N, and S(O)o_Z.
[00858] 42. A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a compound of one of clauses 1-41 or a pharmaceutically acceptable salt.
[00859] 43. A pharmaceutical composition for treating type 2 diabetes, comprising a compound according to any of the clauses 1-41 together with one or more pharmaceutically acceptable carriers or excipients.
[00860] 44. A pharmaceutical composition for treating dyslipidemia, syndrome X
(including the metabolic syndrome, e.g., hypertension, impaired glucose tolerance (IGT), insulin resistance, hypertrigyceridaemia, and obesity), cardiovascular diseases (e.g., atherosclerosis and related diseases, including mortality reduction, coronary artery diseases, coronary heart diseases, heart attack, myocardial ischemia, myocardial infarct, coronary infarct, transient ischemic attack (TIA), and stroke), hyperglycemia, hyperlipidemia, hypercholesterolemia, and hyperinsulinemia, comprising a compound according to any of the clauses 1-41 together with one or more pharmaceutically acceptable carriers or excipients.
[00861] 45. A pharmaceutical composition for treating dyslipidemia comprising a compound according to any of the clauses 1-41 together with one or more pharmaceutically acceptable carriers or excipients.
[00862] 46. A pharmaceutical composition for treating syndrome X (including the metabolic syndrome, e.g., hypertension, impaired glucose tolerance (IGT), insulin resistance, hyper-trigyceridaemia, and obesity), comprising a compound according to any of the clauses 1-41 together with one or more pharmaceutically acceptable carriers or excipients.
[00863] 47. A pharmaceutical composition for treating cardiovascular diseases (e.g., atherosclerosis and related diseases, including mortality reduction, coronary artery diseases, coronary heart diseases, heart attack, myocardial ischemia, myocardial infarct, coronary infarct, transient ischemic attack (TIA), and stroke), comprising a compound according to any of the clauses 1-41 together with one or more pharmaceutically acceptable carriers or excipients [00864] 48. A pharmaceutical composition for treating hyperglycemia comprising a compound according to any of the clauses 1-41 together with one or more pharmaceutically acceptable carriers or excipients.
[00865] 49. A pharmaceutical composition for treating hyperlipidemia comprising a compound according to any of the clauses 1-41 together with one or more pharmaceutically acceptable carriers or excipients.
[00866] 50. A pharmaceutical composition for treating hypercholesterolemia comprising a compound according to any of the clauses 1-41 together with one or more pharmaceutically acceptable carriers or excipients [00867] 51. A pharmaceutical composition for treating hyperinsulinemia comprising a compound according to any of the clauses 1-41 together with one or more pharmaceutically acceptable carriers or excipients [00868] 52. A pharmaceutical composition according to any one of the clauses 42-51 for oral, nasal, transdermal, pulmonal or parenteral administration.
[00869] 53. Use of a compound according to any one of the clauses 1-41 as a pharmaceutical composition.
[00870] 54. Use of a compound according to any one of the clauses 1-41 for the preparation of a pharmaceutical composition for treating type 2 diabetes.
[00871] 55. Use of a compound according to any one of the clauses 1-41 for the preparation of a pharmaceutical composition for treating dyslipidemia, syndrome X
(including the metabolic syndrome, e.g., hypertension, impaired glucose tolerance (IGT), insulin resistance, hypertrigyceridaemia, and obesity), cardiovascular diseases (e.g., atherosclerosis and related diseases, including mortality reduction, coronary artery diseases, coronary heart diseases, heart attack, myocardial ischemia, myocardial infarct, coronary infarct, transient ischemic attack (TIA), and stroke), hyperglycemia, hyperlipidemia, hypercholesterolemia, and hyperinsulinemia.
[00872] 56. Use of a compound according to any one of the clauses 1-41 for the preparation of a pharmaceutical composition for treating dyslipidemia.
[00873] 57. Use of a compound according to any one of the clauses 1-41 for the preparation of a pharmaceutical composition for treating syndrome X (including the metabolic syndrome, e.g., hypertension, impaired glucose tolerance (IGT), insulin resistance, hypertrigyceridaemia, and obesity).
[00874] 58. Use of a compound according to any one of the clauses 1-41 for the preparation of a pharmaceutical composition for treating cardiovascular diseases (e.g., atherosclerosis and related diseases, including mortality reduction, coronary artery diseases, coronary heart diseases, heart attack, myocardial ischemia, myocardial infarct, coronary infarct, transient ischemic attack (TIA), and stroke).
[00875] 59. Use of a compound according to any one of the clauses 1-41 for the preparation of a pharmaceutical composition for treating hyperglycemia.
[00876] 60. Use of a compound according to any one of the clauses 1-41 for the preparation of a pharmaceutical composition for treating hyperlipidemia.
[00877] 61. Use of a compound according to any one of the clauses 1-41 for the preparation of a pharmaceutical composition for treating hypercholesterolemia.
[00878] 62. Use of a compound according to any one of the clauses 1-41 for the preparation of a pharmaceutical composition for treating hyperinsulinemia [00879] 63. A method of treating type 2 diabetes, comprising: administering a therapeutically effective amount of a compound of one of clauses 1-41 or a pharmaceutically acceptable salt.
[00880] 64. A method of treating a disease, comprising: administering a therapeutically effective amount of a compound of one of clauses 1-41 or a pharmaceutically acceptable salt, wherein the disease is selected from dyslipidemia, syndrome X (including the metabolic syndrome, e.g., hypertension, impaired glucose tolerance (IGT), insulin resistance, hypertrigyceridaemia, and obesity), cardiovascular diseases (e.g., atherosclerosis and related diseases, including mortality reduction, coronary artery diseases, coronary heart diseases, heart attack, myocardial ischemia, myocardial infarct, coronary infarct, transient ischemic attack (TIA), and stroke), hyperglycemia, hyperlipidemia, hypercholesterolemia, and hyperinsulinemia.
[00881] 65. A compound of one of clauses 1-41 or a pharmaceutically acceptable salt thereof, wherein the compound has a solubility in water of at least 0.1 mg/L as determined at 25 C and pH 7Ø
[00882] 66. The compound of clause 65, wherein the compound has a solubility in water of at least 0.5 mg/L.
[00883] 67. The compound of clause 66, wherein the compound has a solubility in water of at least 1 mg/L.
[00884] 68. The compound of clause 67, wherein the compound has a solubility in water of at least 2 mg/L.
[00885] 69. The compound of clause 68, wherein the compound has a solubility in water of at least 10 mg/L.
[00886] 70. The compound of clause 69, wherein the compound has a solubility in water of at least 50 mg/L.
[00887] 71. The compound of clause 70, wherein the compound has a solubility in water of at least 200 mg/L.
[00888] 72. A compound of one of clauses 1-41 or a pharmaceutically acceptable salt thereof, wherein the compound has an IC5o value of less than 1 m as determined by the PPAR transient transactivation assay.
[00889] 73. The compound of clause 72, wherein the compound has an IC50 value of less than 500 nm.
[00890] 74. The compound of clause 73, wherein the compound has an IC5o value of less than 100 nm.
[00891] 75. The compound of clause 74, wherein the compound has an IC50 value of less than 50 nm.
[00892] 76. The compound of clause 75, wherein the compound has an IC50 value of less than 25 nm.
[00893] 77. The compound of clause 76, wherein the compound has an IC5o value of less than 10 nm.
[00894] 78. The compound of clause 77, wherein the compound has an IC5o value of less than 5 nm.
[00895] 79. A compound of one of clauses 1-41, wherein the compound has a molecular weight of less than 750 g/mol.
[00896] 80. The compound of clause 79, wherein the compound has a molecular weight of less than 600 g/mol.
[00897] 81. The compound of clause 80, wherein the compound has a molecular weight of less than 550 g/mol.
[00898] 82. The compound of clause 81, wherein the compound has a molecular weight of less than 500 g/mol.
[00899] 83. The compound of clause 82, wherein the compound has a molecular weight of less than 400 g/mol.
[00900] 84. A compound of one of clauses 1-41, wherein the compound is ionized at a pH of from 5.5-9.
[00901] 85. The compound of clause 84, wherein the compound has only one ionized car-boxylic acid group at a pH of from 6-8.
[00902] 86. The compound of clause 85, wherein the compound has only one ionized car-boxylic acid group at a pH of from 6.5-7.5.
[00903] 87. The compound of clause 86, wherein the compound has only one ionized car-boxylic acid group at pH 7.4.
[00904] 88. A compound of one of clauses 1-41, wherein the compound is a zwitter-ion with one ionized amine group and one ionized carboxylic acid group at a pH of from 5.5-9.
[00905] 89. The compound of clause 88, wherein the compound is a zwitter-ion with one ionized amine group and one ionized carboxylic acid group at a pH of from 6-8.
[00906] 90. The compound of clause 89, wherein the compound is a zwitter-ion with one ionized amine group and one ionized carboxylic acid group at a pH of from 6.5-7.5 [00907] 91. The compound of clause 90, wherein the compound is a zwitter-ion with one ionized amine group and one ionized carboxylic acid group at pH 7.4.

Claims (24)

1. A compound of formula I:

or a pharmaceutically acceptable salt thereof, wherein:
X is selected from O, S, OCH2, and SCH2;

X1 is O or S;

R1 is selected from H, C1-8 alkyl, C2-8 alkenyl, aryl, heteroaryl,C3-10 cycloalkyl, and a hetero-cyclyl, wherein each R1 group is substituted with 0-4 R1a;

R1a, at each occurrence, is selected from S substituted with 0-1 R1b, O
substituted with 0-1 R1b, halogen, NH2 substituted with 0-2 R1b, -CN, NO2, C1-6 alkyl substituted with 0-3 R1b, C2-6 alkenyl substituted with 0-2 R1b, C2-6 alkynyl substituted with 0-2 R1b, aryl substituted with 0-
2 R1b, heteroaryl substituted with 0-2 R1b, C3-10 cycloalkyl substituted with 0-2 R1b, and het-erocycle substituted with 0-2 R1b;

R1b, at each occurrence, is selected from S substituted with 0-1 R1c, 0 substituted with 0-1 R1c, halogen, methanesulfonyl, NH2 substituted with 0-2 R1c, -CN, NO2, C1-6 alkyl substituted with 0-3 R1c, C2-6 alkenyl substituted with 0-2 R1c, aryl substituted with 0-2 R1c, heteroaryl substituted with 0-2 R1c, C3-10 cycloalkyl substituted with 0-2 R1c, and a heterocycle substi-tuted with 0-2 R1c;

R1c, at each occurrence, is selected from S substituted with 0-1 R1d, 0 substituted with 0-1 R1d, halogen, NH2 substituted with 0-2 R1d, -CN, NO2, C1-6 alkyl substituted with 0-2 R1d, C2-6 alkenyl substituted with 0-2 R1d, aryl substituted with 0-2 R1d, heteroaryl substituted with 0-2 R1d, C3-10 cycloalkyl substituted with 0-2 R1d, and a heterocycle substituted with 0-2 R1d;

R1d, at each occurrence, is selected from OH, SH, S, O, halogen, NH2, -CN, NO2, C1-6 alkyl, C2-6 alkenyl, aryl, CF3, and OCF3;

R2 is selected from -C.ident.C-R2a, -CH=CH-R2a, aryl substituted with 0-3 R2a, and heteroaryl sub-stituted with 0-3 R2a;

R2a, at each occurrence, is selected from S substituted with 0-1 R2b, O
substituted with 0-1 R2b, halogen, NH2 substituted with 0-2 R2b, -CN, NO2, C1-6 alkyl substituted with 0-2 R2b, C2-6 alkenyl substituted with 0-2 R2b, aryl substituted with 0-2 R2b, heteroaryl substituted with 0-2 R2b, C3-10 cycloalkyl substituted with 0-2 R2b, and a heterocycle substituted with 0-2;

R2b, at each occurrence, is selected from S substituted with 0-1 R2c, O
substituted with 0-1 R2c, halogen, methanesulfonyl, NH2 substituted with 0-2 R2c, -CN, NO2, C1-6 alkyl substituted with 0-2 R2c, C2-6 alkenyl substituted with 0-2 R2c, aryl substituted with 0-2 R2c, heteroaryl substituted with 0-2 R2c, C3-10 cycloalkyl substituted with 0-2 R2c, and a heterocycle substi-tuted with 0-2 R2c;

R2c, at each occurrence, is selected from S substituted with 0-1 R2d, 0 substituted with 0-1 R2d, halogen, NH2 substituted with 0-2 R2d, -CN, NO2, C1-6 alkyl substituted with 0-2 R2d, C2-6 alkenyl substituted with 0-2 R2d, aryl substituted with 0-2 R2d, heteroaryl substituted with 0-2 R2d, C3-10 cycloalkyl substituted with 0-2 R2d, and a heterocycle substituted with 0-2 R2d R2d, at each occurrence, is selected from OH, SH, S, O, halogen, NH2, -CN, NO2, C1-6 alkyl, C2-6 alkenyl, aryl, CF3, and OCF3;

R3 is selected from halogen and C1-6 alkyl substituted with 0-2 R3a;

R3a, at each occurrence, is selected from OH, O, S, halogen, C(O)NH2, C(O)NH-C1-4 alkyl, and C(O)N(C1-4 alkyl)2;

alternatively, R3 and R5e combine to form a 5, 6, or 7 membered ring consisting of carbon at-oms and 0-2 heteroatoms selected from O, N, and S(O)0-2 and there are 0-2 ring double bonds in the bridging portion formed by R3 and R5e;

R4a at each occurrence, is selected from H, halogen, and C1-6 alkyl substituted with 0-2 R4d;
R4d, at each occurrence, is selected from OH, O, halogen, NH2, NH-C1-4 alkyl, and N(C1-4 al-kyl)2;

R4b, at each occurrence, is selected from H, halogen, and C1-6 alkyl substituted with 0-2 R4e;
R4e, at each occurrence, is selected from OH, O, halogen, NH2, NH-C1-4 alkyl, and N(C1-4 al-kyl)2;

R4c, at each occurrence, is selected from H, halogen, and C1-6 alkyl substituted with 0-2 R4f;
R4f, at each occurrence, is selected from OH, O, halogen, NH2, NH-C1-4 alkyl, and N(C1-4 al-kyl)2;

R5a, at each occurrence, is selected from H, halogen, CH3, and CH2CH3;
R5b, at each occurrence, is selected from H, halogen, CH3, and CH2CH3;
R5c, at each occurrence, is selected from H, halogen, CH3, and CH2CH3;

R5d, at each occurrence, is selected from H, halogen, CH3, and CH2CH3; and, R5e, at each occurrence, is selected from H, halogen, CH3, and CH2CH3.

2. A compound of claim 1, wherein the compound is of formula Ia:

or a pharmaceutically acceptable salt thereof.
3. A compound of claim 1, wherein the compound is of formula II:

or a pharmaceutically acceptable salt thereof, wherein:

RI is H, C1-8 alkyl, heteroaryl, and C3-10 cycloalkyl, wherein each R1 group is substituted with 0-4 R1a;

R1a, at each occurrence, is selected from C1-6 alkyl substituted with 0-3 R1b;
C2-6 alkynyl sub-stituted with 0-2 R1b; aryl substituted with 0-2 R1b, heteroaryl substituted with 0-2 R1b, C3-10 cycloalkyl substituted with 0-2 R1b, and a heterocycle substituted with 0-2 R1b;

R1b, at each occurrence, is selected from OH substituted with 0-1 R1c, SH
substituted with 0-1 R1c, Cl, F, NH2 substituted with 0-2 R1c, -CN, NO2, methanesulfonyl, C1-4 alkyl substituted with 0-3 R1c, C2-4 alkenyl substituted with 0-2 R1c, aryl substituted with 0-2 R1c, heteroaryl substituted with 0-2 R1c, C3-6 cycloalkyl substituted with 0-2 R1c, and a heterocycle substituted with 0-2 R1c;

R1c, at each occurrence, is selected from OH, SH, Cl, F, NH2, -CN, NO2, C1-4 alkyl, and C2-4 alkenyl, aryl substituted with 0-2 R1d, heteroaryl substituted with 0-2 R1d and, C3-6 cycloalkyl substituted with 0-2 R1d, and a heterocycle substituted with 0-2 R1a;

R1d, at each occurrence, is selected from OH, SH, Cl, F, NH2, -CN, NO2, C1-4 alkyl, and C2-4 alkenyl;

R2a is selected from C1-6 alkyl substituted with 0-2 R2b, aryl substituted with 0-2 R2b, and het-eroaryl substituted with 0-2 R2b;

R2b, at each occurrence, is selected from OH substituted with 0-1 R2c, SH
substituted with 0-1 R2c, Cl, F, NH2 substituted with 0-2 R2c, -CN, NO2, methanesulfonyl, C1-4 alkyl substituted with 0-2 R2c, C2-4 alkenyl substituted with 0-2 R2c, aryl substituted with 0-2 R2c, heteroaryl substituted with 0-2 R2c, C3-6 cycloalkyl substituted with 0-2 R2c, and a heterocycle substituted with 0-2 R2c;

R2c, at each occurrence, is selected from OH, SH, Cl, F, NH2, -CN, NO2, C1-4 alkyl, C2-4 al-kenyl, aryl substituted with 0-2 R2d, and heteroaryl substituted with 0-2 R2d;

R2d, at each occurrence, is selected from OH, SH, Cl, F, NH2, -CN, NO2, C1-4 alkyl, and C2-4 alkenyl;

R3 is selected from Cl, F, CH3, and CH2CH3;

alternatively, R3 and R5e combine to form a 5, 6, or 7 membered ring consisting of carbon at-oms and 0-2 heteroatoms selected from 0, N, and S(O)0-2 and there are 0-2 ring double bonds in the bridging portion formed by R3 and R5e;

R4a, at each occurrence, is selected from H, Cl, F, and CH3;
R4b, at each occurrence, is selected from H, Cl, F, and CH3;
R4c, at each occurrence, is selected from H, Cl, F, and CH3;

R5a, at each occurrence, is selected from H, Cl, F, and CH3;
R5b, at each occurrence, is selected from H, Cl, F, and CH3;
R5c, at each occurrence, is selected from H, Cl, F, and CH3;

R5d, at each occurrence, is selected from H, Cl, F, and CH3; and, R5e, at each occurrence, is selected from H, Cl, F, and CH3.
4. A compound of claim 3, wherein the compound is of formula IIa:

or a pharmaceutically acceptable salt thereof, wherein:

R1 is H, C1-6 alkyl, aryl, heteroaryl, and C3-10 cycloalkyl, wherein each R1 group is substituted with 0-1 R1a;

R1a, at each occurrence, is selected from C1-6 alkyl substituted with 0-3 R1b;
C2-6 alkynyl sub-stituted with 0-2 R1b; aryl substituted with 0-2 R1b, heteroaryl substituted with 0-2 R1b and, C5-6 cycloalkyl substituted with 0-2 R1b, and a heterocycle substituted with 0-2 R1b and;

R1b, at each occurrence, is selected from OH, SH, Cl, F, NH2, -CN, NO2, methanesulfonyl, C1-4 alkyl substituted with 0-3 R1c, C2-4 alkenyl substituted with 0-2 R1c, aryl substituted with 0-2 R1c, heteroaryl substituted with 0-2 R1c, C5-6 cycloalkyl substituted with 0-2 R1c, and a hetero-cycle substituted with 0-2 R1c;

R1c, at each occurrence, is selected from OH, SH, Cl, F, NH2, -CN, NO2, CI-4 alkyl, and C2-4 alkenyl, aryl substituted with 0-2 R1d, heteroaryl substituted with 0-2 R1d, C5-6 cycloalkyl sub-stituted with 0-2 R1d, and a heterocycle substituted with 0-2 R1d;

R1d, at each occurrence, is selected from OH, SH, Cl, F, NH2, -CN, NO2, C1-4 alkyl, and C2-4 alkenyl;

R2a is selected from C1-6 alkyl substituted with 0-2 R2b, aryl substituted with 0-2 R2b, and het-eroaryl substituted with 0-2 R2b;

R2b, at each occurrence, is selected from OH substituted with 0-1 R2c, SH, Cl, F, NH2, -CN, NO2, methanesulfonyl, C1-4 alkyl, C2-4 alkenyl, aryl, heteroaryl, C5-6 cycloalkyl, and a hetero-cycle;

R2c, at each occurrence, is C1-4 alkyl;

R3 is selected from Cl, F, CH3, and CH2CH3; and, alternatively, R3 and R5e combine to form a 5, 6, or 7 membered ring consisting of carbon at-oms and 0-2 heteroatoms selected from O, N, and S(O)0-2 and there are 0-2 ring double bonds in the bridging portion formed by R3 and R5e.
5. A compound of claim 4 wherein:

R1 is H, C1-6 alkyl, aryl, 5-6 membered heteroaryl consisting of carbon atoms and 1-2 heteroa-toms selected from 0 and N; C3-10 cycloalkyl, wherein each R1 group is substituted with 0-1 R1a;

R1a, at each occurrence, is selected from C1-4 alkyl substituted with 0-3 R1b;
C2-6 alkynyl sub-stituted with 0-1 R1b aryl substituted with 0-1 R1b, heteroaryl substituted with 0-1 R1b, C5-6 cycloalkyl substituted with 0-1 R1b, and a heterocycle substituted with 0-1 R1b;

R1b, at each occurrence, is selected from Cl, F, methanesulfonyl, and C1-4 alkyl substituted with 0-3 R1c, and;

R1c, at each occurrence, is selected from Cl, F and a heterocycle ;

R2a is selected from C1-6 alkyl substituted with 0-2 R2b, aryl substituted with 0-2 R2b, and het-eroaryl substituted with 0-2 R2b;

R2b, at each occurrence, is selected from OH optionally substituted with C1-4 alkyl, Cl, F, methanesulfonyl, aryl, heteroaryl, C5-6 cycloalkyl, and a heterocycle ;

R3 is selected from Cl, F, CH3, and CH2CH3..
6. A compound of claim 5 wherein R1 is C1-4 alkyl substituted with 0-1 R1a.
7. A compound of claim 3, wherein the compound is of formula IIb or a pharmaceutically acceptable salt thereof.
8. A compound of claim 7, wherein R2a is C1-4 alkyl substituted with a heterocycle.
9. A compound of claim 7, wherein R3 is selected from Cl and CH3.
10. A compound of claim 7, wherein X is selected from S and SCH2
11. A compound of claim 7, wherein X is S.
12. A compound of claim 7, wherein X1 is O.
13. A compound of any one of the precding claims wherein the compound is selected from:
{2-Chloro-4-[3-(4-chloro-phenylethynyl)-5-(3-piperidin-1-yl-propoxy)-phenylsulfanyl]-phenoxy}-acetic acid;
{2-Methyl-4-[3-(3-morpholin-4-yl-propoxy)-5-phenylethynyl-phenylsulfanyl]-phenoxy}-acetic acid;
{2-Chloro-4-[3-(4-chloro-phenylethynyl)-5-(3-morpholin-4-yl-propoxy)-phenylsulfanyl]-phenoxy}-acetic acid;
{2-Chloro-4-[3-(4-chloro-phenylethynyl)-5-(4-morpholin-4-ylmethyl-benzyloxy)-phenyl-sulfanyl]-phenoxy}-acetic acid;
{2-Chloro-4-[3-(4-chloro-phenylethynyl)-5-(1-methyl-piperidin-4-ylmethoxy)-phenyl-sulfanyl]-phenoxy}-acetic acid;

{2-Methyl-4-[3-(3-morpholin-4-yl-propoxy)-5-(3-phenyl-prop-1-ynyl)-phenylsulfanyl] -phenoxy}-acetic acid;
{4-[3-(4-Fluoro-benzyloxy)-5-(3-morpholin-4-yl-prop-1-ynyl)-phenylsulfanyl]-2-methyl-phenoxy}-acetic acid;
{4-[3-Cyclohexylmethoxy-5-(3-morpholin-4-yl-prop-1-ynyl)-phenylsulfanyl]-2-methyl-phenoxy}-acetic acid;
{4-[3-Isobutoxy-5-(3-morpholin-4-yl-prop-1-ynyl)-phenylsulfanyl] -2-methyl-phenoxy}-acetic acid;
{4-[3-(4-Chloro-benzyloxy)-5-(3-morpholin-4-yl-prop-1-ynyl)-phenylsulfanyl]-2-methyl-phenoxy}-acetic acid;
{2-Chloro-4-[3-(4-chloro-phenylethynyl)-5-hydroxy-phenylsulfanyl]-phenoxy}-acetic acid;
{4-[3-But-2-ynyloxy-5-(3-morpholin-4-yl-prop-1-ynyl)-phenylsulfanyl]-2-methyl-phenoxy}-acetic acid;
{2-Methyl-4-[3-(2-morpholin-4-yl-ethoxy)-5-phenylethynyl-phenylsulfanyl]-phenoxy}-acetic acid;
{2-Chloro-4-[3-(3-methoxy-prop-1-ynyl)-5-(3-morpholin-4-yl-propoxy)-phenylsulfanyl] -phenoxy}-acetic acid;
{2-Chloro-4-[3-(3-morpholin-4-yl-propoxy)-5-pent-1-ynyl-phenylsulfanyl]-phenoxy}-acetic acid;
{2-Methyl-4-[3-(3-morpholin-4-yl-propoxy)-5-(3-phenyl-prop-1-ynyl)-benzylsulfanyl]-phenoxy}-acetic acid;
{4-[3-(4-Fluoro-benzyloxy)-5-(3-morpholin-4-yl-prop-1ynyl)-benzylsulfanyl]-2-methyl-phenoxy}-acetic acid; and, {2-Methyl-4-[3-(3-morpholin-4-yl-ethoxy)-5-(3-phenyl-prop-1-ynyl)-benzylsulfanyl]-phenoxy}-acetic acid;
or a pharmaceutically acceptable salt thereof.
14. A compound any one of the claims 1-12, wherein the compound is selected from:
{4-[3-Cyclohexylmethoxy-5-(4-methanesulfonyl-phenylethynyl)-phenylsulfanyl] -2-methyl-phenoxy}-acetic acid;

{4-[3-Cyclopentylmethoxy-5-(4-methanesulfonyl-phenylethynyl)-phenylsulfanyl]-2-methyl-phenoxy}-acetic acid;
{4-[3-Isobutoxy-5-(4-methanesulfonyl-phenylethynyl)-phenylsulfanyl]-2-methyl-phenoxy}-acetic acid ;
{4-[3-[2-(4-Chloro-phenyl)-ethoxy]-5-(4-methanesulfonyl-phenylethynyl)-phenylsulfanyl]-2-methyl-phenoxy}-acetic acid;
{4-[3-[2-(4-Chloro-phenyl)-ethoxy]-5-(3-morpholin-4-yl-prop-1-ynyl)-phenylsulfanyl]-2-methyl-phenoxy}-acetic acid;
{4-[3-[2-(4-Chloro-phenyl)-ethoxy]-5-(4-hydroxymethyl-phenylethynyl)-phenylsulfanyl]-2-methyl-phenoxy}-acetic acid;
{4-[3-(2-Ethyl-butoxy)-5-phenylethynyl-phenylsulfanyl]-2-methyl-phenoxy}-acetic acid;
[4-(3-Cyclopentyloxy-5-phenylethynyl-phenylsulfanyl)-2-methyl-phenoxy]-acetic acid;
{4-[3-(4-Fluoro-phenylethynyl)-5-(4-methanesulfonyl-benzyloxy)-phenylsulfanyl]-2-methyl-phenoxy}-acetic acid;
[4-(3-Cyclopentylmethoxy-5-phenylethynyl-phenylsulfanyl)-2-methyl-phenoxy]-acetic acid;
{4-[3-(2-Cyclohexyl-ethoxy)-5-phenylethynyl-phenylsulfanyl]-2-methyl-phenoxy}-acetic acid;
{4-[3-(2-Ethyl-butoxy)-5-(3-morpholin-4-yl-prop-1-ynyl)-phenylsulfanyl]-2-methyl-phenoxy}-acetic acid;
{4-[3-Cyclopentyloxy-5-(3-morpholin-4-yl-prop-1-ynyl)-phenylsulfanyl]-2-methyl-phenoxy}-acetic acid;
{4-[3-(2-Cyclohexyl-ethoxy)-5-(3-morpholin-4-yl-prop-l-ynyl)-phenylsulfanyl]-2-methyl-phenoxy}-acetic acid;
{4-[3-Cyclopentylmethoxy-5-(3-morpholin-4-yl-prop-1-ynyl)-phenylsulfanyl]-2-methyl-phenoxy}-acetic acid;
{4-[3-Cyclopentylmethoxy-5-(3-morpholin-4-yl-prop-1-ynyl)-phenylsulfanyl]-2-methyl-phenoxy}-acetic;
{4-[3-Isobutoxy-5-(3-morpholin-4-yl-prop-1-ynyl)-benzylsulfanyl]-2-methyl-phenoxy}-acetic acid;
[4-(3-Isobutoxy-5-phenylethynyl-benzylsulfanyl)-2-methyl-phenoxy]-acetic acid;

{4-[3-Isobutoxy-5-(4-methanesulfonyl-phenylethynyl)-benzylsulfanyl]-2-methyl-phenoxy}-acetic acid;
{4-[3-(4-Methanesulfonyl-phenylethynyl)-5-(5-trifluoromethyl-pyridin-2-yloxy)-phenyl-sulfanyl]-2-methyl-phenoxy}-acetic acid;
{4-[3-(4-Methanesulfonyl-phenylethynyl)-5-(3-trifluoromethyl-pyridin-2-yloxy)-phenyl-sulfanyl]-2-methyl-phenoxy}-acetic acid;
{2-Methyl-4-[3-(3-morpholin-4-yl-prop-1-ynyl)-5-(3-trifluoromethyl-pyridin-2-yloxy)-phenylsulfanyl]-phenoxy}-acetic acid;
{2-Methyl-4-[3-(3-morpholin-4-yl-prop-1-ynyl)-5-(5-trifluoromethyl-pyridin-2-yloxy)-phenylsulfanyl]-phenoxy}-acetic acid;
{2-Methyl-4-[3-(3-morpholin-4-yl-prop-1-ynyl)-5-(3-trifluoromethyl-phenoxy)-phenyl-sulfanyl]-phenoxy}-acetic acid;
{4-[3-(4-Methanesulfonyl-phenylethynyl)-5-(3-trifluoromethyl-phenoxy)-phenylsulfanyl]-2-methyl-phenoxy}-acetic acid; and {2-Methyl-4-[3-phenylethynyl-5-(5-trifluoromethyl-pyridin-2-yloxy)-phenylsulfanyl]-phenoxy}-acetic acid, or a pharmaceutically acceptable salt thereof.
15. A compound of claim 1, wherein the compound is of formula formula III:

or a pharmaceutically acceptable salt thereof, wherein:
R1 is C1-4 alkyl substituted with 1-2 R1a;

R1a, at each occurrence, is selected from aryl substituted with 0-2 R1b, heteroaryl substituted with 0-2 R1b, C3-10 cycloalkyl substituted with 0-2 R1b, and a heterocycle substituted with 0-2 R1b;
R1b, at each occurrence, is selected from OH substituted with 0-1 R1c, SH
substituted with 0-1 R1c, Cl, F, NH2 substituted with 0-2 R1c, -CN, NO2, C1-4 alkyl substituted with 0-2 R1c, C2-4 alkenyl substituted with 0-2 R1c, aryl substituted with 0-2 R1c, heteroaryl substituted with 0-2 R1c, C3-6 cycloalkyl substituted with 0-2 R1c, and a heterocycle substituted with 0-2 R1c;

R1c, at each occurrence, is selected from OH, SH, Cl, F, NH2, -CN, NO2, C1-4 alkyl, and C2-4 alkenyl, aryl substituted with 0-2 R1d, heteroaryl substituted with 0-2 R1d, C3-6 cycloalkyl sub-stituted with 0-2 R1d, and a heterocycle substituted with 0-2 R1a;

R1d, at each occurrence, is selected from OH, SH, Cl, F, NH2, -CN, NO2, C1-4 alkyl, and C2-4 alkenyl;

R2a is selected from aryl substituted with 0-2 R2b and heteroaryl substituted with 0-2 R2b;

R2b, at each occurrence, is selected from OH substituted with 0-1 R2c, SH
substituted with 0-1 R2c, Cl, F, NH2 substituted with 0-2 R2c, -CN, NO2, C1-4 alkyl substituted with 0-2 R2c, C2-4 alkenyl substituted with 0-2 R2c, aryl substituted with 0-2 R2c, heteroaryl substituted with 0-2 R2c, C3-6 cycloalkyl substituted with 0-2 R2c, and a heterocycle substituted with 0-2 R2c;

R2c, at each occurrence, is selected from OH, SH, Cl, F, NH2, -CN, NO2, C1-4 alkyl, C2-4 al-kenyl, aryl substituted with 0-2 R2d, and heteroaryl substituted with 0-2 R2d;

R2d, at each occurrence, is selected from OH, SH, Cl, F, NH2, -CN, NO2, C1-4 alkyl, and C2-4 alkenyl;

R3 is selected from Cl, F, CH3, and CH2CH3;

alternatively, R3 and R5e combine to form a 5, 6, or 7 membered ring consisting of carbon at-oms and 0-2 heteroatoms selected from O, N, and S(O)0-2 and there are 0-2 ring double bonds in the bridging portion formed by R3 and R5e;

R4a at each occurrence, is selected from H, Cl, F, and CH3;
R4b, at each occurrence, is selected from H, Cl, F, and CH3;
R4c, at each occurrence, is selected from H, Cl, F, and CH3;
R5a, at each occurrence, is selected from H, Cl, F, and CH3;
R5b, at each occurrence, is selected from H, Cl, F, and CH3;
R5c, at each occurrence, is selected from H, Cl, F, and CH3;

R5d, at each occurrence, is selected from H, Cl, F, and CH3; and, R5e, at each occurrence, is selected from H, Cl, F, and CH3.
16. A compound of claim 15, wherein the compound is of formula formula IIIa or a pharmaceutically acceptable salt thereof, wherein:

R1a, at each occurrence, is selected from aryl substituted with 0-2 R1b, heteroaryl substituted with 0-2 R1b, C5-6 cycloalkyl substituted with 0-2 R1b, and a heterocycle substituted with 0-2 R1b;, R1b, at each occurrence, is selected from OH, SH, Cl, F, NH2, -CN, NO2, C1-4 alkyl substituted with 0-2 R1c, C2-4 alkenyl substituted with 0-2 R1c, aryl substituted with 0-2 R1c, heteroaryl substituted with 0-2 R1c, C5-6 cycloalkyl substituted with 0-2 R1c, and a heterocycle substituted with 0-2 R1c;

R1c, at each occurrence, is selected from OH, SH, Cl, F, NH2, -CN, NO2, C1-4 alkyl, and C2-4 alkenyl, aryl substituted with 0-2 R1d, heteroaryl substituted with 0-2 R1d, C3-6 cycloalkyl sub-stituted with 0-2 R1d, and a heterocycle substituted with 0-2 R1d;

R2a is selected from aryl substituted with 0-2 R2b and heteroaryl substituted with 0-2 R2b and;
and, R2b, at each occurrence, is selected from OH, SH, Cl, F, NH2, -CN, NO2, C1-4 alkyl, C2-4 al-kenyl, aryl, heteroaryl, C5-6 cycloalkyl, and a heterocycle.
17. A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a compound of one of the claims 1-14 or a pharmaceutically acceptable salt.
18. A pharmaceutical composition for treating type 2 diabetes, comprising a compound according to any of the claims 1-14 together with one or more pharmaceutically acceptable carriers or excipients.
19. A pharmaceutical composition for treating dyslipidemia, syndrome X
(including the metabolic syndrome, e.g., hypertension, impaired glucose tolerance (IGT), insulin resistance, hypertrigyceridaemia, and obesity), cardiovascular diseases (e.g., atherosclerosis and related diseases, including mortality reduction, coronary artery diseases, coronary heart diseases, heart attack, myocardial ischemia, myocardial infarct, coronary infarct, transient ischemic attack (TIA), and stroke), hyperglycemia, hyperlipidemia, hypercholesterolemia, and hyperinsulinemia, comprising a compound according to any of the claims 1-14 together with one or more pharmaceutically acceptable carriers or excipients.
20. The use of a compound according to any one of the claims 1-14 as a pharmaceutical composition.
21. Use of a compound according to any one one of the claims 1-14 for the preparation of a pharmaceutical composition for treating type 2 diabetes.
22. Use of a compound according to any one of the claims 1-14 for the preparation of a pharmaceutical composition for treating dyslipidemia, syndrome X (including the metabolic syndrome, e.g., hypertension, impaired glucose tolerance (IGT), insulin resistance, hyper-trigyceridaemia, and obesity), cardiovascular diseases (e.g., atherosclerosis and related diseases, including mortality reduction, coronary artery diseases, coronary heart diseases, heart attack, myocardial ischemia, myocardial infarct, coronary infarct, transient ischemic attack (TIA), and stroke), hyperglycemia, hyperlipidemia, hypercholesterolemia, and hyperinsulinemia.
23. A method of treating type 2 diabetes, comprising: administering a therapeutically effective amount of a compound of one of claims 1-14 or a pharmaceutically acceptable salt.
24. A method of treating a disease, comprising: administering a therapeutically effective amount of a compound of one of claims 1-14 or a pharmaceutically acceptable salt, wherein the disease is selected from dyslipidemia, syndrome X (including the metabolic syndrome, e.g., hypertension, impaired glucose tolerance (IGT), insulin resistance, hypertrigyceridaemia, and obesity), cardiovascular diseases (e.g., atherosclerosis and related diseases, including mortal-ity reduction, coronary artery diseases, coronary heart diseases, heart attack, myocardial ischemia, myocardial infarct, coronary infarct, transient ischemic attack (TIA), and stroke), hyperglycemia, hyperlipidemia, hypercholesterolemia, and hyperinsulinemia.
CA2613365A 2005-06-30 2006-06-29 Phenoxy acetic acids as ppar delta activators Expired - Fee Related CA2613365C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP05105937 2005-06-30
EP05105937.6 2005-06-30
EP05112755.3 2005-12-22
EP05112755 2005-12-22
PCT/EP2006/063703 WO2007003581A1 (en) 2005-06-30 2006-06-29 Phenoxy acetic acids as ppar delta activators

Publications (2)

Publication Number Publication Date
CA2613365A1 true CA2613365A1 (en) 2007-01-11
CA2613365C CA2613365C (en) 2013-08-13

Family

ID=36721389

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2613365A Expired - Fee Related CA2613365C (en) 2005-06-30 2006-06-29 Phenoxy acetic acids as ppar delta activators

Country Status (13)

Country Link
US (3) US7943669B2 (en)
EP (2) EP1899302B1 (en)
JP (1) JP5052511B2 (en)
KR (1) KR101333101B1 (en)
AT (1) ATE529404T1 (en)
AU (1) AU2006265172B2 (en)
BR (1) BRPI0612730A2 (en)
CA (1) CA2613365C (en)
ES (2) ES2449618T3 (en)
MX (1) MX2007016374A (en)
RU (1) RU2412935C2 (en)
TW (1) TWI371446B (en)
WO (1) WO2007003581A1 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005105726A1 (en) 2004-05-05 2005-11-10 Novo Nordisk A/S Novel compounds, their preparation and use
US7943613B2 (en) 2005-12-22 2011-05-17 High Point Pharmaceuticals, Llc Compounds, their preparation and use
US7943612B2 (en) 2006-03-09 2011-05-17 High Point Pharmaceuticals, Llc Compounds that modulate PPAR activity, their preparation and use
US9317222B1 (en) 2006-04-24 2016-04-19 Emc Corporation Centralized content addressed storage
US9235477B1 (en) 2006-04-24 2016-01-12 Emc Corporation Virtualized backup solution
US8065273B2 (en) 2006-05-10 2011-11-22 Emc Corporation Automated priority restores
US9684739B1 (en) 2006-05-11 2017-06-20 EMC IP Holding Company LLC View generator for managing data storage
US8987328B2 (en) * 2008-10-30 2015-03-24 Trinity Laboratories, Inc. Esters of capsaicinoids as dietary supplements
MY169485A (en) * 2010-12-28 2019-04-15 Cadila Healthcare Ltd Heterocyclic compounds suitable for the treatment of dyslipidemia
CA2923422C (en) 2013-09-09 2021-09-07 Vtv Therapeutics Llc Use of a ppar-delta agonist for treating muscle atrophy
CN105092770B (en) * 2015-01-12 2017-03-29 上海中医药大学 A kind of method of screening four inhibitor of dipeptidyl peptidase
WO2022020376A1 (en) 2020-07-22 2022-01-27 Reneo Pharmaceuticals, Inc. Crystalline ppar-delta agonist
JP2023550643A (en) * 2020-11-25 2023-12-04 レネオ ファーマシューティカルズ，インク． Method for producing PPAR delta agonist
WO2023147309A1 (en) 2022-01-25 2023-08-03 Reneo Pharmaceuticals, Inc. Use of ppar-delta agonists in the treatment of disease

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4920132A (en) 1987-11-03 1990-04-24 Rorer Pharmaceutical Corp. Quinoline derivatives and use thereof as antagonists of leukotriene D4
US5324743A (en) 1992-12-10 1994-06-28 Eli Lilly And Company Leukotriene B4 antagonists
GB2279659B (en) 1993-07-05 1998-04-22 Merck Patent Gmbh Liquid crystalline material
EP0876379A1 (en) 1996-01-17 1998-11-11 Novo Nordisk A/S Fused 1,2,4-thiadiazine and fused 1,4-thiazine derivatives, their preparation and use
WO1997027847A1 (en) 1996-02-02 1997-08-07 Merck & Co., Inc. Method of treating diabetes and related disease states
AU1856997A (en) 1996-02-02 1997-08-22 Merck & Co., Inc. Method for raising hdl cholesterol levels
CA2245524A1 (en) 1996-02-02 1997-08-07 Wei Han Antidiabetic agents
ES2194179T3 (en) 1996-02-02 2003-11-16 Merck & Co Inc HETEROCICLIC DERIVATIVES AS ANTIDIABETIC AGENTS AND ANTIOBESITY.
ES2202582T3 (en) 1996-02-02 2004-04-01 MERCK & CO., INC. ANTIDIABETIC AGENTS.
HU227021B1 (en) 1996-08-30 2010-05-28 Novo Nordisk As Glp-1 derivatives
EP0948327B1 (en) 1996-12-23 2006-03-08 Merck & Co., Inc. Antidiabetic agents
BR9810378A (en) 1997-07-01 2000-08-29 Novo Nordisk As Compound, use of the same, pharmaceutical composition, and, processes of treating type i or type ii diabetes, of treating hyperglycemia, and of decreasing blood glucose in a mammal
KR20010021936A (en) 1997-07-16 2001-03-15 한센 핀 베네드, 안네 제헤르, 웨이콥 마리안느 Fused 1,2,4-thiadiazine derivatives, their preparation and use
ATE421336T1 (en) 1997-07-24 2009-02-15 Astellas Pharma Inc MEDICINAL COMPOSITIONS HAVING A CHOLESTEROL-LOWERING EFFECT
PL344977A1 (en) 1997-10-17 2001-11-19 Aventis Pharm Prod Inc Therapeutic uses of quinoline derivatives
EP1185230A1 (en) 1999-06-01 2002-03-13 University Of Texas Southwestern Medical Center Method of treating hair loss using diphenylether derivatives
GB9914977D0 (en) 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
TWI262185B (en) 1999-10-01 2006-09-21 Eisai Co Ltd Carboxylic acid derivatives having anti-hyperglycemia and anti-hyperlipemia action, and pharmaceutical composition containing the derivatives
WO2001025226A1 (en) 1999-10-05 2001-04-12 Bethesda Pharmaceuticals, Inc. Dithiolane derivatives
CN1423566A (en) 1999-11-10 2003-06-11 武田药品工业株式会社 Body weight gain inhibitor
EP1231938A2 (en) 1999-11-11 2002-08-21 Eli Lilly And Company Oncolytic combinations for the treatment of cancer
EP1259494A4 (en) 2000-02-18 2004-09-15 Merck & Co Inc Aryloxyacetic acids for diabetes and lipid disorders
JP2004500389A (en) 2000-03-09 2004-01-08 アベンティス・ファーマ・ドイチユラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Use of PPAR mediators in therapy
US6448293B1 (en) 2000-03-31 2002-09-10 Pfizer Inc. Diphenyl ether compounds useful in therapy
JP2001354671A (en) 2000-04-14 2001-12-25 Nippon Chemiphar Co Ltd ACTIVATOR FOR PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR delta
WO2002014291A1 (en) 2000-08-11 2002-02-21 Nippon Chemiphar Co.,Ltd. PPARδ ACTIVATORS
US6630504B2 (en) 2000-08-31 2003-10-07 Pfizer Inc. Phenoxyphenylheterocyclyl derivatives as SSRIs
GB0024361D0 (en) 2000-10-05 2000-11-22 Glaxo Group Ltd Medicaments
JPWO2002046154A1 (en) 2000-12-05 2004-04-08 日本ケミファ株式会社 Activator of peroxisome proliferator-activated receptor δ
GB0031103D0 (en) 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
GB0031107D0 (en) 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
GB0031109D0 (en) 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
EP1357115B1 (en) 2000-12-28 2009-06-17 Takeda Pharmaceutical Company Limited Alkanoic acid derivatives, process for their production and use thereof
EP1357914A2 (en) 2001-02-02 2003-11-05 SmithKline Beecham Corporation Treatment of ppar mediated diseases
EP1371650A4 (en) 2001-03-23 2005-05-04 Nippon Chemiphar Co Activator for peroxisome proliferator-activated receptor
JP4256166B2 (en) 2001-03-28 2009-04-22 エーザイ・アール・アンド・ディー・マネジメント株式会社 Carboxylic acid compound
JPWO2002080899A1 (en) 2001-03-30 2005-01-06 エーザイ株式会社 Gastrointestinal disease treatment
TWI311133B (en) 2001-04-20 2009-06-21 Eisai R&D Man Co Ltd Carboxylic acid derivativeand the salt thereof
WO2002098840A1 (en) 2001-06-04 2002-12-12 Eisai Co., Ltd. Carboxylic acid derivative and medicine comprising salt or ester of the same
FR2826574B1 (en) 2001-06-29 2005-08-26 Oreal COMPOSITIONS CONTAINING A HYDROXYDIPHENYL ETHER DERIVATIVE INHIBITING THE DEVELOPMENT OF BODY ODORS
EP1424330B1 (en) 2001-08-10 2011-09-28 Nippon Chemiphar Co., Ltd. Activator for peroxisome proliferator-responsive receptor delta
EP1452521A4 (en) 2001-08-17 2007-03-14 Eisai R&D Man Co Ltd Cyclic compound and ppar agonist
JP4269052B2 (en) 2001-09-14 2009-05-27 アムジエン・インコーポレーテツド Linked biaryl compounds
ATE434616T1 (en) 2001-10-12 2009-07-15 Nippon Chemiphar Co PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR DELTA ACTIVATOR
CN1571766A (en) 2001-10-17 2005-01-26 诺沃挪第克公司 Novel compounds, their preparation and use
DE10151390A1 (en) 2001-10-18 2003-05-08 Bayer Ag acetic acid derivatives
JP2003171275A (en) 2001-12-11 2003-06-17 Sumitomo Pharmaceut Co Ltd Ppar delta agonist
US6648293B1 (en) * 2001-12-20 2003-11-18 Braeside Plastics Corporation Foldable display container and method for assembling the same
EP1480640B1 (en) 2002-02-25 2007-08-15 Eli Lilly And Company Peroxisome proliferator activated receptor modulators
US7319104B2 (en) 2002-03-01 2008-01-15 Smithkline Beecham Corporation hPPARs activators
US20030207924A1 (en) 2002-03-07 2003-11-06 Xue-Min Cheng Compounds that modulate PPAR activity and methods of preparation
US6833380B2 (en) 2002-03-07 2004-12-21 Warner-Lambert Company, Llc Compounds that modulate PPAR activity and methods of preparation
US6867224B2 (en) 2002-03-07 2005-03-15 Warner-Lambert Company Compounds that modulate PPAR activity and methods of preparation
US6875780B2 (en) 2002-04-05 2005-04-05 Warner-Lambert Company Compounds that modulate PPAR activity and methods for their preparation
DE10222034A1 (en) 2002-05-17 2003-11-27 Bayer Ag New 2-benzenesulfonyl-3,4-dihydro-2(1H)-isoquinoline derivatives, are PPAR-delta activators useful e.g. for treating coronary heart disease, dyslipidemia or restenosis
GB0214149D0 (en) 2002-06-19 2002-07-31 Glaxo Group Ltd Chemical compounds
GB0214254D0 (en) 2002-06-20 2002-07-31 Glaxo Group Ltd Chemical compounds
DE10229777A1 (en) 2002-07-03 2004-01-29 Bayer Ag Indoline-phenylsulfonamide derivatives
AU2003281040A1 (en) 2002-07-10 2004-02-02 Sumitomo Pharmaceuticals Co., Ltd. Biaryl derivatives
WO2004056740A1 (en) 2002-12-20 2004-07-08 Novo Nordisk A/S Dicarboxylic acid derivatives as ppar-agonists
US7816385B2 (en) 2002-12-20 2010-10-19 High Point Pharmaceuticals, Llc Dimeric dicarboxylic acid derivatives, their preparation and use
US20060241157A1 (en) 2003-01-06 2006-10-26 Conner Scott E Heterocyclic ppar modulators
DE10300099A1 (en) 2003-01-07 2004-07-15 Bayer Healthcare Ag Indole-phenylsulfonamide derivatives
WO2004071447A2 (en) 2003-02-12 2004-08-26 Transtech Pharma Inc. Substituted azole derivatives as therapeutic agents
WO2004073606A2 (en) 2003-02-14 2004-09-02 Eli Lilly And Company Sulfonamide derivatives as ppar modulators
US20070105959A1 (en) 2003-03-11 2007-05-10 Shinya Kusuda Cynnamyl alcohol derivative compounds and drugs containing the compounds as active ingredient
AU2004220221A1 (en) 2003-03-13 2004-09-23 Ono Pharmaceutical Co., Ltd. Imino ether derivative compounds and drugs containing the compounds as the active ingredient
CA2521175A1 (en) 2003-04-07 2004-10-28 Kalypsys, Inc. Para-sulfonyl substituted phenyl compounds as modulators of ppars
US7244763B2 (en) 2003-04-17 2007-07-17 Warner Lambert Company Llc Compounds that modulate PPAR activity and methods of preparation
ES2273282T3 (en) 2003-04-17 2007-05-01 Kalypsys, Inc. (3- (3- (2,4-BIS-TRIFLUOROMETIL-BENCIL) - (5-ETIL-PIRIMIDIN-2-IL) -AMINO) -PROPOXI) -PHENILE) -ACTICAL AND RELATED COMPOUNDS AS MODULATORS OF PPARS AND METHODS OF TREATMENT OF METABOLIC DISORDERS.
CA2524235A1 (en) 2003-04-30 2004-11-18 The Institutes For Pharmaceutical Discovery, Llc Phenyl substituted carboxylic acids as inhibitors of protein tyrosine phosphatase-1b
ES2299906T3 (en) * 2003-11-25 2008-06-01 Eli Lilly And Company RECEIVER MODULATORS ACTIVATED BY PEROXISOM PROLIFERATORS.
MXPA06011218A (en) 2004-04-01 2007-01-16 Aventis Pharma Inc Use of ppr delta agonists for treating demyelinating diseases.
EP1781648A2 (en) 2004-04-01 2007-05-09 Aventis Pharmaceuticals Inc. 1,3,4-oxadiazol-2-ones as ppar delta modulators
AU2005230837A1 (en) 2004-04-01 2005-10-20 Aventis Pharmaceuticals Inc. 1,3,4-oxadiazol-2-ones as PPAR delta modulators
WO2005105726A1 (en) 2004-05-05 2005-11-10 Novo Nordisk A/S Novel compounds, their preparation and use
KR20070026503A (en) 2004-05-14 2007-03-08 아이알엠 엘엘씨 Compounds and compositions as ppar modulators
US7943612B2 (en) 2006-03-09 2011-05-17 High Point Pharmaceuticals, Llc Compounds that modulate PPAR activity, their preparation and use

Also Published As

Publication number Publication date
ES2372617T3 (en) 2012-01-24
US8426473B2 (en) 2013-04-23
KR101333101B1 (en) 2013-11-26
MX2007016374A (en) 2008-03-05
ES2449618T3 (en) 2014-03-20
WO2007003581A1 (en) 2007-01-11
RU2007147050A (en) 2009-08-10
US20120232080A1 (en) 2012-09-13
US20110183982A1 (en) 2011-07-28
AU2006265172B2 (en) 2011-09-15
TW200734306A (en) 2007-09-16
US20090192162A1 (en) 2009-07-30
RU2412935C2 (en) 2011-02-27
US7943669B2 (en) 2011-05-17
JP5052511B2 (en) 2012-10-17
EP1899302A1 (en) 2008-03-19
EP2298742A1 (en) 2011-03-23
TWI371446B (en) 2012-09-01
AU2006265172A1 (en) 2007-01-11
US8217086B2 (en) 2012-07-10
ATE529404T1 (en) 2011-11-15
KR20080025747A (en) 2008-03-21
CA2613365C (en) 2013-08-13
JP2009501704A (en) 2009-01-22
BRPI0612730A2 (en) 2010-11-30
EP1899302B1 (en) 2011-10-19
EP2298742B1 (en) 2014-01-08

Similar Documents

Publication Publication Date Title
AU2006265172B2 (en) Phenoxy acetic acids as PPAR delta activators
US10947180B2 (en) Phenoxy acetic acids and phenyl propionic acids as PPAR delta agonists
US7943612B2 (en) Compounds that modulate PPAR activity, their preparation and use

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20220629